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Monoclonal Antibody Production Via Fluidized Bioreactor Technology
Abstract
Monoclonal antibodies (mAbs) are biologically identical antibodies created by homogenous immune cells
originating from the same parent cell. MAbs target a specific epitope of an antigen on a cell’s surface, allowing
it to neutralize the antigen. This unique characteristic has made them a key tool in the biopharmaceutical
industry for the production of therapeutic drugs. One of these drugs is Rituxan® (rituximab), a mAb drug for
the treatment of various cancers and autoimmune diseases. Currently, most mAb products are grown via cell
suspension technology in stirred tank bioreactors. However, we have found that by using an integrated
bioprocessing model, including conventional cell suspension culture tanks and fluidized bioreactor
technology, overall product yield per day is increased by about 7-fold for the production of Rituxan®.
Additionally, an economic analysis shows the fluidized bioreactor process is more profitable. Furthermore,
though it requires a higher initial investment than the stirred tank process, the differential present worth of the
fluidized bioreactor process in comparison to the stirred tank process is $13 billion. Overall, for the
production of Rituxan®, the use of fluidized bioreactor technology is a more productive and lucrative process
than the conventional stirred tank process.
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April 23, 2014 
 
Professor Leonard Fabiano 
University of Pennsylvania 
School of Engineering and Applied Science 
Department of Chemical and Biomolecular Engineering 
220 S. 33rd Street 
Philadelphia, PA 19104 
 
Dear Professor Fabiano, 
 
Enclosed herewith is a detailed process design and economic analysis comparing two methods of 
monoclonal antibody production. The traditional stirred tank bioreactor process currently used in 
industry was compared to a hybrid process involving a fluidized bioreactor. A fluidized 
bioreactor process was chosen as comparison because it allows for greater product formation and 
ultimately a more profitable method to produce generic rituximab. The production goal was set 
at 650kg of generic Rituxan® (rituximab), a monoclonal antibody currently sold by Roche. 
However, it was determined that five parallel processes of the stirred tank process would be 
required to meet the production requirement while only one fluidized bioreactor process is 
necessary.  
 
The report provides significant details regarding the process unit operations along with a detailed 
design of the fluidized bioreactor, which is a new, unique and difficult concept. Furthermore, a 
fluidized bioreactor model was also developed to model the growth of cells in the environment 
along with the effect of various factors on product formation.  
 
Based on the economic analysis, we recommend implanting the fluidized bioreactor process to 
create product at the lowest dollar and time cost. This process can produce 650 kg of product 
(after downstream purification) in 212 days. This design process will require an initial capital 
investment of about $1.8 billion. The project will have an internal rate of return (IRR) of 225% 
and a net present value (NPV) of $17 billion, assuming a 10-year operational life.  
 
All calculations for the report were done based on literature values. Please contact us regarding 
any questions or concerns that you may have about either process covered in the report.  
 
Best, 
 
 
 
_________________        _________________      _________________      _________________ 
     Lydia Atangcho         Meghan McCullough      Shenali Parikh    Alexandra Stambaugh 
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1. Abstract 
Monoclonal antibodies (mAbs) are biologically identical antibodies created by homogenous 
immune cells originating from the same parent cell. MAbs target a specific epitope of an antigen 
on a cell’s surface, allowing it to neutralize the antigen. This unique characteristic has made 
them a key tool in the biopharmaceutical industry for the production of therapeutic drugs. One of 
these drugs is Rituxan® (rituximab), a mAb drug for the treatment of various cancers and 
autoimmune diseases. Currently, most mAb products are grown via cell suspension technology 
in stirred tank bioreactors. However, we have found that by using an integrated bioprocessing 
model, including conventional cell suspension culture tanks and fluidized bioreactor technology, 
overall product yield per day is increased by about 7-fold for the production of Rituxan®. 
Additionally, an economic analysis shows the fluidized bioreactor process is more profitable. 
Furthermore, though it requires a higher initial investment than the stirred tank process, the 
differential present worth of the fluidized bioreactor process in comparison to the stirred tank 
process is $13 billion. Overall, for the production of Rituxan®, the use of fluidized bioreactor 
technology is a more productive and lucrative process than the conventional stirred tank process. 
2. Introduction 
2.1. Project Background 
2.1.1. Rituxan® 
While most mAbs are made on a small to medium scale for laboratory use, 
successful mAb drugs used for medicinal treatment are responsible for a multibillion-
dollar industry with each mAb responsible for at least $1 million in sales for its 
respective companies (U.S. Pharmaceutical Sales, National Research Council).  For the 
larger blockbuster drugs, the sales of mAb may bring in billions every year. In such large 
domestic and international markets, there is great potential for generics. For the purpose 
of this project, we will examine the production optimization for Rituxan® (rituximab). By 
developing a more profitable process, a generic drug can be produced at a lower cost.  
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Rituxan® (rituximab) is a CD-20 monoclonal antibody. It has an affinity for cells 
that overexpress the CD-20 target receptor, a common sign of non-Hodgkins lymphoma, 
Crohn’s disease, chronic lymphocytic leukemia, and rheumatoid arthritis. Rituxan® 
depletes the body’s B-cells. It has three proposed mechanisms of action: complement-
dependent cytotoxicity, antibody-dependent cell-mediated cytotoxicity and apoptosis. 
Though the mechanisms are not fully understood, all three essentially require the mAb to 
bind to immune system B-cells by recognizing the protein receptor, CD-20, after which 
the drug can successfully kill the target cell (Proposed Mechanism of Action). 
2.1.2. Fluidized Bioreactor Process 
Since the introduction of mAbs to the field of therapeutic medicine, factories have 
adapted their designs to produce pure, high-quality mAbs. However, because mAbs 
require strict purification processes and a moderately long production process in 
comparison to small molecule drugs, plants are generally over-capacity. MAb production 
is dependent significantly on the cell culture conditions, which commonly include 
growing cells in suspension. Suspension culture is widely used because it presents the 
simplest way of achieving a high cell density for a maximum product yield. With larger 
batches, larger-scale purification is necessary, but cannot be accommodated by current 
plant designs (Kelley 450). We propose to introduce a different cell culture technique for 
application in large-scale mAb production – one that will provide several useful 
advantages over traditional suspension culture techniques. 
Many mammalian cell lines, including those most commonly used for mAb 
production, such as Chinese Hamster Ovary (CHO) cells, are anchorage dependent unless 
modified for suspension culture growth. By utilizing microcarriers, small porous particles 
capable of remaining in suspension, cells can grow in psuedo-suspension by adhering on 
or inside these particles. Two major advantages of this are increased production capacity 
and reduced labor requirement in comparison to traditional suspension culture processes. 
Due to a high surface area to volume ratio, the use of microcarriers provides higher cell 
and product yields than is possible with a traditional suspension bioreactor. Another 
advantage of using microcarriers is easier downstream purification. Because cells are 
retained on the carriers and product is secreted into the medium, separation of cells and 
product is achieved by a simple filtration step instead of the typical centrifugation step, a 
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more costly process. Furthermore, microcarriers help protect against physical and 
chemical stress. Since the cells grow inside the porous beads, they are protected from 
shear stresses caused by the tip of the stirrer as well as the sparged oxygen bubbles. 
Additionally, cells tolerate more chemical stress such as lactate build up when growing 
inside the porous carriers (Rodrigues, et al.) (GE Microcarrier Handbook). 
In the proposed design, a fluidized bioreactor with GE Cytoline™ 1 microcarriers 
is used as the main production step for the product. These beads, shown in Figure 2.1, are 
ellipsoid particles with 0.4-1.1mm thickness, 1.7-2.5mm length, and 10-400µm pores. A 
recombinant CHO cell line will be used as the mAb-producing cell line. Though specific 
cell productivity is likely to be less than that of the cell suspension process, overall 
productivity will be higher due to a 
higher sustainable cell density. A 
traditional stirred tank process that 
utilizes stirred tank bioreactors for both 
seed train and production steps to a new 
process containing a near-identical seed 
train and a fluidized bioreactor as the 
production step.  
 
  
Figure 2.1 Cytoline 1 Microcarriers Covered with Cells 
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2.2. Project Charter 
 
Project Name Monoclonal Antibody Production via Fluidized Bioreactor Technology 
Project Leaders Lydia Atangcho, Meghan McCullough, Shenali Parikh, Alexandra Stambaugh 
Specific Goal Design a biopharmaceutical plant and process to produce a generic version of 
Rituxan® (rituximab) using a fluidized bioreactor as the final production step 
rather than using a traditional cell suspension culture.  
Project Scope In Scope: 
• Manufacturing process for rituximab beginning from prepared inoculum 
of cells to final growth step 
o Design main process to include fluidized bioreactor technology as 
the final production step 
! Expected increase in overall volume productivity 
o Design a traditional industry standard process without fluidized 
bioreactor steps as a basis for comparison 
• Post-manufacturing purification steps beginning from the first harvest 
step (centrifugation or filtration) to final sterile filtration 
• Meet current safety and health regulations for biological products 
• Maintain process integrity and compliance by adhering to good 
manufacturing practices (GMP) 
• Determine which process (fluidized v. traditional) is best when compared 
on basis of amount of drug produced per time per dollar 
Out of Scope: 
• Research and development of generic rituximab (produced in laboratory)  
• Cell line development  
• Clinical trials 
• Packaging and distribution of drugs 
• FDA approval of generic drug 
• FDA approval of use of large-scale fluidized  
Deliverables Business opportunity assessment  
• What is the market for generic production of Rituxan® and monoclonal 
antibodies in general? 
• How does the fluidized bioreactor process compare to the traditional 
process? 
Technical feasibility assessment 
• Is it technically feasible to manufacture antibodies on a large scale using 
a fluidized bioreactor setup? 
Manufacturing capability assessment 
• Can this facility be built and the process utilized without significant 
capital investment? 
• Will the process satisfy the stringent FDA requirements for a pure, 
consistent product? 
Time Line Facility and process design along with economic analysis within four months. 
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2.3. Technology Readiness Assessment  
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3. Concept Stage 
In 2013, the sales of Rituxan® reached over $3.2 billion in the US market and $2.12 billion in 
the European market. Since its introduction in the US market in 2011, Rituxan® has experienced 
a general upward trend in sales, which is expected to continue until its patent expiration in 2014 
in Europe and in 2018 in the United States. In general, the mAb market is expected to have a 
compound annual growth rate of about 5.3% indicating almost $58 billion in sales globally (U.S. 
Pharmaceutical Sales).  
With an increase in monoclonal antibody drugs in the pipelines of big pharmaceuticals such 
as Genentech and Abbott LabsTM and in increasing global demand for the drugs, current 
production facilities must be able to meet the necessary production goals. As previously 
mentioned, current facilities often struggle to produce more than a certain amount of antibody 
per batch due to the restrictions of maximum cell density in a cell suspension culture. When a 
fluidized bioreactor is used as the final upstream step, the cells can adhere to the microcarriers 
and grow to a 100 times higher sustainable cell density than the traditional process. This allows 
for an overall increase in cell productivity.  
3.1. Competition in the Generic Market and Production Goal 
Before drugs lose their patent protection, generic manufacturers have already begun to 
manufacture a competitor for the market, which is ready to launch as soon as the patent 
expires. Currently, Roche expects to maintain exclusivity in the international market well into 
2015 because no other company has been able to gain approval for generic Rituxan®. This 
opens up a great opportunity to potentially build a more lucrative and more productive 
process and gain hold of the rituximab market once Roche’s patent expires. However, Teva 
Laboratories may become a competitor since their mAb is in Phase III clinical trials (Roche: 
Impact Of Rituxan Patent Expiration In Europe).  
In 2013, over 2.2 million units of Rituxan® were sold in the US alone amounting to $3.2 
billion in US revenue. In Europe, Rituxan® earned about $2.1 billion in revenue. Based on 
the units of Rituxan® sold (each unit refers to either a 100mg/10mL or 500mg/50mL vials) 
and the average price per dose of $586 (100mg/10mL vial) and $2,840 (500mg/50mL vial), a 
production goal can be determined. Assuming that the facility will eventually produce 
enough product to capture 70% of the domestic and European markets, 650 kg of generic 
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rituximab will ultimately become the production goal (see Section 13.1) (U.S. 
Pharmaceutical Sales).  
3.2. Process and Facility Requirements 
The new facility will be built on a brownfield site on the Delaware River. The East 
Coast is the preferred location for the facility because it allows the facility easy access to land 
and sea transportation. Furthermore, the Eastern seaboard, and in particular, the Philadelphia 
and Delaware areas have become a hub of innovation for the biotechnology field. The 
brownfield site will be retrofitted to match the desired needs of the new design. It will also 
help reduce the initial investments cost for the land and building as well as equipment. Rather 
than purchasing equipment, an annual fee can be paid in order to utilize the preexisting 
equipment at the site.  
The new facility requires a new-unique-and difficult design concept. The facility is 
being designed for a company attempting to enter the generic monoclonal antibody market 
wishing to specifically produce rituximab. Though out of scope for this project, the proposed 
designs can be used to produce any mAb allowing for some minor changes. The new facility 
will be equipped with the most updated, cost-effective equipment. Specifically, the facility 
will be equipped with disposable unit operations wherever applicable. The rising trend of 
using disposable bioreactors and tanks, the disposable route offers shorter batch times, 
eliminates SIP and CIP procedures, and provides long-term savings. According to a report of 
A. Sinclair, single-use bioreactors will help to save 30% of electrical energy for operation, 
62% of the energy input for the production of the system, 87% of water and finally 95% of 
detergents, all compared to conventional bioreactors.1  
 
 
  
                                                
1 Sinclaire A., Leveen L. et al. (2008). "The Environmental Impact of Disposable Technologies". 
BioPharm International Supplements. 
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3.3. Block Flow Diagram 
The diagram below depicts the overall process design for the stirred tank bioreactor and 
fluidized bioreactor processes. The overall processes are very similar, but the fluidized 
bioreactor process has a slightly different downstream purification process.  
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4. Process Flow Diagrams 
The following pages include the process flow diagrams (PFD) for the two main processes: 
monoclonal antibody production via traditional stirred tank bioreactor process and production via 
the fluidized bioreactor process. The overall diagram for each process is divided into two 
sections: production and purification of product.  
4.1. Production PFD for Stirred Tank Bioreactor Process (PFD 01)  
 
4.1.1. Overall Mass Balance for PFD 01 
 
 
PFD 01- Stirred Tank Inoculum Prep & Bioreaction 
Component Input (kg/batch) Output (kg/batch) 
Cells 0.00524 356.32 
Media 0.002 0 
Water 0.098 19600 
Endotoxin 0 36.34 
Product 0 9.41 
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4.2. Purification PFD for Stirred Tank Bioreactor Process (PFD 02) 
 
 
 
4.2.1. Overall Mass Balance for PFD 02 
 
PFD 02- Stirred Tank Downstream Purification 
Component Input  (kg/batch) Output (kg/batch) 
Cells 356.32 0.0 
Media 0.0 0.0 
Water 19600 2000 
Endotoxin 36.34 0.0 
Product 9.41 7.76 
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4.3. Production PFD for Fluidized Bioreactor Process (PFD 03) 
 
 
 
4.3.1. Overall Mass Balance for PFD 03 
 
PFD 03- Fluidized Bioreactor Inoculum Prep & 
Bioreaction 
Component Input  (kg/batch) Output (kg/batch) 
Cells 0.00524 2672.4 
Media 0.002 1.17x105 
Water 0.098 5.90x106 
Endotoxin 0.0 272.58 
Product 0.0 65.75 
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4.4. Purification PFD for Fluidized Bioreactor Process (PFD 04) 
 
 
 
 
4.4.1. Overall Mass Balance for PFD-04 
 
PFD 4- Fluidized Bioreactor Downstream Purification 
Component Input  (kg/batch) Output (kg/batch) 
Cells 2672.4 0.0 
Media 1.17x105 0.0 
Water 5.90x106 2000 
Endotoxin 272.58 0.0 
Product 65.74 54.21 
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4.5. Microcarrier Handling PFD for Fluidized Bioreactor Process (PFD 05) 
 
 
 
 
  
14 Monoclonal Antibody Production via Fluidized Bioreactor Technology 
 
 
5. Production Process Description 
All seeding densities for cells were calculated to minimize cell growth time while 
maximizing production rate (See Appendix F). 
5.1. Media Preparation – Stirred Tank and Fluidized Bioreactor Process 
Both processes will use Ex-Cell® ACF CHO Media from Sigma-AldrichTM. This is 
chemically defined, serum-free, and protein-free media specially formulated for optimal 
CHO cell growth. For efficiency, prepared media will be purchased directly from Sigma-
AldrichTM for the inoculum preparation steps. For the bioreactors the media will be prepared 
in various mixing tanks (refer to process flow diagrams) by adding dry powder media to 
water-for-injection (WFI). The prepared media solution will be filtered with a 0.2 micron 
sterile filter to remove any foreign particles and large viruses. The media concentration will 
remain at about 20 grams of dry media per liter of prepared solution.  
5.2. CytolineTM Microcarrier Prep – Fluidized Bioreactor Process Only 
To prepare the CyotlineTM 1 beads for sterilization, two volumes of distilled water are 
added to one volume of microcarrier beads. Then, the mixture is degassed and autoclaved for 
10 minutes at 121°C (1 bar). The water supernatant is removed with a sterilized pipette. 
Fresh distilled water is added and the microcarriers are stirred for 10 minutes. Again, the 
water supernatant is removed and 0.1M NaOH is added. The mixture is then incubated 
overnight and washed with distilled water until the pH stabilizes. Next, the microcarriers are 
autoclaved in distilled water or PBS at 121°C (1 bar) for 30 min.  
5.3. Inoculum Preparation Section 
5.3.1. Stirred Tank Bioreactor Process 
To prepare the inoculum for seed bioreactor, twenty 0.2L disposable bag 
bioreactors with 0.1 L working volume will each be inoculated with 2.0mL of cells at a 
concentration of 1x108 cells/mL. Fifty percent of the total volume is used to allow for 
proper agitation of the culture and allow for ample air space. The culture will require 
about 3.5 days to grow to the desired cell density of 1.0x107 cells/mL. The temperature is 
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monitored and controlled at 37°C, the pH at 7.0 and the dissolved oxygen level at 50% 
via PID (positive-integral-differential) feedback controls. 
5.3.2. Fluidized Bioreactor Process 
To prepare the inoculum for the seed bioreactor, thirty 0.2L disposable bag 
bioreactors with 0.1L working volume will each be inoculated with 2.0mL of cells at a 
concentration of 1x108 cells/mL. Fifty percent of the total volume is used to allow for 
proper agitation of the culture and allow for ample air space. The culture will require 
about 3.5 days to grow to the desired cell density of 1.0x107 cells/mL. The temperature is 
monitored and controlled at 37°C, the pH at 7.0 and the dissolved oxygen level at 50% 
via PID (positive-integral-differential) feedback controls. 
5.4. Seed Bioreactor Section 
5.4.1. Stirred Tank Bioreactor Process 
 At the end of the inoculum preparation, 98L of prepared and sterilized media 
solution will be added to a 200L bag seed bioreactor with 100L working volume. The cell 
cultures from all inoculum bag bioreactors will be transferred via a peristaltic pump to the 
seed bioreactor. The culture will be rocked continuously to ensure proper mixing. The 
culture will be allowed to grow for four days with a target final cell density of 1.12x106 
cells/mL. Assuming a product growth rate of 90 pg/cell/day, about 24 grams of antibody 
product will be produced. Throughout the process, the temperature will be monitored and 
controlled at 37°C, the pH at 7.0, and the dissolved oxygen level at 50% via PID controls.  
After the culture in the first seed bioreactor is allowed to grow for 4 days, the 
contents will be transferred via peristaltic pump to the 2,000L second bag seed bioreactor 
containing 900L of sterilized media solution. The second seed bioreactor will have a 
working volume of 1,000L. The culture will be rocked continuously to ensure proper 
mixing. The culture will be allowed to grow for 4 days with a target final cell density of 
6.29x105 cells/ml. Over this time, 134 grams of antibody product will be produced. 
Throughout the process, the temperature will be monitored and controlled at 37°C, the 
pH at 7.0, and the dissolved oxygen level at 50% via PID controls. 
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5.4.2. Fluidized Bioreactor Process   
At the end of the inoculum preparation, the cell cultures from 0.2L bag 
bioreactors will be distributed equally (via sterile tubing) to three 200L bag seed 
bioreactor with a working volume of 100L (running in parallel). This design setup was 
chosen to help limit the cell growth time to 5 days but still provide enough cells to 
inoculate the second seed bioreactor. Upon transfer, the bag bioreactors will already 
contain 98L of prepared and sterilized media solution. The culture will be rocked 
continuously to ensure proper mixing. It will be allowed to grow for four days with a 
target final cell density of 2.0x106 cells/mL. Assuming a product growth rate of 90 
pg/cell/day, about 51 grams of antibody product will be produced. Throughout the 
process, the temperature will be maintained at 37°C, the pH at 7.0, and the dissolved 
oxygen level at 50% via PID controls.  
After 5 days, the culture from all three reactors is transferred into a single 2000L 
seed bioreactor with a 1000L working volume. Upon transfer, the bioreactor will contain 
900L of prepared and sterilized media solution will be immediately added to the seed 
bioreactor. The culture will be rocked continuously to ensure proper mixing. The culture 
will be allowed to grow for 5.5 days with a target final cell density of 1.5x106 cells/mL. 
Over this time, 409 grams of antibody product will be produced. Throughout the process, 
the temperature will be maintained at 37°C, the pH at 7.0, and the dissolved oxygen level 
at 50% via PID controls. 
5.5. Production Bioreactor Section 
While the seed bioreactor section served to grow up the culture, the final bioreactor 
serves to maximize product formation. 
5.5.1. Stirred Tank Bioreactor Process 
For the traditional stirred tank bioreactor process, the cell culture will be 
transferred via a peristaltic pump into the 25,000L production bioreactor with a working 
volume of 20,000L. Upon transfer, 19,000L of prepared and sterilized media solution will 
have been immediately added to the seed bioreactor. The culture will be stirred 
continuously to ensure proper mixing. The culture will be allowed to grow for 16 days 
with a target final cell density of 6.11x105 cells/ml. Assuming a productivity rate of 90 
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pg/cell/day, 9.3 kg of antibody product will be produced. Throughout the process, the 
temperature will be maintained at 37°C, the pH at 7.0, and the dissolved oxygen level at 
50% via PID controls. 
5.5.2. Fluidized Bioreactor Process 
The reactor must be inoculated with the cells from the previous seed bioreactor 
steps, which will first have to adhere to the CytolineTM 1 beads. These cells should be in a 
logarithmic growth phase and in a good nutritional state. This adherence protocol is a 
continuation upon the microcarrier prep protocol (Section 5.2). The culture medium is 
first removed completely from the equilibrated microcarrier-cell culture medium 
mixture. The cells from the previous seed bioreactor along with 9,000L of fresh culture 
medium are added to 730L CytolineTM 1 beads in the fluidized bed bioreactor. The 
culture will have an initial cell density of 2.0x106 cells/mL microcarrier, as specified by 
the GE Microcarrier and Cell Culture Handbook. The mixture is agitated gently every 30 
minutes for a total of 5 hours. After 5 hours, culture medium is added to the final working 
volume of 20,000L and incubated overnight while stirred at 100 rpm.  
The fluidized bioreactor will then be operated to circulate media while spinning at 
approximately 300 rpm, which corresponds to a flow rate of about 19 cm/min of media. 
The culture media will circulate through the bottom of the annular fluidized bed 
bioreactor. From the top, about 78% of culture media will be removed continuously and 
moved to a holding tank. The remaining 27% will be circulated back through the internal 
circulation loop to be enriched in the bottom of the reactor and circulated through again. 
The culture will be allowed to grow for 12.8 days with a final cell target density of 
1.4x108 cells/mL microcarrier. Assuming a cell productivity rate of 90 pg/cell/day, 65 kg 
of antibody product will be produced. Throughout the process, temperatures will be 
maintained at 37°C, pH of 7.0, and the dissolved oxygen level at 40% via PID controls. 
5.6. Theoretical Model for Fluidized Bioreactor Process 
The fluidized bioreactor, shown in Figure 5.1, is a unit that is fluidized with an internal 
circulation system. This component is modeled as a combination of a CytopilotTM 
(Vogelbusch GmbH Vienna) and a typical annular fluidized bed reactor. As with the 
CytopilotTM, this fluidized bed bioreactor will have two components: an upper cylindrical 
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chamber and a lower cylindrical chamber. The lower chamber is outfitted with a double-
jacket heating circuit, sampling and discharge facilities, a magnetic stirrer, and pH and 
dissolved oxygen probe nozzles. The media is agitated by 
the magnetic stirrer and delivered through the distributer 
plate to the microcarriers in the upper chamber of the 
fluidized bioreactor. The hydrodynamic pressure lifts the 
settled microcarriers to form a fluidized bed, and the 
chamber is tall enough such that there is an apparent 
separation between the top of the fluidized microcarriers 
and the top of the media volume. A portion of the media 
flows down the channel that defines the internal 
circulation loop, where it will be deposited back into the 
lower chamber. Micro-bubbles of oxygen are sparged 
into the downflow of the internal circulation tube and 
distributed homogeneously by the impeller in the lower 
chamber. The working volume of the annular fluidized bed in the upper chamber was 
designed to be 20,000L with an aspect ratio of height to diameter of 4:1. The bed has a 
diameter of 2 meters and a height of 8.13 meters, which is reasonable for an industrial scale 
bioreactor.  
5.6.1. Fluidization Velocity 
Practical operations of the fluidization stream in typical annular fluidized beds are 
conducted at two or more multiples of the fluidization velocity. The maximum flow rate 
of the bioreactor is dictated by the sedimentation rates of the CytolineTM 1 beads.  If the 
bed is fluidized at a velocity higher than that of the sedimentation rate, then the 
microcarriers will be carried to the top of the reactor. This is known as flush out, and 
usually occurs when the media is run through the bed at velocities exceeding 10 times the 
minimum fluidization velocity. The sedimentation rate for the CytolineTM 1 microcarriers 
is 120-220 cm/min of media, dictated by the CytolineTM 1 microcarrier product 
information brochure.  To avoid flush out and to achieve optimal operation, the fluidized 
bed bioreactor will flow media at about 1.9 times the minimum fluidization velocity for 
the average sized CytolineTM 1 bead bed, which corresponds to around 28,000L of media 
Figure 5.1 Fluidized Bioroeactor 
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per hour or a flow rate of approximately 19 cm/min. This value was determined by 
performing a sensitivity analysis upon the minimum fluidization rates for the bead size 
distribution within the reactor. Calculations for the minimum fluidization velocity are 
shown in Appendix A. The fluidized bed reactor will operate at the minimum fluidization 
velocity of the largest particles, which is 1.9 times the minimum fluidization velocity for 
an average sized CytolineTM 1 bead and about 6.2 times the minimum fluidization 
velocity of the smallest CytolineTM 1 beads. The void fraction of the CytolineTM 1 bed is 
estimated for an ellipsoidal packed bed as ε = 0.35, which is equivalent to near-perfect 
packing for ellipsoidal particles. The CytolineTM 1 particles are ellipsoidal, and due to the 
gentle agitation before fluidization in the inoculation step, it is fair to assume that the 
beads will fall into the confirmation for optimal packing. Additionally, edge effects from 
the sides of the fluidized bioreactor are considered to be negligible in comparison to the 
size of the bed because the effective diameter of the beads is on the order of millimeters, 
while the diameter of the bed is on the order of meters. More precisely, the equivalent 
spherical diameter of the CytolineTM 1 particles is around 0.912 mm, while the effective 
diameter of the annular fluidized bed is about 1 meter. Therefore, we can negate the 
imperfections in packing due to the walls of the reactor. Perfect packing for smooth 
ellipsoidal particles corresponds to a void fraction of 0.31, but because the CytolineTM 1 
particles are porous, the void fraction is estimated to be slightly higher due to the uneven 
surface of the particle. 
5.6.2. Nutrient Transport in Fluidized Microcarrier Culture 
For microcarrier culture, the normalized gradient between the concentration of 
substrate in the local bulk medium and concentration of substrate at the cell surface is 
given by the expression found in Appendix B. For all substrate analysis, glucose was used 
as the nutrient under investigation. Glucose consumption inside the bioreactor is a good 
indication of cell growth and health—when cells are healthy and the exponential growth 
phase, glucose consumption is relatively simple to model. Experimentally, glucose assays 
are easy and non-cost intensive perform on effluent media samples. Lastly, for the 
purposes of this report, there are many well-documented mass transport parameters 
published for glucose, as opposed to other media components. When typical values were 
substituted for the parameters specific to glucose transport through cell culture media at 
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37oC, the normalized gradient between glucose concentration at the cell surface and in the 
bulk was at a value of approximately 0.01, which is far less than unity. Therefore, it is 
assumed in the fluidized bioreactor model with using microcarrier culture that there exists 
an adequate amount of mass transport between the microcarriers and the medium. It is 
noted that when the same analysis is applied to the packed bed reactor, the normalized 
gradient for glucose between the bulk and the cell surface concentrations is about 0.27, 
which is less than unity but non-negligible. This corresponds to the concentration of 
glucose at the cell surface to be 73% of the glucose concentration in the bulk media. All 
calculations and constants are given in Appendix B. Mass transfer between the 
microcarrier surface and the cell surface is generally not accounted for due to the fact that 
the microcarriers are designed in a manner that minimizes mass transfer resistance.  
5.6.3. Fluidized Bed versus Packed Bed—Nutrient Composition Temporal Analysis 
In order to determine if fluidizing the bed was necessary, an analysis of cell growth 
profiles with fresh substrate influx was conducted, with mass balance equations and 
derivation shown in Appendix C. The novelty behind the fluidized bed reactor is the 
ability to sustain cell concentrations that are about two orders of magnitude greater than 
cell concentrations in traditional stirred tank cultures due to increased surface area and a 
nutrient-replenishing fluidizing stream. In order to determine the efficacy of fluidizing 
the replenishing nutrient stream, glucose consumption was examined inside the three 
different reactor conformations: a fluidized bed reactor, a packed bed reactor, and a batch 
reactor. It it is determined that the bed could be operated at a velocity that is smaller than 
the fluidization velocity determined in section 5.6.1—which would correspond to packed 
bed reactor operations—or without replenishing the nutrients in the reactor at all—
corresponding to batch reactor operations—then the fluidization of the reactor would be 
unnecessary and wasteful in terms of media and energy requirements to operate the 
reactor. For the fluidized bed, the nutrient replenishing stream propagates through the 
reactor at the fluidization velocity dictated earlier in this section. The packed bed is 
characterized by an influx of glucose that is propagating slower than the minimum 
fluidization velocity for all particle sizes (chosen to be 4,430 L/hr). A batch reactor was 
also considered which had neither inflow nor outflow of glucose. 
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There are a few key assumptions that outline the validity of this model. The first 
concerns the contents of the reactor. The media is assumed to have 8 g/L of glucose 
initially and that the reactor has been charged initially with media. The cells are assumed 
to be in exponential growth phase, a protocol that was suggested from the GE 
microcarrier handbook. Because the bed is fluidized and the cells are on microcarriers, it 
is assumed that there is no notable cell loss from the reactor. In the same vein, there is no 
additional cell addition to the reactor other than the growth inside the reactor. Glucose 
consumption is also assumed to be solely due to the metabolic activity of the cells and not 
for product formation. Lastly, we are assuming that all reactor systems are well mixed 
such that there exists no spatial dependence on cell or substrate concentration inside the 
reactor at a given time point. 
The results of this analysis are plotted and shown in Appendix C. The time interval 
considered in this analysis was the total run time of the fluidized bioreactor, 12.8 days. 
The cells were considered nutrient starved when the glucose concentration within the 
reactor was below 4 g/L. The batch reactor was considered nutrient starved after less than 
two days of operation. The cells in the packed bed reactor were considered nutrient 
starved after about 8 days of operation. The fluidized bioreactor maintained a glucose 
concentration of 4.8 g/L after the 12.8 day operating time and was therefore found to be 
able to sustain the cell culture. 
5.6.4. Fluidized Bed v. Packed Bed—Nutrient Consumption Spatial Analysis 
The glucose consumption and cell growth profiles were modeled for a packed bed 
to examine the spatial dependence of nutrient mass transfer to the cells. This analysis is 
conducted in order to determine if the reactor could be operated using a packed bed 
model as opposed to a fluidized bed model.  Running the reactor in a packed bed 
confirmation would decrease media requirements and operational energy requirements, 
and would therefore be more advantageous from a financial standpoint.  In the previous 
section, it was assumed that the concentration of glucose in the reactor was spatially 
independent with regards to the bulk concentration. While this is a good assumption for 
the fluidized bed reactor, it was shown earlier in this report that the normalized gradients 
between the bulk and cell surface concentrations in a packed bed bioreactor is non-
negligible at 0.27. To further explore the spatial nutrient consumption in the packed 
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bioreactor, a simple model was implemented using the Transport of Diluted Species 
(chds) module of the Comsol Multiphysics Software. In order to execute the model, a few 
assumptions are made, like in the temporal analysis of the reactors. The media is assumed 
to have 8 g/L of glucose initially, which corresponds to 44.406 mol/m3 of glucose, in the 
reactor. It is also assumed the reactor is initially charged with media. The cells are 
assumed to be in exponential growth phase, a protocol that was suggested from the GE 
Microcarrier Handbook. Because the bed is fluidized and the cells are on microcarriers, it 
is assumed that there is no notable cell loss from the reactor. Furthermore, there is no 
additional cell addition to the reactor other than the growth inside the reactor. Glucose 
consumption is also assumed to be solely due to the metabolic activity of the cells and not 
for product formation.  
Results from this analysis are plotted in Appendix D. After 60 hours of operation, 
the concentration of glucose over most of the packed bed has dropped to about 20% of its 
original value, creating a nutrient deprived environment in over half of the bed. After 72 
hours, the cells at the bottom of the packed bed fully consume the glucose in the media 
before it can get to any other cell layer in the bed, leaving the majority of the bed nutrient 
deprived.  After 72 hours, the cells are completely nutrient deprived over the majority of 
the bed and would most certainly be dead. Time points shown were determined to show 
when the reactor would be fully nutrient deprived and therefore unable to sustain cell 
growth. In order to meet the monoclonal antibody production goals, the packed bed 
reactor would need to operate for 306 hours, which using the model presented, would 
lead to widespread cell death over the majority of the bed. Therefore, fluidization of the 
microcarrier bed is necessary in order to meet the monoclonal antibody production goals. 
6. Purification Process Description 
After the upstream process, the extracellularly secreted product must be separated from the 
media solution and purified according to FDA standards. Furthermore, each batch of downstream 
purification will be quality checked to ensure quality standards are met and that the generic drug 
matches the brand name formulation of Ritxan®. All following descriptions apply to both 
processes unless otherwise specficied.   
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6.1. Buffer Preparation 
Many downstream operations, such as the chromatography columns, will require various 
buffers for each batch. Buffers will be purchased from GE Healthcare and mixed with WFI in 
disposable containers. Disposable containers will help minimize cross-contamination and 
eliminate any cleaning and sterilization procedures. Once prepared, the pH and conductivities 
of the buffers will be checked and controlled until the buffers are used. If the buffers are 
improperly prepared, they will have to be altered to reach the proper pH.  
6.2. Holding Tank 
For both cases, a large amount of spent media solution (20,000L or more) containing 
product will be recovered at the end of the production step. However, downstream 
purification must be done in smaller batches to accommodate the volume capacity of the 
Protein A column.  
6.2.1. Stirred Tank Bioreactor Process 
For the stirred tank process, the cells will be transferred via a peristaltic pump into 
a holding tank for eventual purification. Then, the approximately 20,000L solution of 
cells, media, and product will proceed downstream in ten batches of 2,000L each.  
6.2.2. Fluidized Bioreactor Process 
Unlike the traditional stirred process, the fluidized bioreactor process will be 
continuous. Therefore, spent media will be continuously collected from the top at a rate 
of 19 cm/min. Approximately 5.7 million liters of spent media and product will have to 
be collected in stored in fifty-eight 50,000L storage tanks. From these tanks, Protein A 
purification will be conducted in two batches. The eluted product will then be processed 
further downstream in two batches.   
6.3. Microcarrier and Cell Disposal 
As a part of downstream processes, after the media solution (containing product) has 
been removed from the fluidized bioreactor, the cells and microcarriers must be disposed 
appropriately. Per batch, 730L of microcarriers and cells will be heat treated to 250°C in 
order to kill the cells. Then, the microcarriers and cells will be disposed according to FDA 
regulations.  
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6.4. Centrifugation 
For the stirred tank bioreactor process, contents of the holding tank are transferred into a 
centrifuge by a peristaltic pump in smaller batch sizes of 10,000L per batch. The centrifuge 
helps remove the product and other components suspended in the media solution from the 
solid biomass and other waste. The centrifuge will operate at a throughput rate of 10,000 
L/hr. The centrifuge is operated at 25°C and has a yield of 98% product with about 2% of 
desired product being discarded in the solid waste stream. Centrifugation for stirred tank 
batches will require a total time of 6 hours including CIP and SIP.  
6.5. Tangential Flow Filtration 
For the fluidized bioreactor process, the media will not have to be separated from the 
cells due to the nature of the setup. Therefore, tangential flow filtration offers a more 
efficient and cost-effective method to perform a primary purification step. TFF helps filter 
large molecular weight aggregates, large proteins, and any remaining cells. The feed (media 
containing product and other particles) is passed tangentially over a membrane in order to 
prevent filter caking. This will be a continuous process but six TFF filters will be used in 
parallel to help reduce the individual operational time of the unit. The feed will be filtered at 
a speed of 5 L/min/m2 and each filter membrane will have a cross sectional area of 1.8m2. In 
the case of the fluidized bioreactor process, the filtration step will require 58 TFF units with a 
cross sectional area of 3.0m2 and about 4.5 days to process the media output of the bioreactor 
and have a 98% yield.  
6.6. Protein A Chromatography 
Protein A Chromatography is the first chromatography column in the downstream 
process. It acts as the first main isolation step for product and isolates the monoclonal 
antibody via affinity chromatography. Therefore, the column is useful in eliminating host cell 
DNA, media components and endogenous viral particles.  
After centrifugation (for the stirred tank bioreactor process) or after tangential flow 
filtration (for the fluidized bioreactor process), the supernatant pH is equilibrated to 7.0 using 
H3PO4. Then, the solution is directly transferred to the Protein A column via a peristaltic 
pump. Before the first batch, the column must be loaded with resin. Then, at the beginning of 
each batch, the column must be equilibrated with 2-3 bed volumes of equilibration buffer 
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(20mM sodium phosphate at pH 7.0). The supernatant from the centrifugation step is then 
directly applied to the column. Then, an intermediate wash step is used with wash buffer 
(containing 0.25M TMAC or 0.25M TEAC) at a pH of 6. Finally, the monoclonal antibody 
product is eluted from the column by washing with elution buffer (25mM sodium citrate) at a 
pH of 2.8. The low pH allowed for the removal of the product from the resin so it could be 
collected in the elution stream. The elution stream will be transferred into a storage tank. 
Finally, the column is then regenerated with 2-3 bed volumes of regeneration buffer. The 
maximum linear flow rate for the column will be about 400 cm/hr. The Protein A column is 
expected to have about 98% product yield. For the stirred tank process, it will require a total 
of 1.5 days to process all input (each input refers to a batch of 2000L of solution). For the 
fluidized bioreactor process, a linear flow rate of 40 cm/min will be used and require 4.5 days 
to process all media input (where each input refers to half of the media output of the fluidized 
bioreactor). These times also account for the sterilization required in between each batch.  
6.7. Cation Exchange Chromatography 
Cation exchange chromatography is used to reduce high molecular weight aggregates, 
charge variants, residual DNA and host cell proteins. Cation exchange uses positively 
charged resin to bind to negatively charged particles (including the product) while positive 
and neutral particles pass through the column.  
Before the first batch, the column must be loaded with resin. Then, before each batch, 
the column must be equilibrated with a buffer (60nM NaCl) at a pH of 5.5 and conductivity 
of 6.5 mS/cm. Then, about 2000L from the holding tank after the Protein A step will be 
transferred into the column from both processes. The first wash buffer is salt free and has a 
pH between 7.0 and 7.8 and conductivity between 0.2 and 2 mS/cm. A second buffer wash is 
performed at pH 5.5 and conductivity between 0.5 and 3.0 mS/cm. Finally, the column is 
eluted to remove the desired product from the resin using elution buffer (160-175mM NaCl) 
at pH 5.5 and a conductivity of 12-20 mS/cm. The eluted stream is transferred to a storage 
tank. Finally, the column is regenerated using regeneration buffer .The maximum linear flow 
rate for the column will be about 400 cm/hr. The column is expected to have about 98% 
product yield. Including sterilization in between batches, it will require about 1-1.5 days to 
process the input into the columns for both processes.  
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6.8. Anion Exchange Chromatography 
Anion exchange chromatography is also used to reduce high molecular weight 
aggregates, charge variants, residual DNA and host cell proteins. Anion exchange uses 
negatively charged resin to bind to positively charged particles while negative particles (such 
as the product) pass through the column. Before each batch, the column must be equilibrated 
with equilibration buffer (20-100mM NaCl) at pH 8.0. The media solution is applied to the 
column in batch sizes of 2000L for both processes. Then, the column is washed with buffer. 
The product is removed in the wash step and stored in a storage tank. Finally, the column is 
washed with elution buffer (1M NaCl) at pH 8.0. Then, the column is regenerated using 
regeneration buffer. The maximum linear flow rate for the column will be about 400 cm/hr. 
The column is expected to have about 98% product yield. Including sterlization in between 
batches, it will require about 1-1.5 days to process all batches for both processes.  
6.9. Viral Nanofiltration 
Viral nanofilration will be used after the anion exchange chromatography step to filter 
the viruses. Viral nanofiltration is a size-based membrane separation in which proteins can 
easily pass through the hollow fiber walls of the membrane while viruses are captured within 
the pores. This type of filtration is dependent upon pressure, flow rate, protein concentration, 
and the ratio of product volume to membrane surface area. First, the filters and unit must be 
flushed thoroughly with WFI. Then, the unit must be equilibrated with equilibration buffer. 
Finally, the sample (in sizes of 2000L for each process) can be loaded and the permeate will 
be collected for further purification. Its recovery rate of monoclonal IgG at 20mg/ml product 
concentration is about 99%. With six units running in parallel, this process will require about 
6 hours for both processes. 
6.10. Ultrafiltration 
After viral inactivation, size-based ultrafiltration is used to remove small viral and 
foreign particles. A filter with a 100kD MWCO will be used to keep the desire product in the 
retentate but allow for smaller particles to be removed. This step will also help concentrate 
the product to a final concentration of about 10 mg/mL. To help decrease the process time for 
the filtration step, six filters will be run in parallel. The process will require about 6 hours 
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where each batch size equals 2000 L for both processes. Its recovery rate of monoclonal 
antibody will be about 96%. 
6.11. Sterile Filtration 
Sterile filtration serves as the last purification step to help remove any final endotoxins 
and also to help concentrate the product to the appropriate concentration. To help decrease 
the process time for the filtration step, six filters will be run in parallel. The process will 
require about 6 hours to process all input (where the input for each process is about 2000L). 
The recovery rate is expected to be about 96%.  
7. Major Unit Operation Specifications 
7.1. Common Units 
7.1.1. Pumps 
A peristaltic pump is used to transfer fluid from throughout the process as 
depicted by the pump icon in the process flow diagrams. The pump can be purchased 
from Watson Marlow and is the 825 Peristaltic Pump. In both the stirred tank and 
fluidized bioreactor processes, the power of the pump ranges from 1.5-5.0 hp. The pumps 
operate at room temperature and a 50 psi (3.5 bar) pressure drop with maximum flow rate 
of 33.3 L/min. The pump will be sterilized and are purchased from Watson Marlow for 
the cost of $13,000 per pump. The same company also offers a variety of pumps with 
maximum flow rates of ~300L/min which will be used for the fluidized bioreactor 
process. Watson Marlow Bioprene sterile tubing is used to transfer the fluid through the 
variety of processes.  
7.1.2. Media Sterilization Filters 
The 0.2 micron filter is used to purify the media by removing any impurities and 
toxins before introduction to the bioreactors. The filter is 30 inches in size and the 
filtration area is 1.8m2 (18ft2). The membrane filter material is Polyethersulfone (PES) 
and operates at room temperature with a max differential pressure of 0.5 bar. The filters 
require a type of housing for security that requires a one-time purchase from Sartorius 
Stedim Biotech for the cost of $2,000. The filters are disposable and replaced after every 
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batch. They are purchased from Sartorious Stedim Bioteach under the model name 
Sartopore 2 for the cost of $650/unit. The filters are disposable so no CIP or SIP will be 
required, but SIP is required for the housing unit.  
7.1.3. Digital Control Unit 
This system is used to control agitation speeds, temperature at 37°C, pH between 
7.0-7.2 and dissolved oxygen at a specified level for all bioreactors in both processes. 
The control units are $300 per unit and are purchased from Vernier Software and 
Technology.  Each unit will control one parameter. A total of 24 control units will be 
needed for all the bioreactors. 
7.2. Inoculum Prep 
7.2.1. Bag Bioreactor (PFD 01/P-02)  
The WAVETM Bioreactor created by GE Life Sciences will be used for the bag 
bioreactors. The WAVETM Bioreactor 2/10EH – electric rocker base comes equipped 
with integrated temperature control and aeration pump. It is an efficient and cost-
effective method for expansion of CHO cells in suspension. The rocking action of the 
base provides continual mixing and oxygen transfer.  For each batch, a new pre-sterilized 
cell bag can be used. The system requires no cleaning or sterilization and helps eliminate 
cross-contamination between batches. Each bioreactor unit for this stage of the process is 
able to hold one 200mL bag. The unit is purchased from GE Healthcare for $16,480. The 
bags are plastic pre-sterilized, single use chambers for non-invasive mixing of fluids 
using the WAVETM rocker. The unit is kept at 37°C, 1 bar, a pH ranging from 7.0-7.2, 
and 50% DO. The process time for this unit is 3.5 days. The 20 disposable bags have 
sensors and ports for oxygen and media and are purchased from GE Healthcare for 
$202.00 per bag.  
7.3. Seed Bioreactor Section (Stirred Tank Process) 
7.3.1. Storage/Mixing Tank (PFD 01/P-03) 
This tank is used to store and mix powder serum-free media with water for 
injection before being filtered and then transferred into the first seed bioreactor. The tank 
will be manufactured from Stainless Steel 316L, has a volume of 150L and a working 
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capacity of 70%. It stands 0.9m tall and is 0.4m in diameter. For sterilization, CIP and 
SIP will be conducted after each batch. The tank operates at room temperature and at 1 
bar. The tank is manufactured by Sharpsville Container and costs $110,000.  
7.3.2. Seed Bioreactor 1 (PFD 01/P-07) 
The first seed bioreactor is the disposable WAVETM 500/1000 bioreactor 
purchased from GE Healthcare. The unit consists of a permanent base used for rocking 
along with disposable cell culture bags. It is stainless steel with dimensions of 
201x124x160 cm. Each bioreactor unit for this stage of the process is able to hold one 
200 L bag. The unit is the GE WAVETM Bioreactor purchased from GE Healthcare for 
$404,500. The bag has a 200L volume with 50% working volume. The 200L bags are 
plastic pre-sterilized, single use chambers for non-invasive mixing of fluids using the 
WAVETM rocker. The unit is kept at 37°C, 1 bar, a pH ranging from 7.0-7.2, and 50% 
DO. The pH, temperature, and oxygen levels will be controlled with PID controls. The 
process time for this unit is 4 days. The plastic disposable bags have sensors and ports for 
oxygen and media and are purchased from GE Healthcare for $1,200 per bag.  
7.3.3. Storage/Mixing Tank (PFD 01/P-09) 
This tank is used to store and mix powder serum-free media with water for 
injection before being filtered and then transferred into the second seed bioreactor. The 
tank will be manufactured from Stainless Steel 316L, has a volume of 1,500L and a 
working capacity of 70%. Its height is 2.3m and its diameter 0.9m. For sterilization, CIP 
and SIP will be conducted after each batch. The tank operates at room temperature and at 
1 bar. The tank is manufactured by Sharpsville Container and costs $120,000. 
7.3.4. Seed Bioreactor 2 (PFD 01/P-13) 
The second seed bioreactor is another disposable bag bioreactor from GE 
Healthcare. The unit is the XDR-50 to 2000 Single Use Bioreactor and provides use with 
working culture volume up to 2,000L. The unit consists of a permanent base used for 
rocking along with disposable cell culture bags. Each bioreactor unit for this stage of the 
process is able to hold one 2,000L bag. The unit is purchased from GE Healthcare for 
$600,000. The bag has a 2,000L volume with 50% working volume. The 2000 L bags are 
plastic pre-sterilized, single use chambers for non-invasive mixing of fluids using the 
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WAVETM rocker. The unit is kept at 37°C, 1 bar, a pH ranging from 7.0-7.2, and 50% 
DO. The pH, temperature, and oxygen levels will be controlled with PID controls. The 
process time for this unit is 4 days. The plastic disposable bags have sensors and ports for 
oxygen and media and are purchased from GE Healthcare for $1,800 per bag.  
7.4. Seed Bioreactor Section (Fluidized Process) 
7.4.1. Storage/Mixing Tank (PFD-03/P-03) 
This tank is used to store and mix powder serum-free media with water for 
injection before being filtered and then transferred into the first seed bioreactor. The tank 
will be manufactured from Stainless Steel 316L, has a volume of 150L and a working 
capacity of 70%. It stands 0.9m tall and is 0.4m in diameter. For sterilization, CIP and 
SIP will be conducted after each batch. The tank operates at room temperature and at 1 
bar. The tank is manufactured by Sharpsville Container and costs $110,000. The outflow 
from the tank will be split into three equal streams into three seed bioreactors running in 
parallel.  
7.4.2. Seed Bioreactors in Parallel (PFD 03/P-07) 
The first set of seed bioreactors involves three disposable bag bioreactors in 
parallel. Each has a 70L bag volume with a 33.3L working volume. The bioreactors are 
the disposable WAVETM 500/1000 bioreactor purchased from GE Healthcare. The unit 
consists of a permanent base used for rocking along with disposable cell culture bags. It 
is stainless steel with dimensions of 201x124x160 cm. Each bioreactor unit for this stage 
of the process is able to hold one 70L bag. The unit is the GE WAVETM Bioreactor 
purchased from GE Healthcare for $404,500. The bag has a 70L volume with 50% 
working volume. The unit is kept at 37°C, 1 bar, a pH ranging from 7.0-7.2, and 50% 
DO. The pH, temperature, and oxygen levels will be controlled with PID controls. The 
process time for this unit is 5 days. The plastic disposable bags have sensors and ports for 
oxygen and media and are purchased from GE Healthcare for $1,000 per bag.  
7.4.3. Storage/Mixing Tank  (PFD 03/P-09) 
This tank is used to store and mix powder serum-free media with water for 
injection before being filtered and then transferred into the second seed bioreactor. The 
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tank will be manufactured from Stainless Steel 316L, has a volume of 1,500L and a 
working capacity of 70%. Its height is 2.3m and its diameter 0.9m. For sterilization, CIP 
and SIP will be conducted after each batch. The tank operates at room temperature and at 
1 bar. The tank is manufactured by Sharpsville Container and costs $120,000. 
7.4.4. Second Seed Bioreactor (PFD 03/ P-13) 
The second seed bioreactor is another disposable bag bioreactor from GE 
Healthcare. The unit is the XDR-50 to 2000 Single Use Bioreactor and provides use with 
working culture volume up to 2,000L. The unit consists of a permanent base used for 
rocking along with disposable cell culture bags. Each bioreactor unit for this stage of the 
process is able to hold one 2,000L bag. The unit is purchased from GE Healthcare for 
$600,000. The bag has a 2,000L volume with 50% working volume. The 2000L bags are 
plastic, pre-sterilized, single use chambers for non-invasive mixing of fluids using the 
WAVETM rocker. The unit is kept at 37°C, 1 bar, a pH ranging from 7.0-7.2, and 50% 
DO. The pH, temperature, and oxygen levels will be controlled with PID controls. The 
process time for this unit is 5.5 days. The plastic disposable bags have sensors and ports 
for oxygen and media and are purchased from GE Healthcare for $1,800 per bag.  
7.5. Production Section 
7.5.1. Storage/Mixing Tank (PFD 01/ P-15 & P-19) 
This tank is used to store and mix powder serum-free media with water for 
injection before being filtered and then transferred into the third tank bioreactor. The tank 
will be manufactured from Stainless Steel 316L, has a volume of 10,000L and a working 
capacity of 70%. Its height is 3.5m and its diameter is 2.0m. For sterilization, CIP and 
SIP will be conducted after each batch. The tank operates at room temperature and at 1 
bar. The tank is manufactured by Sharpsville Container and costs $130,000. There are 
two of these media storage tanks for a total of 20,000L. 
7.5.2. Stirred Tank Bioreactor (PFD 01/ P-23) 
The production stirred tank bioreactor is a stainless steel jacketed bioreactor 
purchased from Techniserv Inc (SCAL-TECH Products). It has a 25,000L volume with a 
height of 5.0m and a diameter of 2.5m. Following each batch, CIP and SIP is used to 
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sterilize the unit. The pH, temperature and oxygen levels will be controlled with PID 
controls and will run for 16 days. The bioreactor operates at 37°C and about 1.5-2 bar. 
The bioreactor will be bought for $900,000.  
7.5.3. Storage/Mixing Tank (for fluidized bioreactor) (PFD 03/ P-15 & P-19) 
This tank is used to store and mix powder serum-free media with water for 
injection before being filtered and then transferred into the last holding tank. As soon as 
media is mixed, it will be filtered and fed to the following storage tank before a new 
batch of media is mixed. This process will continue in order to meet the media 
requirement for the fluidized bioreactor. The tank will be manufactured from Stainless 
Steel 316L, has a volume of 10,000L and a working capacity of 70%. Its height is 3.5m 
and its diameter is 2.0m. For sterilization, CIP and SIP will be conducted after each 
batch. The tank operates at room temperature and at 1 bar. The tank is manufactured by 
Sharpsville Container and costs $130,000. 
(Note: There are two of these media storage tanks for a total of 20,000L.) 
7.5.4. Media Storage Tank (for fluidized bioreactor) (PFD 03/ P-23) 
This tank is used to store the media before it enters the fluidized bioreactor. This 
unit has a volume of 50,000L, with a height of 6.0m and a diameter of 3.25m. Media 
from the mixing tanks (PFD 03/ P-15 & P-19) is fed to this storage tank and the fed to the 
fluidized bioreactor. As media is being transferred from the storage tank to the bioreactor, 
media from the mixing tanks is also being transferred to the storage tank. As previously 
stated, this continuous media transfer process is used in order to meet the total media 
requirement of 5.7 million liters for the fluidized bioreactor. For sterilization, CIP and 
SIP will be conducted after each batch. It will be purchased from Sharpsville Container 
for a cost of $165,000.  
7.5.5. Fluidized Bioreactor (PFD 03/P-25) 
The fluidized bioreactor is the GE Healthcare CytopilotTM Production Bioreactor. 
It has a 25,000L volume and annular shape. Following each batch, CIP and SIP is used to 
sterilize the unit. The pH, temperature and oxygen levels will be controlled with PID 
controls and will run for 13 days. The bioreactor operates at 37°C, about 1 bar, and DO 
of 30%. The bioreactor will be bought for $1,500,000.  
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7.6. Downstream Purification 
7.6.1. Holding Tank (Stirred Tank Process) (PFD-03/P-25) 
The holding tank is used to store the output from the production process so that 
smaller batches can be sent downstream for purification. The unit has a volume of 
25,000L with 80% capacity. It has a height of 5.0m and a diameter of 2.5m. For 
sterilization, CIP and SIP will be conducted after each batch. It will be purchased from 
Sharpsville Container for a cost of $145,000.  
7.6.2. Holding Tank (Fluidized Process) (PFD-04/P-27) 
The holding tank is used to store the output for the production process so that 
smaller batches can be sent downstream for purification.  It has a volume of 50,000L with 
80% capacity. The tank has height of 6.0m and a diameter of 3.25m. The material is 
Stainless Steel 316L with an electro-polished finish. It will be purchased from Sharpsville 
Container and costs $165,000. 
7.6.3. Tangential Flow Filtration Unit (PFD 04/ P-29) 
  In the fluidized bioreactor process, the contents of the production bioreactor must 
be separated and the TFF unit allows the product or feed to flow directly tangentially 
along the surface of the membrane. The unit is purchased from Pall Corporation and each 
unit costs $500,000. The model is the Cadence Single Pass TFF System and is Stainless 
Steel 316L with an electro-polished finish. It operates between 4-40°C, from 4-6 bar and 
pH between 2-13. The flow range is between 6-1000 L/h.  
7.6.4. TFF Holding Tank  (PFD 04/ P-31) 
The holding tank is used to store the output from the TFF unit so that batches can 
be sent downstream for purification. The unit has a height of 6.0m, a diameter of 3.25m, 
and a volume of 50,000L with 80% capacity. It will be purchased for $165,000 from 
Sharpsville Container.  
7.6.5. Centrifuge (PFD 02/P-27) 
In the stirred tank bioreactor process, the contents of the production bioreactor 
must be separated into a solid waste stream and liquid stream containing the desired 
product. A hermetic disc-stack centrifuge produced by Alfa Laval is used. The 
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Culturefuge 400 model, constructed with Stainless Steel 316L, can be purchased from 
Alfa Laval for $480,000. The centrifuge’s throughput flow rate is 10,000 L/h. The unit 
operates at 25°C. CIP and SIP is used to sterilize the unit after each batch.  
7.6.6. Centrifuge Holding Tank (PFD 02/P-29) 
The centrifuge holding tank is used to store the output from the centrifuge unit so 
that batches can be sent downstream for purification. The unit has a height of 5.0m, a 
diameter of 2.5m, and a volume of 25,000L with 80% capacity. For sterilization, CIP and 
SIP will be conducted after each batch. It will be purchased from Sharpsville Container 
for a cost of $145,000.  
7.6.7. Protein A Chromatography Column (PFD 02 & 04/P-31 & P-33) 
The Protein A affinity chromatography column is used to further purify the 
mainstream fluid to help isolate the product. The Chromaflow 2000/100-300 column will 
be purchased from GE Healthcare for $200,000. The column is made of Stainless Steel 
316L. The column is packed with nProtein A Sepharose 4 Fast Flow resin (distributed by 
GE Healthcare). The bed (portion of column occupied by resin) will be sized at a bed 
height of 0.5m and diameter of 2.54m. The bed volume is 2000L. The resin has a binding 
capacity of 50 mg/ml. The resin has a working velocity of 30-400 cm/h. The resin will 
flow through the column at 40 cm/min for the fluidized bed. The column is operated at 
4°C, at 1 bar. The cost of the column is $200,000 and the resin is $8,000 per liter.  
7.6.8. Protein A Holding Tank (PFD 02 & 04 / P-33 & P-35) 
The Protein A holding tank is used to store the output from the Protein A column. 
The unit has a height of 3.0m, a diameter of 1.5m, and a volume of 5,000L with 80% 
capacity. For sterilization, CIP and SIP will be conducted after each batch. It will be 
purchased from Sharpsville Container for a cost of $122,000.  
7.6.9. Cation Exchange Chromatography Column (PFD 02 & 04/ P-35 & P-37) 
The cation exchange chromatography column is used to further purify the 
mainstream fluid to help isolate the product. The Chromaflow 1000 column will be 
purchased from GE Healthcare for $250,000. The column is made of Stainless Steel 
316L. The column is packed with Eshmuno S resin (distributed by EMD Millipore). The 
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bed (portion of column occupied by resin) will be sized at a height of 0.5m and diameter 
of 2.54m. The resin has a binding capacity of  greater than 60 mg antibody/mL media and 
a working velocity of up to 800 cm/hr. The column is operated at 25°C, at 1 bar. The cost 
of the column is $250,000 and the resin is $1,500 per liter.  
7.6.10. Cation Exchange Holding Tank (PFD 02 & 04 / P-37 & P-39) 
The cation exchange holding tank is used to hold and mix product from cation 
exchange chromatography with buffer solutions in preparation for anion exchange 
chromatography. The unit has a height of 3.0m, a diameter of 1.5m, and a volume of 
5,000L with 80% capacity. For sterilization, CIP and SIP will be conducted after each 
batch. It will be purchased from Sharpsville Container for a cost of $122,000.  
7.6.11. Anion Exchange Chromatography Column (PFD 02 & 04/ P-39 & P-41) 
The anion exchange chromatography column is used to further purify the 
mainstream fluid to help isolate the product. The Chromaflow 1000 column will be 
purchased from GE Healthcare. The column is made of Stainless Steel 316L 
electroporated. The column is packed with Capto Q resin (GE Healthcare). The bed 
(portion of column occupied by resin) will be sized at a height of 0.5m and diameter of 
2.54m. The bed volume is 2,000L. The resin has a binding capacity of greater than 100 
mg antibody/mL medium and a working velocity of 700 cm/hr. The column is operated at 
25°C, at 1 bar. The cost of the column is $250,000 and the resin is $1,800 per liter.  
7.6.12. Anion Exchange Holding Tank (PFD 02 & 04/ P-41 & P-43) 
The anion exchange holding tank is used to collect the product from the anion 
exchange column. The unit has a height of 5.0m, a diameter of 2.5m, and a volume of 
25,000L with 80% capacity. For sterilization, CIP and SIP will be conducted after each 
batch. It will be purchased from Sharpsville Container for a cost of $145,000.  
7.6.13. Viral Nanofiltration Unit (PFD 02 & 04/ P-43& P-45) 
The viral filtration unit will be purchased from AsahiKasei Bioprocess. The 
Planova BioEX membrane is effective against enveloped and non-enveloped viruses as 
small as 18nm while allowing proteins as large as 200kD to pass through without 
denaturing. This membrane is ideal for our 145kD product. The unit consists of a 
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permanent virus filtration controller along with disposable filters. The unit can handle up 
to 5000L of volume at for each batch run. The MW cutoff for this filter is 200kD and the 
protein throughput is 6.5 kg/m2 per 3 hours. The filter effective surface area is 1.8m2 and 
the suggested operating pressure is less than 343 kPa. The filter housing can be purchased 
from AsahiKasei Bioprocess for $15,000 and will be SIP sterilized. The membrane filters 
are disposable and cost $2,000 per filter.  
7.6.14. Ultrafiltration Unit (PFD 02 & 04/ P-45 & P-47) 
The ultrafiltration unit will be purchased from Pall Corporation. The membrane 
has a MW cutoff of 100kD. The unit consists of a permanent base along with disposable 
filters. The material of the disc filters is Omega Polyethersulfone and the filter has an 
effective surface area of 1.8m2. The housing unit will be sterilized through SIP. The filter 
housing and membranes are purchased from Pall Corporation and cost 12,000 per 
housing unit and $1,000 per filter membrane.  
7.6.15. Final Sterile Filtration Unit (PFD 02 & 04/ P-47 & P-49) 
The final sterile filtration unit will be purchased from Sartorious Biotech. The 
Sartopore 2 membrane has a pore size of 0.2 micron and the filter material is 
Polyethersulfone. The filtration area is 1.8m2 and the max differential pressure is 5 bar at 
20°C. The unit consists of a permanent base along with disposable filters. The hosing 
membrane unit sterilization is SIP and the membranes are disposable. The housing unit 
costs $2,000 and the filter membranes cost $650/unit.  
7.7. Additional Downstream Separation (Fluidized Bioreactor Process) 
7.7.1. High Temperature Inactivation (PFD 05/ P-52) 
An industrial size autoclave can be purchased from WSF Industries Inc. This unit 
serves to kill the cells attached to the microcarriers in order to allow for safe disposal. 
The unit is made of Stainless Steel 316L with an electro-polished finish. For sterilization, 
CIP and SIP will be conducted after each batch. The autoclave will operate at 25°C. The 
cost of this unit is $500,000.   
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8. Additional Equipment Description 
Additional costs will need to be considered for equipment not depicted in the process flow 
diagrams. These items help maintain good manufacturing practices. Since we are working at a 
refurbished green site, the site is equipped with many of these individual operations and 
processes so some of the equipment expenses are added to the annual expenses. Individual prices 
for the equipment are not needed because it does not have to be bought. Some equipment will 
have to be bought and the price will be included. A summary of these costs can be found in 
Section 10.   
8.1. Biosafety Cabinet  
Three biosafety cabinets will be required to provide a sterile environment to handle and 
transfer the vial of cells into the bag bioreactors in the inoculum prep section. The biosafety 
cabinet is manufactured by Thermo ScientificTM. The biosafety cabinets will already be in the 
plant and the costs will be included in the annual expenses.  
8.2. Cell Bank 
Though out of scope of this project, a cell bank will be required to provide the initial 
inoculum for the inoculum prep sections. The cell bank will store optimized recombinant 
CHO cells designed to produce rituximab and be created in a clean lab. These cells will be 
cultured and grown to a final cell density of 1x108 cells/mL and aliquoted into 2mL vials. 
Before either facility begins operation, a cell bank will be created to sustain the inoculum 
requirements with more cells being added to the cell bank as needed.  
8.3. Air Generator (HVAC Equipment)  
Purified air will be the source of oxygen throughout the process and will be provided by 
an HVAC system. The system will supply clean air to bioreactors, clean rooms, and other 
process equipment. The air generator will be in the plant and the costs will be included in the 
annual expenses.  
8.4. Clean Steam Generator  
The clean steam generator is used to produce steam from WFI for SIP procedures. The 
clean steam generator will already be in the plant and the costs will be included in the annual 
expenses.  
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8.5. CIP Skids  
Clean-In-Place (CIP) is a technique used to clean equipment. A CIP skid is portable and 
contains the cleanings solutions and equipment necessary. In order to clean all the unit 
operations and storage tanks, ten CIP skids will be needed for this process. They will be 
manufactured by Sani-matic and each will cost about $100,000.  
8.6. Buffer Transfer Bags  
Buffer transfer bags are used to transfer media or buffer to appropriate unit operations. 
These disposable bags and bag holders are manufactured by HyClone and will cost 
approximately $70,000 a year.  
8.7. Filter Integrity Tester  
Though disposable filters are used throughout the process, they must be tested before 
each use to assure they are not clogged, torn or general unusable. The filter integrity tester 
from Millipore and is in the plant so the costs will be included in the annual expenses.   
8.8. Tube Fuser and Sealer  
At various times in the process, a tube fuser will be necessary to connect tubing between 
disposable and permanent process equipment such as buffer transfer steps or filtration steps. 
A tube sealer is also necessary to seal any plastic tubing to prevent leaks in bags during 
transport. The Sartorius Stedim Biotech’s Sterile Tube Fuser is a fully automatic device that 
cuts and fuses tube ends together to ensure sterility. The tube fuser and sealer are in the plant 
and the costs will be included in the annual expenses.  
8.9. Water Treatment Package  
Though WFI will be used for most of the water requirements in the process, U.S. 
Pharmacopeia (USP) grade water is needed for temperature control needs in the bioreactor 
process. This water will not be in contact with the cell culture suspension, but inserted into 
the stainless steel bioreactor jackets for cooling. The cost for the water treatment package is 
included in the annual expenses.  
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8.10. WFI Still  
The WFI still is used to purify water produced for the water treatment package for use 
with cell culture. WFI is used to ensure sterility of not only the product but also of the 
process equipment to help eliminate cross-contamination issues. The still is manufactured by 
the Paul Mueller Co. The WFI still will already be in the plant and the costs will be included 
in the annual expenses.  
8.11. Biowaste and Neutralization Tanks  
All biowaste produced in the process will have to be treated appropriately before 
disposal. All waste potentially containing live culture is sent to the biowaste tank. All other 
waste, such as used buffers, is sent directly to a neutralization tank. Approximately 178L of 
cells are coming out of the tank bioreactor process. The neutralization tank will need to be 
about 125,000L so five 25,000L tanks will be used. The tanks can be bought from 
Sharpsville Container for $145,000 each. 
A facility will be contracted out to help dispose of the non-liquid waste. This non-
liquid waste includes the disposable WAVETM bags and other disposable products. The 
disposable bags and all their parts are mainly made from plastics that are derived from 
petroleum. Current recycling concepts are focused on incineration in outsourced power plants 
to recover the energy from the petroleum. The costs of the outsourcing will also be added to 
the annual expenses.  
8.12. Biowaste Inactivation System  
This system is needed to kill any live mass remaining in the biowaste tank. This 
includes all CIP and SIP washes, from the main bioreactors and primary recovery. The 
biowaste inactivation system is in the plant and costs will be included in the annual expenses.  
8.13. Waste Neutralization System  
The waste neutralization system is needed to adjust the pH of cell-free waste to 7.0. 
Then, the waste can be disposed directly into the sewer line. This allows the wastes to be sent 
to the sewer. The waste neutralization system is in the plant and the costs will be included in 
the annual expenses.  
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8.14. Quality Control Lab 
  A quality control lab will review the quality of all factors involved in production. In 
the quality control lob, a set of procedures will be performed to ensure that the manufactured 
product adheres to a defined set of quality criteria. The costs of this lab will be included in 
the annual expenses.  
8.15. Laboratory Information Management System (LIMS)  
The Laboratory Information Management system (LIMS) is software that is used to 
manage a laboratory. It manages samples, users, instruments, and many laboratory functions. 
The LIMS unit will already be in the plant and the costs will be included in the annual 
expenses.  
8.16. Portable Pump on Cart  
In the case of pump malfunction, three extra pumps will be stored on portable carts as 
a replacement. An extra Watson-Marlow 825 pump and a cart will cost $13,000 each. 
8.17. Refrigeration 
Freezing of the monoclonal antibody is necessary to keep the product stable for as 
long as possible. Effective temperatures for long term storage range from -20°C to - 80°C. 
The freezing is done using an ultra cold freezer, which can reach temperatures up to - 85°C. 
The freezer can hold up to 1050L (or 21 bags). Manufactured by Thermo ScientificTM, the 
two freezers are a part of the plant and the costs are included in the annual expenses.  
8.18. Final Packaging  
The final output of the purification process will not have ready-to-administer product. 
The product will be shipped out to a facility that can add the proper fillers for storage and 
stability and ship the product to the necessary destinations. Final packaging, including both 
shipping and lyophilization, and will be performed by Quality BioResources, Inc. This 
process costs $280,000 per batch. 
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9. Unit Specification Sheets 
9.1. Stirred Tank Bioreactor Process 
Bag Bioreactor (PFD 01/P-02) 
 
Description and Function  
To prepare the inoculum for seed bioreactor. An electric rocker base, 
with integral temperature control, weight controllers for perfusion 
culture, aeration pump, pH probe, and various rocking speeds is used 
along with 200mL Cellbag bioreactor chambers. The bags are plastic 
pre-sterilized, single-use chambers for non-invasive mixing of fluids 
using the WAVETM rocker. 
Vendor GE Healthcare  
 
PFD Reference 
 
 
PFD #01 
 
 
Operation 
 
Batch 
Materials Handled 
 Input (kg/Batch) Output (kg/Batch) 
Cells 0.00524 0.0262 
Media 0.002 0 
Water 0.098 0.098 
Endotoxin 0 0 
Product 0 0 
 
 
 
Characteristics 
 
Model:                              GE Healthcare WAVETM Base 2/10EH 
Construction:                    High quality stainless steel and aluminum 
Bag Bioreactor:                Cellbag 200mL Bioreactor Chamber 
Sterilization:                     Plastic Disposable Bags   
 
 
Operations Conditions 
 
 
 
Temp:                                        37 ̊ C                 
Pressure:                                    1 bar 
pH:                                             7.0 – 7.2 
DO:                                            50% 
Duration:                                    3.5 days 
Purchase Cost 
 
Rocker and Control Unit:                          $ 16,480 
200 mL Cellbag Bioreactor Chamber:      $ 202.00 per bag (need 20) 
PI control for pH, Temp, DO, Flow Rate, Volume, and Pressure:     
                                                                   $ 2,500/control = $12,500 
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Media Prep (PFD 01/P-03) 
 
Description and Function  Tank used to store and mix powdered serum free media with water 
for injection prior to being pumped through a sterile filter. 
 
Vendor 
 
Sharpsville Container 
 
 
PFD Reference 
 
 
PFD #01 
 
 
Operation 
 
 
Batch 
 
 
 
 
Materials Handled 
 
Input Quantity 
(L) 
Output Quantity 
(L) 
Dry Powder Media 0.2 Media Solution 98.00 
Water 97.8   
    
    
    
 
 
 
 
Characteristics 
 
Material of Construction:                 Stainless Steel 316L 
Finish:                                               Electro-polish finish 
Volume:                                            150L 
Height:                                              0.9m 
Diameter:                                          0.4m 
Sterilization:                                     SIP/CIP 
 
 
 
Operations Conditions 
 
 
 
Temp:                                               25°C         
Pressure:                                           1 bar 
 
Purchase Cost 
 
Storage Tank:                        $ 110,000 
PI control for pH, Temp, DO, Flow Rate, Volume, and Pressure:     
                                               $ 2,500/control = $12,500 
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Seed Bioreactor (PFD 01/P-07) 
 
Description and Function  
Bioreactor used for continued cell growth and production of 
monoclonal antibodies. The WAVETM Bioreactor 500/1000 is a self-
contained system with integral temperature control, aeration pump, 
and rocking controller for use with working culture volumes between 
50L and 500L. The 200L bags are plastic pre-sterilized, single-use 
chambers for non-invasive mixing of fluids using the WAVETM 
bioreactor. 
Vendor 
 
GE Healthcare  
 
 
PFD Reference 
 
 
PFD #01 
 
 
Operation 
 
 
Batch 
 
Materials Handled 
 
 Input (kg/Batch) Output (kg/Batch) 
Cells 0.52 3.04 
Media 2 0 
Water 98 98 
Endotoxin 0 0.81 
Product 0 0.02 
   
 
Characteristics 
 
Model:                    GE Healthcare WAVETM Bioreactor 500/1000  
Construction:         Stainless Steel 316L   
Finish:                    Electro-polished  
Dimensions:          201x124x160cm 
Bag Bioreactor:     Cellbag 200L Bioreactor Chamber 
Sterilization:          Plastic Disposable Bags   
 
 
 
Operations Conditions 
 
 
 
Temp:                                         37 ̊ C                 
Pressure:                                     1 bar 
pH:                                              7.0 – 7.2 
DO:                                             50% 
Duration:                                     4 days 
 
Purchase Cost 
 
WAVETM Bioreactor system:                                   $ 404,500 
200 L Cellbag Bioreactor Chamber:                  $ 1,200 per bag  
PI control for Temp, pH, DO, Flow Rate, and Volume:     
                                               $ 2,500/control = $10,000 
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Media Prep (PFD 01/P-09) 
 
Description and Function  Tank used to store and mix powdered serum free media with water 
for injection prior to being pumped through a sterile filter. 
 
Vendor 
 
Sharpsville Container 
 
 
PFD Reference 
 
 
PFD #01 
 
 
Operation 
 
Batch 
 
 
Materials Handled 
 
Input Quantity (L) Output Quantity (L) 
Dry Media 
Powder 
18.00 Media 
Solution 
900.0 
Water 882.0   
    
 
 
 
Characteristics 
 
Material of Construction:                 Stainless Steel 316L 
Finish:                                               Electro-polished  
Volume:                                            1500L 
Height:                                              2.3m 
Diameter:                                          0.9m 
Sterilization:                                     SIP/CIP 
 
 
 
 
 
Operations Conditions 
 
 
 
 
Temp:                                               25°C         
Pressure:                                           1 bar  
 
 
 
Purchase Cost 
 
Storage Tank:                               $ 120,000 
PI control for pH, Temp, DO, Flow Rate, Volume, and Pressure:     
                                                      $ 2,500/control = $12,500 
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Seed Bioreactor (PFD 01/P-13) 
 
Description and Function  
Bioreactor used for continued cell growth and production of 
monoclonal antibodies. The XDR 2000 Single-Use Bioreactor offers 
a smooth transfer from development to manufacturing scale. It has 
robust industrial automation with an aeration pump. It provides 
exacting temperature control for use with working culture volumes 
up to 2000L. The 2000L bags are plastic pre-sterilized, single-use 
chambers for non-invasive mixing of fluids using the XDR 
bioreactor.  
Vendor 
 
GE Healthcare  
 
 
PFD Reference 
 
PFD #01 
 
Operation 
 
 
Batch 
 
Materials Handled 
 
 Input (kg/Batch) Output (kg/Batch) 
Cells 3.04 15.21 
Media 20 0 
Water 980 980 
Endotoxin 0.81 4.06 
Product 0.02 0.16 
   
 
Characteristics 
 
Model:                                XDR-2000 Single-Use Bioreactor  
Construction:                      Jacketed stainless steel vessel  
Bag Bioreactor:                  Cellbag 2000 L Bioreactor Chamber 
Sterilization:                       Plastic Disposable Bags   
 
 
 
Operations Conditions 
 
 
 
Temp:                                        37 ̊ C                 
Pressure:                                    1 bar 
pH:                                             7.0 – 7.2 
DO:                                            50% 
Duration:                                    4 days 
Purchase Cost 
 
WAVETM Bioreactor system:                                   $ 600,000 
2000 L Cellbag Bioreactor Chamber:                $1,800 per bag  
PI control for pH, Temp, DO, Flow Rate, Volume, and Pressure:     
                                               $ 2,500/control = $12,500 
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Media Prep (PFD 01/P-15) 
 
Description and Function  Tank used to store and mix powdered serum free media with water 
for injection prior to being pumped through a sterile filter. 
 
Vendor 
 
Sharpsville Container 
 
 
PFD Reference 
 
 
PFD #01 
 
 
Operation 
 
 
Batch 
 
 
 
 
Materials Handled 
 
Input Quantity (L) Output Quantity (L) 
Dry Media 
Powder 
190.0 Media 
Solution 
9500.0 
Water 9310.0   
    
    
 
 
 
Characteristics 
 
Material of Construction:                 Stainless Steel 316L 
Finish:                                              Electro-polished  
Volume:                                           10,000L  
Height:                                              3.5m 
Diameter:                                          2.0m 
Sterilization:                                     SIP/CIP 
 
 
 
 
 
Operations Conditions 
 
 
 
Temp:                                               25°C         
Pressure:                                           1 bar  
 
 
 
Purchase Cost 
 
Storage Tank:                        $ 130,000   
PI control for pH, Temp, DO, Flow Rate, Volume, and Pressure:     
                                               $ 2,500/control = $12,500 
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Media Prep (PFD 01/P-19) 
 
Description and Function  Tank used to store and mix powdered serum free media with water 
for injection prior to being pumped through a sterile filter. 
 
Vendor 
 
Sharpsville Container 
 
 
PFD Reference 
 
 
PFD #01 
 
 
Operation 
 
 
Batch 
 
 
 
 
Materials Handled 
 
Input Quantity (L) Output Quantity (L) 
Dry Media 
Powder 
190.0 Media 
Solution 
9500.0 
Water 9310.0   
    
    
 
 
 
Characteristics 
 
Material of Construction:                 Stainless Steel 316L 
Finish:                                              Electro-polished  
Volume:                                           10,000L  
Height:                                              3.5m 
Diameter:                                          2.0m 
Sterilization:                                     SIP/CIP 
 
 
 
Operations Conditions 
 
 
 
Temp:                                               25°C         
Pressure:                                           1 bar  
 
 
 
Purchase Cost 
 
Storage Tanks:                       $ 130,000  
PI control for pH, Temp, DO, Flow Rate, Volume, and Pressure:     
                                               $ 2,500/control = $12,500 
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Production Bioreactor (PFD 01/P-23) 
 
Description and Function  
Bioreactor used for continued cell growth and production of 
monoclonal antibodies. The final bioreactor serves to maximize 
product formation. Utilizes state-of-the-art bus technologies and 
supports process analytical technology (PAT). 
 
Vendor 
 
Techniserv, Inc (SCAL-TECH Products) 
 
 
PFD Reference 
 
 
PFD #01 
 
 
Operation 
 
 
Batch 
 
Materials Handled 
 Input (kg/Batch) Output (kg/Batch) 
Cells 6.73 356.32 
Media 400 0 
Water 19600 19600 
Endotoxin 4.056 36.34 
Product 0.16 9.41 
   
 
Characteristics 
 
Model:                                         SCAL-TECH Pro Suites Bioreactor  
Finish:                                          Electro-polished  
Volume:                                       25,000L  
Height:                                         5.0m 
Diameter:                                     2.5m 
Sterilization:                                SIP/CIP 
 
 
 
 
Operations Conditions 
 
 
 
Temp:                                        37 ̊ C                 
Pressure:                                    1 bar 
pH:                                             7.0 – 7.2 
DO:                                            50% 
Duration:                                   16 days 
 
Purchase Cost 
 
Bioreactor:                                                         $900,000 
PI control for pH, Temp, DO, Flow Rate, Volume, and Pressure:     
                                              $ 2,500/control = $12,500 
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Media Prep Sterile Filtration (PFD 01/P-05, P-11, P-17, P-21) 
 
 
 
Description and Function  
0.2 µm dead end filter to remove bacteria and other impurities from 
the serum free media prior to feeding the cultivators and production 
bioreactor. The sanitary stainless steel filter housings are designed 
for filtration applications. The filter capsules membranes are 
disposable ready-to-use filter or depth filter capsules. 
 
Vendor 
 
Sartorious Stedim Biotech 
 
 
PFD Reference 
 
 
PFD #01 
 
 
Operation 
 
 
Batch 
 
 
 
 
 
Characteristics 
 
Model:                                               Sartopore 2 0.2 µm 
Membrane Filter Material:                Polyethersulfone (PES) 
Size:                                                   30” 
Filtration Area:                                  1.8m2 (18ft2) 
Max. Differential Pressure:               5 bar (75 psi) at 20 °C 
Membrane Unit Sterilization:            SIP 
Membrane Sterilization:                    Disposable  
 
 
 
 
Operations Conditions 
 
 
 
Temp:                                               25°C         
Pressure:                                           0.5 bar (7.5 psi) 
 
 
 
 
Purchase Cost 
 
Filter Housing:        $ 2,000 
Filter Membrane:    $ 650/unit 
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Pump (PFD 01 & 02/P-04, P-06, P-08, P-10, P-12, P-14, P-16, P-18, P-20, P-22, P-24, P-26, 
P-28, P-30, P-32, P-34, P-36, P-38, P-40, P-14, P-42, P-44, P-46, P-48)  
 
 
Description and Function  
Pump to transfer fluid. High-flow hygienic pumps that are designed 
for low-shear sanitary pumping. They are ideal for viscous or shear 
sensitive products. 
 
Vendor 
 
Watson-Marlow 
 
 
PFD Reference 
 
 
PFD #01 and #02 
 
 
Operation 
 
 
Batch 
 
 
 
Characteristics 
 
Model:                                              825 Peristaltic Pump 
Material Construction:                     304 Stainless Steel 
Flow Rate:                                        33.3 L/min 
Max Pressure:                                   3.5 bar    
Tubing:                                             Sterilized Bioprene, 40mm 
Sterilization  
 
 
 
Operations Conditions 
 
 
 
Temp:                                                25°C         
Pressure Change:                               50 psi (3.5 bar) 
Power:                                               1.5 – 5.0 hp 
 
 
Purchase Cost 
 
825 Peristaltic Pump:           $13,000 
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Storage Tank (PFD 02/P-25) 
 
Description and Function  To store output from production bioreactor before being centrifuged. 
 
Vendor 
 
Sharpsville Container 
 
 
PFD Reference 
 
 
PFD #02 
 
 
Operation 
 
 
Batch 
 
 
 
 
Characteristics 
 
Material of Construction:                 Stainless Steel 316L 
Finish:                                               Electro-polished  
Volume:                                            25,000 L  
Height:                                              5.0m 
Diameter:                                          2.5m 
Sterilization:                                     SIP/CIP 
 
 
 
 
Operations Conditions 
 
 
 
Temp:                                               25°C         
Pressure:                                           1 bar  
 
 
 
Purchase Cost 
 
Storage Tank:                        $ 145,000  
PI control for pH, Temp, DO, Flow Rate, Volume, and Pressure:     
                                               $ 2,500/control = $12,500 
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Centrifuge (PFD 02/P-27) 
 
Description and Function  To remove cells from the stream containing the monoclonal antibody product. 
 
Vendor 
 
Alfa – Laval 
 
 
PFD Reference 
 
 
PFD #02 
 
 
Operation 
 
 
Batch 
 
Materials Handled 
 
 Input (kg/Batch) Output (kg/Batch) 
Cells 356.32 0 
Media 0 0 
Water 19600 19208 
Endotoxin 36.34 33.44 
Product 9.41 9.22 
   
 
Characteristics 
 
Model:                                               Culturefuge 400 
Centrifuge Type:                               Hermetic Disk Stack 
Material of Construction:                  Stainless Steel 316L  
Finished:                                            Electro-polished product                  
Capacity Range:                                5,000 to 20,000 L/hr 
Sterilization:                                      SIP/CIP 
 
 
 
 
Operations Conditions 
 
 
 
Temp:                                               25°C 
Throughput:                                     10,000 L/h 
 
Purchase Cost 
 
$ 480,000 
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Centrifugation Pool Tank (PFD 02/P-29) 
 
Description and Function  To store sterilized supernatant from the centrifugation process.  
 
Vendor 
 
Sharpsville Container 
 
 
PFD Reference 
 
 
PFD #02 
 
 
Operation 
 
 
Batch 
 
Characteristics 
 
Material of Construction:                  Stainless Steel 316L  
Finish:                                                Electro-polished      
Volume:                                             25,000L           
Height:                                               5.0m 
Diameter:                                           2.5m 
Sterilization:                                      SIP/CIP 
 
 
 
 
 
Operations Conditions 
 
 
 
Temp:                                              25°C 
Operating Pressure:                         1 bar 
 
 
 
Purchase Cost 
 
Storage Tank:                        $ 145,000 
PI control for pH, Temp, DO, Flow Rate, Volume, and Pressure:     
                                               $ 2,500/control = $12,500 
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Protein A Chromatography Column (PFD 02/P-31) 
 
 
 
Description and Function  
To purify the antibody Fab fragments. It acts as the first main 
isolation step for product and isolates the monoclonal antibody via 
affinity chromatography. Therefore, the column is useful in 
eliminating host cell DNA, media components, and endogenous viral 
particles.  
 
Vendor 
 
GE Healthcare 
 
 
PFD Reference 
 
 
PFD #02 
 
 
Operation 
 
Batch 
 
 
 
 
 
 
Materials Handled 
 Input (kg/Batch) Output (kg/Batch) 
Cells 0 0 
Media 0 0 
Water Streams:  
Centrifuge effluent 19208  
Equilibration buffer 2000  
Wash buffer 2000  
Elution buffer 4000 4000 
Regeneration buffer 6000  
Protein A waste  29208 
Endotoxin 33.44 20.06 
Product 9.22 9.04 
 
Characteristics 
 
Model :                                             Chromaflow 2000/100-300 
Column Diameter:                            2.54m 
Bed Height:                                      0.4m 
Material of Construction:                 Stainless Steel 316L 
Bed Volume:                                    2,000L 
Resin                                                 n-Protein A Sepharose 4  
Binding Capacity:                             50 mg antibody / ml media 
Working Flow Velocity:                   30-400 cm/h 
Temperature Stability:                      4-40°C 
 
 
Operations Conditions 
 
Temp:                                                4°C 
Pressure:                                            1.01 bar 
 
Purchase Cost 
Column:                         $ 200,000  
Resin:                             $ 8,000/ liters (need 2,000L) 
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Protein A Pool Tank (PFD 02/P-33) 
 
Description and Function  To collect product from anion exchange column. 
Vendor 
 
Sharpsville Container 
 
 
PFD Reference 
 
 
PFD #02 
 
 
Operation 
 
 
Batch 
 
Characteristics 
 
Material of Construction:                  Stainless Steel 316L 
Finish:                                                Electro-polished   
Volume:                                             5,000L           
Height:                                               3.0m 
Diameter:                                           1.5m 
Sterilization:                                      SIP/CIP 
 
 
 
Operations Conditions 
 
 
 
Temp :                                                    25°C 
Operating Pressure:                                1 bar 
Purchase Cost 
 
Storage Tank:                        $ 122,000 
PI control for pH, Temp, DO, Flow Rate, Volume, and Pressure:     
                                               $ 2,500/control = $12,500 
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Cation Exchange Chromatography Column (PFD 02/P-35) 
 
Description and Function  To purify and isolate antigen binding fragments from impurities. 
 
Vendor 
 
GE Healthcare 
 
 
PFD Reference 
 
 
PFD #02 
 
 
Operation 
 
 
Batch 
 
 
 
 
 
 
Materials Handled 
 
 Input (kg/Batch) Output (kg/Batch) 
Cells 0 0 
Media 0 0 
Water Streams:   
Prot A effluent 2000  
Cat wash 1 buffer 2000  
Cat wash 2 buffer 2000  
Elution buffer 2000 2000 
Regeneration buffer 6000  
Cat ex waste  12000 
Endotoxin 20.06 10.03 
Product 9.04 8.77 
   
 
 
 
 
 
 
Characteristics 
 
Model:                                               Chromaflow 1000 
Material of Construction:                  Stainless Steel 316L 
Finish:                                               Electro-polished 
Bed Volume:                                     2,000L 
Column Diameter:                             2.54m 
Bed Height:                                       0.5m 
Resin:                                                Eshmuno S (EMD Millipore) 
Binding Capacity:                             > 60 mg antibody/ ml media 
Working Flow Velocity:                   800 cm/hr 
 
 
Operations Conditions 
 
 
 
Temp:                                              25°C 
Pressure:                                          1 bar 
 
Purchase Cost 
 
Column:                 $ 250,000  
Resin:                     $ 15,000/10 Liters (need 200 of these) 
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Cation Exchange Pool Tank (PFD 02/P-37) 
 
 
Description and Function  
To hold and mix product from cation exchange chromatography 
with buffer solutions in preparation for anion exchange 
chromatography. 
 
Vendor 
 
Sharpsville Container 
 
 
PFD Reference 
 
 
PFD #02 
 
 
Operation 
 
 
Batch 
 
 
 
 
Characteristics 
 
Material of Construction:                Stainless Steel 316L            
Finish:                                             Electro-polished 
Total Volume:                                 5,000L 
Height:                                             3.0m 
Diameter:                                         1.5m 
Sterilization:                                    SIP/CIP 
 
 
 
Operations Conditions 
 
 
 
Temp :                                               25°C 
Operating Pressure:                           1 bar 
 
Purchase Cost 
 
Storage Tank:                        $ 122,000 
PI control for pH, Temp, DO, Flow Rate, Volume, and Pressure:     
                                               $ 2,500/control = $12,500 
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Anion Exchange Chromatography Column (PFD 02/P-39) 
 
Description and Function  To remove impurities and purify antigen binding fragments. 
 
Vendor 
 
GE Healthcare 
 
 
PFD Reference 
 
 
PFD #02 
 
 
Operation 
 
 
Batch 
 
 
 
 
 
 
Materials Handled 
 
 Input (kg/Batch) Output (kg/Batch) 
Cells 0 0 
Media 0 0 
Water Streams:   
Cat ex effluent 2000  
Cat wash 1 2000  
Cat wash 2 2000  
Elution buffer 2000 2000 
Regeneration buffer 6000  
Anion ex waste  12000 
Endotoxin 10.03 5.02 
Product 8.77 8.50 
   
 
 
 
 
 
 
 
Characteristics 
 
Model:                                               Chromaflow 1000 
Material of Construction:                  Stainless Steel 316L 
Finish:                                               Electro-polished 
Bed Volume:                                     2,000L 
Column Diameter:                             2.54m 
Bed Height:                                       0.5m 
Resin:                                                Capto Q (GE Healthcare) 
Binding Capacity:                             > 100 mg antibody/mL media 
Working Flow Velocity:                   700 cm/hr 
 
 
Operations Conditions 
 
 
 
Temp:                                              25°C        
Pressure:                                          1 bar 
 
Purchase Cost 
 
Column:               $ 250,000  
Resin:                   $ 109.00/60 liters (need 40 of these) 
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Anion Exchange Pool Tank (PFD 02/P-41) 
 
Description and Function  To collect product from anion exchange column. 
 
Vendor 
 
Sharpsville Container 
 
 
PFD Reference 
 
 
PFD #02 
 
 
Operation 
 
 
Batch 
 
 
 
Characteristics 
 
Material of Construction:                Stainless Steel 316L            
Finish:                                             Electro-polished 
Total Volume:                                 25,000L 
Height:                                             5.0m 
Diameter:                                         2.5m 
Sterilization:                                    SIP/CIP 
 
 
 
Operations Conditions 
 
 
 
Temp:                                               25°C 
Operating Pressure:                          1 bar 
 
Purchase Cost 
 
Storage Tank:                        $ 145,000 
PI control for pH, Temp, DO, Flow Rate, Volume, and Pressure:     
                                               $ 2,500/control = $12,500 
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Nanofiltration Unit (PFD 02/P-43) 
 
 
Description and Function  
To remove viruses. It is a size based membrane separation in which 
the product flows through while viruses are captured within the 
pores. 
 
Vendor 
 
Asahi Kasei Bioprocess 
 
 
PFD Reference 
 
 
PFD #02 
 
 
Operation 
 
 
Batch 
 
 
 
 
Materials Handled 
 
 Input (kg/Batch) Output (kg/Batch) 
Cells 0 0 
Media 0 0 
Water 2000 2000 
Endotoxin 5.02 2.51 
Product 8.50 8.42 
   
 
 
 
 
 
Characteristics 
 
Model:                                              Planova BioEx  
MW Cutoff:                                      200 kD 
Protein Throughput:                          6.5 kg/m2 per 3 hours 
Filtration pressure:                            294 kPa (42.6 psi) 
Filter effective surface area:             1.8m2   
Sterilization:                                      SIP (autoclave) 
Membrane:                                        Disposable 
 
 
 
Operations Conditions 
 
 
 
Temp:                                                   25°C 
Suggested Operating Pressure:             < 343 kPa 
Operating pH:                                       2-9 
 
 
Purchase Cost 
 
Filter Housing:      $ 15,000 
Membrane Filter:   $ 2,000 
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Ultrafiltration (PFD 02/P-45) 
 
Description and Function  To remove small viral and foreign particles. The desired product will 
stay in the retentate but smaller particles will be removed.  
 
Vendor 
 
Pall Corporation 
 
 
PFD Reference 
 
 
PFD #02 
 
 
Operation 
 
 
Batch 
 
 
 
Materials Handled 
 
 Input (kg/Batch) Output (kg/Batch) 
Cells 0 0 
Media 0 0 
Water 2000 2000 
Endotoxin 2.51 1.25 
Product 8.42 8.08 
   
 
 
 
 
Characteristics 
 
Model:                                         Membrane Unit 
Disc Filters:                                 Omega polyethersulfone membrane           
MW Cutoff:                                100 kD 
Filter effective surface area:       1.8m2   
Sterilization:                               SIP (autoclave) 
Membrane Treatment:                Sterilized, washed, and reused    
 
 
Operations Conditions 
 
 
 
Temp:                                               0 - 40°C  
Operating Pressure:                          1 bar 
 
 
Purchase Cost 
 
 
Filter Housing:               $ 12,000 
Filter Membrane:           $ 1,000 
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Final Sterile Filtration (PFD 02/P-47) 
 
 
 
Description and Function  
.2 µm dead end filter to remove bacteria and other impurities from 
the serum free media prior to feeding the cultivators and production 
bioreactor. The sanitary stainless steel filter housings are designed 
for filtration applications. The filter capsules membranes are 
disposable ready-to-use filter or depth filter capsules. 
 
Vendor 
 
Sartorious Biotech 
 
 
PFD Reference 
 
 
PFD #02 
 
 
Operation 
 
 
Batch 
 
 
 
Materials Handled 
 
 Input (kg/Batch) Output (kg/Batch) 
Cells 0 0 
Media 0 0 
Water 2000 2000 
Endotoxin 1.25 0 
Product 8.08 7.76 
   
 
 
 
 
 
Characteristics 
 
Model:                                               Sartopore 2 0.2 µm 
Membrane Filter Material:                Polyethersulfone (PES) 
Size:                                                   30 inches 
Filtration Area:                                  1.8m2 (18ft2) 
Max. Differential Pressure:               5 bar (75 psi) at 20 °C 
Membrane Unit Sterilization:            SIP 
Membrane Sterilization:                    Disposable  
 
 
 
Operations Conditions 
 
 
 
Temp :                                               25°C         
Pressure :                                           0.5 bar (7.5 psi) 
 
 
 
Purchase Cost 
 
Filter Housing:                  $ 2,000 
Filter Membrane:              $ 650/unit 
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9.2. Fluidized Bed Bioreactor Process 
Bag Bioreactor (PFD 03/P-02) 
 
 
 
Description and Function 
To prepare the inoculum for seed bioreactor. An electric rocker base, 
with integral temperature control, weight controllers for perfusion 
culture, aeration pump, pH probe, and various rocking speeds is 
used along with 200mL Cellbag bioreactor chambers. The bags are 
plastic pre-sterilized, single-use chambers for non-invasive mixing 
of fluids using the WAVETM rocker. 
 
Vendor 
 
GE Healthcare  
 
 
PFD Reference 
 
 
PFD #03 
 
 
Operation 
 
Batch 
 
 
 
Materials Handled 
 
 Input (kg/Batch) Output (kg/Batch) 
Cells 0.00524 0.0262 
Media 0.002 0 
Water 0.098 0.098 
Endotoxin 0 0 
Product 0 0 
   
 
 
 
 
Characteristics 
 
Model :                             GE Healthcare WAVETM Base 2/10EH 
Construction:                    High quality stainless steel and aluminum 
Bag Bioreactor :               Cellbag 200mL Bioreactor Chamber 
Sterilization:                     Plastic Disposable Bags  
                                         SIP for rocker 
 
 
 
Operations Conditions 
 
 
 
Temp :                                         37 ̊ C                 
Pressure :                                     1 bar 
pH :                                             7.0 – 7.2 
DO :                                            50% 
Duration:                                     3.5 days 
 
 
Purchase Cost 
 
Rocker and Control Unit:                          $16,480 
200 mL Cellbag Bioreactor Chamber:      $202.00 per bag (need 30) 
PI control for pH, Temp, DO, Flow Rate, Volume, and Pressure:     
                                      $ 2,500/control = $12,500 
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Media Prep (PFD 03/P-03) 
 
Description and Function  Tank used to store and mix powdered serum free media with water 
for injection prior to being pumped through a sterile filter. 
 
Vendor 
 
Sharpsville Container 
 
 
PFD Reference 
 
 
PFD #03 
 
 
Operation 
 
 
Batch 
 
 
 
 
Materials Handled 
 
Input Quantity 
(L) 
Output Quantity 
(L) 
Dry Powder Media 0.2 Media Solution 98.00 
Water 97.8   
    
    
    
 
 
 
 
Characteristics 
 
Material of Construction:                 Stainless Steel 316L 
Volume:                                            150L 
Height:                                              0.9m 
Diameter:                                          0.4m 
Sterilization:                                     SIP/CIP 
 
 
Operations Conditions 
 
 
Temp:                                               25°C         
Pressure:                                           1 bar  
 
 
Purchase Cost 
 
Storage Tank:                        $ 110,000 
PI control for pH, Temp, DO, Flow Rate, Volume, and Pressure:     
                                               $ 2,500/control = $12,500 
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Seed Bioreactor (PFD 03/P-07) 
 
 
 
 
Description and Function  
Bioreactor used for continued cell growth and production of 
monoclonal antibodies. The WAVETM Bioreactor 500/1000 is a self-
contained system with integral temperature control, aeration pump, 
and rocking controller for use with working culture volumes 
between 50L and 500L. The 70L bags are plastic pre-sterilized, 
single-use chambers for non-invasive mixing of fluids using the 
WAVETM bioreactor. 
 
Vendor 
 
GE Healthcare  
 
 
PFD Reference 
 
 
PFD #03 
 
 
Operation 
 
 
Batch 
 
 
 
 
Materials Handled 
 
 Input (kg/Batch) Output (kg/Batch) 
Cells 0.26 1.75 
Media 2 0 
Water 98 98 
Endotoxin 0 0.47 
Product 0 0.02 
   
 
 
 
 
Characteristics 
 
Model:                                         WAVETM Bioreactor 500/1000  
Construction:                               Stainless Steel 
Dimensions:                                 201x124x160 cm 
Bag Bioreactor:                           Cellbag 70L Bioreactor Chamber 
Sterilization:                                Plastic Disposable Bags   
 
 
 
Operations Conditions 
 
 
 
Temp:                                        37 ̊ C                 
Pressure:                                    1 bar 
pH:                                             7.0 – 7.2 
DO:                                            50% 
Duration:                                    5 days 
 
 
 
Purchase Cost 
 
WAVETM Bioreactor system:                $ 404,500 (3x) 
70L Cellbag Bioreactor Chamber:        $ 1,000 per bag  
PI control for pH, Temp, DO, Flow Rate, Volume, and Pressure:     
                                                                $ 2,500/control = $12,500 
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Media Prep (PFD 03/P-09) 
 
Description and Function  Tank used to store and mix powdered serum free media with water 
for injection prior to being pumped through a sterile filter. 
 
Vendor 
 
Sharpsville Container 
 
 
PFD Reference 
 
 
PFD #03 
 
 
Operation 
 
 
Batch 
 
 
Materials Handled 
 
Input Quantity (L) Output Quantity (L) 
Dry Media 
Powder 
18.00 Media 
Solution 
900.0 
Water 882.0   
    
 
 
 
 
Characteristics 
 
Material of Construction:                  Stainless Steel 316L 
Finish:                                               Electro-polished 
Volume:                                            1500L 
Height:                                              2.3m 
Diameter:                                          0.9m 
Sterilization:                                     SIP/CIP 
 
 
 
Operations Conditions 
 
 
 
Temp :                                               25°C         
Pressure :                                           1 bar  
 
Purchase Cost 
 
Storage Tank:                        $ 120,000 
PI control for pH, Temp, DO, Flow Rate, Volume, and Pressure:     
                                               $ 2,500/control = $12,500 
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Seed Bioreactor (PFD 03/P-13) 
 
 
 
 
Description and Function  
Bioreactor used for continued cell growth and production of 
monoclonal antibodies. The XDR-2000 Single-Use Bioreactor offers 
a smooth transfer from development to manufacturing scale. It has 
robust industrial automation with an aeration pump. It provides 
exacting temperature control for use with working culture volumes 
up to 2000L. The 2000L bags are plastic pre-sterilized, single-use 
chambers for non-invasive mixing of fluids using the XDR 
bioreactor.  
 
Vendor 
 
GE Healthcare  
 
 
PFD Reference 
 
 
PFD #03 
 
 
Operation 
 
 
Batch 
 
 
 
 
Materials Handled 
 
 Input (kg/Batch) Output (kg/Batch) 
Cells 5.24 38.25 
Media 20 0 
Water 980 980 
Endotoxin 1.40 10.20 
Product 0.05 0.46 
   
 
 
 
Characteristics 
 
Model:                            XDR-2000 Single-Use Bioreactor  
Construction:                  Jacketed stainless steel vessel  
Bag Bioreactor:              Cellbag 2000L Bioreactor Chamber 
Sterilization:                  Plastic Disposable Bags   
 
 
 
Operations Conditions 
 
 
 
Temp:                                         37 ̊ C                 
Pressure:                                     1 bar 
pH:                                              7.0 – 7.2 
DO:                                             50% 
Duration:                                    5.5 days 
 
 
 
Purchase Cost 
 
WAVETM Bioreactor system:                $ 600,000 
125L Cellbag Bioreactor Chamber:      $ 1,800 per bag  
PI control for pH, Temp, DO, Flow Rate, Volume, and Pressure:     
                                   $ 2,500/control = $12,500 
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Media Prep (PFD 03/P-15) 
 
Description and Function  Tank used to store and mix powdered serum free media with water 
for injection prior to being pumped through a sterile filter. 
 
Vendor 
 
Sharpsville Container 
 
 
PFD Reference 
 
 
PFD #03 
 
 
Operation 
 
 
Batch 
 
 
 
 
Materials Handled 
 
Input Quantity (L) Output Quantity (L) 
Dry Media 
Powder 
8.6E+05 
 
Media 
Solution 
4.29E+06 
 
Water 4.21E+06 
 
  
    
    
 
 
 
 
Characteristics 
 
Material of Construction:                 Stainless Steel 316L 
Finish:                                              Electro-polished 
Volume:                                           10,000L  
Height:                                              3.5m 
Diameter:                                          2.0m 
Sterilization:                                     SIP/CIP 
 
 
 
Operations Conditions 
 
 
 
Temp:                                               25°C         
Pressure:                                           1 bar  
 
 
 
Purchase Cost 
 
Storage Tank:                        $ 130,000  
PI control for pH, Temp, DO, Flow Rate, Volume, and Pressure:     
                                               $ 2,500/control = $12,500 
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Media Prep (PFD 03/P-19) 
 
Description and Function  Tank used to store and mix powdered serum free media with water 
for injection prior to being pumped through a sterile filter. 
 
Vendor 
 
Sharpsville Container 
 
 
PFD Reference 
 
 
PFD #03 
 
 
Operation 
 
 
Batch 
 
 
 
Materials Handled 
 
Input Quantity (L) Output Quantity (L) 
Dry Media 
Powder 
8.6E+05 
 
Media 
Solution 
4.29E+06 
 
Water 4.21E+06 
 
  
    
    
 
 
 
 
Characteristics 
 
Material of Construction:                 Stainless Steel 316L 
Finish:                                              Electro-polished finish 
Volume:                                           10,000L  
Height:                                              3.5m 
Diameter:                                          2.0m 
Sterilization:                                     SIP/CIP 
 
 
 
Operations Conditions 
 
 
 
Temp:                                               25°C         
Pressure:                                           1 bar  
 
 
 
Purchase Cost 
 
Storage Tank:                        $ 130,000  
PI control for pH, Temp, DO, Flow Rate, Volume, and Pressure:     
                                               $ 2,500/control = $12,500 
 
 
 
 
 
  
70 Monoclonal Antibody Production via Fluidized Bioreactor Technology 
 
 
Media Storage (PFD 03/P-23) 
 
Description and Function  To store media before entering the production fluidized bioreactor. 
 
Vendor 
 
Sharpsville Container 
 
 
PFD Reference 
 
 
PFD #03 
 
 
Operation 
 
 
Batch 
 
 
 
 
Materials Handled 
 
Input Quantity (L) Output Quantity (L) 
Dry Media 
Powder 
1.72E+05 
 
Media 
Solution 
8.60E+06 
 
Water 8.42E+06 
 
  
    
    
 
 
 
 
Characteristics 
 
Model:                                               Stainless Steel 316L 
Finish:                                               Electro-polished 
Volume:                                            50,000L  
Height:                                               6.0m 
Diameter:                                           3.25m 
Sterilization:                                      SIP/CIP 
 
 
 
Operations Conditions 
 
 
 
Temp:                                               25°C         
Pressure:                                           1 bar  
 
 
 
Purchase Cost 
 
Storage Tank:                        $ 165,000  
PI control for pH, Temp, DO, Flow Rate, Volume, and Pressure:     
                                               $ 2,500/control = $12,500 
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Production Bioreactor (PFD 03/P-25) 
 
 
Description and Function  
Fluidized Bioreactor with internal circulation used for continued cell 
growth and production of monoclonal antibodies. The final 
bioreactor serves to maximize product formation.  
 
Vendor 
 
GE Healthcare 
 
 
PFD Reference 
 
 
PFD #03 
 
 
Operation 
 
 
Batch 
 
 
 
Materials Handled 
 
 Input (kg/Batch) Output (kg/Batch) 
Cells 38.25 2672.4 
Media 1.72E+05 1.17E+05 
Water 8.42E+06 5.90E+06 
Endotoxin 10.20 272.58 
Product 0.46 65.75 
   
 
 
 
Characteristics 
 
Model:                       25,000L CytopilotTM Production Bioreactor  
Material:                    Stainless Steel 316L 
Finish:                       Electro-polished 
Sterilization:             SIP/CIP   
 
 
 
 
Operations Conditions 
 
 
 
Temp:                                         37 ̊ C                 
Pressure:                                     1 bar 
pH:                                              7.0 – 7.2 
DO:                                             40% 
Duration:                                     13 days 
 
 
Purchase Cost 
 
Bioreactor:                                              $1,500,000 
PI control for pH, Temp, DO, Flow Rate, Volume, and Pressure:     
                                                                $2,500/control = $12,500 
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Sterile Filtration (PFD 03/P-05, P-11, P-17, P-21) 
 
 
 
Description and Function  
.2 µm dead end filter to remove bacteria and other impurities from 
the serum free media prior to feeding the cultivators and production 
bioreactor. The sanitary stainless steel filter housings are designed 
for filtration applications. The filter capsules membranes are 
disposable ready-to-use filter or depth filter capsules. 
 
Vendor 
 
Sartorious Biotech 
 
 
PFD Reference 
 
 
PFD #03 
 
 
Operation 
 
 
Batch 
 
 
 
 
 
Characteristics 
 
Model:                                               Sartopore 2 0.2 µm 
Membrane Filter Material:                Polyethersulfone (PES) 
Size:                                                   30” 
Filtration Area:                                  1.8m2 (18ft2) 
Max. Differential Pressure:               5 bar (75 psi) at 20 °C 
Membrane Unit Sterilization:            SIP 
Membrane Sterilization:                    Disposable  
 
 
Operations Conditions 
 
 
Temp:                                               25°C         
Pressure:                                           0.5 bar (7.5 psi) 
 
 
Purchase Cost 
 
Filter Housing:                          $ 2,000 
Filter Membrane:                      $ 650/unit 
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Pump (PFD 03 & 04/ P-04, P-06, P-08, P-10, P-12, P-14, P-16, P-18, P-20, P-22, P-24, P-26, 
P-28, P-30, P-32, P-34, P-36, P-38, P-40, P-14, P-42, P-44, P-46, P-48, P-50, P-51) 
 
 
Description and Function  
Pump to transfer fluid. High-flow hygienic pumps that are designed 
for low-shear sanitary pumping. They are ideal for viscous or shear 
sensitive products. 
 
Vendor 
 
 
Watson-Marlow 
 
PFD Reference 
 
 
PFD #03 and #04 
 
 
Operation 
 
 
Batch 
 
 
 
Characteristics 
 
Model:                                               825 Peristaltic Pump 
Material Construction:                      304 Stainless Steel 
Flow Rate:                                        33.3 L/min 
Max Pressure :                                  3.5 bar    
Tubing:                                             Bioprene, 25mm 
 
 
 
Operations Conditions 
 
 
 
Temp:                                               25°C         
Pressure Change:                              50 psi 
Power:                                               1.5 – 5.0 hp 
 
 
Purchase Cost 
 
$13,000 
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Storage Tank (PFD 04/P-27) 
 
Description and Function  To store output of production bioreactor before tangential flow 
filtration.  
 
Vendor 
 
Sharpsville Container 
 
 
PFD Reference 
 
 
PFD #04 
 
 
Operation 
 
 
Batch 
 
 
 
 
Characteristics 
 
Material of Construction:                 Stainless Steel 316L 
Finish:                                               Electro-polished  
Volume:                                            50,000L  
Height:                                              6.0m 
Diameter:                                          3.25m 
Sterilization:                                     SIP/CIP 
 
 
Operations Conditions 
 
 
 
Temp:                                               25°C         
Pressure:                                           1 bar  
 
 
Purchase Cost 
 
Storage Tank:                       $165,000  (x58) 
PI control for pH, Temp, DO, Flow Rate, Volume, and Pressure:     
                                              $2,500/control = $12,500 (x58) 
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Tangential Flow Filtration (PFD 04/P-29) 
 
 
Description and Function  
To remove cells, viruses, and bacteria from the stream containing 
the monoclonal antibody product. It a process by which the product 
or feed is directed tangentially along the surface of the membrane.  
 
Vendor 
 
Pall Corporation  
 
 
PFD Reference 
 
 
PFD #04 
 
 
Operation 
 
 
Batch 
 
 
 
Materials Handled 
 
 Input (kg/Batch) Output (kg/Batch) 
Cells 2672.4 0 
Media 1.17E+05 0 
Water 5.90E+06 5.84E+06 
Endotoxin 272.58 250.78 
Product 65.75 64.43 
   
 
 
 
 
Characteristics 
 
Model:                                            Cadence Single Pass TFF System 
Material:                                         Stainless Steel 316L 
Finished:                                         Electro-polished                  
Sterilization:                                   SIP/CIP 
 
 
 
 
Operations Conditions 
 
 
 
Temp:                                              4-40°C 
Flow Range:                                    6-1,000 L/h 
Pressure Range:                               4-6 bar 
pH Range:                                         2-13 
 
 
Purchase Cost 
 
$500,000 (x50) 
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TFF Pool Tank (PFD 04/P-31) 
 
Description and Function  To store sterilized supernatant from the tangential flow filtration 
process.  
 
Vendor 
 
Sharpsville Container 
 
 
PFD Reference 
 
 
PFD #04 
 
 
Operation 
 
 
Batch 
 
 
 
 
Characteristics 
 
Material of Construction:                  Stainless Steel 316L 
Finish:                                                Electro-polished    
Volume:                                             50,000 L  
Height:                                               6 m 
Diameter:                                           3.25 m 
Sterilization:                                      SIP/CIP 
 
 
 
Operations Conditions 
 
 
Temp:                                               25 ° C 
Operating Pressure:                          1 bar 
 
 
 
Purchase Cost 
 
Storage Tank:                    $145,000 (x58) 
PI control for pH, Temp, DO, Flow Rate, Volume, and Pressure:     
                                           $ 2,500/control = $12,500 (x58) 
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Protein A Chromatography Column (PFD 04/P-33) 
 
 
 
Description and Function  
To purify the antibody Fab fragments. It acts as the first main 
isolation step for product and isolates the monoclonal antibody via 
affinity chromatography. Therefore, the column is useful in 
eliminating host cell DNA, media components, and endogenous viral 
particles.  
 
Vendor 
 
GE Healthcare 
 
 
PFD Reference 
 
 
PFD #04 
 
 
Operation 
 
Batch 
 
 
 
 
 
 
 
 
Materials Handled 
 Input (kg/Batch) Output (kg/Batch) 
Cells 0 0 
Media 0 0 
Water Streams:  
Centrifuge 
effluent 5.84E+06  
Equilibration buffer 2000  
Wash buffer 2000  
Elution buffer 4000 4000 
Regeneration 
buffer 6000  
Protein A waste  5.85E+06 
Endotoxin 250.78 130.40 
Product 64.43 63.14 
 
 
 
 
 
 
Characteristics 
 
Model:                                              Chromaflow 2000/ 100-300 
Column Diameter:                             2.54m 
Bed Height:                                       0.4m 
Material of Construction:                  Stainless Steel 316L 
Bed Volume:                                     2000L 
Resin                                                  n-Protein A Sepharose 4  
Binding Capacity:                              50 mg antibody / ml media 
Working Flow Velocity:                    40 cm/min 
Temperature Stability:                       4-40 °C 
 
Operations Conditions 
 
Temp:                                          4 °C 
Pressure:                                      1.01 bar 
Purchase Cost Column:                      $ 200,000  
Resin:                          $ 8,000/ liters (need 2,000 L) 
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Protein A Pool Tank (PFD 04/P-35) 
 
Description and Function  To collect product from anion exchange column. 
 
Vendor 
 
Sharpsville Container 
 
 
PFD Reference 
 
 
PFD #04 
 
 
Operation 
 
Batch 
 
 
Characteristics 
 
Material of Construction:               Stainless Steel 316L            
Finish:                                             Electro-polished 
Total Volume:                                 5,000.0 L 
Height:                                            3.0 m 
Diameter:                                        1.5 m 
Sterilization:                                    SIP/CIP 
 
 
 
Operations Conditions 
 
 
 
Temp:                                                      25 ° C 
Operating Pressure:                                1 bar 
 
Purchase Cost 
 
Storage Tank:                        $ 122,000 
PI control for pH, Temp, DO, Flow Rate, Volume, and Pressure:     
                                               $ 2,500/control = $12,500 
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Cation Exchange Chromatography Column (PFD 04/P-37) 
 
Description and Function  To purify and isolate antigen binding fragments from impurities. 
 
Vendor 
 
GE Healthcare 
 
 
PFD Reference 
 
 
PFD #04 
 
 
Operation 
 
 
Batch 
 
 
 
 
 
 
 
Materials Handled 
 
 Input (kg/Batch) Output (kg/Batch) 
Cells 0  
Media 0  
Water Streams:   
Prot A effluent 2000  
Cat wash 1 buffer 2000  
Cat wash 2 buffer 2000  
Elution buffer 2000 2000 
Regeneration buffer 6000  
Cat ex waste  12000 
Endotoxin 130.40 50.16 
Product 63.14 61.25 
   
 
 
 
 
 
 
Characteristics 
 
Model:                                               Chromaflow 1000 
Material of Construction:                  Stainless Steel 316L 
Finish:                                               Electro-polished 
Bed Volume:                                     2,000.0 L 
Column Diameter:                             2.54 m 
Bed Height:                                       0.5 m 
Resin:                                                Eshmuno S (EMD Millipore) 
Binding Capacity:                             > 60 mg antibody/ ml media 
Working Flow Velocity:                  800 cm/hr 
 
 
Operations Conditions 
 
 
 
Temp :                                              25 ° C 
Pressure:                                           1 bar 
 
 
Purchase Cost 
 
Column: $ 250,000  
Resin:     $ 15,000/10 Liters (need 200 of these) 
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Cation Exchange Pool Tank (PFD 04/P-39) 
 
 
Description and Function  
To hold and mix product from cation exchange chromatography 
with buffer solutions in preparation for anion exchange 
chromatography. 
 
Vendor 
 
Sharpsville Container 
 
 
PFD Reference 
 
 
PFD #04 
 
 
Operation 
 
 
Batch 
 
 
 
 
 
Characteristics 
 
Material of Construction:               Stainless Steel 316L            
Finish:                                             Electro-polished 
Volume:                                          5,000.0 L 
Height:                                            3.0 m 
Diameter:                                        1.5 m 
Sterilization:                                    SIP/CIP 
 
 
 
 
Operations Conditions 
 
 
 
Temp:                                                25 ° C 
Operating Pressure:                           1 bar 
 
Purchase Cost 
 
Storage Tank:                        $ 122,000 
PI control for pH, Temp, DO, Flow Rate, Volume, and Pressure:     
                                               $ 2,500/control = $12,500 
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Anion Exchange Chromatography Column (PFD 04/P-41) 
 
Description and Function  To remove impurities and purify antigen binding fragments 
 
Vendor 
 
GE Healthcare 
 
 
PFD Reference 
 
 
PFD #04 
 
 
Operation 
 
 
Batch 
 
 
 
 
 
 
 
 
Materials Handled 
 
 Input (kg/Batch) Output (kg/Batch) 
Cells 0  
Media 0  
Water Streams:   
Cat ex effluent 2000  
Anion wash 1 
buffer 2000  
Anion wash 2 
buffer 2000  
Elution buffer 2000 2000 
Regeneration buffer 6000  
Anion ex waste  12000 
Endotoxin 50.16 30.09 
Product 61.25 59.41 
 
 
 
 
 
 
 
Characteristics 
 
Model:                                               Chromaflow 1000 
Material of Construction:                  Stainless Steel 316L 
Finish:                                               Electro-polished 
Bed Volume:                                     2,000.0 L 
Column Diameter:                             2.54 m 
Bed Height:                                       0.5 m 
Resin :                                               Capto Q (GE Healthcare) 
Binding Capacity:                              > 100 mg antibody/ ml media 
Working Flow Velocity:                   700 cm/hr 
 
 
Operations Conditions 
 
 
 
Temp:                                              25 °C      
Pressure:                                         1 bar 
 
Purchase Cost 
Column:                      $ 250,000  
Resin:                          $ 109.00/60 Liters (need 40 of these) 
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Anion Exchange Pool Tank (PFD 04/P-43) 
 
Description and Function  To collect product from anion exchange column. 
 
Vendor 
 
Sharpsville Container 
 
 
PFD Reference 
 
 
PFD #04 
 
 
Operation 
 
 
Batch 
 
 
 
 
Characteristics 
 
Material of Construction:               Stainless Steel 316L            
Finish:                                             Electro-polished 
Total Volume:                                 25,000.0 L 
Height:                                             5.0 m 
Diameter:                                         2.5 m 
Sterilization:                                    SIP/CIP 
 
 
 
Operations Conditions 
 
 
 
Temp:                                               25 ° C 
Operating Pressure:                          1 bar 
 
Purchase Cost 
 
Storage Tank:                        $ 145,000 
PI control for pH, Temp, DO, Flow Rate, Volume, and Pressure:     
                                               $ 2,500/control = $12,500 
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Viral Nanofiltration Unit (PFD 04/P-45) 
 
 
Description and Function  
To remove viruses. It is a size based membrane separation in which 
the product flows through and the viruses are captured within the 
pores. 
 
Vendor 
 
Asahi Kasei Bioprocess 
 
 
PFD Reference 
 
 
PFD #04 
 
 
Operation 
 
 
Batch 
 
 
 
 
Materials Handled 
 
 Input (kg/Batch) Output (kg/Batch) 
Cells 0 0 
Media 0 0 
Water 2000 2000 
Endotoxin 30.09 10.03 
Product 59.41 58.82 
   
 
 
 
 
 
Characteristics 
 
Model:                                               Planova BioEx (EX1-0000) 
MW Cutoff:                                      200 kD 
Protein Throughput:                          6.5 kg/m2 per 3 hours 
Filtration pressure:                            294 kPa (42.6 psi) 
Filter effective surface area:             1.8 m2   
Sterilization:                                      SIP (autoclave) 
Membrane:                                        Disposable 
 
 
 
 
Operations Conditions 
 
 
 
Temp:                                                25 ° C 
Suggested Operating Pressure:          <343 kPa 
Operating pH:                                    2-9 
 
 
Purchase Cost 
 
Filter Housing:                          $ 15,000 (x6) 
Membrane Filter:                      $ 2,000 
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Ultrafiltration (PFD 04/P-47) 
 
Description and Function  To remove small viral and foreign particles. The desired product 
will stay in the retentate but smaller particles will be removed.  
 
Vendor 
 
Pall Corporation 
 
 
PFD Reference 
 
 
PFD #04 
 
 
Operation 
 
 
Batch 
 
 
 
 
Materials Handled 
 
 Input (kg/Batch) Output (kg/Batch) 
Cells 0 0 
Media 0 0 
Water 2000 2000 
Endotoxin 10.03 3.34 
Product 58.82 56.47 
   
 
 
 
 
Characteristics 
 
Model:                                         Membrane Unit 
Disc Filters:                                 Omega polyethersulfone membrane           
MW Cutoff:                                100 kD 
Filter effective surface area:       1.8 m2   
Sterilization:                               SIP (autoclave) 
Membrane Treatment:                Sterilized, washed, and reused    
 
 
Operations Conditions 
 
 
 
Temp:                                              0 - 40°C  
Operating Pressure:                          1 bar 
 
 
Purchase Cost 
 
Filter Housing:                      $ 12,000 (x6) 
Filter Membrane:                  $ 1,000 
  
 
 
 
 
 
 
 
 
 
85 Monoclonal Antibody Production via Fluidized Bioreactor Technology 
 
 
Sterile Filtration (PFD 04/P-49) 
 
 
 
Description and Function  
.2 µm dead end filter to remove bacteria and other impurities from 
the serum free media prior to feeding the cultivators and production 
bioreactor. The sanitary stainless steel filter housings are designed 
for filtration applications. The filter capsules membranes are 
disposable ready-to-use filter or depth filter capsules. 
 
Vendor 
 
Sartorious Biotech 
 
 
PFD Reference 
 
 
PFD #04 
 
 
Operation 
 
 
Batch 
 
 
 
 
Materials Handled 
 
 Input (kg/Batch) Output (kg/Batch) 
Cells 0 0 
Media 0 0 
Water 2000 2 00 
Endotoxin 3.34 0 
Product 56.47 54.21 
   
 
 
 
 
 
Characteristics 
 
Model:                                               Sartopore 2 0.2 µm 
Membrane Filter Material:                Polyethersulfone (PES) 
Size:                                                   30” 
Filtration Area:                                  1.8 m2 (18 ft2) 
Max. Differential Pressure:               5 bar (75 psi) at 20 °C 
Membrane Unit Sterilization:            SIP 
Membrane Sterilization:                    Disposable  
 
 
 
 
Operations Conditions 
 
 
 
Temp:                                               25 °C         
Pressure:                                           0.5 bar (7.5 psi) 
 
 
 
Purchase Cost 
 
Filter Housing:                      $ 2,000 
Filter Membrane:                  $ 650/unit 
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High Temperature Inactivation (PFD 05/P-52) 
 
Description and Function  An industrial size autoclave sterilizer that serves to kill the cells 
attached to the microcarriers in order to allow for safe disposal.  
 
Vendor 
 
WSF Industries Inc. 
 
 
PFD Reference 
 
 
PFD #05 
 
 
Operation 
 
 
Batch 
 
 
Characteristics 
 
Material of Construction:                  Stainless Steel 316L  
Finished:                                            Electro-polished      
Volume:                                             5,000L           
Sterilization:                                      SIP/CIP 
 
 
Operations Conditions 
 
 
 
Temp:                                              250°C 
Pressure:                                          20-30 psi 
 
 
Purchase Cost 
 
$ 500,000 
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10. Overall Process Cost for Stirred Tank Bioreactor Process 
10.1. Utility Costs 
The major utility needs of the plant consists of electricity and process water. 
Electricity is the most expensive and costs approximately $38,250 per batch. This calculation 
is based off a $0.085 per kWh rate obtained from a Philadelphia energy provider. 450,000 
kWh of energy are used per batch for the tank process. These energy requirements are due to 
operation of process machinery, the production bioreactor, the pumps, the WFI still, the clean 
steam generators, and other various units.  
Process water is the other major utility that will be used to produce monoclonal 
antibodies. The plant will require about 108,000 kg/batch, which is approximately 
2,052,000kg per year. This water will be used to generate WFI and steam for buffers and SIP 
in addition to the water needed for the powder media. At a rate of $0.00473/kg, a rate 
obtained from a Philadelphia water company, the costs of process water will be about $9,700 
per year.  
10.2. Material Resource Costs 
The costs of media and buffers can be found in this section. Ex-Cell® ACF CHO dry 
powder media can be purchased from Sigma-AldrichTM for $35.20 per kilogram. 
Approximately 10,000kg of dry media are needed for each batch when using the tank 
process. All of the buffers for the Protein A, Cation Exchange, and Anion Exchange columns 
can be purchased from GE Healthcare at a price of $1.24 per kilogram. Approximately 
460,000kg of buffers are need per batch for the tank process. 
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10.3. Major Unit Operation Costs  
 
Innoculum Prep - Bioreaction 
Number Type Units Size Vendor Purchase Cost ($/unit) 
P-02 Bioreactor Rocker 1  GE Healthcare $16,480.00 
 Bag 20 200mL GE Healthcare $202.00 
P-03 Mixing Tank 1 150L Sharpsville Container $110.00 
P-04 Pump 1  Watson Marlow $13,000.00 
P-05 Sterile Filter 1 1.8m2 Sartorious Biotech $2,000.00 
 Filter Membrane 1  Sartorious Biotech $650.00 
P-06 Pump 1  Watson Marlow $13,000.00 
P-07 WAVE
TM Bioreactor 
System 1  GE Healthcare $404,500.00 
 Bag 1 200L GE Healthcare $1,200.00 
P-08 Pump 1  Watson Marlow $13,000.00 
P-09 Mixing Tank 1 1,500L Sharpsville Container $1200.00 
P-10 Pump 1  Watson Marlow $13,000.00 
P-11 Sterile Filter 1 1.8m2 Sartorious Biotech $2,000.00 
 Filter Membrane 1  Sartorious Biotech $650.00 
P-12 Pump 1  Watson Marlow $13,000.00 
P-13 Bioreactor System 1  GE Healthcare $600,000.00 
 Bag 1 2,000L GE Healthcare $1,800.00 
P-14 Pump 1  Watson Marlow $13,000.00 
P-15 Mixing Tank 1 10,000L Sharpsville Container $130,000.00 
P-16 Pump 1  Watson Marlow $13,000.00 
P-17 Sterile Filter 1 1.8m2 Sartorious Biotech $2,000.00 
 Filter Membrane 1  Sartorious Biotech $650.00 
P-18 Pump 1  Watson Marlow $13,000.00 
P-19 Mixing Tank 1 10,000L Sharpsville Container $130,000.00 
P-20 Pump 1  Watson Marlow $13,000.00 
P-21 Sterile Filter 1 1.8m2 Sartorious Biotech $2,000.00 
 Filter Membrane 1  Sartorious Biotech $650.00 
P-22 Pump 1  Watson Marlow $13,000.00 
P-23 Production Bioreactor 1 25,000L Techniserv, Inc $900,000.00 
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Primary Recovery 
Number Type Units Size Vendor Purchase Cost ($/unit) 
P-24 Pump 1  Watson Marlow $13,000.00 
P-25 Storage Tank 1 25,000L Sharpsville Container $145,000.00 
P-26 Pump 1  Watson Marlow $13,000.00 
P-27 Centrifuge 1 10,000 L/hr Alfa-Laval $480,000.00 
P-28 Pump 1  Watson Marlow $13,000.00 
P-29 Centrifugation Pool Tank 1 25,000L 
Sharpsville 
Container $145,000.00 
      
Protein A Chromatography 
Number Type Units Size Vendor Purchase Cost ($/unit) 
P-30 Pump 1  Watson Marlow $13,000.00 
P-31 Protein A Column 1 2,000L GE Healthcare $200,000.00 
 n-Protein A Sepharose 4 Resin 2,000 1L GE Healthcare $8,000.00 
P-32 Pump 1  Watson Marlow $13,000.00 
P-33 Protein A Pool Tank 1 5,000L Sharpsville Container $122,000.00 
      
Cation Exchange Chromatography 
Number Type Units Size Vendor Purchase Cost ($/unit) 
P-34 Pump 1  Watson Marlow $13,000.00 
P-35 Cation Exchange Column 1 2,000L GE Healthcare $250,000.00 
 Eshmuno S Resin 200 10L EMD Millipore $15,000.00 
P-36 Pump 1  Watson Marlow $13,000.00 
P-37 Cation Exchange Pool Tank 1 5,000L 
Sharpsville 
Container $122,000.00 
      
Anion Exchange Chromatography 
Number Type Units Size Vendor Purchase Cost ($/unit) 
P-38 Pump 1  Watson Marlow $13,000.00 
P-39 Anion Exchange Column 1 2,000L GE Healthcare $250,000.00 
 Capto Q Resin 40 60L GE Healthcare $109,000 
P-40 Pump 1  Watson Marlow $13,000.00 
P-41 Anion Exchange Pool Tank 1 25,000L 
Sharpsville 
Container $145,000.00 
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Viral Nanofiltration 
Number Type Units Size Vendor Purchase Cost ($/unit) 
P-42 Pump 1  Watson Marlow $13,000.00 
P-43 Nanofiltration Housing Unit 6  
Asahi Kasei 
Bioprocess $15,000.00 
 Filters 1 1.8m2 Asahi Kasei Bioprocess $2,000.00 
      
Final Filtration 
Number Type Units Size Vendor Purchase Cost ($/unit) 
P-44 Pump 1  Watson Marlow $13,000.00 
P-45 Ultrafiltration Unit 6 1.8m2 Pall Corporation $12,000.00 
 Filters 1  Pall Corporation $1,000.00 
P-46 Pump 1  Watson Marlow $13,000.00 
P-47 Sterile Filter 1 1.8m2 Sartorious Biotech $2,000.00 
 Filter Membrane 1  Sartorious Biotech $650.00 
P-48 Pump 1  Watson Marlow $13,000.00 
 
10.4. Additional Equipment Costs 
 
Additional Equipment 
Type Units Vendor Purchase Cost ($/Unit) 
Incubators 2 Thermo Scientific $15,000.00 
CIP Skids 3 Sani-matic $100,000.00 
Buffer Transfer Bags 80 HyClone – (Thermo Scientific) 80,000/year 
Portable Pump 3 Watson Marlow $13,000.00 
Biowaste and Neutralization 
Tanks 5 Sharpsville Container $145,000.00 
Final Packaging 1 Quality BioResources, Inc. $280,000.00 
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Additional Equipment Included in Annual Expenses 
Type Units Vendor 
Biosafety Cabinet 3 Thermo Scientific 
Air Generator (HVAC Equipment) 1  
Clean Steam Generator 1  
Filter Integrity Tester 1 Millipore 
Tube Fuser and Sealer 1 Sartorius Stedim Biotech 
Water Treatment Package 1  
WFI Still 1 Paul Mueller Co 
Biowaste Inactivation System 1  
Waste Neutralization System 1  
Laboratory Information Management System 1  
Refrigeration 2 Thermo Scientific 
 
11. Overall Process Cost for Fluidized Bioreactor Process 
11.1. Utility Costs 
The major utility needs of the plant consists of electricity and process water. 
Electricity is the most expensive and costs approximately $59,500 per batch. This calculation 
is based off a $0.085 per kWh rate obtained from a Philadelphia energy provider. 
700,000kWh of energy are used per batch for the stirred tank process. These electricity 
requirements are higher than the stirred tank process due to the increased number of pumps 
and the increased amount of water. Again, electricity is required for operation of process 
machinery, the production bioreactor, the pumps, the WFI still, the clean steam generators, 
and other various units.  
Process water is the other major utility that will be used to produce monoclonal 
antibodies. The plant will require about 8,500,000kg/batch, which is approximately 100 
million kg per year. This large amount of increased water is due to the increased amount of 
media for the fluidized bed process. Again, this water will be used to generate WFI and 
steam for buffers and SIP in addition to the water needed to mix with the media. At a rate of 
$0.00473/kg, a rate obtained from a Philadelphia water company, the costs of process water 
will be about $40,205 per batch.  
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11.2. Material Resource Costs 
The costs of media, buffers, and microcarriers can be found in this section. Ex-Cell® 
ACF CHO dry powder media can be purchased from Sigma-AldrichTM for $35.20 per 
kilogram. Approximately 2 million kg of dry media are needed for each batch when using the 
fluidized bed system. All of the buffers for the Protein A, Cation Exchange, and Anion 
Exchange columns can be purchased from GE Healthcare at a price of $1.24 per kilogram. 
Approximately 400,000kg of buffers are need per batch for the fluidized bed process. Lastly, 
the CytolineTM 1 microcarriers can be purchased from GE Healthcare at a cost of $4,488 per 
kilogram. Approximately 12,000kg of microcarriers are needed for the production bioreactor 
for each batch.   
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11.3. Major Unit Operation Costs 
 
Innoculum Prep - Bioreaction 
Number Type Units Size Vendor Purchase Cost ($/unit) 
P-02 Bioreactor Rocker 1  GE Healthcare $16,480.00 
 Bag 30 200mL GE Healthcare $202.00 
P-03 Mixing Tank 1 150L Sharpsville Container $110.00 
P-04 Pump 1  Watson Marlow $13,000.00 
P-05 Sterile Filter 1 1.8m2 Sartorious Biotech $2,000.00 
 Filter Membrane 1  Sartorious Biotech $650.00 
P-06 Pump 1  Watson Marlow $13,000.00 
P-07 WAVE
TM Bioreactor 
System 3  GE Healthcare $404,500.00 
 Bag 1 70L GE Healthcare $1,000.00 
P-08 Pump 1  Watson Marlow $13,000.00 
P-09 Mixing Tank 1 1,500L Sharpsville Container $120.00 
P-10 Pump 1  Watson Marlow $13,000.00 
P-11 Sterile Filter 1 1.8m2 Sartorious Biotech $2,000.00 
 Filter Membrane 1  Sartorious Biotech $650.00 
P-12 Pump 1  Watson Marlow $13,000.00 
P-13 Bioreactor System 1  GE Healthcare $600,000.00 
 Bag 1 2,000L GE Healthcare $1,800.00 
P-14 Pump 1  Watson Marlow $13,000.00 
P-15 Mixing Tank 1 10,000L Sharpsville Container $130,000.00 
P-16 Pump 1  Watson Marlow $13,000.00 
P-17 Sterile Filter 1 1.8m2 Sartorious Biotech $2,000.00 
 Filter Membrane 1  Sartorious Biotech $650.00 
P-18 Pump 1  Watson Marlow $13,000.00 
P-19 Mixing Tank 1 10,000L Sharpsville Container $130,000.00 
P-20 Pump 1  Watson Marlow $13,000.00 
P-21 Sterile Filter 1 1.8 m2 Sartorious Biotech $2,000.00 
 Filter Membrane 1  Sartorious Biotech $650.00 
P-22 Pump 1  Watson Marlow $13,000.00 
P-23 Media Storage Tank 1 50,000L Sharpsville Container $165,000.00 
P-24 Pump 1  Watson Marlow $13,000.00 
P-25 Production Bioreactor 1 25,000L GE Healthcare $1,500,000.00 
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Primary Recovery 
Number Type Units Size Vendor Purchase Cost ($/unit) 
P-26 Pump 1  Watson Marlow $13,000.00 
P-27 Storage Tank 58 50,000L Sharpsville Container $165,000.00 
P-28 Pump 58  Watson Marlow $13,000.00 
P-29 Tangential Flow Filtration 50  Pall Corporation $500,000.00 
P-30 Pump 50  Watson Marlow $13,000.00 
P-31 TFF Pool Tank 58 50,000L Sharpsville Container $165,000.00 
      
Protein A Chromatography 
Number Type Units Size Vendor Purchase Cost ($/unit) 
P-32 Pump 58  Watson Marlow $13,000.00 
P-33 Protein A Column 1 2,000L GE Healthcare $200,000.00 
 n-Protein A Sepharose 4 Resin 5 1L GE Healthcare $8,000.00 
P-34 Pump 1  Watson Marlow $13,000.00 
P-35 Protein A Pool Tank 1 5,000L Sharpsville Container $122,000.00 
      
Cation Exchange Chromatography 
Number Type Units Size Vendor Purchase Cost ($/unit) 
P-36 Pump 1  Watson Marlow $13,000.00 
P-37 Cation Exchange Column 1 2,000L GE Healthcare $250,000.00 
 Eshmuno S Resin 1 10L EMD Millipore $15,000.00 
P-38 Pump 1  Watson Marlow $13,000.00 
P-39 Cation Exchange Pool Tank 1 5,000L 
Sharpsville 
Container $122,000.00 
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Anion Exchange Chromatography 
Number Type Units Size Vendor Purchase Cost ($/unit) 
P-40 Pump 1  Watson Marlow $13,000.00 
P-41 Anion Exchange Column 1 2,000L GE Healthcare $250,000.00 
 Capto Q Resin 40 60L GE Healthcare $109,000 
P-42 Pump 1  Watson Marlow $13,000.00 
P-43 Anion Exchange Pool Tank 1 25,000L 
Sharpsville 
Container $145,000.00 
       
Viral Nanofiltration 
Number Type Units Size Vendor Purchase Cost ($/unit) 
P-44 Pump 1  Watson Marlow $13,000.00 
P-45 Nanofiltration Housing Unit 6  
Asahi Kasei 
Bioprocess $15,000.00 
 Filters 1 1.8m2 Asahi Kasei Bioprocess $2,000.00 
      
Final Filtration 
Number Type Units Size Vendor Purchase Cost ($/unit) 
P-46 Pump 1  Watson Marlow $13,000.00 
P-47 Ultrafiltration Unit 6 1.8 m2 Pall Corporation $12,000.00 
 Filters 1  Pall Corporation $1,000.00 
P-48 Pump 1  Watson Marlow $13,000.00 
P-49 Sterile Filter 1 1.8m2 Sartorious Biotech $2,000.00 
 Filter Membrane 1  Sartorious Biotech $650.00 
P-50 Pump 1  Watson Marlow $13,000.00 
  
96 Monoclonal Antibody Production via Fluidized Bioreactor Technology 
 
 
Microcarrier Handling 
Number Type Units Size Vendor Purchase Cost ($/unit) 
P-51 Pump 1  Watson Marlow $13,000.00 
P-52 Autoclave Sterilizer 1 5,000L WSF Industries Inc $500,000.00 
 
11.4. Additional Equipment Costs 
 
Additional Equipment 
Type Units Vendor Purchase Cost ($/Unit) 
Incubators 2 Thermo Scientific $15,000.00 
CIP Skids 3 Sani-matic $100,000.00 
Buffer Transfer Bags 80 HyClone (Thermo Scientific) 80,000/year 
Portable Pump 3 Watson Marlow $13,000.00 
Biowaste and Neutralization 
Tanks 5 Sharpsville Container $145,000.00 
Final Packaging 1 Quality BioResources, Inc. $280,000.00 
 
 
Additional Equipment Included in Annual Expenses 
Type Units Vendor 
Biosafety Cabinet 3 Thermo Scientific 
Air Generator (HVAC Equipment) 1  
Clean Steam Generator 1  
Filter Integrity Tester 1 Millipore 
Tube Fuser and Sealer 1 Sartorius Stedim Biotech 
Water Treatment Package 1  
WFI Still 1 Paul Mueller Co 
Biowaste Inactivation System 1  
Waste Neutralization System   
Laboratory Information Management System 1  
Refrigeration 2 Thermo Scientific 
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12. Scheduling 
Scheduling is an important aspect to consider when building biopharmaceutical plants. 
Each process will be operated for about 330 days per year, allowing for about 35 days for 
maintenance and any contingency time needed in case of plant shutdown during operation. A 
Gantt chart can be used to easily visualize the occupation times of each piece of equipment in a 
given process to help identify any bottlenecks or inefficient design strategies. A two-batch Gantt 
chart for each process is included below. Only major units are shown and operation time includes 
transfer in and out times, loading times, and CIP and SIP times.  
12.1. Gantt Chart 
12.1.1. Stirred Tank Bioreactor Process 
The Gantt chart for the stirred tank bioreactor process is shown in Figure 12.1. 
Though this chart only shows two batches (the first batch in green and the second in 
purple), 16 total batches can be run every year in about 330 days. The first batch will 
require about 33 days and each incremental batch will require an additional 16 days.  
12.1.2. Fluidized Bioreactor Process 
Figure 12.2 shows the Gantt chart for the fluidized bioreactor process. For this 
process, 24 batches can be run every year in about 330 days. The first batch requires 
about 32 days and each incremental batch will require an additional 13 days.  
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Figure 12.1 Figure 12.2 
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13. Economic Analysis 
The fluidized bioreactor process offers the advantage of a lower batch time, fewer required 
batches per year, and a significant increase in product formation. However, it also requires 
investment in additional equipment, increases the sizes of various upstream and downstream 
unites such as storage tanks or tangential filtration units. A profitability analysis can more 
accurately compare the fluidized bioreactor process to the traditional tank process to help 
determine which is the most fiscally conservative option.   
13.1. Market Analysis 
In the European Union (EU), Rituxan®’s patent will expire in 2014 and in 2018 in 
the United States (US). This creates an incredible opportunity for generic competition. 
With various blockbuster drugs also approaching a “patent cliff,” the biotechnology 
market, particularly the generic monoclonal antibody market, will be booming. In 2013, 
560kg and 370kg of Rituxan® was sold in the US and EU respectively. Table 13.1 below 
shows the projected fractional market share of generic rituximab. It is projected that in 
the first year of a patent expiration, a generic is able to capture 50% of the market and 
that the market share increases every year until reaching a steady rate of 70%. Assuming 
that by 2021, 70% of the international and domestic market will be controlled by 
generics, the facility will be designed to produce 650kg of rituximab after accounting for 
downstream production losses.  
 
Table 13.1: Expected market share projections for the European Union and United States markets. The expected market share 
will determine the amount of generic rituximab sold to customers.  
Year Fractional EU Market Share  
Fractional US 
Market Share  
Total Kg Sold 
by Facility 
2015 0.50  279 
2016 0.60  335 
2017 0.70  391 
2018 0.70  391 
2019 0.70 0.50 576 
2020 0.70 0.60 613 
2021 0.70 0.70 650 
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13.2. Profitability Analysis 
For the profitability analysis, it is assumed that the plant’s effective tax rate will be 
22%, which reflects the sector average tax rate, and that the cost of capital for the plant will 
be 18%. A higher cost of capital was assumed due to the riskiness of the project and is also a 
reflection of the sector average.  
The economic analysis shows that the stirred tank process has a net present value (at 
18% and a life of 12 years) of about $3.8 billion. It has a return on investment (ROI) of 249% 
and an internal rate of return (IRR) of 243%. The fluidized bioreactor process has a net 
present value of about $17 billion, an ROI of about 229% and IRR of 226%. The IRR and 
ROI values for biotechnology projects are incredibly high due to the high market price of the 
product. Furthermore, drug companies rarely see a drug as successful as Rituxan®. The 
success of one drug helps pay for the failures of 10,000 others. A high ROI and IRR are to be 
expected in processes such as these due to the relatively low investment compared to the 
generated earnings. Furthermore, the cost of development is out-of-scope of this project and 
therefore not included in the economic analysis. However, each successful drug costs a 
company several millions of dollars and therefore the realized ROI or IRR of a 
biopharmaceutical process is much less than 500-600%.  
13.2.1. Stirred Tank Process 
 
 
Profitability Measures
The Internal Rate of Return (IRR) for this project is
The Net Present Value (NPV) of this project in 2015 is
ROI Analysis (Third Production Year)
Annual Sales
Annual Costs
Depreciation
Income Tax
Net Earnings
Total Capital Investment
ROI
243.03%
3,807,362,600$   
1,611,764,957     
(253,790,021)      
(1,734,736)         
(302,441,565)      
1,053,798,635     
423,677,306       
248.73%
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13.2.2. Fluidized Bioreactor Process 
 
13.2.3. Price of Generic Rituximab 
Currently, pricing information for Rituxan® is available for the United States 
market alone. Each unit of Rituxan® (assuming a unit refers to 100mg of product) is sold 
for about $1450 per 100mg. The generic version can be marketed for 30% lower prices 
than the brand-name drug. Normally, most generic small molecule drugs are marketed at 
70% lower prices. However, due to the high cost of production and the high market price 
of therapeutic proteins, even a 30% decrease offers a great discount to consumers. 
Therefore, generic rituximab will be marketed at about $10.3 million per kg.  
13.2.4. Plant Life 
The new facility is expected to have a life of about 10 years. Most of the capital 
investment (main production units and machinery) normally has a longer lifespan, but the 
marketing life of the drug can be assumed to be about 10 years for a preliminary analysis. 
In the unfortunate case that the plant ahs to be shut down in as little as five years due to 
inability to sell generic rituximab or due to other innovations in the field, the plant will 
have some finite salvage value. However, for the purposes of the economic calculations, 
it is assumed the plant will operate for 10 years and allow two additional years for design 
and construction.  
Profitability Measures
The Internal Rate of Return (IRR) for this project is
The Net Present Value (NPV) of this project in 2015 is
ROI Analysis (Third Production Year)
Annual Sales
Annual Costs
Depreciation
Income Tax
Net Earnings
Total Capital Investment
ROI
224.53%
16,625,953,100$ 
7,104,371,792     
(1,155,142,234)    
(20,597,570)        
(1,304,299,037)    
4,624,332,951     
2,020,253,396     
228.90%
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13.2.5. Input and Cost Summaries 
13.2.5.1. Stirred Tank Process 
 
General Information
Process Title: Monoclonal Antibody Production via Fluidized Bed Bioreactor
Product: Rituximab
Plant Site Location: Philadelphia, PA
Site Factor: 1.00
Operating Hours per Year: 7920
Operating Days Per Year: 330
Operating Factor: 0.9041
Product Information
This Process will Yield
0 kg of Rituximab per hour
0 kg of Rituximab per day
152 kg of Rituximab per year
Price $10,262,244.00 /kg
Chronology
Production Depreciation Product Price
Year Action Capacity 7 year MACRS
2015 Design 0.0%
2016 Construction 0.0%
2017 Production 100.0% 14.29% $10,262,244.00
2018 Production 100.0% 24.49% $10,426,439.90
2019 Production 100.0% 17.49% $10,593,262.94
2020 Production 100.0% 12.49% $10,762,755.15
2021 Production 100.0% 8.93% $10,934,959.23
2022 Production 100.0% 8.92% $11,109,918.58
2023 Production 100.0% 8.93% $11,287,677.28
2024 Production 100.0% 4.46% $11,468,280.11
2025 Production 100.0% $11,651,772.60
2026 Production 100.0% $11,838,200.96
0%
Distribution of
Permanent Investment
100%
0%
0%
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Variable Cost Summary
Variable Costs at 100% Capacity:
General Expenses
Selling / Transfer Expenses: 15,614,004$    
Direct Research: 156,140,042$  
Allocated Research: 7,807,002$      
Administrative Expense: 31,228,008$    
Management Incentive Compensation: 19,517,505$    
Total General Expenses 230,306,563$  
Raw Materials $21,364.976000 per kg of Rituximab $3,250,681
Byproducts $0.000000 per kg of Rituximab $0
Utilities $7,533.844106 per kg of Rituximab $1,146,274
Total Variable Costs 234,703,518$  
Fixed Cost Summary
Operations
Direct Wages and Benefits 5,241,600$      
Direct Salaries and Benefits 786,240$        
Operating Supplies and Services 314,496$        
Technical Assistance to Manufacturing -$              
Control Laboratory -$              
Total Operations 6,342,336$      
Maintenance
Wages and Benefits 871,240$        
Salaries and Benefits 217,810$        
Materials and Services 871,240$        
Maintenance Overhead 43,562$          
Total Maintenance 2,003,852$      
Operating Overhead
General Plant Overhead: 505,299$        
Mechanical Department Services: 170,805$        
Employee Relations Department: 419,897$        
Business Services: 526,650$        
Total Operating Overhead 1,622,651$      
Property Taxes and Insurance
Property Taxes and Insurance: 387,218$        
Other Annual Expenses
Rental Fees (Office and Laboratory Space): -$              
Licensing Fees: -$              
Miscellaneous: 800,000$        
Total Other Annual Expenses 800,000$        
Total Fixed Costs 11,156,057$     
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Investment Summary
Bare Module Costs
Fabricated Equipment -$              
Process Machinery 14,915,939$    
Spares -$              
Storage -$              
Other Equipment -$              
Catalysts -$              
Computers, Software, Etc. -$              
Total Bare Module Costs: 14,915,939$    
Direct Permanent Investment
Cost of Site Preparations: 745,797$        
Cost of Service Facilities: 745,797$        
Allocated Costs for utility plants and related facilities: -$              
Direct Permanent Investment 16,407,533$    
Total Depreciable Capital
Cost of Contingencies & Contractor Fees 2,953,356$      
Total Depreciable Capital 19,360,889$    
Total Permanent Investment
Cost of Land: 387,218$        
Cost of Royalties: -$              
Cost of Plant Start-Up: 1,936,089$      
Total Permanent Investment - Unadjusted 21,684,196$    
Site Factor 1.00
Total Permanent Investment 21,684,196$    
Working Capital
2016
Accounts Receivable 385,002,844$  
Cash Reserves 945,397$        
Accounts Payable (1,084,181)$     
Rituximab Inventory 17,111,238$     
Raw Materials 17,812$          
Total 401,993,110$   
Present Value at 18% 340,672,127$  
Total Capital Investment 362,356,323$  
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13.2.5.2. Fluidized Bioreactor Process 
 
 
General Information
Process Title: Monoclonal Antibody Production via Fluidized Bed Bioreactor
Product: Rituximab
Plant Site Location: Philadelphia, PA
Site Factor: 1.00
Operating Hours per Year: 7920
Operating Days Per Year: 330
Operating Factor: 0.9041
Product Information
This Process will Yield
0 kg of Rituximab per hour
2 kg of Rituximab per day
671 kg of Rituximab per year
Price $10,262,244.00 /kg
Chronology
Production Depreciation Product Price
Year Action Capacity 7 year MACRS
2015 Design 0.0%
2016 Construction 0.0%
2017 Production 100.0% 14.29% $10,262,244.00
2018 Production 100.0% 24.49% $10,426,439.90
2019 Production 100.0% 17.49% $10,593,262.94
2020 Production 100.0% 12.49% $10,762,755.15
2021 Production 100.0% 8.93% $10,934,959.23
2022 Production 100.0% 8.92% $11,109,918.58
2023 Production 100.0% 8.93% $11,287,677.28
2024 Production 100.0% 4.46% $11,468,280.11
2025 Production 100.0% $11,651,772.60
2026 Production 100.0% $11,838,200.96
0%
Distribution of
Permanent Investment
100%
0%
0%
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Variable Cost Summary
Variable Costs at 100% Capacity:
General Expenses
Selling / Transfer Expenses: 68,823,739$      
Direct Research: 688,237,394$    
Allocated Research: 34,411,870$      
Administrative Expense: 137,647,479$    
Management Incentive Compensation: 86,029,674$      
Total General Expenses 1,015,150,156$ 
Raw Materials $81,786.793414 per kg of Rituximab $54,850,313
Byproducts $0.000000 per kg of Rituximab $0
Utilities $2,569.985019 per kg of Rituximab $1,723,560
Total Variable Costs 1,071,724,029$ 
Fixed Cost Summary
Operations
Direct Wages and Benefits 10,483,200$      
Direct Salaries and Benefits 1,572,480$        
Operating Supplies and Services 628,992$          
Technical Assistance to Manufacturing -$                
Control Laboratory -$                
Total Operations 12,684,672$      
Maintenance
Wages and Benefits 10,344,762$      
Salaries and Benefits 2,586,190$        
Materials and Services 10,344,762$      
Maintenance Overhead 517,238$          
Total Maintenance 23,792,952$      
Operating Overhead
General Plant Overhead: 1,774,051$        
Mechanical Department Services: 599,679$          
Employee Relations Department: 1,474,211$        
Business Services: 1,849,011$        
Total Operating Overhead 5,696,952$        
Property Taxes and Insurance
Property Taxes and Insurance: 4,597,672$        
Other Annual Expenses
Rental Fees (Office and Laboratory Space): -$                
Licensing Fees: -$                
Miscellaneous: 550,000$          
Total Other Annual Expenses 550,000$          
Total Fixed Costs 47,322,248$      
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Investment Summary
Bare Module Costs
Fabricated Equipment -$                
Process Machinery 177,106,004$    
Spares -$                
Storage -$                
Other Equipment -$                
Catalysts -$                
Computers, Software, Etc. -$                
Total Bare Module Costs: 177,106,004$    
Direct Permanent Investment
Cost of Site Preparations: 8,855,300$        
Cost of Service Facilities: 8,855,300$        
Allocated Costs for utility plants and related facilities: -$                
Direct Permanent Investment 194,816,605$    
Total Depreciable Capital
Cost of Contingencies & Contractor Fees 35,066,989$      
Total Depreciable Capital 229,883,593$    
Total Permanent Investment
Cost of Land: 4,597,672$        
Cost of Royalties: -$                
Cost of Plant Start-Up: 22,988,359$      
Total Permanent Investment - Unadjusted 257,469,625$    
Site Factor 1.00
Total Permanent Investment 257,469,625$    
Working Capital
2016
Accounts Receivable 1,697,023,711$ 
Cash Reserves 3,985,957$        
Accounts Payable (13,949,722)$     
Rituximab Inventory 75,423,276$      
Raw Materials 300,550$          
Total 1,762,783,771$ 
Present Value at 18% 1,493,884,552$ 
Total Capital Investment 1,751,354,176$ 
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13.2.6. Fixed Costs 
For both designs, the plant will run for 24 hours and require 3 total shifts. Each 
shift for the stirred tank process will have 20 operators and each shift for the fluidized 
bed reactor will have 40 operators. Because this is a brownfield site, annual expenses 
were estimated to include the cost of using the site’s existing equipment such as quality 
control labs, waste treatment systems, and WFI stills.  The operators will have direct 
wages and benefits totaling $42.00/hr. Engineers and scientists will be placed throughout 
the facility for the production of monoclonal antibody. They will work with the seed 
train, production, and purification process and will operate all the machinery. There will 
also be people working in the culture labs and managing the material, for example 
measuring media, buffer, etc. For the fluidized bed process, many more workers are 
needed per shift in order to manage all of the media and buffer prep solutions. There 
needs to be maintenance and utility personnel, IT and auto control personnel, and people 
to manage quality control, CIP & SIP procedures, and waste management. Again, 
additional workers are needed to manage the fluidized bed facility because it is larger in 
surface area due to the increased number of storage tanks and pumps. For the facilities, 
regulatory personnel are also needed. Lastly, management positions will be needed to 
manage the engineering, financial, and human resources related issues.  
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13.2.6.1. Stirred Tank Process 
 
Fixed Costs
Operations
Operators per Shift: 20 (assuming 3 shifts)
Direct Wages and Benefits: $42 /operator hour
Direct Salaries and Benefits: 15% of Direct Wages and Benefits
Operating Supplies and Services: 6% of Direct Wages and Benefits
Technical Assistance to Manufacturing: $0.00 per year, for each Operator per Shift
Control Laboratory: $0.00 per year, for each Operator per Shift
Maintenance
Wages and Benefits: 4.50% of Total Depreciable Capital
Salaries and Benefits: 25.00% of Maintenance Wages and Benefits
Materials and Services: 100.00% of Maintenance Wages and Benefits
Maintenance Overhead: 5.00% of Maintenance Wages and Benefits
Operating Overhead
General Plant Overhead: 7.10% of Maintenance and Operations Wages and Benefits
Mechanical Department Services: 2.40% of Maintenance and Operations Wages and Benefits
Employee Relations Department 5.90% of Maintenance and Operations Wages and Benefits
Business Services 7.40% of Maintenance and Operations Wages and Benefits
Property Taxes and Insurance
Property Taxes and Insurance: 2.00% of Total Depreciable Capital
Straight Line Depreciation
Direct Plant: 8.00% of Total Depreciable Capital, less 1.18 times the Allocated Costs 
for Utility Plants and Related Facilities
Allocated Plant: 6.00% of 1.18 times the Allocated Costs for Utility Plants and Related Facilities
Other Annual Expenses
Rental Fees (Office and Laboratory Space): $0
Licensing Fees: $0
Miscellaneous: $800,000
Depletion Allowance
Annual Depletion Allowance: $0
110 Monoclonal Antibody Production via Fluidized Bioreactor Technology 
 
 
13.2.6.2. Fluidized Bioreactor Process 
 
13.2.7. Raw Materials and Equipment Costs 
Equipment costs were combined for similar units. The bare module cost was 
assumed to be 3.21 for all equipment.  
 
 
 
 
 
Fixed Costs
Operations
Operators per Shift: 40 (assuming 3 shifts)
Direct Wages and Benefits: $42 /operator hour
Direct Salaries and Benefits: 15% of Direct Wages and Benefits
Operating Supplies and Services: 6% of Direct Wages and Benefits
Technical Assistance to Manufacturing: $0.00 per year, for each Operator per Shift
Control Laboratory: $0.00 per year, for each Operator per Shift
Maintenance
Wages and Benefits: 4.50% of Total Depreciable Capital
Salaries and Benefits: 25.00% of Maintenance Wages and Benefits
Materials and Services: 100.00% of Maintenance Wages and Benefits
Maintenance Overhead: 5.00% of Maintenance Wages and Benefits
Operating Overhead
General Plant Overhead: 7.10% of Maintenance and Operations Wages and Benefits
Mechanical Department Services: 2.40% of Maintenance and Operations Wages and Benefits
Employee Relations Department 5.90% of Maintenance and Operations Wages and Benefits
Business Services 7.40% of Maintenance and Operations Wages and Benefits
Property Taxes and Insurance
Property Taxes and Insurance: 2.00% of Total Depreciable Capital
Straight Line Depreciation
Direct Plant: 8.00% of Total Depreciable Capital, less 1.18 times the Allocated Costs 
for Utility Plants and Related Facilities
Allocated Plant: 6.00% of 1.18 times the Allocated Costs for Utility Plants and Related Facilities
Other Annual Expenses
Rental Fees (Office and Laboratory Space): $0
Licensing Fees: $0
Miscellaneous: $550,000
Depletion Allowance
Annual Depletion Allowance: $0
Bare Module Factor Calculator:
Cost of Installation Materials: 71% of Equipment Purchase Cost
Cost of Installation Labor: 54% of Equipment Purchase Cost
Cost for Freight, Insurances, and Taxes: 9% of Equipment Purchase Cost
Cost of Construction Overhead: 57% of Equipment Purchase Cost
Cost of Contractor Engineering Expenses: 30% of Equipment Purchase Cost
Total Derived Bare Module Factor: 3.21 of Equipment Purchase Cost
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13.2.7.1. Stirred Tank Process 
 
 
 
 
 
 
13.2.7.2. Fluidized Bioreactor Process 
 
 
 
Raw Materials
Raw Material: Unit: Required Ratio: Cost of Raw Material:
1 Resin L 3.947 L per kg of Rituximab $4000.000 per L
2 Media kg 52.755 kg per kg of Rituximab $35.200 per kg
3 Rituximab kg 1 kg per kg of Rituximab $0.000E+00 per kg
4 Buffer kg 3000 kg per kg of Rituximab $1.240 per kg
5 Microcarriers kg 0 kg per kg of Rituximab $4488.000 per kg
6
7
8
9
10
Total Weighted Average: $21364.976 per kg of Rituximab
Equipment Costs
Equipment Description Type Purchase Cost
Name
PID Controls Process Machinery $162,500
Bioreactor Rocker Process Machinery $1,020,980
Pump Process Machinery $299,000
Mixing Tank Process Machinery $260,230
Sterile Filter Process Machinery $10,000
Ultrafiltration Unit Process Machinery $120,000
Production Bioreactor Process Machinery $900,000
Centrifuge Process Machinery $480,000
Storage Tank Process Machinery $679,000
Protein A Column Process Machinery $200,000
Cation Ex Column Process Machinery $250,000
Anion Ex Column Process Machinery $250,000
Nanofiltration Unit Process Machinery $15,000
Bare Module Cost
$521,625
$3,277,346
$959,790
$835,338
$32,100
$385,200
$2,889,000
$1,540,800
$2,179,590
$642,000
$802,500
$802,500
$48,150
Raw Materials
Raw Material: Unit: Required Ratio: Cost of Raw Material:
1 Resin L 0.895 L per kg of Rituximab $4000.000 per L
2 Media kg 3080.597 kg per kg of Rituximab $0.035 per kg
3 Rituximab kg 1 kg per kg of Rituximab $0.000E+00 per kg
4 Buffer kg 517.91 kg per kg of Rituximab $1.240 per kg
5 Microcarriers kg 17.2585 kg per kg of Rituximab $4488.000 per kg
6
7
8
9
10
Total Weighted Average: $81786.793 per kg of Rituximab
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13.2.8. Other Variable Costs and Working Capital 
For the purposes of working capital, it was assumed that about one percent of 
sales would be spent on selling/transfer costs paid to a sister facility. Ten percent of sales 
would be recycled back into research and development. Furthermore, the accounts 
payable and receivable periods were extended to 90 days.  
13.2.8.1. Stirred Tank Process 
 
 
 
Equipment Costs
Equipment Description Type Purchase Cost Bare Module Cost
Name
PID Controls Process Machinery $1,620,000 $5,200,200
Bioreactor Rocker Process Machinery $3,329,980 $10,689,236
Pump Process Machinery $2,444,000 $7,845,240
Mixing Tank Process Machinery $405,230 $1,300,788
Sterile Filter Process Machinery $10,000 $32,100
Ultrafiltration Unit Process Machinery $72,000 $385,200
Fluidized Bioreactor Process Machinery $1,500,000 $4,815,000
Tangential Flow Filtration Process Machinery $25,000,000 $80,250,000
Storage Tanks Process Machinery $19,529,000 $62,688,090
Protein A Column Process Machinery $200,000 $642,000
Cation Ex Column Process Machinery $250,000 $802,500
Anion Ex Column Process Machinery $250,000 $802,500
Nanofiltration Unit Process Machinery $15,000 $48,150
Autoclave Sterilizer Process Machinery $500,000 $1,605,000
Other Variable Costs
General Expenses
Selling / Transfer Expenses: 1.00% of Sales
Direct Research: 10.00% of Sales
Allocated Research: 0.50% of Sales
Administrative Expense: 2.00% of Sales
Management Incentive Compensation: 1.25% of Sales
Working Capital
Accounts Receivable ! 90 Days
Cash Reserves (excluding Raw Materials) ! 30 Days
Accounts Payable ! 90 Days
Rituximab Inventory ! 4 Days
Raw Materials ! 2 Days
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13.2.8.2. Fluidized Bioreactor Process 
 
 
13.2.9. Utilities 
As described in the previous section 10, large amounts of process water and 
electricity will be required for both processes.   
13.2.9.1. Stirred Tank Process 
 
13.2.9.2. Fluidized Bioreactor Process 
 
 
Other Variable Costs
General Expenses
Selling / Transfer Expenses: 1.00% of Sales
Direct Research: 10.00% of Sales
Allocated Research: 0.50% of Sales
Administrative Expense: 2.00% of Sales
Management Incentive Compensation: 1.25% of Sales
Working Capital
Accounts Receivable ! 90 Days
Cash Reserves (excluding Raw Materials) ! 30 Days
Accounts Payable ! 90 Days
Rituximab Inventory ! 4 Days
Raw Materials ! 2 Days
Utilities
Utility: Unit: Required Ratio Utility Cost
1 High Pressure Steam lb 0 lb per kg of Rituximab per lb
2 Low Pressure Steam lb 0 lb per kg of Rituximab $0.000E+00 per lb
3 Process Water kg 20368.73275 kg per kg of Rituximab $4.730E-03 per kg
4 Cooling Water lb 0 lb per kg of Rituximab per lb
5 Electricity kWh 8.75E+04 kWh per kg of Rituximab $0.085 per kWh
6
7
8
9
10
Total Weighted Average: $7533.844 per kg of Rituximab
Utilities
Utility: Unit: Required Ratio Utility Cost
1 High Pressure Steam lb 0 lb per kg of Rituximab per lb
2 Low Pressure Steam lb 0 lb per kg of Rituximab $0.000E+00 per lb
3 Process Water kg 157107.69 kg per kg of Rituximab $4.730E-03 per kg
4 Cooling Water lb 0 lb per kg of Rituximab per lb
5 Electricity kWh 2.15E+04 kWh per kg of Rituximab $0.085 per kWh
6
7
8
9
10
Total Weighted Average: $2569.985 per kg of Rituximab
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13.3. Sensitivity Analysis 
A sensitivity analysis must be conducted to determine the effect of key variables on 
the profitability of a plant. Furthermore, a sensitivity analysis will help determine which 
process design is superior.  
13.3.1. Variable Cost 
In the base cases for both designs, the variable costs for the stirred tank process 
are about $235 million and about $1 billion for the fluidized bioreactor. There is a 
significant difference between the two cases because variable costs were calculated as a 
percentage of products produced. In terms of variable costs per kg, the stirred tank costs 
$1.5 million per kg while the fluidized bioreactor costs $1.6 million per kg. The fluidized 
bioreactor process does have a higher variable cost to produce the same amount of 
product. However, other factors such as total permanent investment, product price, and 
ultimately the cash flow from revenue can affect the profitability of a project. 
Furthermore, changes in product price and variable costs, which may positively or 
negatively impact revenue, can drastically change the internal rate of return for the 
processes. For both processes, the internal rates of return are extremely high, but can 
yield negative IRR values for low variable costs and low product prices. 
  
Table 13.2: The effect of variable costs and product prices on the internal rate of return of the stirred tank process.  
 
 
Sensitivity Analyses
$2,347,035 $48,818,332 $95,289,628 $141,760,925 $188,232,222 $234,703,518 $281,174,815 $327,646,111 $374,117,408 $420,588,704 $467,060,001
Variable Costs
$102,622
$2,134,547
$4,166,471
$6,198,395
$8,230,320
$10,262,244
$12,294,168
$14,326,093
$16,358,017
$18,389,941
$20,421,866
Pr
od
uc
t P
ric
e
0.08% Negative IRR Negative IRR Negative IRR Negative IRR Negative IRR Negative IRR Negative IRR Negative IRR Negative IRR Negative IRR
205.86% 175.45% 145.05% 114.63% 84.16% 53.53% 22.12% -12.92% Negative IRR Negative IRR Negative IRR
249.20% 230.68% 212.16% 193.64% 175.13% 156.61% 138.09% 119.56% 101.03% 82.47% 63.87%
268.17% 254.86% 241.55% 228.23% 214.92% 201.61% 188.30% 174.98% 161.67% 148.35% 135.04%
278.82% 268.43% 258.04% 247.65% 237.26% 226.86% 216.47% 206.08% 195.69% 185.29% 174.90%
285.64% 277.12% 268.60% 260.07% 251.55% 243.03% 234.51% 225.98% 217.46% 208.94% 200.42%
290.38% 283.16% 275.93% 268.71% 261.49% 254.27% 247.04% 239.82% 232.60% 225.37% 218.15%
293.86% 287.60% 281.33% 275.06% 268.80% 262.53% 256.26% 249.99% 243.73% 237.46% 231.19%
296.53% 291.00% 285.47% 279.93% 274.40% 268.86% 263.33% 257.79% 252.26% 246.72% 241.19%
298.65% 293.69% 288.73% 283.78% 278.82% 273.87% 268.91% 263.96% 259.00% 254.04% 249.09%
300.36% 295.87% 291.38% 286.90% 282.41% 277.93% 273.44% 268.95% 264.47% 259.98% 255.49%
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Table 13.3: The effect of variable costs and product prices on the internal rate of return of the fluidized bioreactor 
process.  
 
 
13.3.2. Overall Product Yield 
In the base case, it is assumed that 85% of the product will be recovered after 
downstream purification. However, technical errors or errors in process design may often 
lower the yield of a process. Assuming only the yield changes but all other costs remain 
constant, product yield can dramatically change the profitability of a project. For the 
stirred tank process, in the lower limit of only 5% yield, the NPV is about $175 million, 
the IRR and ROI are about 115%. In the upper limit of complete product recovery, the 
ROI and IRR are approximately 250% and the NPV is about $4.5 billion. On the other 
hand, the range of 5% to 100% product yield for the fluidized bioreactor process yields 
an NPV range of  $654 million to $19.6 billion and IRR and ROI ranges of 65% to 230%. 
For all product yields, the fluidized bioreactor process is the fiscally superior process.   
 
Sensitivity Analyses
$10,717,240 $222,918,598 $435,119,956 $647,321,314 $859,522,672 $1,071,724,029 $1,283,925,387 $1,496,126,745 $1,708,328,103 $1,920,529,461 $2,132,730,819
Variable Costs
$102,622
$2,134,547
$4,166,471
$6,198,395
$8,230,320
$10,262,244
$12,294,168
$14,326,093
$16,358,017
$18,389,941
$20,421,866
Pr
od
uc
t P
ric
e
-5.73% Negative IRR Negative IRR Negative IRR Negative IRR Negative IRR Negative IRR Negative IRR Negative IRR Negative IRR Negative IRR
161.27% 136.79% 112.28% 87.73% 63.04% 37.87% 10.87% Negative IRR Negative IRR Negative IRR Negative IRR
213.27% 196.92% 180.57% 164.22% 147.86% 131.51% 115.14% 98.76% 82.36% 65.90% 49.31%
239.35% 227.08% 214.80% 202.53% 190.25% 177.97% 165.70% 153.42% 141.14% 128.86% 116.58%
255.03% 245.20% 235.37% 225.55% 215.72% 205.90% 196.07% 186.24% 176.41% 166.59% 156.76%
265.49% 257.30% 249.11% 240.91% 232.72% 224.53% 216.34% 208.14% 199.95% 191.76% 183.57%
272.97% 265.94% 258.92% 251.90% 244.87% 237.85% 230.82% 223.80% 216.77% 209.75% 202.73%
278.58% 272.43% 266.28% 260.14% 253.99% 247.84% 241.69% 235.55% 229.40% 223.25% 217.10%
282.95% 277.48% 272.01% 266.55% 261.08% 255.62% 250.15% 244.69% 239.22% 233.76% 228.29%
286.44% 281.52% 276.60% 271.68% 266.76% 261.84% 256.92% 252.00% 247.08% 242.16% 237.24%
289.30% 284.83% 280.35% 275.88% 271.41% 266.94% 262.46% 257.99% 253.52% 249.04% 244.57%
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Figure 13.1: The impact of product yield on net present value of project, the internal rate of return, and the 
return on investment for the stirred tank process.  
 
Figure 13.2: The impact of product yield on net present value of project, the internal rate of return, and the 
return on investment for the fluidized bioreactor process.  
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13.3.3. Product Price 
In the base case, it is assumed that the product will be sold for about 
$10.3MM/kg. Due to the unpredictability of pharmaceutical markets, the product’s 
selling price may change due to an increase in process costs or a decrease in the demand 
for the drug. For the stirred tank process, given the range of product price to be 
$100,000/kg to $20.5MM/kg, the NPV ranges from -$26MM to $7.6 billion and the IRR 
and ROI values range from negative values to 255%. For the fluidized bioreactor process, 
the NPV ranges from -$340MM to $34 billion and the IRR and ROI values range from 
negative values to 245%. In the case that the product price is greater than $105,000/kg, 
the fluidized bioreactor process is more favorable.  
13.3.3.1. Stirred Tank Process 
 
Figure 13.3: The impact of product price on net present value of project, the internal rate of return, and the 
return on investment for stirred tank process.  
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13.3.3.2. Fluidized Bioreactor Process 
 
Figure 13.4: The impact of product price on net present value of project, the internal rate of return, and the return on 
investment for the fluidized bioreactor process.  
13.3.4. Plant Life 
In the base case, it is assumed the plant has an operational life of 10 years. For 
both processes, if as the life span increases, the NPV also increases but then levels out to 
an approximately constant value. Regardless of plant life, the fluidized bioreactor process 
has a significantly larger NPV.  
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Figure 13.5: The impact of plant life on the net present value of the project for both processes. 
13.3.5. Cost of Capital 
The cost of capital determines the riskiness of a project and gives a minimum 
value of return required for a project to be acceptable. The cost of capital of the project is 
assumed to be 18% for the base case. However, as the cost of capital increases, the NPV 
of the project will decrease. Regardless of the cost of capital, the fluidized bioreactor 
consistently has a significantly higher NPV of the project.   
 
Figure 13.6: The impact of cost of capital on the net present value of the project for both processes.  
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13.3.6. Differential Present Worth Analysis 
To ultimately determine which process is preferable the after-tax cash flows 
have to be analyzed for both projects. The after-tax cash flow includes capital costs, 
working capital, variable and fixed costs, depreciation, and taxes.  
 
Table 13.4: The after-tax cash flow for the stirred tank process.  
 
 
Table 13.5: The after-tax cash flow for the stirred tank process.  
 
 
Next, the stirred tank process is chosen as the “base case” because it has the 
lowest initial investment. The fluidized bioreactor process is chosen as the “alternative.” 
For the years 2015 to 2026, the cash flow of the stirred tank process was subtracted from 
the cash flow for the fluidized bioreactor process.  
 
Year
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Sales Capital Costs
-                     -                 
-                     (21,684,196)    
1,561,400,400    -                 
1,586,382,800    -                 
1,611,765,000     -                 
1,637,553,200    -                 
1,663,754,000    -                 
1,690,374,100    -                 
1,717,420,100    -                 
1,744,898,800    -                 
1,772,817,200    -                 
1,801,182,300    -                 
Working Capital Var Costs
-                     -                   
(401,993,100)      -                   
-                     (234,703,518)    
-                     (238,458,774)    
-                     (242,274,115)    
-                     (246,150,501)    
-                     (250,088,909)    
-                     (254,090,331)    
-                     (258,155,776)    
-                     (262,286,269)    
-                     (266,482,849)    
401,993,100       (270,746,575)    
Fixed Costs
-                 
-                 
(11,156,057)    
(11,334,554)    
(11,515,906)    
(11,700,161)    
(11,887,364)    
(12,077,561)    
(12,270,802)    
(12,467,135)    
(12,666,609)    
(12,869,275)    
Depreciation
-               
-               
(2,766,700)   
(4,741,500)   
(3,386,200)   
(2,418,200)   
(1,728,900)   
(1,727,000)   
(1,728,900)   
(863,500)      
-               
-               
Taxible Income Taxes
-                     -                   
-                     -                   
1,312,774,200    (292,748,642)    
1,331,848,000    (297,002,109)    
1,354,588,700    (302,073,284)    
1,377,284,400    (307,134,412)    
1,400,048,800    (312,210,893)    
1,422,479,200    (317,212,868)    
1,445,264,600    (322,294,004)    
1,469,281,900    (327,649,868)    
1,493,667,700    (333,087,906)    
1,517,566,400    (338,417,313)    
Cash Flow
-                     
(423,677,306)      
1,022,792,208    
1,039,587,395    
1,055,901,652    
1,072,568,122    
1,089,566,882    
1,106,993,351    
1,124,699,515    
1,142,495,547    
1,160,579,835    
1,581,142,223    
Year
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Sales Capital Costs
-                      -                    
-                      (257,469,625)    
6,882,373,900     -                    
6,992,491,900     -                    
7,104,371,800     -                    
7,218,041,700     -                    
7,333,530,400     -                    
7,450,866,900     -                    
7,570,080,800     -                    
7,691,202,100     -                    
7,814,261,300     -                    
7,939,289,500     -                    
Working Capital Var Costs
-                      -                    
(1,762,783,800)   -                    
-                      (1,071,724,029) 
-                      (1,088,871,614) 
-                      (1,106,293,560) 
-                      (1,123,994,257) 
-                      (1,141,978,165) 
-                      (1,160,249,815) 
-                      (1,178,813,812) 
-                      (1,197,674,833) 
-                      (1,216,837,631) 
1,762,783,800     (1,236,307,033) 
Fixed Costs
-                  
-                  
(47,322,248)    
(48,079,404)    
(48,848,674)    
(49,630,253)    
(50,424,337)    
(51,231,127)    
(52,050,825)    
(52,883,638)    
(53,729,776)    
(54,589,452)    
Depreciation
-               
-               
(32,850,400) 
(56,298,500) 
(40,206,600) 
(28,712,500) 
(20,528,600) 
(20,505,600) 
(20,528,600) 
(10,252,800) 
-               
-               
Taxible Income Taxes
-                      -                    
-                      -                    
5,730,477,300     (1,260,705,005) 
5,799,242,400     (1,275,833,331) 
5,909,022,900     (1,299,985,042) 
6,015,704,800     (1,323,455,050) 
6,120,599,300     (1,346,531,846) 
6,218,880,300     (1,368,153,674) 
6,318,687,500     (1,390,111,255)  
6,430,390,800     (1,414,685,971) 
6,543,693,900     (1,439,612,655) 
6,648,393,000     (1,462,646,457) 
Cash Flow
-                      
(2,020,253,396)   
4,502,622,656     
4,579,707,573     
4,649,244,516     
4,720,962,182     
4,794,596,061     
4,871,232,279     
4,949,104,873     
5,025,957,616     
5,104,081,230     
6,948,530,301     
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Table 13.6: The after-tax cash flow for the stirred tank process. 
 
 
Then, the net present value of the differential cash flow amounts is calculated to 
determine which process is more favorable. The NPV was calculated for costs of capital 
ranging from 5% to 30%. For all values, the differential NPV was extremely positive 
indicating the fluidized bioreactor is the more favorable process.  
 
 
Figure 13.7: Differential net present value of the difference in cash flows between the two processes for 
varying costs of capital.  
 
 
 
 
Year (FB-Tank) Cash Flows
2015 -$                            
2016 (1,596,576,090)$           
2017 3,479,830,448$            
2018 3,540,120,179$            
2019 3,593,342,865$            
2020 3,648,394,060$            
2021 3,705,029,179$            
2022 3,764,238,928$            
2023 3,824,405,359$            
2024 3,883,462,068$            
2025 3,943,501,394$            
2026 5,367,388,078$            
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14. Additional Consideration 
Along with creating a cost-effective design to produce rituximab, FDA 
regulations and good manufacturing practices (GMP) must always be followed. 
Furthermore, plants of this caliber will have significant waste requirements and all 
disposal must also abide by the rules instated by the Environmental Protection Agency.  
14.1. Environmental Concerns 
The monoclonal antibody production process creates biological and non-biological 
waste. First, several disposable units are used throughout the process which must be 
sterilized and disposed properly. Second, a variety of buffers are also used throughout 
downstream purification. Third, a significant amount of biowaste is generated. Any streams 
containing living cells and viruses are considered class II biohazarads and must be treated by 
the biowaste inactivation package. This package will heat the waste to 80°C for one minute 
and inactivate the CHO cells. After inactivation, the waste is combined with non-biological 
waste in the waste neutralization tank (which neutralizes content pH to 7.0). This waste can 
then be safely disposed into the sewage system.  
All disposable bags and filter membranes must be autoclaved or sterilized (if 
autoclaving is not possible for a certain unit) to thoroughly kill all cells and toxins. A 
contract waste disposal facility will be responsible for handling all landfill waste. 
Unfortunately, recycling services still do not exist for disposable bag bioreactors, which 
results in a significant carbon footprint for the plant.  
14.2. Current Good Manufacturing Practices 
Following good manufacturing practices, as set forth by the United States Food and 
Drug Administration (FDA), quality materials and units must be used, a strictly regulated and 
well-trained staff must be on the floor at all times to monitor plant and product safety, and 
the plant layout must be approved. To help ensure that product from every batch is 
consistently safe, operators will monitor various quality checkpoints throughout the process. 
These checkpoints are usually placed strategically throughout the process, especially at key 
decisions points. For example, there will be in-process quality checks after each 
chromatography column as well as a check at the end of the production process. Several 
other quality checks will also be routinely performed. A final quality check will be 
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performed at the end of the purification process before the drug is shipped to a contract 
facility for final packaging and shipping.  
All quality checks involve removing small samples from transfer streams and testing 
the samples in a quality control lab. Every check is documented and follows a validation 
protocol; these documents are stored to provide reference for the manufacturer and the FDA 
(refer to FDA’s Code of Federal Regulations Title 21, Subchapter C). Furthermore, sterility 
throughout the process is maintained by using standard CIP and SIP techniques (see 
Appendix G). As discussed before, disposable units such as the bag bioreactors help 
eliminate cross contamination and increase the sterility of the process.  
It is also important to note that changes in facility design or innovative facility ideas 
such as the fluidized bioreactor design require FDA approval before operating. In general, 
the FDA will analyze new designs and facilities on the basis of maintain product integrity. As 
long as sufficient trials can prove the consistency and safety of a design and as long as the 
process can produce the desired drug at the mandated purity level, a new design can receive 
FDA approval. 
14.3. Plant Layout 
Designing a plant is equally as important as designing the process. In a 
biopharmaceutical plant, all rooms must comply with stringent quality standards in order to 
avoid cross contamination during operation. Figure 14.1 shows a sample plant layout. The 
manufacturing and purification chambers are completely separated. A separate room is used 
for the cell bank and preparatory areas. Finally, quality control has been placed at the far side 
of the plant to ensure ample testing space and to decrease the any possibility of sample 
contamination. Similarly, the autoclave and waste area rooms are located further away from 
the main process area. In general, the plant will be equipped with air locks where needed, 
include air purification filters in each room, and include a closed layout so that each room 
can be completely isolated from the remainder of the plant in case of emergencies or spillage. 
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Figure 14.1: Sample facility design. 
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15. Conclusions and Recommendations 
Ultimately, it is recommended that the fluidized bioreactor process be 
implemented for the new facility. However, before the process is implemented, pilot-
scale studies should be conducted to verify that the calculations and assumptions made in 
the project are applicable on a larger scale. Assuming an 85% yield for the overall 
process and capturing 70% of the domestic and European markets, the overall production 
goal is 650 kg of rituximab. The fluidized bioreactor process requires only one process 
running for 212 days per year while the traditional stirred tank process requires 4 parallel 
processes running for 325 days to reach the production goal. Furthermore, the overall 
product yield per day for the fluidized bioreactor process is about 7-fold greater. An 
incremental analysis between the two processes at an assumed MARR of 18% gives a 
differential present worth of about $13 billion indicating that it is a favorable project. The 
fluidized bioreactor process has a higher total permanent investment but ultimately offers 
a more profitable payout. 
The fluidized bioreactor process is also superior to the stirred tank process for 
significant changes in plant life, variable cost, overall product yield, product price, and 
cost of capital. It is an extremely innovative process that requires deviation from the 
traditional stirred tank structure, but ultimately offers the solution to a key industry 
problem. It allows cells to grow to a higher cell density by two orders of magnitude, 
which ultimately allows for increased product formation. Despite disadvantages including 
increased media requirements and a heavier load on downstream purification, the 
fluidized bioreactor process is superior to the traditional stirred tank process. 
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Appendix A: Minimum Fluidization Velocity Calculations 
 
Particle Volume Calculation 
! = 4!"#$ 
Where a = major axis radius, b = minor axis radius, and c = vertical axis radius.  
Particle Surface Area Calculation 
 
!" = 4!( !"
!.! + !" !.! + !" !.!
3 )
!/!.! 
 
Effective Spherical Diameter  
! = !6 ∗ !!"  
 
Three values were calculated for D; Dmax = 1.31E-03 m, Davg = 9.12E-04 m, and Dmin = 4.98E-04 m. 
Minimum fluidization velocities were calculated for each of the three diameter sizes 
using the Ergun equation coupled with the bed mass balance: 
 
! !! − !!! = !
150!!
!!!!!!
(1 − !!)
!!!
!!" + !
1.75!!
!!!!!
1
!!!
!!"!  
Values  
ρs = 1320 kg/m3; ρf = 992.9 kg/m3; µf = 6.73E-4 kgm-1s-1; Φs = 0.99; εM = 0.35. 
 
Solving for  
Dmax, VoM  = 0.003158 m/s 
Davg, VoM = 0.001643 m/s 
Dmin, VoM = 0.000507 m/s 
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Appendix B: Nutrient Transport in a Fluidized Bed Reactor 
 
Cell-liquid mass transport. For Glucose, in microcarrier culture 
[S]b defined as the concentration of species S, glucose, in the bulk 
[S]s defined as the concentration of species S, glucose, at the surface of the cell 
Y defined as the cell surface coverage on the microcarrier 
RS is defined as the uptake rate per cell of species S.  
ShS is the Sherwood Number, given by the relation below.   
DS is the diffusion coefficient for glucose in media at 37oC.   
!ℎ! = 2+ !0.552!"
!
!!"!!/! 
Where Sc is the Schmidt Number which is the ratio of the viscous diffusion rate 
to the molecular mass diffusion rate.  
!"!! = !
!!
!!!!
 
And Re is the Reynold’s Number, given by the correlation for flow in an annular 
channel 
!" = !!(!! − !!)!!!!
 
The Sherwood number for the packed bed bioreactor, ShS,pb = 16; 
The Sherwood number for the fluidized bioreactor, ShS,fb = 338.3. 
The normalized concentration gradient of Glucose between the bulk medium and 
at the cell surface is given by the expression: 
 
[!]! − [!]!
[!]!
= ! !!!!!!![!]!!ℎ!
 
 
Using values of Y = 3.53E+08 cell/m2; RS = 4.03E-02 mol cell-1day-1; DS = 
0.0000864 m2day-1; de = 0.000911795 m; [S]b = 44.406 mol/m3; and the 
Sherwood Relations given above,  
 
[!]!![!]!
[!]!
= 0.01 for the fluidized bed bioreactor 
[!]!![!]!
[!]!
= 0.27 for the packed bed bioreactor 
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Appendix C: Fluidized Bed versus Packed Bed—Nutrient 
Composition Temporal Analysis 
 
Assumptions:   
1) Media has 8 g/L of glucose initially and the reactor has been charged initially with media.  
2) Cells in exponential growth phase (µnet = µg) 
3) No notable cell loss from the reactor, nor notable gain from the incoming stream. 
4) Glucose consumption is solely due to metabolic consumption of glucose by the cell.  No 
glucose consumption is attributed directly to product formation.   
5) All reactor systems are well mixed, such that there exists no spatial dependence on cell or 
substrate concentrations inside the reactor at a given time point.   
 
Cell Growth  
X is defined as cell concentration within the reactor 
µnet is defined as the specific growth rate of the cell culture 
!"
!" = !!!"#! 
Solving for µnet: 
ln !!!
= !!!"#! 
t = 12.8 days; µnet = 0.3325 day-1 
 
Substrate Consumption  
Glucose mass balance is given by the equation below: 
!!
!"
!" = !! !!! − !(!) − !
!!!!"#
!!
!
!(!)!
Where  
VR is the Volume of the Reactor (L);  
F is the flow rate of the nutrient rich stream through the reactor (L/day);  
So is the concentration of glucose at time zero (g Glucose/L);  
S is concentration of glucose in the reactor at time t (g Glucose/L);  
µnet is the specific growth rate calculated above (day-1);  
YX/S is the yield coefficient of cells on glucose (g cell/g glucose);  
X(t) is the concentration of cells in the reactor at time t (g cell/L).   
 
This equation was solved as follows:  
!!
!"
!" = !! !!! − !(!) − !
!!!!"#
!!
!
!(!)!
!"
!" = !
!
!!
!!! − !(!) − !
!!"#
!!
!
!(!)!
!"
!" + !
!
!!
! = ! !!!
!! − !
!!"#
!!
!
!(!)!
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With values of YX/S = 0.411 g cell/g glucose; Xo = 1.9 g cell/L; VR = 20000 L;  
µnet = 0.3325 day-1;  
So = 8 g/L.   
 
For Batch reactor, F = 0 L/day; for the Packed Bed Bioreactor, F = 106262.2 L/day; for the 
Fluidized Bioreactor, F = 671152 L/day.  These values were substituted into the equation and 
plotted for each bioreactor confirmation over the entire growth time of 12.8 days.  The results are 
plotted below:  
135 Monoclonal Antibody Production via Fluidized Bioreactor Technology 
 
 
 
Figure 1: The Glucose concentration plotted over the total growth time in different reactor confirmations.    The blue 
line corresponds to batch operation, the red line corresponds to packed bed operation, and the green line corresponds 
to a fluidized bioreactor operation.  In the packed bed and batch operation, the reactor will become nutrient deprived 
(<4g/L of glucose) before the end of the growth period. The fluidized bed bioreactor will be able to sustain cell 
growth and culture throughout the entirety of the growth period, having 4.78 g/L of glucose by the end of the 12.8 
day growth period.    
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Appendix D: Fluidized Bed versus Packed Bed—Nutrient 
Composition Spatial Analysis 
 
Assumptions:   
1) Media has 8 g/L of glucose initially and the reactor has been charged initially with media.  
2) Cells in exponential growth phase (µnet = µg) 
3) No notable cell loss from the reactor, nor notable gain from the incoming stream. 
4) Glucose consumption is solely due to metabolic consumption of glucose by the cell.  No 
glucose consumption is attributed directly to product formation.   
 
With spatial gradients, the diffusion equation becomes 
 
!"
!" + !∇ −!!∇! + !∇! = !! 
 
Where  
!! = !
!!"#
!!
!
!(!) 
 
u = 0.0005 m/s in the + y direction; 
DS = DS = 0.0000864 m2day-1 
 
These numbers were programmed into the Comsol Multiphysics 2D Transport of Diluted Species 
module.  The results are seen in Figure 2 below.  
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Figure D1: Comsol Multiphysics surface plots of Glucose Concentration Gradients in a Packed Bed Reactor. 
Surface concentration gradients are shown when the reactor was initially charged (A), after running for 60 hours (B), 
and after running for 72 hours (c).  Initially, the concentration is uniform at 44.406 mol/m3 in A.  By 60 hours (B), 
the majority of the packed bed will only have 9.27 mol/m3 (1.93 g/L) of glucose.  After 72 hours, the majority of the 
bed will have 0 g/L of glucose.  The reactor will be nutrient deprived after 60 hours, and have no glucose 
propagating through by 72 hours.   
 
A 
B 
C 
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Figure D2: Comsol Multiphysics surface plots of Glucose Concentration Gradients in a Packed Bed Reactor. 
Surface concentration gradients are shown when the reactor was initially charged (A), after running for 60 hours (B), 
and after running for 72 hours (c).  Initially, the concentration is uniform at 44.406 mol/m3 in A.  By 60 hours (B), 
the majority of the packed bed will only have 9.27 mol/m3 (1.93 g/L) of glucose.  After 72 hours, the majority of the 
bed will have 0 g/L of glucose.  The reactor will be nutrient deprived after 60 hours, and have no glucose 
propagating through by 72 hours.   
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Appendix E: Design Calculations for Fluidized Bioreactor 
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Appendix F: Process Design Calculations 
 
Stirred Tank Process 
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Fluidized Bed 
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Appendix G: CIP and SIP Procedures 
 
Clean-in-place and steam in place (CIP and SIP) procedures are used in biological processes to 
sterilize permanent equipment between each batch. These procedures are critical to preventing 
cross contamination2.  
 
The following CIP procedure will be used for the process where required:  
 
Each vessel will be washed with an amount of sterile water equal to half its 
volume for 10 minutes.  
Next, a cleaning solution of caustic (NaOH 0.5 M) equal to half the vessel’s 
volume will be sprayed into the tank.  
Sterile water will then be used as in step 1 to wash away the cleaning solution for 
10 minutes.  
Next, a cleaning solution of acid (H3PO4 5% w/w) equal to half the vessel’s 
volume will be sprayed into the tank.  
Sterile water will then be used as in step 1 to wash away the cleaning solution.  
Lastly, another half volume of sterile water will be used to wash the vessel once 
more before the next batch. This washing regime will use approximately 2 vessel 
volumes of water. This includes the water to be used to make the sterile wash solution.  
 
For certain units, the CIP procedure may be determined by the manufacturer protocol.  
 
 
Steam-in-place procedures are required for large, sturdy pieces of equipment such as stainless 
steel bioreactors.  
 
The following SIP procedure will be used for the process where required: 
 
Each reactor will be washed with an amount of sterile water equal to half its 
volume. 
Next, a cleaning solution of caustic (NaOH 0.5 M) equal to half the vessel’s 
volume will be sprayed into the vessel.  
Sterile water will then be used as in step 1 to wash away the cleaning solution.  
                                                
2 Stewart, J.m Seiberling, D., “The Secret’s Out: Clean in Place” Chemical Engineering, 1996 
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Next, a cleaning solution of acid (H3PO4 5% w/w) equal to half the vessel’s 
volume will be sprayed into the tank.  
Sterile water will then be used as in step 1 to wash away the cleaning solution.  
Five lb/hr of pure steam per cubic foot of vessel volume will be pumped into the 
vessel to heat it up to the temperature of the steam, 130°C. Note: The steam used in this 
procedure will be generated by a sterile steam generator at 130°C and 2 bars.  
Once the 130°C has been reached in the vessel, the steam flow rate will be 
reduced to one lb/hr of pure steam per cubic foot of vessel volume and held at the flow 
rate.  
Lastly, after thirty minutes, the flow rate of steam will be stopped and a half 
volume of sterile water will then be sprayed into the tank to wash it and cool it down to 
room temperature.  
 
For certain units, the SIP procedure may be determined by the manufacturer 
protocol.  
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Material for the production ofbiopharmaceuticals fortherapeutics and diagnostics is
often produced using different cell culture
techniques. One technique is to use
microcarriers for cell culture.
Microcarriers help improve yield, lower
serum and media costs and provide a low
physical and chemical stress environment
for anchorage dependent cells.
Cytopilot™ Mini is a laboratory-scale
reactor that achieves high productivity
from a small reactor volume. It is
designed for maximum ease of use, with
easy filling and discharging, simple
cleaning-in-place (CIP) routines and
reliable operation. Cytopilot Mini
achieves very high cell densities of
immobilised cells which, due to its novel
method of oxygen and nutrient transfer, it
can sustain in a continuous perfusion
production system. Such high cell
densities often require volumes of culture
medium per day in the order of 25 times
the bed matrix volume, depending on the
optimisation of culture. 
High productivity
The reactor is easy to use and highly
productive. As an indication of its
productivity, Cytopilot Mini together with
Cytoline™ microcarriers can give a
volumetric productivity of 400 mg
antibodies/litre microcarriers per day, with
a titre of up to 100–200 mg/l (data
supplied by customer) from a hybridoma
culture. Furthermore, processes run on
Cytopilot Mini are easy to scale up,
reactors at 100 litre scale are already in
operation. 
Cytopilot Mini is a laboratory-scale
reactor which enables cell culture on
porous Cytoline microcarriers in a low
shear stress environment. Cytopilot
Mini provides controlled, fluidised bed,
perfusion culture for the evaluation of
parameters for engineering and
feasibility studies, for product testing,
or as a production tool for diagnostic
purposes. Cytopilot Mini is now
available world-wide.
Easy change to serum-free
media
Continuous supply of nutrients to cells in
a fluidised bed constitutes the perfusion
culture. A perfusion culture system like
Cytopilot Mini gives very stable culture
conditions and facilitates changing from
serum-containing to serum-free media, or
switching from growth to production
media.
Cytopilot Mini reactor
– low volume,
high productivity
Figure 1. Cytopilot Mini fluidised bed reactor
has a total volume of 2 litres with a working
volume of 100-500 ml microcarriers. It has a
novel internal circulation loop through which
oxygen microbubbles circulate, ensuring a
high level of dissolved oxygen throughout the
fluidised bed. 
11
D o w n s t r e a m  2 8
How does it work?
Figure 2 describes the principle of
operation. Cytopilot Mini consists of two
chambers separated by the distribution
plate. The novel internal recycling loop
runs through both chambers. Liquid
agitated by the magnetic stirrer in the
bottom chamber is conveyed via the
distribution plate into the upper chamber.
Settled microcarriers are then lifted by
hydrodynamic pressure to form a
fluidised bed. The degree of expansion of
the fluidised bed is dependent on the
stirrer speed. When the bed is fluidised, a
clear zone forms between the top of the
suspended microcarriers and the top of
the culture medium. Culture medium
circulates back in through the upper
sieve/filter and down through the internal
recycling loop to the stirrer in the lower
chamber.
Near-perfect oxygen transfer
Oxygen bubbles are sparged into the
culture medium in the upper microcarrier-
free zone. Coalescent bubbles immediately
rise to the surface and only the liquid
saturated with microbubbles flows down
through the recycling loop to the
magnetic stirrer. The gas bearing capacity
of these microbubbles provides the system
with an oxygen reserve. The microcarriers
are freely suspended in the medium, and
statistically, all microcarriers obtain the
same amount of oxygen and nutrients.
This near-perfect oxygen transfer
minimises the formation of gradients in
the culture medium and makes scale up
very simple. Furthermore, excess C02 can
be drawn off via the headspace. The
benefit gained from this type of aeration
system and cells immobilised inside the
porous matrix of Cytoline, is the dramatic
reduction in cell damage.
Cytoline, its favoured partner 
Optimal fluidisation of the microcarriers
is achieved by selecting the microcarrier
with optimum features, i.e. specific
density, size, rigidity, non-abrasive, simple
to use, sterilisable. Cytopilot Mini
fluidised bed reactor is designed
specifically to exploit the potential of
Cytoline microcarriers. These are
macroporous microcarriers weighted with
silica designed for culture of CHO cells,
hybridoma and other stress sensitive cells.
Cytopilot Mini together with Cytoline
provides a controlled fluidised bed,
perfusion environment.
Cell cultures and areas of use
Cytopilot Mini is useful for evaluating
fluidised bed cell culture at laboratory-
scale, feasibility studies for large-scale cell
culture and for producing enough
material for product testing or diagnostic
purposes. It is ideal for use with the
following cell cultures: 
• Adherent cell lines with strong
anchorage properties, for example
fibroblast cells in combination with
heavy microcarriers such as Cytoline 1
with a high sedimentation rate.
• Semi-adherent cells in combination with
heavy or light microcarriers such as
Cytoline 1 and 2, respectively.
• Suspension cell lines in combination
with light macroporous carriers
(Cytoline 2) for very sensitive cells or
heavy microcarriers (Cytoline 1) for
more rigid cells.
For more information, ask for the following Data Files: 
Cytopilot Mini Code no. 18-1060-74
Cytoline 1 and Cytoline 2
macroporous microcarriers Code no. 18-1060-65 
Other microcarrier products:
Cytodex™ microcarriers for cell culture Code no. 18-1060-61
Cytopore™ macroporous microcarriers Code no. 18-1132-68
Exhaust air
Headspace
Microsparger
pH, TI, pO2
Distribution plate
Magnetic stirrer
Cytoline microcarrier
(blue)
Oxygen bubbles
Figure 2. Principle of oxygenation in
Cytopilot fluidised bed reactors. Oxygen
microbubbles are sparged into the culture
medium as it is drawn down through the
central recycling loop.
Thermo Scientific Precision Incubators
Performance, Quality and Value for Your Incubation Needs
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Global Leader in
Quality and Reliability
For more than 50 years, Thermo Scientific products have been
trusted by the world’s leading biotechnology, pharmaceutical,
academic, industrial and clinical laboratories. Our solutions deliver
the performance, quality and reliability required by researchers
and clinicians worldwide.
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Our new Thermo Scientific Precision incubator series
delivers excellent temperature uniformity, performance
and value for a wide range of microbiological incubation
applications – from everyday needs to demanding
incubation and storage tasks.
Precision® High-Performance Incubators pg. 3-6
> Superior Temperature Uniformity
Precision Standard Incubators pg. 7
> For Everyday Incubation Applications
Precision Compact Incubators pg. 8
> Space-Saving Design for Basic Applications
Precision Refrigerated Incubators pg. 9-10
> For Various Applications at Temperatures
Below and Above Ambient
APPLICATIONS
Precision
High-Performance
Incubators
Precision
Standard
Incubators
Precision
Compact
Incubators
Precision
Refrigerated
Incubators
Bacterial Research • • •
Biochemical Oxygen Demand (BOD) •
Chemical Storage • • •
Chick Embryo Studies • •
Coliform Determinations • • • •
Crystallization Studies • •
Drying And Staining Procedures • • •
Entomological Studies •
Enzyme Digestion Studies • • •
Hematological Testing • • • •
Microbiological Determinations • • • •
Paraffin Embedding • •
Pharmaceutical Stability Testing •
Sample Storage • •
Tissue Culturing • • • •
Plant Growth Studies •
Thermo Scientific
Precision
Incubators
-473-
Thermo Scientific Precision High-Performance Incubators
Choice of Mechanical or
Gravity Convection
• Mechanical convection provides
uniform heating and precise
temperature control. A blower
circulates heated air in a horizontal
airflow pattern for efficient heat
distribution with tight temperature
tolerances of up to ±0.3°C
• Gravity convection offers safe
incubation with reduced air changes,
minimizing drying-out of samples
while providing a stable environment
Advanced Microprocessor
Controls
• Sophisticated microprocessor
controls feature easy-to-view digital
LED readout and reliable temperature
control
• Fixed setpoints on control panel
eliminate the need for tuning and off-
set feature enables easy calibration
• Temperature is displayed on large,
three-character screen and can be
easily set from 5°C above ambient
to 75°C in 0.1°C increments using
touch-sensitive arrow keys
Built-In Safety
• Built-in safety back-up maintains
control at 3°C above setpoint if
primary heater control fails
• Visual alarm indicates when
temperature exceeds 3°C setpoint
• Silicone gasket on outer door
and 3” thick fiberglass insulation
prevents heat loss and ensures
excellent temperature uniformity
• Circuit breaker protects against
power surges.
Simplicity and Flexibility
• Inner glass door permits viewing
of samples without disturbing the
chamber environment
• Internal electrical outlet allows
operation of a shaker, stirrer or
other lab apparatus
Durable and Robust
• Cabinet has durable, enamel-coated
steel exterior. Interior chamber
features easy-to-clean stainless steel
• Low-watt density heater elements
are designed for long life and energy
efficiency
Featuring advanced microprocessor controls, our Precision
high-performance incubators are available with mechanical
or gravity convection for your most important applications that
require excellent temperature distribution or gentle sample
incubation and handling between 5°C above ambient to 75°C.
Mechanical or
Gravity Convection
Mechanical Convention Models
• Stackable, table-top units
• Outer door opens to 180˚ for unhindered access
• Double door unit and large capacity units also available
• Choice of 120V and 240V versions
• Internal electrical outlet in all models
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High-Performance Mechanical Convection Double Doors Large Capacity
Chamber Volume 2.2 cu. ft./62 L 3.4 cu. ft./96 L 4.5 cu. ft. /127 L 11.2 cu. ft./317 L 30 cu. ft./850 L
Temperature Control Microprocessor PID Microprocessor PID Microprocessor PID Hydraulic Thermostat Hydraulic Thermostat
Temperature Display LED LED LED LED Thermometer
Temperature Range ambient +5° to 75°C ambient +5° to 75°C ambient +5° to 75°C ambient +5° to 65°C ambient +5° to 70°C
Uniformity @37˚C ±0.5°C ±0.5°C ±0.5°C ± 0.6°C ±0.5°C
Dimensions (W x H x D)
Chamber 18 x 12.5 x 18 in. 18 x 19 x 18 in. 18 x 25.5 x 18 in. 37 x 25 x 21 in. 30 x 72 x 24.25 in.
(46 x 32 x 46 cm) (46 x 48 x 46 cm) (46 x 65 x 46 cm) (94 x 64 x 53 cm) (72.2 x 182.9 x 61.6 cm)
Exterior 25 x 26 x 23.5 in. 25 x 33 x 23.5 in. 25 x 39 x 23.5 in. 39.8 x 34.5 x 25 in. 36 x 88.5 x 31.5 in.
(64 x 66 x 60 cm) (64 x 84 x 60 cm) (64 x 99 x 60 cm) (101 x 88 x 64 cm) (91.4 x 224.5 x 74.3 cm)
Electrical Specs
120 V (60Hz) 330 watts/8.3 amps 330 watts/8.3 amps 410 watts /8.9 amps 520 watts/4.3 amps 450 watts/12.1 amps
240 V (50/60Hz) 330 watts/6.6 amps 330 watts/6.6 amps 410 watts/7.0 amps 520 watts/2.2 amps —
Shelves 1 supplied, 3 max 1 supplied, 6 max 2 supplied, 10 max 6 supplied, 36 max* 6 supplied, 30 max
Catalog Number
120 V PR205045M PR205055M PR205065M PR205075M 3971, solid door3973, glass door
240 V PR205040M PR205050M PR205060M PR205070M
Shipping Weight 150 lb/68 kg 165 lb/74.5 kg 190 lb/86.2 kg 215 lb/98 kg 685 lb/310.7 kg
*18 shelves per door opening
Additional shelf kits for table top units: Catalog Number 13247S
Additional shelf kits for double door units: Catalog Number AY2076X1
Additional shelf kits for large capacity units: Catalog Number 3166190
All 120V table top units are UL/cUL listed.
12 month warranty (parts and labor)
4
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Gravity Convection Models
• Three stackable, table-top units
• Outer door opens to 180° for unhindered access
• Choice of 120 V and 240 V versions
• Electrical outlet in all models
5
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Data file 18-1060-65 AE Cell culture & processing
Cytoline™ 1 macroporous 
microcarriers
Cytoline™ microcarriers are designed for use in packed, 
fluidized bed reactors for the culture of CHO and suspension 
cells intended for the production of recombinant proteins 
for therapeutic use. Cytoline microcarriers are macroporous 
and consist of a matrix based on polyethylene weighted with 
silica. The microcarriers yield high cell concentrations that 
can be sustained over long periods of time.
• Macroporous microcarriers
• High density cell culture
• Designed for fluidized bed cultures
Macroporous microcarriers
Cells gain easy access to the interior of Cytoline due to 
the macroporous structure of the microcarriers (Figure 1). 
Inside Cytoline, cells are protected from both physical and 
environmental stresses, and are able to create their own 
micro-environment. This micro-environment increases 
metabolic communication between the cells and permits 
protein-free perfusion, which in turn decreases media costs, 
particularly in long-term continuous processes.
The polyethylene base matrix causes the microcarriers to be 
hydrophobic while the silica content gives Cytoline a slight 
negative charge. Cytoline is further primed by an NaOH wash 
during preparation to optimize performance, the effects of 
which are particularly noticeable in protein-free media.
High density culture
Cytoline microcarriers offer both an external surface and an 
interior space that can be populated by anchorage- 
dependent cells or cells grown in suspension. Cell retention during 
perfusion is improved due to metabolic communication. As 
a result, cell density per reactor volume is high in contrast to 
when conventional microcarriers are used (Figure 2).
Fig 1. Scanning electron micrograph of Cytoline 1.
Fig 2. Close-up reveals the tight clustering of CHO cells on Cytoline 1.
GE Healthcare
Life Sciences
imagination at work
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Designed for fluidized bed culture
Cytoline 1 is optimized for the culture of CHO cells in fluidized 
beds. CHO cells attach well to Cytoline 1 and final cell densities 
are very high. These high densities are possible because of the 
high sedimentation rate of Cytoline 1, 120 to 220 cm/min.  
A high sedimentation rate enables the use of a high circulation 
rate, which ensures an adequate supply of oxygen to the 
reactor in order to maintain the high cell concentration. 
Good adhesion during long periods  
of culture
When culturing recombinant CHO cells using Cytodex™ 
microcarriers, the cells occasionally have a tendency to peel 
off the microcarriers after about 10 days in culture. When 
using Cytoline to culture CHO cells, there is no sign of cell 
detachment even after more than 60 days in culture.
Characteristics of Cytoline microcarriers
• Steam sterilizable (in situ) 121 °C, 1 bar
• Alkali and acid resistant
• Lot-to-lot consistency
• No material of biological origin is used
• Suitable for immobilization and growth of adherent 
and non-adherent cell types
• Suitable for bioreactor systems that are in use in 
industrial environments, such as stirred tanks, airlift 
culture systems and fluidized beds
• Increases culture surface area when used in routine 
laboratory culture techniques, such as roller, spinner 
culture, or shaker flasks
• Lens-shape is advantageous for nutrient /oxygen 
supply diffusion
• Storage in the dark gives optimal shelf-life
Specifications of Cytoline
 Cytoline 1
Sedimentation velocity (cm/min) 120–220
Length (mm) 1.7–2.5
Thickness (mm) 0.4–1.1
Density (g/cm3) 1.32
Pore size (µm) 10–400
Surface area (m2/g) >0.3
Ordering information
Product Quantity Code Number
Cytoline 1 50 mL 17-1268-01
Cytoline 1 500 mL 17-1268-02
Cytoline 1 5 L 17-1268-03
High-flow 
Hygienic Pumps
S      E       R       I       E       S
S
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PERISTALTIC PUMPS
ARE IDEAL FOR
■ Abrasive and aggressive fluids
■ Beverage dispensing
■ Cell culture
■ Fermentation
■ Filtration and separation
■ Food processing
■ Industrial chemicals
■ Inks and pigments
■ Pharmaceuticals
■ Photographic solutions
■ Water treatment
The benefits of peristaltic pumping
Compared to lobe pumps, diaphragm
pumps, gear pumps and piston pumps,
and every other type of pump, these
are the advantages of Watson-Marlow
pumps: 
1 No contamination of the fluid.
2 No contamination of the pump.
3 Ideal for shear-sensitive and aggressive
fluids.
4 Self-priming, dry-running.
5 No valves, seals or glands.
6 Automatic check valve action prevents
backflow.
Watson-Marlow leads the world in
solving fluid handling problems with
peristaltic pumping technology. The
company is accredited for design and
manufacture to ISO9001, and
provides its customers with nothing
less than the best products, service and
knowledge. Watson-Marlow conducts
its business ethically, and stands by 
its word, its recommendations and 
its products.
Put Watson-Marlow to work
on your pumping problems
■ Watson-Marlow peristaltic pumps are problem
solving pumps, best applied where other pump
types fail or frustrate.Watson-Marlow works only
through trained engineers, and, wherever you are,
they will work with you, using the experience of
meeting and solving literally thousands of pumping
problems.
■ As the largest peristaltic pump 
manufacturer, with a range of pumps
and tubing for flow rates from
microlitres per hour to thousands of
litres per hour, we stand every
chance of helping you, but if we
cannot we will tell you. 
■ If we can help, we will do whatever
is necessary to prove to you that it will
do the job. Any product we
recommend, we will stand by
completely, and if it fails to meet the
agreed need, then that will be our
problem and not yours. 
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Purchasers in the EU please note
825 and 840 pumpheads are specially designed
for connection by the user to gearboxes of the
users choice and they do not carry the CE mark.
These pumpheads are supplied with
“Declarations of Incorporation” as required by
the EU Machinery Directive.
The B/RA and the RA bare shaft pumps carry
the CE mark, but the complete motorised pump
assembly must also carry the assembler's CE
mark in addition to the Watson-Marlow CE
mark.
Customers in EU member States must note that
self assembly of machines carries with it the
responsibility to ensure that the final working
assembly complies with all the relevant EU
safety directives and the assembler’s CE mark
is affixed on completion.
Standards
CE Conforms to all relevant Directives
IEC 335-1 is the International Electrotechnical
Commission standard dealing with the
“Safety of household and similar appliances,
general requirements”. Equivalents are
BS3456: Part 101 and DIN VDE 0700: Part 1).
EN60529 is the European Norm standard
dealing with the “Classification of degrees of
protection provided by enclosures for
rotating machines. Equivalents are BS 4999:
Part 105, IEN 60034: Part 5, and DIN VDE
0530: Part 5. IP numbers (such as IP34, IP42,
IP55) indicate the degree of ingress
protection of the product, with the first digit
indicating protection against the ingress of
objects, and the second digit indicating the
degree of protection against the ingress of
water.
EN60204-1 is the European Norm covering
“The Safety of Machines - Electrical
Equipment of Machines”.
EN61010-1 is the European Norm covering
“Safety requirements for electrical
equipment for measurement, control and
laboratory use”.
EN50081-1 is the European Norm covering
“Electromagnetic compatibility - Generic
Emission standard - Residential, commercial
and light industry”.
EN50082 - 1 is the European Norm covering
“Electromagnetic compatibility - Generic
Immunity standard - Residential, commercial
and light industry”.
Spare parts availability
Watson-Marlow’s policy is to provide spare
parts for all products for a minimum of eight
years from discontinuation. For major
products, this period is extended to twelve
years. The ability to implement this policy is
not entirely within Watson-Marlow’s control
and cannot be guaranteed, but every effort
will be made to honour this policy.
Common conversions
To go from Multiply by To get to
bar 14.50377 psi
inches 25.4 mm
deg C (1.8 x C) + 32 deg F
gal (IMP) 4.5460 litres
gal (US) 3.7854 litres
gal (IMP) 1.20095 gal (US)
gpm (US) 0.22712 m3/hr
gpm (IMP) 0.27276 m3/hr
inches Hg 1.1329 ft H2O
inches Hg 0.4912 psi
kg/cm2 14.22334 psi
kW 1.341 hp
kPa 0.14504 psi
N/m2 1.0 Pa
Pa 0.00001 bar
litre 0.0001 m3
kgcm 0.098 Nm
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25mm High-flow, hygienic pump
Provides 2000 litre/hr 
(0.33 litre/rev)
Twin stainless steel rollers
Hinged door with only two
captive bolts makes
changing tube extremely
simple and safe
Use USP Class VI Bioprene
tubing for 2 bar (29 psi) and
3.5 bar (51 psi) operation
Tube elements complete
with hygienic connectors
Tubing in extended element
lengths for fitting customers
own connectors
Bareshaft pumpheads to
take a range of foot-
mounted motors with
flexible couplings
Pumpheads to accept IEC B5
output flange-mounted gear
motors
Pumps
825B/R Baseplate mounted bareshaft pumphead 080.2500.000
825RA Pumphead with bareshaft adaptor (no baseplate) 083.2510.000
Bioprene tubing for 825 pumps
Tube bore
25mm 1” 2 bar TM tube element 770mm length 088.0250.E0M
25mm 1” 3.5 bar TH tube element 770mm length 088.0250.E0H
25mm 1” 2 bar TM tube element 2.3m length 088.0250.00M
25mm 1” 3.5 bar TH tube element 2.3m length 088.0250.00H
Connectors for 825 pumps
825CT Triclamp hygienic connector 1” 089.0250.00T
825CS SMS hygienic connector 089.0250.00S
825CI IDF/ISS hygienic connector 089.0250.00R
825CQ Quick coupling (MIL-C-2748F) 1” 089.0250.00Q
825CR Quick RJT (BS1864) connector 089.0250.00R
Tube lubricant
400g Translucent food machinery grease (USDA-H1) approved 098.0005.000
BS800, IEC 335-1, 
EN60529 (IP55) CE
Ordering information
Standards
800 SERIES2
825R or B/R Motor power/tube life
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Configurations
All 800 series pumps are available
from Watson-Marlow as complete,
ready to run, motorised pumps
with a two year warranty.
Each pump supplied by Watson-
Marlow is a fully assembled,
ready-to-run unit, or a B/RA or an
RA bare shaft, ready-to-drive
pumphead, which complies with
all relevant EU (European Union)
safety directives and carries the 
relevant CE mark or declaration of
incorporation.
Fixed speed pumps
825 and 840 pumps can be supplied as a
complete speed units fitted with an IP55 motor
and gearbox in 4 different speeds.
825FB/R pump speeds are 22, 38, 68 and 98
rpm. 840FB/R pump speeds are 22, 39, 62 and
100 rpm.
Variable speed inverter controlled pumps
We supply complete electronically variable
speed pumps with two maximum speeds with a
5:1 reduction ratio. The minimum flow rate will
be approximately 20% of the maximum
achievable.
Watson-Marlow have selected as standard
accessories, single phase input/three phase
output inverters for use with the 800 series
pumps (maximum power requirement 1.5KW,
for use with the 825 pumps and 2.2KW for use
with 840 pumps).
All Watson-Marlow pumps are available fitted
with motorised geared units to suit the users
own choice of inverter.
Mechanically variable speed pumps
All Zone 1 Exd 800 series pumps and those
rated above 2.2KW are fitted with belt driven
mechanically variable speed gearboxes and
IP55 standard motors.
Accessories
Pulsation dampers will be required for certain
applications. Watson-Marlow will supply
pulsation dampers from the Flowguard
range. 
Tube failure detectors are available to order.
A choice of feet or castors for fitting to 825
and 840 pump frames are available.
Explosion-proof pumps
All pumps are available fitted with Exd IIB T4
specification explosion-proof motors that
meet all EU explosion-proof standards.
Specially selected combinations of explosion-
proof motors and electronic inverters are
available. These inverters are not fitted with
explosion-proof casework and therefore must
be sited outside the hazardous area.
800 SERIES 7
Drive options
A number of motor/gearbox
options and control options are
available for these pumps
including fixed and variable speed
with mechanical variatiors. The
options include inverter control
enabling 4-20mA and 0-10V
process control, remote stop/start
and reverse, and frequency output.
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800
Tube life High pressure tube life
800 SERIES6
Operating and storage
temperatures
Unless otherwise stated, all
pumps listed in this brochure may
be operated at ambient
temperatures between 5C and 40C
(41F and 104F). They may be
stored at temperatures between 
-40C and 70C (-40F and 158F), but
allow time for acclimatisation
before operating.
Flow rates
All flow rates quoted in this brochure were obtained
pumping water at 20C (68F) with zero suction and
delivery heads. 
The Watson-Marlow 800 series pumps use a
Bioprene tube which meets USP and NFS Class
VI requirements. Bioprene also complies with
FDA 21 CFR 177.260 and meets USDA
standards for food handling.
High pressure applications
For specific higher pressure
applications, use 3.5 bar “TH” tubing
elements for intermittent periods only.
Do not use quick connectors for this
process. Tubing previously used as a
pumping element should not be used
as a transfer section.
Tube lubricant
Translucent food machinery grease
(USDA-H1 approved for food contact)
is available for 800 series tubing to
prolong tube life.
Connectors
800 series pumps may be used
with either tube elements fitted
with hygienic  connectors or
extended element lengths. A
choice of connector types is
offered, including Triclamp
(Triclover and 3A compatible), IDF
and SMS sanitary, and RJT. These
are constructed from 316 stainless
steel and are totally autoclavable.
Tubing
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825RA 825B/RA 825FB/R or DFB/R 825VBI/R 825VB/R or DVB/R
825B/RA
825FB/R, 825VBI/R, 825DFB/R, 825DVB/R
Dimensions mm
800 SERIES 3
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800
Paint specification
The 800 series epoxy polyester powder coating
is based on a mixed polymer thermosetting
resin designed to combine the durability
associated with epoxies with the enhanced UV
and heat stability associated with polyesters.
This results in a high quality finish which is
abrasive and impact resistant.
Installation drawings
Installation drawings of all 800 series pumps
are available on request in A3 size.
Reproducible drawings are also available for a
modest fee.
Custom-built pumps
Watson-Marlow Limited’s team of technical
support engineers is available to advise and
quote for your custom-built pumps with
electric, hydraulic or pneumatic motors, trolley
mounting, stainless steel baseplates etc.
800 SERIES8
Description Material
Pumphead body Aluminium alloy with epoxy polyester powder coat finish
Pumphead door Aluminium alloy with epoxy polyester powder coat finish
Pumphead rotor Aluminium alloy
Rotor rollers 316 stainless steel
Frame Stainless steel 304L
Optional motor housing Stainless-steel 304L
Door fixings Stainless steel
Motor fixings Zinc plated high tensile steel bolts, stainless steel nuts and washers
Frame fixings Stainless steel
Materials of construction
CIP
The 800 series pumphead incorporates
retractable roller mechanisms which allow
clean-in-place or steam-in-place hose cleaning.
The roller mechanisms are simply unlocked and
disengaged from the standard pumping
position, providing maximum cleaning capacity
via a free flow of cleaning agents through the
hose.
SIP
The 800 series can be steamed-in-place at 
135°C (2 bar) for a duration of one hour. Allow
15 minutes for pump to return to ambient
temperature prior to restarting pump.
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Unmatched warranties
The high quality of the design and
manufacture of Watson-Marlow
products allows us to offer
international warranties far
exceeding those available for
other pump types. 
All 800 series pumps carry a two
year warranty.
25mm hygienic pumps
40mm hygienic pumps
Flow rates
Up to 8,000 litres/hour depending
upon motor speed.
Pressures
Up to 3.5 bar continuous operation
governed by motor sizing.
Drive options
Fixed speed, variable speed
(inverter or mechanical variator),
all drives available with Exd
options. Contact Watson-Marlow
Technical Support for further
information.
Duty rating
24 hour governed by motor sizing.
The 800 series pumps have been designed for hygienic
pumping up to 8000 litre/hour and pressures to 3.5
bar (51 psi), in the biotechnology, pharmaceutical and
food industries. Pumpheads are constructed of
aluminium with an epoxy powder coated white finish
and they offer true CIP (clean-in-place) and SIP
(steam-in-place) as the rollers retract to a non-
occluding position, allowing a complete flow-through
for cleaning.
All pumps are mounted on a stainless steel frame with
the option of a brushed stainless steel motor housing,
where belt variators are not required.
Watson-Marlow’s focus has been to minimise the total
cost of ownership over the lifetime of the pumps by
making them reliable, long-lasting, and simple to use
and maintain. Downtime is the true enemy of
productivity, and so minimising downtime and
whatever essential maintenance is required rewards
our care and your choice of pump.
For instance and (uniquely), access to the tube is
through a hinged door rather than a lift-off cover, and
the door is secured by two captive bolts rather than
sixteen or twenty loose ones, making tube changing
fast, simple and safe. 
Bioprene tube elements with hygienic connectors are
autoclavable and can be fitted quickly and cleanly.
Where hygiene and system up-time is valued,
there is no better pump than a Watson-Marlow 800
series.
800 SERIES 1
years
W
2
warranty
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■
ST DESIGN 
Belgium
Telephone 02 529 5858
Fax 02 529 5861
Web www.watson-marlow.com/watson-marlow/
Email bs.support@watson-marlow.com
France
Telephone (1) 30 62 12 47
Fax (1) 30 66 11 22
Web www.watson-marlow.com/watson-marlow/
Email fs.support@watson-marlow.com
Germany
Telephone 02183 42040
Fax 02183 82592
Web www.watson-marlow.com/watson-marlow/
Email ds.upport@watson-marlow.com
Italy
Telephone (03) 0687 1184
Fax (03) 0687 1352
Korea
Telephone 02 525 5755
Telex K26177
Fax 02 525 5764
Web www.watson-marlow.com/watson-marlow/
Email k.support@watson-marlow.com
Watson-Marlow Limited
The Netherlands
Telephone 010 462 1688
Fax 010 462 3486
Web www.watson-marlow.com/watson-marlow/
Email nl.support@watson-marlow.com
Singapore
Telephone (65) 456 7274
Fax (65) 457 5912
United Kingdom
Telephone +44 1326 370370
Fax +44 1326 376009
www.watson-marlow.com/watson-marlow/
Email support@watson-marlow.co.uk
United States of America
Telephone 800 282 8823
Fax 508 658 0041
Web www.watson-marlow.com/watson-marlow/
Email us.support@watson-marlow.com
Members of the Spirax-Sarco Engineering Group
Watson-Marlow is a registered trademark of
Watson-Marlow Limited.
Publication ref: HB 0057
The information contained in this document is
believed to be correct but Watson-Marlow Limited
accepts no liability for any errors it contains, and
reserves the right to alter specifications without
notice.
600
Mid flow pumps
Cased pumps or baseplate-mounted
pumps for flows up to 15.8 litre/min
(4.2 US gpm). Fixed or variable speed
and single channel. 
● HB 0063           
300
Low-cost pumps
Flow rates from 0.2  to 2,000 ml/min.
Fixed and variable speeds.
● HB 0060
500
Microprocessor controlled
pumps
Flow rates from 0.01 to 2,200 ml/min. 
1 to 48 channels. Manual, auto and
digital control.
IP55 rated pumps
Washdown pumps for tough
environments, and pneumatic or
baseplate-mounted pumps with Exd
motors for hazardous areas. Flow
rates to 2.2litre/min. 
● HB 0062
100/200
Low-flow pumps
100 series flow rates from 0.01 to 53
ml/min. Single channel. Fixed and
variable flow rates.
Multi-channel pumps
200 series flow rates from microlitres
to 32 ml/min. through up to 32
channels. Manual and auto-control.
● HB 0065
700
High-flow pumps
IP55 rated pumps with manual or auto
control and baseplate-mounted
industrial pumps provide flows to 2,000
litre/hr (8.8 US gpm). Single or twin
channel. 
● HB 0060
800
High-flow hygienic pumps
Use Bioprene USP Class VI tubing for
flow rates up to 8,000 litre/hr (35 US
gpm). and pressures up to 3.5 bar (50
psi). True CIP and SIP facilities ideal
for biotech, pharmaceutical and food
industries. Single channel.
● HB 0057
900
High-flow, high-pressure
pumps
Use reinforced tubing in five different
materials for flow rates up to 10,000
litre/hr and pressures up to 15 bar
(210 psi). Single channel.
● HB 0056
Dispensers &
Robotic fillers
For repetitive and accurate dosing and
dispensing duties. Straightforward
stop/start volumes up to one litre in
five seconds or precision, balance-
controlled dispensing.
● HB 0039
OEM pumps
Pumpheads for use with customers’
own drives or plate-mounted
pumpheads and motors. Compact,
easy to install and to use. Single and
multi-channel with flow rates up to
2,700 ml/min.
● HB 0076
Tubing
Twelve different materials and over 50
sizes of tubing for the complete range
of Watson-Marlow pumps. Full
chemical compatibility tables with 450
fluids tabulated. Performance and
physical data.
● HB 0065
● These brochures describe the full Watson-Marlow range
of peristaltic pumps, tubing and accessories.
S       E        R        I        E        S
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BIOPRENE TUBING
Thermoplastic elastomer tubing
USP, ISO and FDA approvals matter in maintaining 
validated processes. Bioprene peristaltic pump tubing
offers long life and chemical resistance, and carries 
the widest range of safety approvals
! USP Class VI FDA approvals
! Fully documented bio-compatibility and comprehensive 
validation pack
! Safe for use in biomedical applications
! Ex-stock availability
! Comprehensive stock of a wide range of sizes
! UV opaque
! Fully weldable
! No odour
! Low extractables
! Suitable for repeated autoclave cycles
Highly resistant to oxidising
agents
!
"
Watson-Marlow Bioprene: the best peristaltic pump tube
life with excellent chemical resistance
Bioprene peristaltic pump
tubing is fully approved for
food and pharmaceutical
applications. Validated
processes are supported.
Like Marprene, Bioprene
lasts at least 10 times as
long as tubing in other
materials. Long-life tubing
means stoppages for a
tube change are rare
events, easily fitted in with
general maintenance. 
Validated
processes
Clean-in-place and
steam-in-place (with 
tubing elements) are no
problem for the tube that
has everything.
Easy sterilisation
-505-
For long life and chemical compatibility
Meeting or exceeding FDA regulations
Bioprene for validation
Bore Wall
Coil size Part number Coil size Part number Coil size Part number
inch mm inch mm
1/50 0.5 1/16 1.6
50ft / 15m
903.0005.016
16ft / 5m
903.0005.J16
500ft / 152m
903.0005.R16
1/32 0.8 1/16 1.6 903.0008.016 903.0008.J16 903.0008.R16
1/16 1.6 1/16 1.6 903.0016.016 903.0016.J16 903.0016.R16
3/32 2.4 1/16 1.6 903.0024.016 903.0024.J16 903.0024.R16
1/8 3.2 1/16 1.6 903.0032.016 903.0032.J16 903.0032.R16
3/16 4.8 1/16 1.6 903.0048.016 903.0048.J16 903.0048.R16
1/4 6.4 1/16 1.6 903.0064.016 903.0064.J16 903.0064.R16
5/16 8.0 1/16 1.6 903.0080.016 903.0080.J16 903.0080.R16
903.0005.024 903.0005.J24
903.0008.024 903.0008.J24
1/16 1.6 3/32 2.4 903.0016.024 903.0016.J24 903.0016.R24
1/8 3.2 3/32 2.4 903.0032.024 903.0032.J24 903.0032.R24
3/16 4.8 3/32 2.4 903.0048.024 903.0048.J24 400ft / 122m 903.0048.R24
1/4 6.4 3/32 2.4 903.0064.024 903.0064.J24 300ft / 91m 903.0064.R24
5/16 8.0 3/32 2.4 903.0080.024 903.0080.J24 200ft / 61m 903.0080.R24
3/8 9.6 3/32 2.4 903.0096.024 903.0096.J24 150ft / 46m 903.0096.R24
903.0048.032 903.0048.I32
1/4 6.4 1/8 3.2 903.0064.032
10ft / 3m
903.0064.I32 200ft / 61m 903.0064.R32
3/8 9.6 1/8 3.2 903.0096.032 903.0096.I32 150ft / 46m 903.0096.R32
1/2 12.7 1/8 3.2 903.0127.032 903.0127.I32
5/8 15.9 1/8 3.2 903.0159.032 903.0159.I32
- 8.0 - 4.0 903.0080.040 903.0080.I40
- 12.0 - 4.0 903.0120.040 903.0120.I40
- 16.0 - 4.0 903.0160.040 903.0160.I40
3/8 9.6 3/16 4.8 903.0096.048 903.0096.I48
1/2 12.7 3/16 4.8 903.0127.048 903.0127.I48
5/8 15.9 3/16 4.8 903.0159.048 903.0159.I48
3/4 19.0 3/16 4.8 903.0190.048 903.0190.I48
1 25.4 3/16 4.8 903.0254.048 903.0254.I48
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Custom sizes are
available to order, as
are other specific
requirements
Bioprene Typical values
Material Thermoplastic elastomer
Colour / transparency Beige / opaque
Spallation Fair
Life, hours 313/314, 520R pumpheads: 10,000; 620R pumphead: 6,000
Certification FDA regulations 21 CFR 177.2600 for contactwith aqueous food
Sterilisation methods Gamma, autoclave, EtO. CIP, SIP: refer toWatson-Marlow for details
Operating temperature 5C-80C
Hardness, shore A (5 sec) 64 shore: 66; 73 shore: 74; 87 shore: 88
Specific gravity 64 shore: 0.97; 73 shore: 0.96; 87 shore: 0.95
Tear B, ppi -
Ultimate tensile 
strength, psi 64 shore: 1007; 73 shore: 1410; 87 shore: 2263
Elongation at break, % 64 shore: 473; 73 shore: 510; 87 shore: 547
Tensile stress at 100% 
elongation, psi 64 shore: 367; 73 shore: 525; 87 shore: 987
Compression set, % -
Weather resistance Excellent
Sunlight resistance Excellent
Gas permeability, 
O2cc.cm x 10-8 /
cm2.sec.atm
5.8
Gas permeability rating Fair
Water absorption Good
Odour Excellent
ASTM methods   Hardness: ASTM D 2240; Specific gravity: ASTM D 792; Tear B, Ultimate
tensile strength, Elongation at break, Tensile stress at 100% elongation: ASTM D 412
Bioprene offers exceptionally long life and resistance
to a wide range of chemicals. It is a first choice for
applications including metering tablet-coating materi-
als, pH control and media feed in fermentation and
bioreactor metering, as well as pharmaceutical han-
dling, dispensing, metering, transfer and filtration.
General industrial long-life transfer
tube. Highly resistant to oxidising 
agensts such as ozone, peroxides 
and sodium hypochlorite.
Netherlands
Telephone +31 (0) 10 462 1688
Fax: +31 (0) 10 462 3486
Email info@watson-marlow.nl
www.watson-marlow.nl
South Africa
Telephone +27 11 796 2960
Fax: +27 11 794 1250
Email info@wmbpumps.co.za
www.watson-marlow.co.za
Sweden
Telephone +46 8 556 556 00
Fax: +46 8 556 556 19
Email info@watson-marlow.se
www.watson-marlow.se
United States of America
Telephone 800 282 8823
Fax: +1 978 658 0041
Email support@wmbpumps.com
www.watson-marlow.com
United Kingdom
Telephone +44 (0) 1326 370370
Fax: +44 (0) 1326 376009
Email info@watson-marlow.co.uk
www.watson-marlow.co.uk
Belgium
Telephone +32 (0) 9 225 94 57
Fax: +32 (0) 9 233 06 49
Email info@watson-marlow.be
Brazil
Telephone +55 (11) 2155 4000
Fax: +55 (11) 2155 4001
Email info4brazil@watson-marlow.com
www.watson-marlow.com.br
China
Telephone +86 21 6485 4898
Fax: +86 21 6485 7366
Email mingshao@cn.spiraxsarco.com
www.watson-marlow.cn
Denmark
Telephone +45 43 94 00 65
Fax: +45 43 94 00 85
Email info@watson-marlow.dk
www.watson-marlow.dk
France
Telephone +33 (0) 1 34 87 12 12
Fax: +33 (0) 1 34 87 12 13
Email info@watson-marlow.fr
www.watson-marlow.fr
Germany
Telephone +49 (0) 2183 42040
Fax: +49 (0) 2183 82592
Email info@watson-marlow.de
www.watson-marlow.de
Italy
Telephone +39 03 06871184
Fax: +39 03 06871352
Email info@watson-marlow.it
www.watson-marlow.it
Korea
Telephone +82 (0) 32 820 3973
Fax: +82 (0) 32 811 0321
Email changwoo-
jang@kr.spiraxsarco.com
www.watson-marlow.co.kr
Malaysia
Telephone +60 (3) 5635 3323
Fax: +60 (3) 5635 7717
Email sales@my.spiraxsarco.com
www.watson-marlow.com
www.watson-marlow.co.uk
Members of the Spirax-Sarco Engineering Group
The information contained in this document is believed to be
correct, but Watson-Marlow Bredel accepts no 
liability for any errors it contains, and reserves the right to
alter specifications without notice.
WARNING These products are not designed 
for use in, and should not be used for, patient-
connected applications.
Watson-Marlow, Pumpsil, LoadSure, LaserTraceability,
Bioprene and Marprene are registered trademarks of 
Watson-Marlow Limited. STA-PURE and CHEM-SURE are
trademarks of WL Gore and Associates INC. Fluorel is a
trademark of 3M.
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Specifications
Materials of Construction
Prefilter Membrane: Polyethersulfone,
asymmetric
Endfilter Membrane: Polyethersulfone,
asymmetric
Support Fleece: Polypropylene
Core: Polypropylene
End Caps: Polypropylene
O-Rings: Silicone (optional
EPDM or Viton)
Pore Size 
0.45 µm + 0.2 µm
Available Sizes |Filtration Area
Size 1 10” 0.6 m2|6 ft2
Size 2 20” 1.2 m2|12 ft2
Size 3 30” 1.8 m2|18 ft2
Available Adapters | Connectors
21, 25, 27, 28
Operating Parameters
Max. Allowable 5 bar|75 psi at 20°C
Differential Pressure: 2 bar|29 psi at 80°C
Max. Allowable Back 2 bar|29 psi at 20°C
Pressure:
Sartopore® 2  0.2 µm
Sterilizing Grade Filter Cartridges
Description
Sartopore® 2 0.2 µm rated sterilizing grade 
filter cartridges are designed for filtration 
of a broad range of pharmaceutical products
where compliance with cGMP requirements
has to be fulfilled. Sartopore® 2 cartridges 
feature a unique hydrophilic heterogeneous
double layer Polyethersulfone membrane
with broad chemical compatibility, high 
thermal resistance and higher throughput
and flow-rate than any other sterilizing 
grade filter cartridge. 
Applications
Typical applications include sterilizing 
grade filtration of:
– Therapeutics
– Biological Fluids
– Opthalmics
– SVPs, LVPs
– Antibiotics
– WFI
– Chemicals
– Cleaning and sanitizing agents 
– Bulk pharmaceutical products
Compatibility
The polyethersulfone membrane is compatible
with a pH range from pH 1 to pH 14 and
unaffected by steam sterilization cycles 
making Sartopore® 2 cartridges ideal for 
filtration of solutions with high| low pH and
for SIP|CIP-cycles.
Performance
Sartopore® 2 cartridges provide an exception-
ally high total throughput by fractionated 
filtration due to the "built-in prefiltration" of
the 0.45 µm membrane. The asymmetric pore
structure of the polyethersulfone membrane
provides high flow rates at low pressure
drops.
Wettability
Sartopore® 2 cartridges can be easily wetted
out for integrity testing even after drying 
at 80°C for 12 hours.
Microbiological Retention
Sartopore® 2 filter cartridges are fully 
validated as sterilizing grade filter elements
according to HIMA and ASTM F-838-83
guidelines. 
Quality Control
Each individual element is integrity tested 
by diffusion and bubble point test prior 
to release, assuring absolute reliability.
Documentation
Sartopore® 2 cartridges are designed, devel-
oped and manufactured in accordance with
an ISO 9001 certified Quality Management
System. A Validation Guide and Extractables
Guide are available for compliance with 
regulatory requirements.
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Sartorius Stedim Biotech GmbH
August-Spindler-Strasse 11
37079 Goettingen, Germany
Phone +49.551.308.0
Fax +49.551.308.3289
www.sartorius-stedim.com 
USA Toll-Free +1.800.368.7178
UK +44.1372.737159
France +33.442.845600
Italy +39.055.63.40.41
Spain +34.91.3586102
Japan +81.3.3740.5407
Specifications subject to change 
without notice. Printed and copyrighted 
by Sartorius Stedim Biotech GmbH
W/sart-000 · G
Publication No.: SPK2030-e08066
Order No.: 85030-511-67
Specifications 
Extractables
Sartopore® 2 0.2 µm rated filter cartridges
meet, or exceed the requirements for WFI
quality standards set by the current USP.
Regulatory Compliance
100% Individually integrity tested
Integrity test correlated to HIMA/ASTM 
F 838-83 Bacteria Challenge Test
Non-pyrogenic according to USP Bacterial
Endotoxins
Passes USP Plastics Class VI Test
Non-fiber releasing according to 21 CFR
Sterilization
In-Line Steam Sterilization:
134°C, 20 min. at max differential pressure 
of 0.5 bar|7.25 psi
Autoclaving:
134°C, 2 bar|29 psi, 30 min
Sterilization Cycles
In-Line Sterilization: Min. 25
Autoclaving: Min. 25
Technical References
Validation Guide:
SPK 5732-e
Extractables Guide:
SPK 5731-e
Water Flow Rates for 10!, 20! and 30! Cartridges
Differential pressure [bar]
1
0.75
0.5
0.25
0
15
7.5
0
0           2,000        4,000        6,000        8,000      10,000      12,000      14,000
Flow [l/h]
10!                           20!                            30!
[psi]
Total Throughput Comparison
100
80
60
40
20
0
Total throughput [kg at 95 % blockage]
Sartopore 2
0.45 | 0.2 µm
PVDF
0.2 µm
PVDF
0.22 µm
Nylon
0.2 | 0.2 µm
PESU
0.8 | 0.2 µm
Standardized at 20°C
10! Cartridge format
Ordering Information
Order Code. Pore size Test Max. Min. B.P.
[µm] Pressure Diffusion [bar|psi]
[bar|psi] [ml/min]
544**07H1 0.2 2.5|36 18 3.2|46
544**07H2 0.2 2.5|36 36 3.2|46
544**07H3 0.2 2.5|36 54 3.2|46
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GE Healthcare
Life Sciences
WAVE Bioreactor™  
2/10 system
([SDQG\RXUKRUL]RQVLQFHOOWKHUDS\FXOWXUH
ZZZJHOLIHVFLHQFHVFRPZDYHLQIR
)XQFWLRQDOO\FORVHGV\VWHP
(DV\VFDOHXSDQGVFDOHRXW
1RQHHGIRULQFXEDWRU
&RVWHȺHFWLYH
The WAVE Bioreactor 2/10 system is a widely 
cited cell culture platform based on a single-
use presterilized bag called a Cellbag™ 
bioreactor. The rocking motion of the  
SODWIRUPLQGXFHVZDYHVWRPL[DQGWUDQVIHU
R[\JHQWRWKHFXOWXUHPHGLXPWRFUHDWHDQ
RSWLPDOHQYLURQPHQWIRUFHOOJURZWK 
:DYHLQGXFHGPL[LQJLQDF*03FRPSOLDQW
HQYLURQPHQWHQDEOHVWLPHHȻFLHQWFRVW
HȺHFWLYHDQGVFDODEOHH[SDQVLRQRIFHOOV
suitable for cell therapy research applications.
$FKLHYHKLJKGHQVLW\H[SDQVLRQRIFHOOV
such as T, TIL, and NK cells (1,2,3)
0DLQWDLQWKHSKHQRW\SLFDQGIXQFWLRQDO
FKDUDFWHULVWLFV\RXH[SHFWIURPVWDWLF
culture  (2)
([SDQGFHOOVVXLWDEOHIRUDXWRORJRXV
WUDQVSODQWDWLRQLQDGRSWLYHLPPXQRWKHUDS\
applications (1,3,4,5,6)
,QWHJUDWHLQWRFOLQLFDOWULDOVWXGLHVXVLQJ
functionally closed Cellbag bioreactors free 
of animal products (3)
Scale-up from 250 mL to 5 L of culture in a 
VLQJOH&HOOEDJELRUHDFWRUWRDFKLHYH\RXU
target cell concentrations without the need 
IRUDODPLQDUÀRZFDELQHW
 
Sampling, monitoring, and additions 
all take place within in a functionally 
FORVHGHQYLURQPHQWUHPRYLQJWKHULVNRI
contamination associated with processes 
ZKHUHPXOWLSOHEDJVRUÀDVNVDUHUHTXLUHG
Minimal cross-contamination  
in a functionally closed system
Cellbag bioreactors can be customized with 
DUDQJHRIVSHFLDOL]HG¿WWLQJVDQGSRUWVWR
VXSSRUW\RXUVSHFL¿FSURMHFWQHHGV
For more information,  
YLVLWwww.gelifesciences.com/
waveinfo
Customizable to meet  
your changing needs
Higher cell densities in  
a low-shear environment 
Set the rocking motion of the Cellbag holder to 
GLȺHUHQWDQJOHVDQGGLȺHUHQWUDWHVWRLQGXFH
ZDYHVWKDWSURYLGHHȻFLHQWPL[LQJDQGR[\JHQ
WUDQVIHULQDORZVKHDUHQYLURQPHQW7KHUHVXOWLQJ
homogeneous culture enables higher cell densities 
WREHDFKLHYHGLQDVKRUWHUSHULRGRIWLPHWKDQLV
possible with static bags (2,3,5).
Cell type Yield (cells/mL)
T [7  (5)
TIL [7  (2)
NK [6  (3)
Table 1.&HOOGHQVLWLHVDFKLHYHGXVLQJWKH:$9(
Bioreactor 2/10 system
for your suspension cells
The right system 1 Better
by design
2
Cellbag bioreactor: 7\SLFDO&HOOEDJELRUHDFWRUFRQ¿JXUDWLRQ
2WKHUGHVLJQVDUHDYDLODEOH$UDQJHRISRUWVHQDEOHVDPSOLQJ
LQDIXQFWLRQDOO\FORVHGHQYLURQPHQW2SWLRQDOSRUWVDQG
sensors allow measurement of critical parameters such as pH 
DQG'20D[LPXPFHOOFXOWXUHYROXPHLVKDOIWKHWRWDO&HOOEDJ
ELRUHDFWRUYROXPHDOORZLQJDLUVSDFHIRURSWLPL]HGDJLWDWLRQ
and gas transfer.
*HQWOHURFNLQJRIWKH&HOOEDJELRUHDFWRUHQVXUHVHȻFLHQWPL[LQJRI
culture media.
CO2/Air Mix Controller: An aeration system with CO2 
VHQVRUSURYLGHVDQGFRQWUROVDFRQWLQXRXVVXSSO\RI
CO2-conditioned air to the Cellbag bioreactor.
Perfusion Controller: Includes a scale and peristaltic 
IHHGDQGKDUYHVWSXPSVWRPLQLPL]HFXOWXUHYROXPHV
through weight-based perfusion.
Scale-out using the WAVE Bioreactor 2/10 system 
LQFUHDVHVSURGXFWLYLW\DQGUHGXFHVODERUFRVWV
compared to static cultures. Perform multiple 
applications simultaneously by linking up to 10 
systems together and monitor using the optional 
PCDAQ software on a single PC.
*DLQWKHÀH[LELOLW\QHHGHGWRVXSSRUW\RXUFHOO
FXOWXUHUHTXLUHPHQWVZLWKWKHPRGXODUIRUPDWRI
the WAVE Bioreactor 2/10 system. 
 
Set, maintain, and control CO2 concentration using 
a CO2$LU0L[&RQWUROOHUDQGDXWRPDWHIHHGLQJRI
FXOWXUHVDQGUHPRYDORIZDVWHSURGXFWVZLWKD
Perfusion Controller. Integral temperature control 
means there is no need for an incubator.
Cell
culture
media
Rocking
motion
Wave Wave
Take control
of process parameters
3
Easy scale-out 
for multiple cultures
4
,QOHWDLU¿OWHU
Spare luer port/optional pH probe
2XWOHWDLU¿OWHU
<GLSWXEHIRUSHUIXVLRQKDUYHVW
Needleless sampling port
Inoculation/Feed line
2[\ZHOOSRUW
Static culture
0%        20%       40%      60%      80%      100%
Media consumption
WAVE Bioreactor 2/10 system
Static culture
0%        20%       40%      60%      80%      100%
Production time
WAVE Bioreactor 2/10 system
*URZWKSUR¿OHRIQLQHLQGHSHQGHQW7,/FXOWXUHV&HOOVJURZQLQWKH
&HOOEDJELRUHDFWRUH[KLELWVLJQL¿FDQWO\KLJKHUSUROLIHUDWLRQUDWHV
and absolute cell numbers than cells grown in static conditions. 
(Reproduced with permission) (2).
Optimize nutrient concentration and minimize 
WKHDPRXQWRIFXOWXUHPHGLDUHTXLUHGXVLQJ
the Perfusion Controller (2,3). Automatic media 
H[FKDQJHDQGVFDOHXSXVLQJDVLQJOH&HOOEDJ
bioreactor reduces media consumption by 50% 
compared to static culture.
Using a WAVE Bioreactor 2/10 system reduces 
WKHWRWDOFRVWRIHTXLSPHQWFRQVXPDEOHV 
DQGPHGLDIRUDVLQJOHH[SDQVLRQRIFHOOVWR
DSSUR[LPDWHO\RQHWKLUGWKDWRIDQHTXLYDOHQW
culture performed using static culture bags (2).
Typical percentages of media consumption for an application 
with TIL cells. Data based on an article by Sadeghi, A., et al (4). 
7\SLFDOSHUFHQWDJHVRISURGXFWLRQWLPHUHTXLUHGIRUDQDSSOLFDWLRQ
with TIL cells. Data based on an article by Sadeghi, A., et al (2).
&RQWLQXRXVQRQLQYDVLYHPL[LQJRISUHDFWLYDWHG
FHOOVUHVXOWVLQKLJKHU\LHOGVRI¿QDOSURGXFW
compared to static culture (1,2,3,4,5,6).
,QFUHDVHH[SDQVLRQHȺFLHQF\
 Minimize media consumption
Reduce hands-on-time  
and lower costs
Reduce production time by up to 60% compared 
to static cultures using the WAVE Bioreactor 2/10 
system with perfusion (2,3,4,5) and lower costs 
using a single Cellbag bioreactor for scale-up 
ZKHQPXOWLSOHEDJVRUÀDVNVDUHRIWHQQHHGHG
7KHDPRXQWRIODERUUHTXLUHGWRSURFHVVDQG
KDUYHVWWKHKLJKHUGHQVLWLHVRIYLDEOHFHOOV
DFKLHYHGZLWKDXWRPDWHGPHGLDH[FKDQJHLVDOVR
reduced.
More cells for less  
with the Perfusion Controller
5
$XWRPDWHGPHGLDH[FKDQJHDQGZRUNLQJ
YROXPHVRIXSWR/LQDVLQJOHGLVSRVDEOH
Cellbag bioreactor make the WAVE Bioreactor 
2/10 system easier to use and considerably less 
laborious than static cultures where multiple 
EDJVRUÀDVNVDUHXVXDOO\QHHGHG
Description Code number
Cellbag 500mL (BC10, Basic) 28-9480-89
Cellbag 2L (BC10, Basic) 28-9378-00
Cellbag 2L (BC10, DO) 28-9377-99
Cellbag 2L (BC10, Perfusion, DO) 28-9376-52
Cellbag 10L (BC10, Basic) 28-9378-01
Cellbag 10L,(BC10, Perfusion, DO) 28-9376-62
Cellbag 20L (BC10, Basic) 28-9378-02
Cellbag 20L (BC10, DO) 28-9377-96
Cellbag 20L (BC10, Perfusion, DO) 28-9376-64
WAVE Bioreactor BASE2/10EH 28-9377-86
LID2/10W – OPAQUE 28-9376-33
Perfusion Controller PERFCONT2E 28-9884-64
WAVE Bioreactor BASE20/50EHT-L 100-120 V 28-9616-88
WAVE Bioreactor BASE20/50EHT-L 220-240 V 28-9616-89
WAVE Bioreactor BASE20/50EHTD-L 100-120 V 28-9436-72
WAVE Bioreactor BASE20/50EHTD-L 220-240 V 28-9436-95
WAVE Bioreactor BASE20/50EHT-CO2-L 100-120 V 28-9436-96
WAVE Bioreactor BASE20/50EHT-CO2-L 220-240 V 28-9436-97
Ordering information
imagination at work
29-0176-91AA 08/2012
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Touchscreen
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Fig 3. 
Quick-release bag holder
Optional components
pH Monitor
Dissolved oxygen monitor
O2/air mix controller
CO2/air mix controller
Analog output card
Loadcell
Linear electronic motor
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Xcellerex™ XDR cell culture  
bioreactor systems
The Xcellerex XDR bioreactor product line offers the benefits 
of single-use technology and stirred-tank design in a modular, 
turnkey, bioreactor platform (Fig 1). Designed for scalability and 
robustness, the XDR bioreactor systems provide the performance 
and flexibility needed from process development to large-scale 
biopharmaceutical manufacturing. XDR bioreactor systems 
can be operated in batch, fed-batch, and perfusion modes.
XDR bioreactor systems offer the following benefits:
• Scalable and predictable stirred-tank performance  
up to 2000 L  
• Single-use technology eliminates costly and time-
consuming cleaning and cleaning validation
• Advanced automation and modular system design  
to support a variety of installation scenarios
• Process and operational support from staff with  
extensive manufacturing experience 
System overview
The full line of XDR bioreactor systems are designed and 
characterized to deliver scalable process equivalence from 
4.5 L to 2000 L working volume (Fig 2), in both GMP and 
non-GMP environments. The system design is based on the 
same foundational principles as conventional stainless steel 
bioreactors. Consistent vessel geometries, tight relationship 
between consumables and equipment features, and a host 
of accessories combine for an easily scalable, single-use 
product line. Traditional scaling methodology, based on 
measures such as shear, tip speed, power per unit volume, 
kLa, and specific process sensitivities, can be used during 
scale-up. Technology transfer using the XDR systems is 
straightforward, minimizing the need for costly and time-
consuming process redesign. For enhanced utility across the 
bioreactor platform, the minimum working volume is as low 
as 20% of the maximum working volume. 
Fig 1. Bioreactor system components: XDR vessel with frame-mounted I/O 
cabinet and X-Station mobile control console.
The bioreactor bag assembly (XDA) is disposed after culture 
termination and eliminates costly and time-consuming 
cleaning-in-place (CIP) and steam-in-place (SIP) operations. 
The XDA bag assembly is prepackaged with a low profile 
impeller, a variety of sparge components, filters, and 
tubing, for quick and hassle-free installation. The flexibility 
of single-use technology enables quick changeover 
between productions, for efficient equipment utilization. 
Interconnection of bioreactor bag and equipment is key in 
achieving the excellent performance that XDR bioreactor 
systems deliver.
The modularity of the XDR product line stems from three key 
system components: bioreactor frame, I/O cabinet, and the 
X-Station mobile control console. The system components 
Fig 2. The complete range of XDR bioreactor systems are available with 
maximum working volumes ranging from 10 to 2000 L, from the smallest 
XDR-10 (described separately in data file 29-0929-27) to the largest XDR-2000 
system. Images are representative, some features and accessories may vary 
depending on the bioreactor configuration.
2  29-0929-25 AA
can be used together for a complete turnkey system with true 
plug-and-play performance. Alternatively, the components can 
be used separately and integrated into existing infrastructure, 
for enhanced flexibility. The jacketed vessel has a consistent 
design and delivers integrated heating and cooling for efficient 
temperature control throughout all scales. The versatile I/O 
cabinet houses all critical process instrumentation such 
as mass flow controllers, peristaltic pumps, and probe 
transmitters. This instrumentation can be configured or 
customized with up to six mass flow controllers as well as 
up to four internal and two external pumps. The X-Station 
mobile control console is the heart of the product line’s turnkey 
capability. The power and versatility of the X-Station allow for 
up to six XDR bioreactor systems to be controlled from one 
single control unit. This truly modular design creates a process-
ready system upon delivery and also supports integration into 
a user-preferred automation platform.
XDR system components
Well-mixed bioreactor vessel
Constructed of 304 grade stainless steel (304 SS), the jacketed 
vessel enables efficient heat transfer and, together with an 
external temperature control unit (TCU), offers highly accurate 
temperature control of the cell culture. The bioreactor vessel 
features load cells for weight measurement and locking casters 
with leveling feet. Other features include a bioreactor bag tubing 
manager for convenient positioning and routing of the bag 
tubing and a high-performance, bottom-mounted, magnetically 
coupled drive system. Because of the bottom drive, there are no 
shafts to install from the top of the bioreactor vessel, minimizing 
ceiling height requirements. To aid in coupling and decoupling of 
the drive system with the bioreactor bag, motor lifting assistive 
devices are integral with the two largest bioreactor systems. 
The systems are equipped with inlet and exhaust filter 
holders and vessel sidewall viewing ports. A lower sidewall 
port opening makes room for a sampling port as well as 
probes for pH, dissolved oxygen (DO), and temperature. An 
optional perfusion-specific bag loading door is available to 
accommodate cell retention devices. The 1000 L and 2000 L 
systems feature integrated bag loading doors that, along 
with the semiautomatic bag hoist, simplifies bag insertion 
without the need for climbing ladders. An efficient exhaust 
gas filter heater is also included to avoid condensate that 
could compromise exhaust filter performance.
The complete XDR bioreactor system product portfolio 
supports operating volumes from 4.5 L up to 2000 L. The 
smallest process development system is discussed in detail in 
a separate data file (29-0929-27).
Versatile I/O cabinet 
Fabricated in 304 SS, the NEMA4X-rated I/O cabinet houses 
devices for liquid and gas management as well as pH and 
DO transmitters. Profibus™ standard is used in device 
communication and communication to X-Station or other control 
systems (e.g., Rockwell, DeltaV™, Honeywell, Siemens, and 
Mitsubishi systems). Standard XDR gas and liquid management 
configurations cover the majority of cell culture applications.
Liquid management
The I/O cabinet can be configured with up to four variable-
speed peristaltic pumps with ranges to support liquid addition 
or removal. The pumps can be programmed for fed-batch and 
perfusion culturing and easily calibrated using Wonderware™ 
software.
Gas management
Up to six mass flow controllers offer multiple sparging regimes, 
CO2 abatement at large scale, and overlay gas addition. The 
XDR systems include a gas manifold to distribute the various 
gases to the available bag destinations: sparger or headspace.
Measurements of DO and pH
DO and pH can be measured using conventional polarographic 
sensors and glass electrodes, respectively. These sensors can 
be autoclaved prior to use in a specially designed probe sheath. 
Aseptic insertion into the bioreactor bag is conveniently done 
using single-use connector technology. Alternatively, an optical 
DO sensor and a single-use pH probe are available ready for 
use to minimize start-up time. The flexibility of the system allows 
the sensor technology to be mixed for use of conventional 
and single-use technologies simultaneously. All sensors are 
connected to the I/O panel through transmitters. 
Measurement of dissolved carbon dioxide
Conventional, reusable, insertion-type, probe technology is 
used for monitoring of dissolved carbon dioxide. A dedicated 
transmitter is available optionally for integration into the I/O 
panel. 
Plug-and-play X-Station mobile control console
X-Station is a stand-alone, mobile control console featuring 
intuitive process control, data historian, and industrial-quality 
automation hardware and software (Fig 3). The control 
system provides real-time data acquisition, enables accurate 
process control, and offers convenient, real-time trending. 
X-Station is capable of measuring and controlling up to six 
XDR bioreactor systems simultaneously. 
Fig 3. The X-Station 
mobile control 
console.
Inside the 304 SS cover is housed a 
scalable programmable logic controller 
(PLC)/programmable automation 
controller (PAC) and a server-class 
computer running user interface and 
data historian software. X-station comes 
with a 19” touchscreen, industrial, wash 
down-resistant mouse, a QWERTY 
keyboard and a built-in uninterruptible 
power supply (UPS). Profibus and Ethernet 
communication standards are included 
for equipment and local area network 
connectivity.
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XDA bioprocessing consumables 
The XDR bioreactor bag is an essential part of the process 
performance achieved with XDR bioreactor systems. 
Constructed with a contact layer of USP class VI-compliant 
low-density polyethylene (LDPE) plastic, the bioreactor bags 
are robust to withstand process conditions. All bioreactor 
bag assemblies incorporate a seal-less, bottom-mounted, 
impeller/sparger assembly with a centrally positioned 
integral magnet (Fig 4A). Installed in the bioreactor vessel, the 
impeller/sparger assembly couples with the magnetic drive 
head, creating a powerful and robust agitation system with 
minimal risk of seal leakage. Up to eight sparge elements 
are included in the impeller/sparge assembly (Fig 4B). Each 
sparge element may be configured with various porosities, 
drilled holes, or a combination of both to support both 
macro- and microsparging. Each of the standard sparge 
elements have been validated to provide out-of-the-box 
performance consistent with current cell culture practices. 
Fig 4. (A) Impeller for XDR-2000 with four pitched blades. (B) Impeller/sparger 
assembly for XDR-200 with three pitch blades and eight sparge elements.
Additional bag components include tubing with a combination 
of weldable sections and aseptic connectors for liquid 
addition/removal, a disposable pressure sensor, and filters for 
exhaust, sparge, and overlay/headspace gas. XDA bioreactor 
bags support both insertion-type reusable probes and single-
use probes. Probe configurations include reusable probes 
only, single-use probes only, or mixed reusable and single-
use probes. For details on probes, see section “Measurement 
of DO and pH”.
To assist in efficient bioreactor operation, a number of 
supplementary XDA bag-related accessories are optionally 
available. Like the main bioreactor bags, these accessories 
are tightly coupled to the equipment design to be adaptable 
to varied process requirements and to support operational 
efficiency. XDA accessories include seal-and-store sample 
manifolds, foam traps, X-Connect tubing sets, and exhaust 
filter tubing sets.
Qualification support 
The XDR bioreactor systems are designed for use in 
environments that require 21 CFR Part 11 and Good 
Automated Manufacturing Practice (GAMP) 5. The systems 
are delivered with an operating manual, system specification, 
drawings to support qualification, and major component 
documentation. Industry standard installation and operation 
qualification (IQ/OQ) packages are available as an option. 
Applications
XDR cell culture bioreactor systems have successfully been 
used to cultivate a wide range of cell types and organisms 
including CHO cells, Vero cells, and MDCK cells. In addition, 
a fermentor system is available for microbial applications 
including E. coli, Pseudomonas spp., and yeast (see data 
file 29-0929-29). XDR bioreactor systems can be operated 
in batch, fed-batch, and perfusion (or chemostat) modes. 
Bioreactor bag design can be process-dependent, requiring 
customization for proper use and performance.
System specifications 
Standard cell culture specifications are listed in Table 1.
Ordering information
Related literature Code number
Xcellerex XDR-10 cell culture bioreactor system, data file 29-0929-27
Xcellerex XDR-50 MO fermentor system, data file 29-0929-29
Xcellerex XDUO Quad Mixing System, data file 29-0483-66
Xcellerex XDM Quad Mixing System, data file 29-0483-67
For more information on the bioreactor systems, please contact your local sales representative.
The XDA bioreactor bags are available in Pro, Development, 
or Custom formats. Pro-type bags are available for all 
bioreactor systems and have validated sparge configurations, 
established based on customer feedback and our own 
biomanufacturing experience. Development bags are 
available for XDR-50 and XDR-200 bioreactor systems and 
differ from the Pro bags primarily in the configuration of the 
sparge elements. Development bags may be used in a broad 
array of process development activities where various micro- 
or macrosparging regimes are evaluated. Custom bioreactor 
bags can be modified with tubing type and quantity, 
connection type, filter element, or sparger configuration. 
Custom bags can also incorporate a CO2-removal sparge 
wand to address processes sensitive for dissolved CO2. 
All bioreactor bags for cell culture include a magnetically 
coupled, M40e 40°, pitched-blade impeller with ceramic 
bearings. Ceramic bearings, originally developed for 
aggressive mixing applications and fermentation, provide 
excellent overall performance. The medical-grade ceramic 
bearings meet the relevant industry requirements for 
leachables, extractables, and particulates according to the 
bag validation guide (for more information, please contact 
your sales representative). Special impellers are available for 
microcarrier applications. 
imagination at work
GE, imagination at work, and GE monogram are trademarks of General Electric Company.
Xcellerex is a trademark of GE Healthcare companies.
DeltaV is a trademark of Emerson Electric Co. Wonderware is a trademark of Invensys plc. Profibus is a 
trademark of PROFIBUS Nutzerorganisation e.V. Watson-Marlow is a trademark of Watson Marlow Pumps 
Limited.
© 2014 General Electric Company—All rights reserved. 
First published Feb. 2014
All goods and services are sold subject to the terms and conditions of sale of the company within GE Healthcare 
which supplies them. A copy of these terms and conditions is available on request. Contact your local GE 
Healthcare representative for the most current information.
GE Healthcare UK Limited, Amersham Place 
Little Chalfont, Buckinghamshire, HP7 9NA 
UK
GE Healthcare Europe, GmbH 
Munzinger Strasse 5, D-79111 Freiburg 
Germany
GE Healthcare Bio-Sciences Corp. 
800 Centennial Avenue, P.O. Box 1327, Piscataway, NJ 08855-1327 
USA
GE Healthcare Japan Corporation 
Sanken Bldg., 3-25-1, Hyakunincho, Shinjuku-ku, Tokyo 169-0073 
Japan
29-0929-25 AA 02/2014
For local office contact information, visit
www.gelifesciences.com/contact
www.gelifesciences.com
GE Healthcare Bio-Sciences AB
Björkgatan 30
751 84 Uppsala
Sweden
Table 1. Specifications of standard configuration XDR cell culture bioreactor systems
Specification XDR-50* XDR-200 XDR-500 XDR-1000 XDR-2000
Max. working volume (L) 50 200 500 1000 2000
Min. working volume (L) 22 40 100 200 400
Volume turn-down ratio 2.2:1 5:1 5:1 5:1 5:1
Aspect ratio (H/D) 1.5:1 1.5:1 1.5:1 1.5:1 1.5:1
Vessel Jacketed 304 SS
Filter heater assembly 1 1 1 1 1
Additional filter heater assemblies (optional) 1 1 1 1 1
Bag hoist Not applicable Not applicable Not applicable Semi-automatic Semi-automatic
Impeller, M40e pitched-blade type 3 blades at 40° pitch 4 blades at 40° pitch
Standard bag assembly Development:  
29-0410-65
Pro: 29-0410-60
Development:  
29-0410-66
Pro: 29-0410-61
Pro: 29-0410-62 Pro: 29-0410-63 Pro: 29-0410-64
Custom bag assembly Available on request
Process instrumentation
pH probes† 1 
(optional second probe)
2 2 2 2
DO probes† 1 
(optional second probe)
2 2 2 2
MFC§ (standard) 4 4 4 5 5
Additional MFC‡ (optional) 2 2 2 1 1
Internal pumps (standard) 3 
(2! low flow,  
1! high flow)
3 
(2! low flow,  
1! high flow)
3 
(2! low flow,  
1! high flow)
4
(2! low flow,  
2! high flow)
4
(2! low flow,  
2! high flow)
Additional internal pumps (optional) 1 1 1 Not applicable Not applicable
External pumps (optional)§ 2 2 2 2 2
Temperature control unit¶
(heating, kW/cooling, HP)
3/1 9/1.5 9/1.5 9/1.5 9/1.5
Load cells 3 4 4 4 4
X-Station control unit
Interfaces 19”/52.4 mm touchscreen, wash-down compatible keyboard and mouse; includes built-in UPS
Hardware Rockwell/Allen Bradley
Operator Interface Wonderware HMI††
HMI†† Data Historian Wonderware
Compliance Built to GAMP5 standards/ 21 CFR Part 11 compliant‡‡
* For specifications of XDR-50 MO fermentation system, please see data file 29-0929-29.
† Single-use or reusable probes
‡ Thermal mass flow controllers
§ External pumps are Profibus devices and may be Watson-Marlow™ 520, 620, or 720 series depending on required flow rate.
¶ Optional standalone heating/cooling TCU listed. Other TCU configurations available, including units that use facility chilled water/glycol.
†† Human-machine interface
‡‡ Customer will need to implement appropriate operating procedures to be fully 21 CFR part 11 compliant. The XDR is built to support this two-part compliance.
Note! For specifications of XDR-10 bioreactor system, please see data file 29-0929-27.
SCAL-TECH® Pro Suites  
 
      Established in 1982,the Techniserv Automation & Integration Group can 
supply the Emerson DeltaV, Siemens DCS and/or Allen Bradley Control 
Logics based control systems on Bioreactors from our 3L glass to 25,000L 
production systems with Identical look, feel, and recipe function on any 
size reactor. 
 TECHNISERV 3L GLASS TO 25,000L PRODUCTION                 
 BIOREACTORS POWERED BY CONTROL PLATFORMS 
FROM EMERSON, SIEMENS OR ALLEN BRADLEY.   
 
SCAL-TECH® BENCH 
   15L S/S 20L S/S 30L S/S 
30L S/S Through 200L S/S 
Seed  
Reactor REACTOR # 1 
REACTOR 
# 2 
Filtration 
Unit 
Harvest 
Unit 
TCM 
TCM 
TCM 
TCM 
200L S/S Through 25,000L S/S 
SCAL-TECH® MINI 
Glass Laboratory Scale 
3L,5L,7L,15L,20L 
TECHNISERV, INC. 
Company Profile: 
 
The Techniserv, Inc. Bioreactor and Fermentation and Proc-
ess Equipment divisions are focused on providing both stan-
dard and custom process  
systems to the Pharmaceutical, Biotech and related high pu-
rity industries, and have supplied many large modular sys-
tems to these companies.  Our capabilities in design, fabrica-
tion, software development and validation allow delivery of 
fully Turnkey integrated systems.  Techniserv’s client list en-
compasses the majority of the largest US and International 
Bio-Pharmaceutical manufacturers. 
 
Established in 1982, Techniserv’s Control System Integration 
division also provides alternate customized control solutions utilizing conventional control platforms including Al-
len Bradley PLC’s, Emerson Delta-V DCS and Siemens PCS-7 DCS.  Techniserv has developed many SCADA 
systems utilizing packages such as Intellution, Rockwell RSView, Wonderware and more. 
 
Techniserv, Inc. employs ten (10) electrical and automation engineers in the Control System Integration division, 
eleven (11) mechanical and process engineers in the Bioreactor and Fermentation and Process Equipment  
divisions, and multiple dedicated project managers and validation specialists. 
 
Techniserv’s off the self standard bioreactor and fermentor systems can incorporate the Emerson Delta V control 
package.  For the first time, Techniserv can offer a Delta V based DCS control platform that seamlessly supports 3L 
Glass through 25,000L production reactors. 
 
 
  
Contacts: 
  
Paul Heaps Sr. 
CEO 
paul_heaps1@techniservinc.com 
 
Paul Heaps II 
President 
paul_heaps2@techniservinc.com 
  
Michael S. Smith 
Vice President 
Operations 
michael_smith@techniservinc.com 
x Control Platforms: 
 Allen Bradley PLC 
 Emerson DeltaV DCS 
 Siemens PCS-7 DCS 
  
  
 
x Migration from Lab to Production 
x FDA 21CFR Part 11 Compliant 
x Utilizes Bused I/O Technologies 
x Supports PAT 
 
 
 
Techniserv, Inc. 
351 South Eaton St. 
Berwick PA 18603 
 
Phone: (570) 759-2315 
Fax:     (570) 759-2785 
 
Web Site: 
www.techniservinc.com 
 
Featuring Emerson Delta V Operating System  
Jacketed Tanks
Features at a glance:
• Standard sizes 18 to 7,000 gallon
• 304, 304L, 316, 316L stainless steel
• 2B, #4/180, #7/320, and electropolish available
• Flat, sloped, dished, or 15 ° cone bottom
• ASME or non-ASME code stamped designs
• Jackets available:  embossed, dimple, half pipe, laser
• Jacket design:  pressure 150 psi, temperature 366° F
Our cylindrical jacketed tanks are custom made to satisfy your
process, mixing, and temperature control requirements.  Built
from 304, 304L, 316, or 316L stainless steel.  Our jacketed
tanks can be easily adapted to meet your dimensional
requirements.  All standard sizes have optional features that
allow for made-to-order applications.
Ja
ck
et
ed
 T
an
ks
ISO 9001 Certified
600 Main Street
Sharpsville, PA 16150
office:  724-962-1100
fax:  724-962-1226
email:  Sales@scacon.com
www.sharpsvillecontainer.com
Sharpsville Container is known for high quality fabrication in
stainless steel and exotic alloys.  Our vessels, whether they are
process or transport, ASME, UN, or Heat Transfer are
manufactured for the Food, Chemical, Beverage, Petro-
Chemical and Pharmaceutical markets.  The size of vessels that
we manufacture range from 1 gallon to 25,000 gallons.  With
our standard line and custom design expertise, we are capable
of meeting or exceeding your fabrication requirements.  Our
reputation for quality and service continues to exceed our
customers’ expectations.
-508-
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Autoclave Systems – Heaters – Reactors –
for Vulcanizing Rubber, Plastic Products
and Composites
WSF has the experience and job-proven track
record of manufacturing rubber vulcanizing 
equipment for production, R&D or process 
simulation. We can provide a complete system 
or furnish exactly what you need to maximize 
your efficiency, versatility and profitability.
• Vulcanizers to ASME Code Standards in a wide 
range of sizes and design pressures.
• Vertical or horizontal configurations using steam, 
air-plus-steam, steam-water or “dry” heat.
• Controls to any degree of sophistication.
• Includes patented RAPIDOOR® for quick 
access and external RAPID/LOADER®.
• Innovations include our unique RAPID/CURE®
continuous vulcanizer for wire, cable and hose.
Industries, Inc.
application bulletin
No. 104-03
Automated autoclave system for processing 
rubber hose features a vertical-slide RAPIDOOR 
and unique wheel-less, cart-loading 
mechanism and ergonomic 
load-positioning system.
-537-
-538-
-540-
EMD Millipore is a division of Merck KGaA, Darmstadt, Germany
Eshmuno® S resin characteristics
Type Strong cation exchanger
Functional group -SO3
Base matrix Surface grafted rigid polyvinyl ether 
hydrophilic polymer
Lysozym capacity 115–165 mg/mL settled resin
Ionic capacity 50–100 µeq/mL settled resin
Mean particle size 75–95 µm
IgG dynamic capacity >60 mg/mL (2 min. residence time)
Pressure drop (100 x 16 mm,  
5 mL/min., 150 cm/h) 
<1.0 bar
Eshmuno® S resin
For superior downstream mAB purification
Data Sheet
Benefits
 Superior productivity for mAB downstream 
processing
 More selectivity and HCP removal
 Active tentacle adsorption
 Robust and safe packing procedures
 Tangible savings in cost and development time
Eshmuno® is a unique family of ion-
exchange resins specifically designed for 
highly productive downstream bioprocess-
ing. The cation exchanger Eshmuno® S is 
the first member of the Eshmuno® resin 
family and is highly productive in direct 
capture and post-protein A steps.
Superior productivity for mAB 
downstream processing
Eshmuno® S resin exhibits a superior binding capacity for 
antibodies compared to other modern cation-exchangers. 
Fig. 1 shows the dynamic binding capacity (DBC) for 
direct capture of a monoclonal antibody mAB02 at 5% 
breakthrough and 5 min. residence time from a real 
diluted feedstock. The DBC of Eshmuno® S resin is 
approximately 50% higher than the capacity of other 
surface-grafted cation exchangers. 
A similar superior binding capacity can be shown in  
post-protein A purification steps. Fig. 2 illustrates the 
increased binding capacity of Eshmuno® S resin in an 
intermediate purification step of mAB03.
Pressure versus flow curve of 
Eshmuno® S resin 
In combination with the excellent pressure flow behaviour 
(Fig. 3) an outstanding productivity of more than  
40 mg/mL x h (dimension for productivity) for Eshmuno® S 
resin can be achieved, resulting in considerable manufac-
turing cost savings in mAB production. 
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Superior mAB binding capacity in direct capture step
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Figure 1.
mAB02 DC, 5% breakthrough, 4.3 mS/cm, pH 6.0 [mAB02] 
= 0.62 mg/mL, 5 min. residence time, 1 mL scout column
Figure 2.
DBC of mAB03 5 mg/mL in buffer A, 2 min. residence time,  
1 mL scout column
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Figure 3.
20 cm i.d. column; 19,5 cm bed height; 8% compression 
recorded in 150 mM NaCl
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More selectivity and HCP removal 
A crucial property of any ion exchange material in 
biochromatography is the ability to specifically select the 
biomolecule of interest. While Eshmuno® S resin carries 
the same functional group like Fractogel® SO! resin, a 
slightly modified selectivity can be observed (Fig. 4), 
which allows a wider flexibility for the specific purifica-
tion challenge. 
The result: Eshmuno® S resin is the most efficient resin in 
the removal of host cell proteins (Fig. 5).
Figure 5.
HCP Clearance factor of mAB02, 5% breakthrough, 4.3 mS/cm, 
pH 6.0, 5 min. residence time, 1 mL scout column
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Figure 4.
A mixture of Chymotrypsinogen A, Cytochrome C, and  
Lysozyme was separated under standard conditions
Eshmuno® S resin
Cytochrome C
Chymotrypsinogen A
Lysozyme
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Active tentacle technology 
Merck KGaA was the first manufacturer of a biochroma-
tography resin (Fractogel®) with tentacle structure  
(Fig. 6). The main advantage of this tentacle chemistry  
is the increased amount of sterically accessible ligands  
to more effectively bind the biomolecule of interest thus 
increasing the capacity of the resin. 
Eshmuno® S resin combines both, the reliable tentacle 
technology with the properties of a new hydrophilic 
polyvinyl ether base matrix. The polymer matrix allows 
the use of much higher flow rates, while the biomolecule 
is still strongly bound by the tentacle. 
Figure 6.
Resin tentacles forming a three-dimensional ion exchange 
network, enable easy access of the proteins to the ligands
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Ordering Information
Description Catalogue No.
Eshmuno® S resin 1.20078
Robust and safe packing 
procedures 
Eshmuno® S resin can be easily packed into production 
scale columns for biochromatography either by simple 
flow packing or axial compression. To prevent corrosion 
of the tubing system, Eshmuno® columns can be packed 
using 0.01 M sodium hydroxide solutions and even pure 
water resulting in plate numbers >2400/m with good 
peak symmetry. 
For the packing of Eshmuno® and sanitization of the 
column we recommend EMD Millipore chemicals  
especially dedicated for the use in biopharmaceutical 
production with the brandname EMPROVE® bio. 
Tangible savings in cost and 
development time 
With the use of Eshmuno® S resin in downstream 
processing considerable manufacturing cost savings can 
be achieved. The productivity of purification in a model 
process of a monoclonal antibody could be increased  
5-fold by using Eshmuno® S resin instead of a conven-
tional soft-gel ion exchanger. The use of Eshmuno® S 
resin instead of a protein A based capture step can save 
up to 30% of your purification costs. 
GE Healthcare
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Capto™ S
Capto Q
Capto DEAE
Capto S, Capto Q and Capto DEAE are, respectively, strong cation, strong 
anion and weak anion exchange BioProcess™ media for capture and 
intermediate purification of proteins from large feed volumes by packed 
bed chromatography. 
All Capto media provide: 
• Raised productivity with high dynamic binding capacity at high 
flow. 
• Increased yield with rapid mass transfer. 
• Reduced process time with high volume throughput. 
• Cost-effective processing with smaller unit operations. 
• For effective and rigorous CIP procedures. 
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1 BioProcess media
BioProcess media are developed and supported for production-
scale chromatography. All BioProcess media are produced with 
validated methods and are tested to meet manufacturing 
requirements. Secure ordering and delivery routines give a reliable 
supply of media for production scale. Regulatory Support Files 
(RSF) are available to assist process validation and submissions to 
regulatory authorities. BioProcess media cover all purification 
steps from capture to polishing. 
2 Properties of Capto S, Capto Q 
and Capto DEAE
For ion exchange chromatography, Capto S uses a sulfonate group 
(Fig 1a), Capto Q uses a quartenary amine group (Fig 1b) and Capto 
DEAE uses a diethylaminoethyl group (Fig 1c). 
Fig 1a. The strong cation exchange group of Capto S. 
Fig 1b. The strong anion exchange group of Capto Q. 
O
SO-3
O N(CH3)3
OH +
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Fig 1c. The weak anion exchange group of Capto DEAE. 
Capto S, Capto Q and Capto DEAE are designed to increase speed, 
capacity, and throughput in capture and intermediate purification 
of biomolecules. By offering high capacity at high flow velocities 
with low back pressure, process cycle times may be reduced and 
productivity increased. 
Capto S, Capto Q and Capto DEAE are based on the same high flow 
agarose matrix which is designed to give low back pressures at 
high fluid velocities (700 cm/h in a 1 m diameter column with 20 cm 
bed height at ‹ 3 bar in water). Note that the back pressure will vary 
with column type and medium bed height. Figure 2 shows the 
pressure/flow curve for Capto S packed in AxiChrom™ 1000.
All media have dextran surface extenders for increased capacity, 
and fast mass transfer.
O
+
NH(CH2CH3)2
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Fig 2. Pressure/flow curve for Capto S compared to Q Sepharose™ Fast Flow. 
Running conditions: AxiChrom 1000 for Capto S, Chromaflow™ 1000 for 
Q Sepharose Fast Flow, 20 cm packed bed, with water at 20ºC. The pressure 
includes pressure drop from the bed and the column. System/tubing 
pressure is excluded.
The highly cross-linked agarose base matrix gives the media high chemical 
and physical stability. Characteristics such as capacity, elution behavior, and 
pressure/flow rate are unaffected by the solutions commonly used in 
process chromatography and cleaning procedures (Tables 1, 2 and 3).
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Table 2. Characteristics of Capto Q
1 d50v is the median particle size of the cumulative volume distribution.
2 Dynamic binding capacity at 10% breakthrough as measured at a residence time of 1 
minute, 600 cm/h in a Tricorn 5/100 column with 10 cm bed height, in a 50 mM Tris-
HCl buffer, pH 8.0.
3 Working range pH: pH interval where the medium can be operated without significant 
change in function.
Cleaning-in-place pH: pH stability where the medium can be subjected to cleaning- or 
sanitization-in-place without significant change in function.
4 No significant change in dynamic binding capacity and carbon content after 1 week 
of storage in 1 M NaOH at 40°C.
Matrix High flow agarose with a dextran surface extender
Ion exchange type Strong anion, Q
Charged group –N+(CH3)3
Total ionic capacity 0.16 to 0.22 mmol Cl¯/ml medium
Particle size1 90 µm (d50v)
Flow velocity 700 cm/h in a 1 m diameter column with 20 cm 
bed height at 20°C using process buffers with the 
same viscosity as water at ‹ 3 bar (0.3 MPa) 
Dynamic binding 
capacity2
› 100 mg BSA/ml medium
pH stability3
Working range 2 to 12
Cleaning-in-place 2 to 14
Working temperature 4°C to 30°C
Chemical stability All commonly used aqueous buffers, 1 M acetic 
acid, 1 M NaOH4, 8 M urea, 6 M guanidine 
hydrochloride, 30% isopropanol and 70% ethanol
Avoid Oxidizing agents, anionic detergents
Storage 20% ethanol
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3 Method optimization
The aim of designing and optimizing an ion exchange separation 
process is to identify conditions that promote binding of the 
highest amount of target molecule, in the shortest possible time 
with highest possible product yield and purity. Design the method 
in laboratory scale.
For certain proteins, dynamic binding capacities increase at 
increased conductivity. Therefore, we recommend scouting for 
optimal dynamic binding conditions on Capto S, Capto Q and 
Capto DEAE, for the target protein at conductivities between 
2 mS/cm and 15 mS/cm as well as scouting for optimal binding pH. 
For Capto S and Capto DEAE, the dynamic binding capacities 
decrease for some proteins at lower temperatures. Screening for 
buffer concentration at the temperature where the process is 
intended to be run will give the optimal dynamic binding capacity. 
Since Capto S, Capto Q and Capto DEAE allow efficient capture at 
high fluid velocities, pay special attention to optimizing elution 
conditions to avoid tailing peaks when eluting the protein of 
interest. 
Balancing product recovery against throughput is the major 
consideration when optimizing a method. The dynamic binding 
capacity for the target protein should be determined using process 
feedstock. Since the dynamic binding capacity is a function of the 
fluid velocity applied during sample application, the breakthrough 
capacity must be defined over a range of different residence times 
to show the optimal level of throughput. 
When designing a process it is also important to take the cleaning 
of the media into consideration. Capto DEAE can be more 
challenging to clean than Capto S and Capto Q, for more details, 
see Chapter Maintenance. 
For more information about method development and 
optimization, consult the handbook, Ion exchange 
Chromatography & Chromatofocusing: Principles and Methods, 
(11-0004-21). 
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4 Scale-up
Principles for scale-up
After optimizing the method at laboratory scale, the process can 
be scaled up. Scale-up is typically performed by keeping bed 
height and linear fluid velocity constant while increasing bed 
diameter and volumetric flow rate. However, since optimization is 
preferentially performed with small column volumes, in order to 
save sample and buffer, some parameters such as the dynamic 
binding capacity may be optimized using shorter bed heights than 
those being used in the final scale. As long as the residence time is 
kept constant, the binding capacity for the target molecule 
remains the same. 
Other factors, such as clearance of critical impurities, may change 
when column bed height is modified and should be validated using 
the final bed height. The residence time is approximated as the bed 
height (cm) divided by the linear fluid velocity (cm/h) applied during 
sample loading. 
Suggested procedure for scale-up
1 Select the bed volume according to required binding capacity. 
Keep sample concentration and gradient slope constant. 
2 Select a column diameter to obtain a bed height of 10 cm to 
40 cm. The high rigidity of the Capto S, Capto Q and Capto DEAE 
base matrix allows for bed heights well above 20 cm. 
3 The larger equipment used when scaling up may cause some 
deviations from the method optimized at small scale. In such 
cases, check the buffer delivery system and monitoring system 
for time delays or volume changes. Different lengths and 
diameters of outlet tubing can cause zone spreading on larger 
systems. 
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Calculating amount of medium 
The amount of medium needed can be calculated by: column 
cross-sectional area (cm2) ! bed height (cm) ! compression factor 
(settled medium bed height/ packed medium bed height).
Washing the medium 
Equilibrate all materials to room temperature. Mount the glass 
filter funnel onto the filtering flask. Pour the medium into the funnel 
and wash with approximately 5 to 10 ml 10 mM NaCl per ml 
medium. 
Preparing the packing slurry 
The slurry concentration should be 40 to 60% in 10 mM NaCl, 
measured in a measuring cylinder after settling overnight. 
Equipment needed 
An ÄKTA design system or a stand-alone pump that can deliver 
20 ml/min is used. The pump filter unit and the flow restrictor 
should be removed due to the high flow velocity used in the column 
packing in order to decrease the system backpressure.
For packing Tricorn 5/100 column
Tricorn 5/100 column, Tricorn 5/100 glass tube (used as a packing 
reservoir), packing connector 5-5 and bottom unit.
For packing Tricorn 10/100 column
Tricorn 10/100 column, Tricorn 10/100 packing equipment, which 
includes the 10 mm packing connector, Tricorn 10/100 glass tube 
(used as a packing reservoir), and bottom unit with filter holder, cap 
and stop plug.
When working with large volumes, real feed or repeated loading, 
Tricorn coarse filter kits are recommended to reduce the risk of 
clogging. Use Tricorn 5 Coarse Filter Kit (11-0011-53) or Tricorn 10 
Coarse Filter Kit (11-0012-54). 
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Packing procedure 
To pack the column, use 10 mM NaCl in distilled water and proceed 
as follows:
1 Rinse the column and packing tube in 10 mM NaCl.
2 Insert a bottom filter into the filter holder and wet the filter. 
3 Wet the O-ring on the filter holder by dipping the filter holder 
into water, buffer, or 20% ethanol. 
4  Insert the filter holder into the column tube. Ensure that the 
“keyed” part of the filter holder fits into the slot on the threaded 
section on the column tube. Screw the end cap onto the column 
tube. 
5 Pour the packing solution into the tube and ensure that the 
liquid drips from the column. Insert a stop plug into the bottom 
unit when approximately 1 cm of packing solution remains. 
6 Screw a suitable Tricorn packing connector onto the top of the 
column tube. The Tricorn packing connector must be fitted with 
suitable O-rings (included with the Tricorn packing connector). 
Screw the Tricorn packing tube into the upper fitting of the 
Tricorn packing connector. 
7 Mount the column and packing unit vertically on a lab stand. 
8 Fill both column tube and packing tube with slurry. Avoid 
formation of air bubbles in the gel by pouring it along a thin 
capillary. 
9 Attach an extra bottom unit or an adapter unit to the top of the 
packing tube. Fill the capillary from the pump with packing 
solution and connect the pump to the top of the packing unit , 
remove the stop plug from the bottom of the column tube. 
10 Pack the medium at 540 cm/h (1.8 ml/min in Tricorn 5/100,
7.1 ml/min in Tricorn 10/100). When the liquid above the 
medium bed is clear, continue packing for 10 min. 
11 Pack the medium for an additional 10 min at 3000 cm/h (Tricorn 
5/100: 9.8 ml/min, Tricorn 10/100: 39.3 ml/min). 
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12 Switch off the pump and connect a stop plug into the bottom 
unit. Remove the packing tube and packing connector. If 
necessary, remove excess medium with a Pasteur pipette or 
spatula by re-suspending the top of the packed bed. Ensure 
that the medium surface is as even as possible. 
13 Add packing solution to the upper edge of the column tube. 
14 Place a pre-wetted filter on top of the fluid in the column. 
Note: The top coarse filter is inserted by another procedure. 
See separate instruction included in Tricorn coarse filter 
kits. 
15 Prepare the adapter unit by screwing the guiding ring, inside 
the adapter unit, down to the lower end position. 
16 Wet the O-ring on the adapter unit by dipping it in water, 
packing solution, or 20% ethanol. 
17 Screw the guiding ring back 1.5 turns. 
18 Mount the top adapter unit onto the column tube, ensuring the 
inner part of the guiding ring fits into the slot on the column 
tube threads. Ensure that there are no air bubbles. 
Note: The top adapter should be connected but not fully 
screwed down. 
19 Connect the pump, remove the stop plug and start a flow 
(Tricorn 5/100: 1 ml/min (300 cm/h), Tricorn 10/100: 5 ml/min 
(380 cm/h)). 
20 Slowly screw the adapter unit down until the filter meets the 
bed surface. Ensure that the filter meets the bed horizontally. 
21 Increase the flow to 3000 cm/h (Tricorn 5/100: 9.8 ml/min, 
Tricorn 10/100: 39.3 ml/min). 
22 If the medium bed compresses, slowly screw the adapter unit 
down to the medium surface with maintained flow. 
23 Pack the medium for 5 min. If the bed has compressed further, 
screw the adapter unit down to the medium surface. 
24 Stop the flow and connect a stop plug to the bottom unit. 
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7 Maintenance
For best performance from Capto S, Capto Q and Capto DEAE, and 
to maximize the working life time of the media, follow the 
procedures described below. 
Equilibration 
After packing, and before a chromatographic run, equilibrate with 
equilibration buffer by washing with at least five bed volumes for 
Capto S and Capto Q and at least 10 bed volumes for Capto DEAE, 
or until the column effluent shows stable conductivity and pH 
values. The equilibration step can be shortened by first washing 
with a high concentration buffer to obtain approximately the 
desired pH value and then washing with equilibration buffer until 
the conductivity and pH values are stable. 
Regeneration 
After each separation, elute any reversibly bound material with a 
high ionic strength solution (e.g., 1–2 M NaCl in buffer). Regenerate 
the medium by washing with at least five bed volumes of 
equilibration buffer for Capto S, Capto Q and Capto DEAE, or until 
the column effluent shows stable conductivity and pH values. 
Cleaning-In-Place 
Cleaning-In-Place (CIP) is a procedure that removes contaminants 
such as lipids, endotoxins, and precipitated or denatured proteins 
that remain in the packed column after regeneration. This type of 
contamination occurs frequently when working with feedstock. 
Regular CIP prevents the build-up of contaminants in the packed 
bed and helps to maintain the capacity, flow properties, and 
general performance of Capto S, Capto Q and Capto DEAE. 
A specific CIP protocol should be designed for each process 
according to the type of contaminants present. The frequency of 
CIP depends on the nature and the condition of the feedstock, but 
for capture steps, CIP is recommended after each cycle. 
Note: For some contaminants a more rigorous CIP procedure can 
be required for Capto DEAE than for Capto S and Capto Q, 
see CIP protocols, below. 
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CIP protocols
1 Specific regulations may apply when using 70% ethanol since the use of explosion-
proof areas and equipment may be required. 
Sanitization 
To reduce microbial contamination in the packed column, 
sanitization using 0.5 to 1 M NaOH with a contact time of 1 h is 
recommended. The CIP protocol for precipitated, hydrophobically 
bound proteins or lipoproteins sanitizes the medium effectively. 
Storage 
Store unused medium in the container at a temperature of 
4°C to 30°C. Ensure that the cap is fully tightened. Packed media 
and bulk media should be stored in 20% ethanol containing 0.2 M 
sodium acetate (Capto S) or 20% ethanol (Capto Q and Capto 
DEAE). After storage, equilibrate with at least five column volumes 
of starting buffer for Capto S and Capto Q and at least 10 bed 
volumes of starting buffer for Capto DEAE before use. 
Precipitated, hydrophobically 
bound proteins or lipoproteins
Wash with 1 M NaOH at 40 cm/h with 
reversed flow direction. Contact time 1 
to 4 h, dependent on feed. If the 
removal of contaminants is not 
satisfactory for Capto DEAE, use 1 M 
NaOH containing 1 M NaCl as CIP 
solution.
Ionically bound proteins Wash with 0.5 to 2 column volumes (CV) 
of 2 M NaCl with reversed flow 
direction. Contact time 10 to 15 min.
Lipids and very hydrophobic 
proteins
Wash with 2 to 4 CV of up to 70% 
ethanol1 or 30% isopropanol with 
reversed flow direction. Contact time 1 
to 2 h, dependent on feed. Alternatively, 
wash with 2 to 4 CV of 0.1% nonionic 
detergent with reversed flow direction. 
Contact time 1 to 2 h, dependent on 
feed.
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8 Ordering information 
Capto S bulk media products are supplied in suspension in 20% 
ethanol containing 0.2 M sodium acetate. Capto Q and Capto DEAE 
bulk media products are supplied in suspension in 20% ethanol. 
For additional information, including a Data File, please contact 
your local GE Healthcare representative.
Product Quantity Code No
Capto S 25 ml 17-5441-10
100 ml 17-5441-01
1 l 17-5441-03
5 l 17-5441-04
10 l 17-5441-05
60 l 17-5441-60
Capto Q 25 ml 17-5316-10
100 ml 17-5316-02
1 l 17-5316-03
5 l 17-5316-04
10 l 17-5316-05
60 l 17-5316-60
Capto DEAE 25 ml 17-5443-10
100 ml 17-5443-01
1 l 17-5443-03
5 l 17-5443-04
10 l 17-5443-05
60 l 17-5443-60
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HiScreen Capto S 1 x 4.7 ml 28-9269-79
HiScreen Capto DEAE 1 x 4.7 ml 28-9269-82
Tricorn 5/100 column 1 18-1163-10
Tricorn 10/100 column 1 18-1163-15
HiScale 16/20 1 28-9644-41
HiScale 16/40 1 28-9644-24
HiScale 26/20 1 28-9645-14
HiScale 26/40 1 28-9645-13
HiScale 50/20 1 28-9644-45
HiScale 50/40 1 28-9644-44
Related literature Code No
Movie Column Packing – The Movie 18-1165-33
Handbook Ion Exchange Chromatography & 
Chromatofocusing: Principles and Methods
11-0004-21
Data file Capto Q, Capto S and Capto DEAE 11-0025-76
Application notes High productivity capture of D-chymotrypsin 
on Capto S cation exchange 28-4078-15
Screening and optimization of the loading 
conditions on Capto S 28-4078-16
Capto S cation exchanger for post-Protein A 
purification of monoclonal antibodies 28-4078-17
High-productivity capture of Green 
Fluorescent Protein on Capto Q 11-0026-20
Screening of loading conditions on Capto S 
using a new high-throughput format, 
PreDictor plates 28-9258-40
Process-scale purification of monoclonal 
antibodies - polishing using Capto Q 28-9037-16
Purification of a monoclonal antibody using 
ReadyToProcess columns 28-9198-56
Use of Capto ViralQ for the removal of 
genomic DNA from influenza virus produced in 
MDCK cells 28-9769-69
Related product Quantity Code No
For local office contact information, visit 
www.gelifesciences.com/contact
GE Healthcare Bio-Sciences AB
Björkgatan 30
751 84 Uppsala
Sweden
www.gelifesciences.com/BioProcess
GE Healthcare Europe GmbH
Munzinger Strasse 5, 
D-79111 Freiburg, 
Germany
GE Healthcare UK Ltd
Amersham Place
Little Chalfont
Buckinghamshire, HP7 9NA 
UK
GE Healthcare Bio-Sciences Corp
800 Centennial Avenue
P.O. Box 1327 Piscataway, 
NJ 08855-1327
USA
GE Healthcare Japan Corporation
Sanken Bldg.
3-25-1, Hyakunincho
Shinjuku-ku, Tokyo 169-0073
Japan
GE, imagination at work and GE monogram are trademarks of General Electric Company.
ÄKTA, ÄKTAexplorer, AxiChrom, BioProcess, BPG, Capto, Chromaflow, HiScale, HiScreen, HiTrap, 
PreDictor, Sepharose and Tricorn are trademarks of GE Healthcare companies.
© 2006-2012 General Electric Company – All rights reserved.
First published Jan. 2006.
All goods and services are sold subject to the terms and conditions of sale of the company within 
GE Healthcare which supplies them. A copy of these terms and conditions is available on request. 
Contact your local GE Healthcare representative for the most current information.
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Instructions 28-9034-55 AC  Antibody Purification
GE Healthcare
Ab Buffer Kit
Introduction
Ab Buffer Kit contains 10X stock solutions of Binding and Elution 
buffers and ready to use Neutralizing buffer. The buffers are optimized 
for rapid purification of monoclonal and polyclonal IgG using 
immobilized Protein A or Protein G.
The kit eliminates time-consuming buffer preparation and thus 
promotes fast, reproducible and convenient purification work.
The buffers have been prepared using the highest quality chemicals 
and water, and have been filtered through a 0.45 µm filter.
The following protocols can be used with buffers from Ab Buffer Kit:
• Protocol 1, using 1 ml or 5 ml HiTrap™ columns.
• Protocol 2, using SpinTrap™ columns (Protein A HP SpinTrap, 
Protein G HP SpinTrap and Ab SpinTrap).
• For Ab purification using multiwell plates, please follow the 
instruction provided with the Protein A HP or Protein G HP 
MultiTrap™ product. 
Kit content 
* Containing 20% ethanol as a preservative
Protocol 1
Use this protocol for:
• HiTrap Protein G HP
• HiTrap Protein A HP
• HiTrap Protein A FF 
Recommendations
• Recommended flow rates:
- Approx. 1–3 ml/min for HiTrap 1 ml columns
- Approx. 5–10 ml/min for HiTrap 5 ml columns.
• Prepare buffers according to Table 1 or 2.
• Prepare collection tubes by adding 60 to 200 µl of Neutralizing 
buffer per ml of fraction to be collected. In this way the final pH 
of the eluted antibodies will be approximately neutral, which 
preserves the activity of acid labile IgG.
• Check also the relevant column instructions.
Buffer preparation.
Protocol
1 Prepare the sample by centrifugation (10 000 × g, 20 min) or filter 
(0.45 µm) if there are particles present or the appearance is 
cloudy. 
- If the sample is serum or ascites fluid, dilute the sample 1:1 
with Binding buffer.
2 Fill the syringe with Binding buffer. Remove the stopper and 
connect the column to the syringe (with the provided adapter) 
"drop to drop" to avoid introducing air into the column.
3 Remove the snap-off end at the column outlet.
4 Wash the column with 10 column volumes (CV) of Binding buffer 
(1 CV = 1 ml for HiTrap 1-ml column; 1 CV = 5 ml for HiTrap 5-ml 
column).
5 Apply the sample, using a syringe fitted to the Luer adapter. 
Collect the flowthrough.
6 Wash with 5 to 10 CV of Binding buffer or until no material 
appears in the effluent. Collect wash fractions.
7 Elute with 2 to 5 CV of Elution buffer. Collect 1-ml fractions in 
collection tubes containing Neutralizing buffer.
Buffer Buffer content Formulation Volume
Binding Buffer 0.2 M sodium 
phosphate, pH 7.0*
10X 50 ml
Elution Buffer 1 M glycine-HCl, 
pH 2.7
10X 15 ml
Neutralizing buffer 1 M Tris-HCl, pH 9* Ready to use 25 ml
Table 1. Buffer preparation for 1 purification on 1 ml HiTrap columns.
Buffer Stock 
solution
Distilled 
water
Final 
volume
Binding buffer 2.5 ml 22.5 ml 25 ml
Elution buffer 0.5 ml 4.5 ml 5 ml
Table 2. Buffer preparation for 1 purification on 5 ml HiTrap columns.
Buffer Stock 
solution
Distilled 
water
Final 
volume
Binding buffer 12.5 ml 112.5 ml 125 ml
Elution buffer 2.5 ml 22.5 ml 25 ml
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Protocol 2
Use this protocol for:
• Ab SpinTrap
• Protein A HP SpinTrap
• Protein G HP SpinTrap
Recommendations
• The protocol is optimized for room temperature. If performed at 
a lower temperature, a longer incubation time may be needed.
• Use Ab SpinTrap columns with a standard microcentrifuge. 
Place a column in a 2-ml microcentrifuge tube to collect liquid 
during centrifugation. 
• Prepare buffers according to Table 3.
• Prepare two collection tubes per sample for eluted fractions by 
adding 30 µl Neutralizing buffer to a 2-ml microcentrifuge tube.
• Check also the relevant column instructions.
Buffer preparation
Protocol
1 Invert and shake the Ab SpinTrap column repeatedly to 
resuspend the medium. 
2 Loosen the top cap one-quarter of a turn and break off the 
bottom closure. 
3 Place the column in a 2-ml microcentrifuge tube and centrifuge 
for 30 s at 70 to 100 × g to remove the storage liquid.
4 Remove the top cap. Equilibrate the column by adding 600 µl 
Binding buffer. Centrifuge for 30 s at 70 to 100 × g.
5 Add the sample. Maximum sample volume is 600 µl/load. 
6 Secure the top cap tightly and incubate for 4 min with gentle 
mixing (mixing with an end-over-end mixer machine is 
recommended but other methods can also be used). 
7 Loosen the top cap one-quarter of a turn, centrifuge for 30 s at 
70 to 100 × g. 
Several sample applications can be performed provided that the 
capacity of the column is not exceeded. Repeat this step after 
each application. Empty the microcentrifuge tube as needed.
8 Wash with 600 µl Binding buffer. Centrifuge for 30 s at 70 to 
100 × g. 
9 Repeat the wash.
10 Elute the bound antibody by adding 400 µl Elution buffer to the 
column. 
11 Place the column in a 2-ml microcentrifuge tube containing 30 µl 
Neutralizing buffer. 
12 Centrifuge for 30 s at 70 × g. 
The eluted fraction contains the purified antibody. 
13 Repeat this step one time, collecting the second elution in a fresh 
2-ml microcentrifuge tube containing 30 µl Neutralizing buffer.
 Most of the bound antibody is eluted after two elution steps.
Table 3. Buffer preparation for 10 purifications on Ab SpinTrap 
columns or 20 reactions using MultiTrap multiwell plates.
Buffer Stock 
solution
Distilled 
water
Final 
volume
Binding buffer 2 ml 18 ml 20 ml
Elution buffer 1 ml 9 ml 10 ml
3
Instructions 28-9034-55 AC Antibody Purification
Ordering information
Products
Related products
Literature
Description Quantity Code No.
Ab Buffer Kit 1 28-9030-59
Description Quantity Code No.
Protein A HP SpinTrap 16 columns 28-9031-32
Protein G HP SpinTrap 16 columns 28-9031-34
Ab SpinTrap 50 columns 28-4083-97
Protein A HP MultiTrap 4 × 96-well plates 28-9091-33
Protein G HP MultiTrap 4 × 96-well plates 28-9091-35
HiTrap Protein G HP, 1 ml 2 columns 17-0404-03
HiTrap Protein G HP, 1 ml 5 columns 17-0404-01
HiTrap Protein G HP, 5 ml 1 column 17-0405-01
HiTrap Protein G HP, 5 ml 5 columns 17-0405-03
HiTrap Protein A HP, 1 ml 2 columns 17-0402-03
HiTrap Protein A HP, 1 ml 5 columns 17-0402-01
HiTrap Protein A HP, 5 ml 1 column 17-0403-01
HiTrap Protein A HP, 5 ml 5 columns 17-0403-03
HiTrap rProtein A FF, 1 ml 2 columns 17-5079-02
HiTrap rProtein A FF, 1 ml 5 columns 17-5079-01
HiTrap rProtein A FF, 5 ml 1 column 17-5080-01
HiTrap rProtein A FF, 5 ml 5 columns 17-5080-02
Title Code No.
Antibody Purification Handbook 18-1037-46
Affinity Chromatography Handbook 18-1022-29
Affinity Chromatography Columns and Media 
Product Profile
18-1121-86
imagination at work
28-9034-55 AC 02/2009
www.gelifesciences.com/sampleprep
GE Healthcare Bio-Sciences AB
Björkgatan 30
751 84 Uppsala
Sweden
GE, imagination at work and GE monogram are trademarks of General Electric Company.
Drop Design, SpinTrap, MultiTrap,  and HiTrap are trademarks of GE Healthcare companies. 
© 2007-2009 General Electric Company – All rights reserved.
previously published 2007.
All goods and services are sold subject to the terms and conditions of sale of the company within GE 
Healthcare which supplies them. A copy of these terms and conditions is available on request. Contact 
your local GE Healthcare representative for the most current information.
GE Healthcare Europe GmbH
Munzinger Strasse 5, D-79111 Freiburg, Germany
GE Healthcare UK Ltd
Amersham Place, Little Chalfont, Buckinghamshire, HP7 9NA, UK
GE Healthcare Bio-Sciences Corp
800 Centennial Avenue, P.O. Box 1327, Piscataway, NJ 08855-1327, USA
GE Healthcare Bio-Sciences KK
Sanken Bldg. 3-25-1, Hyakunincho, Shinjuku-ku, Tokyo 169-0073, Japan
Instructions 28-9034-55 AC Antibody Purification
  
Filters
VIRUS REMOVAL FOR 
BIOTHERAPEUTIC 
PRODUCTS
6
 PVDF Hollow Fiber Filter 
Construction
;OL7SHUV]H™)PV,?ÄS[LYTLTIYHULPZ
THKLVMO`KYVWOPSPaLKWVS`]PU`SPKLULÅ\V
YPKL7=+-HYVI\Z[TH[LYPHS^P[OH\UPX\L
Z[Y\J[\YL[OH[WLYTP[ZOPNOÅV^YH[LÄS[YH[PVU
VMOPNOJVUJLU[YH[PVUWYV[LPUZVS\[PVUZ^OPSL
THPU[HPUPUNJHWHJP[`MVY]PY\ZYLTV]HS;OPZ
THRLZP[OPNOS`Z\P[HISLMVYSHYNL]VS\TL
WYVK\J[PVUVMIPV[OLYHWL\[PJWYVK\J[Z
Planova™ BioEX Filters
7SHUV]H)PV,?MPS[LYZHJOPL]LOPNOMSV^
YH[LZ^P[OYLSPHISL]PY\ZYLTV]HS[OHURZ[V
HKLUZLHUKOVTVNLULV\Z7=+-TLT
IYHULWYVK\JLKI`[OLYTHSS`PUK\JLK
WOHZLZLWHYH[PVU;OL7=+-TLTIYHULPZ
THKLO`KYVWOPSPJI`NYHM[WVS`TLYPaH[PVU
7SHUV]HOVSSV^MPILY[LJOUVSVN`
HZZ\YLZOPNOX\HSP[`JVUZPZ[LUJ`HUKWYV
]PKLZV\[Z[HUKPUNZJHSHIPSP[`MVYIPV[OLYH
WL\[PJTHU\MHJ[\YPUN
7
 Effective for High-Pressure and  
High-Concentration Usage
9LZLHYJOKH[HZ\WWVY[Z[OL\ZLVM
7SHUV]H)PV,?MPS[LYZMVYOPNOWYLZZ\YL
OPNOJVUJLU[YH[PVUMPS[YH[PVUZ
-PN\YLZOV^Z[OLL_JLSSLU[JVYYLSH
[PVUIL[^LLUMPS[YH[PVUWYLZZ\YLHUKMSV^
YH[L^OPJOZ[H`ZWYVWVY[PVUHSL]LUPU[OL
OPNOWYLZZ\YLYHUNL
-PN\YL
Relationship between h-IgG throughput  
and h-IgG concentration
Planova BioEX filters can withstand high-concentration solu-
tions, thereby increasing the quantity of protein to be processed. 
-PN\YL
*VYYLSH[PVUIL[^LLUÅV^YH[LVM 
O0N.ZVS\[PVUHUKÄS[YH[PVUWYLZZ\YL
Flow rate is dependent on pressure. Higher pressure yields 
faster processing.
-PN\YLZOV^Z[OH[^P[OH[V
O0N.ZVS\[PVU7SHUV]H)PV,?THPU[HPUZH
OPNO[OYV\NOW\[VMRNT2OYZH[ÄS[YH
[PVUWYLZZ\YLVM R7HWZP

 High LRV for Parvoviruses and  
Larger Viruses
Planova™)PV,?MPS[LYZHYLHISL[V
YLTV]LWHY]V]PY\ZLZ^OPJOHYLHTVUN
[OLZTHSSLZ[RUV^U]PY\ZLZMV\UKPU
UH[\YLHJOPL]PUNSL]LSZILSV^[OLKL[LJ
[PVU[OYLZOVSK7SHUV]H)PV,?MPS[LYZHYL
]HSPKH[LK[VKLSP]LY%SVNZVMYLTV]HS
MVY77=
-VYOPNOWYVK\J[P]P[`[OPZWLYMVYTHUJL
PZZ\Z[HPULKL]LUMVYSHYNL]VS\TLMPS[YH[PVU
VMOPNOJVUJLU[YH[PVUZVS\[PVUZHZZOV^U
PU-PN\YL
,_[LUZP]L[LZ[PUNVM7SHUV]H)PV,?
MPS[LYZ]HSPKH[LZWLYMVYTHUJLMVYSHYNL
]PY\ZLZHZ^LSS-VYL_HTWSL)PV,?
HJOPL]LZ%SVNZMVY(4\3=HZHSZV
ZOV^UPU-PN\YL
 Laboratory-Scale and Process-Scale
0UHKKP[PVU[V[OLWYVJLZZZJHSLT2 
HUKT27SHUV]H)PV,?ÄS[LY[OLSHI
VYH[VY`ZJHSLT2ÄS[LYPZVMMLYLKMVY
KL]LSVWPUNIPVSVNPJHSKY\NWYVK\J[THU\
MHJ[\YPUNWYVJLZZLZ0[ZZTHSSLYTLTIYHUL
Z\YMHJLHYLHPZJVU]LUPLU[MVYZJHSLKKV^U
X\HSPÄJH[PVUVY]HSPKH[PVUZ[\KPLZ
(KKP[PVUHS7SHUV]H)PV,?MPS[LYZPaLZ
PUJS\KPUNT2HUKT2HYLH]HPS
HISL
 Standard Clamp Connections and  
SIP Capability
-VYLHZ`PU[LNYH[PVUPU[VTHU\MHJ[\YPUN
WYVJLZZLZ7SHUV]H)PV,?T2T2 
HUKT2 ÄS[LYZHYLKLZPNULKMVYZ[HUKHYK
ZHUP[HY`JVUULJ[PVUZ
Planova™ BioEX Performance
 
Not detected
-PN\YL
Removability of PPV, MVM and A-MuLV  
for Planova BioEX
4LTIYHULTH[LYPHSHUKJHY[YPKNLLSL
TLU[ZHYLJVUZ[Y\J[LK^P[O[OLZ[YLUN[O
HUKPU[LNYP[`[V^P[OZ[HUKZ[LHTPUWSHJL
:07VWLYH[PVUZ
 Predictable Results 
7SHUV]H)PV,?ÄS[LYZWYV]PKLWYLKPJ[HISL
WLYMVYTHUJL\UKLYHJVUZPKLYHISLYHUNLVM
JVUKP[PVUZPUTHU`JHZLZ^P[OV\[WYLÄS[LYZ
Even for high-volume filtration of high-concentration 
solutions, Planova BioEX removes parvoviruses and larger 
viruses. 
Ferrule connection nozzle design 
enhances connection stability.
O0N.^HZZWPRLK^P[OI`]VS\TLVMLHJO]PY\ZZVS\[PVU
-PS[YH[PVU7YLZZ\YL! R7HWZP

5
5
)PV,?
5
(4\3= HTWOV[YVWPJT\YPULSL\RLTPH]PY\Z
)  O\THUWHY]V]PY\Z) 
)=+= IV]PUL]PYHSKPHYYOLH]PY\Z
*7= JHUPULWHY]V]PY\Z
,4*= LUJLWOHSVT`VJHYKP[PZ]PY\Z
.*:- NYHU\SVJ`[LJVSVU`Z[PT\SH[PUNMHJ[VY
/(= OLWH[P[PZ(]PY\Z
O0N. O\THUPTT\UVNSVI\SPU.
/0= O\THUPTT\UVKLÄJPLUJ`]PY\Z
/0= O\THUPTT\UVKLÄJPLUJ`]PY\Z[`WL
/:= OLYWLZZPTWSL_]PY\Z
0N4 PTT\UVNSVI\SPU4
4*:- THJYVWOHNLJVSVU`Z[PT\SH[PUNMHJ[VY
4VUVJSVUHS0N. TVUVJSVUHSPTT\UVNSVI\SPU.
4=4 TPU\[L]PY\ZVMTPJL
7VSPV WVSPV]PY\Z[`WL
77:) WYV[OYVTIPUJVTWSL_
77= WVYJPULWHY]V]PY\Z
79= WZL\KVYHIPLZ]PY\Z
9LV YLV]PY\Z[`WL
:= ZPTPHU]PY\Z
[7( [PZZ\LWSHZTPUVNLUHJ[P]H[VY
]>- ]VU>PSSLIYHUKMHJ[VY
?4\3= _LUV[YVWPJT\YPULSL\RLTPH]PY\Z
Nomenclature
Product Applications
.*:-
0U[LYMLYVU
0U[LYSL\RPU
4*:-
;OYVTIPU
,Y`[OYVWVPL[PU
-HJ[VY=00
<YVRPUHZL
_HU[P[Y`WZPU
-HJ[VY0?
7YV[LPU*
(U[P[OYVTIPU000
/LTVNSVIPU
(SI\TPU
6Z[LVWVU[PU
77:)
[7(
*PUOPIP[VY
*LY\SVWSHZTPU
4VUVJSVUHS0N.
-HJ[VY?0
7SHZTHKLYP]LK 
THUUHUIPUKPUNSLJ[PU
-HJ[VY=000
O0N.
-PIYPUVNLU
]>-
0N4
    R+H
Examples of Protein Recovery Rate
 
Polyclonal IgG 
(30mg/ml)
Monoclonal IgG 
(20mg/ml)
Factor VIII 
(100IU/ml)
Planova 15N #  %  
Planova 20N %  %  %
Planova 35N   % 
Planova BioEX %  %  5;
NT: Not tested
Contact Information
North & South America
(ZHOP2HZLP)PVWYVJLZZ0UJ
,STKHSL(]L
.SLU]PL^03
<:(
;LSLWOVUL 
-HJZPTPSL 
,THPS!PUMV\Z'HRIPVJVT
Europe
5=(ZHOP2HZLP)PVWYVJLZZ,\YVWL:(
9\L*VSVULS)V\YN
)Y\ZZLSZ
)LSNP\T
;LSLWOVUL
-HJZPTPSL
,THPS!PUMVL\'HRIPVJVT
5=(ZHOP2HZLP)PVWYVJLZZ,\YVWL:(
*VSVNUL;LJOUPJHS*LU[LY
.V[[MYPLK/HNLU:[YHZZL
*VSVNUL
.LYTHU`
;LSLWOVUL   
-HJZPTPSL   
,THPS!PUMVL\'HRIPVJVT
Asia & Oceania
(ZHOP2HZLP4LKPJHS*V3[K
)PVWYVJLZZ+P]PZPVU
2HUKH1PUIVJOV
*OP`VKHR\;VR`V
1HWHU
;LSLWOVUL 
-HJZPTPSL 
,THPS!PUMVQW'HRIPVJVT
(ZHOP2HZLP4LKPJHS*V3[K
:PUNHWVYL9LWYLZLU[H[P]L6MÄJL
 )H[[LY`9VHK--:[YHPUZ;YHKPUN)\PSKPUN
:PUNHWVYL  
;LSLWOVUL  
-HJZPTPSL   
,THPS!PUMVQW'HRIPVJVT
(ZHOP2HZLP*OPUH*V3[K
:OHUNOHP9LWYLZLU[H[P]L6MÄJLVM)PVWYVJLZZ+P]PZPVU
-6UL0**:OHUNOHP0U[LYUH[PVUHS*VTTLYJL*LU[YL
5V   /\HPOHPAOVUN9VHK
:OHUNOHP
*OPUH
;LSLWOVUL! 
-HJZPTPSL! 
,THPS!PUMVQW'HRIPVJVT
=PZP[\ZVU[OL^LIH[^^^HRIPVJVT
Warning
Planova™ ÄS[LYZ HYL UV[TLKPJHS KL]PJLZ HUKT\Z[ UV[
IL\ZLK PU [YHUZM\ZPVUZL_[YHJVYWVYLHSJPYJ\SH[PVUVYV[OLY
TLKPJHS[YLH[TLU[Z
Planova™PZH[YHKLTHYRVM(ZHOP2HZLP4LKPJHS*V3[K
	
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                                  Intelligent BioProcessing Systems 
 
Automated, Aseptic Transfer of Liquids into Multiple, 
Single-use Storage Bags 
Summary: 
 
The Fill Master aseptically transfers solution into multiple, plastic storage bags. The Fill 
Master controls up to twelve, pneumatically operated tube pinch valves to direct the 
liquid flow from the reservoir into sterile storage bags.  Only the internal tube walls and 
the inside bag surfaces are in contact with the liquid. The high-accuracy, low-shear 
peristaltic pump action provides gentle and reproducible bag filling. In the 
programmable, volume dispensing mode, the Fill Master meters a user-defined volume 
of liquid, then automatically switches to the next empty storage bag to be filled. Up to 12 
storage bags can be serially filled in this fashion. Once filled, the bags can be 
aseptically sealed using a sterile tube welder. 
Features: 
 
There are several Fill Master models to choose from.  For example, the Fill Master 104B 
peristaltic pump head (max. pump rate is 14.6 liters/min with #184 Silicone tubing) 
allows for a continuous tube connection to be made between the reservoir and the 
storage bag manifold. A typical sterile fluid handling bag manifold, which may include 
multiple storage bags, as well as integral tubing, QC bags, sterilizing filter and 
connectors, are available pre-sterilized (i.e. gamma irradiated).  Contact SciLog for info.   
 
When ordering a sterile fluid handling bag manifold, the size and material of the integral 
tubing must be specified. The Fill Master 104B peristaltic pump head can accommodate 
the following tubing sizes: #26, 6.4 mm ID (0.15 to 2.60 liters/min); #73, 9.6mm ID (0.31 
to 5.94 liters/min); #82, 12.7 mm ID (0.53 to 9.25 liters/min) and #184, 15.9 mm ID (0.80 
to 14.50 liters/min) A range of tube materials can be used: Silicone, Pharmed, PVC and 
C-Flex (heat sealable).  Other Fill Master models accommodate additional sizes. 
 
An optional, disposable pressure transmitter can be placed in front of the in-line 
sterilizing filter to monitor filter backpressure. With the pressure transmitter connected to 
the Fill Master, excessive pressure build-up as well as associated leaks and bag failures 
are prevented. The Fill Master will stop all pumping action when a user-defined safe 
pressure limit is exceeded. 
SciLog Inc, 8845 S. Greenview Drive #4, Middleton, WI 53562-2562 
Web: www.scilog.com Tel: 800-955-1993 Fax: 608-824-0509 
 
-541-
   
 
Automated Bag Filling Operation: Fill Master Metering Program 
 
The Fill Master Volume-Flow mode (Mode 30) allows you to enter (in “EDIT”) and store an 
automated metering program. The following is a simple program to fill three, 20 liter storage 
bags. Change the RATE and TIME program steps to suit your storage bag volume. Add 
additional “RUN” program blocks to increase the number of bags (up to 12) you want to fill. 
 
000         START   The following program steps have been entered in Mode 30: 
001 CW   Motor Runs Clock-wise 
002 RUN   Motor is turned “ON” 
003 V  100000  Pinch Valve V1 is Energized, other V-valves are De-energized 
004 RATE: 5.0L/min   Pump Rate 5 liters per minute 
005 TIME: 00:04:00   Pump Runs 4 minutes, Bag #1 is filled with 20 Liters 
 
006 STOP   Pump “Off” 
007         V  020000  Pinch Valve V2 is Energized, other V-valve are De-energized 
008 TIME: 00:00:02  2 Second Time delay 
 
009 RUN   Pump “ON” 
010         RATE: 5.0 L/min  Pump Rate 5 liters per minute 
011 TIME: 00:04:00  Pump Runs 4 Minutes, Bag #2 is filled with 20 Liters 
 
012 STOP   Pump “Off” 
013  V  003000  Pinch Valve V3 is Energized, other V-valves are De-energized 
014 TIME: 00:00:02  2 Second Time Delay 
 
015         RUN   Pump “ON” 
016 RATE: 5.0 L/min  Pump Rate 5.0 liters per minute 
017 TIME: 00:04:00  Pump Runs 4 Minutes, Bag #3 is filled with 20 Liters 
018 STOP   Pump “Off” 
019         V 000000  All V-Valves are De-energized 
020         COUNT: 1  The Program Steps 000 to 020 are executed once 
021 END 
 
ORDERING INFORMATION:    SciLog Customer Service: 1-800-955-1993 
 
 Catalog #: Description: 
 
800-104BFILL Fill Master 104B mounted with a Watson-Marlow 620R peristaltic pump head, 0.5 HP motor; 
90VDC; 250 RPM max.; 7.8: 1 Speed Reducer. The 620R peristaltic pump head has two (2) 
pump rollers and accommodates continuous pump tubing of the following sizes: 6.4mm ID (#26), 
0.15 to 2.60 L/M); 9.6mm ID (#73) 0.31 to 5.94 L/M; 12.7mm ID (#82), 0.53 to 9.25 L/M; and 
15.9mm ID (#184), 0.80 to 14.5 L/M, wall thickness is 3.2mm (0.125”) for all tube sizes 
 
800-450 Multiple-Valve Controller: Remote control of twelve (12) electrically actuated air flow valves 
(Clippard) for automated pneumatic operation of twelve (12) pinch valves or sanitary diaphragm 
valves. Fully programmable from the Fill Master via dedicated serial port or manual control from 
front panel of the multi-Valve Box. Optional inputs for valve position sensors. 
 
934-VALVE Tubing Pinch Valve: Specify Tubing OD: 0.125”, 0.250”, 0.375”, 0.50”, 0.75”, and wall thickness. 
The valve is pneumatically actuated. Ideal for maintaining sterility, only tubing comes in contact 
with your process solution. Requires a Multi-Valve Controller for actuation and control. The Multi-
Valve Controller is fully programmable from the Fill Master via dedicated serial port or manual 
control from front panel of multi-Valve Box. Optional inputs for valve position sensors. 
 
  
 
 
 
 
AN 8002, Copyrighted. Last Revision: 12/22/05 
SciLog Inc, 8845 S. Greenview Drive #4, Middleton, WI 53562-2562 
Web: www.scilog.com Tel: 800-955-1993 Fax: 608-824-0509 
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CIP Washers
Clean-In-Place Systems
B I O - P H A R M
Sani-Matic Clean-In-Place Systems for the Bio-Pharm 
industry are custom engineered to specific plant 
application and utility requirements to ensure  
effective and efficient cleaning of process 
equipment automatically.
Proper CIP design and sizing will not only ensure 
sufficient flow and pressure to remove residue 
adequately, and rinse thoroughly. Sani-Matic 
CIP designs will also save cycle time, reduce 
water and chemical usage, and minimize 
discharge and utility costs. Balancing all  
factors to create an optimum system is 
our goal. CIP Systems can be designed to 
recirculate or provide “once-through” 
cleaning, depending on the product residue. 
Multi-tank systems can provide additional 
benefits of faster turnaround time if cleaning 
processes are more frequent.
WHAT MAKES US 
DIFFERENT?
Sani-Matic has the expertise to engineer an effective 
solution for your cleaning application. Specialists in cleaning 
technology, the Sani-Matic team will provide valuable 
insight and guidance during your project from beginning 
to end. Developing a creative design concept based on 
decades of practical experience, we can ensure you are 
purchasing a system which is dependable and cost-effective 
for the long term. Sani-Matic has in-house programming 
staff and field technical service with the expertise to develop 
and optimize your cleaning cycles and integrate the CIP 
functions with your plant Process control systems. 
Because the Sani-Matic team understands the unique 
challenges of cleaning, we add value to your CIP projects.
Our manufacturing 
facilities and processes are 
controlled and efficient,  
ensuring that your system is com-
pliant and on-schedule. Project  
management and documentation 
is detailed and complete, saving 
you time and resources while 
achieving your project’s 
budget and target  
start-up date.
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CIP:  CLEAN-IN-PLACE
• Single-use source of wash solution and rinse water
• Lower space requirement
• Portable or stationary design is available
• Once through or recirculated
One Tank
Single-use System
Two Tank
Detergent & Rinse System
• Permits once through or recirculated flow of wash solution
• Used where water utilities are limited
• Reduced wash cycle times
CIP system sizing is determined by dimensions of the vessels 
and pipelines to be cleaned.
Supply pump flow is determined by the vessel size and the 
largest pipeline diameter. Turbulent cleaning action requires 
5-7 fps flow in lines. Proper cascading cleaning action by 
a sprayball is 3 gpm per ft of tank circumference.  
Pressure is determined by the spray device requirement 
(typically 25psi, plus any line loss). 
Sizing the wash and rinse tank volume is determined by the 
pipeline holdup volume (gal per 100ft) and the available inlet 
water capacity and the estimated cleaning program time. 
CIP DESIGN SIZING FACTORS
®  CLEAN-IN-PLACE
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Controls
THE IDEAL SOLUTION FOR:
• Vessels with low and/or small outlets
• Variable supply and return flow (1 to 100 GPM)
• Portable - Avoid investment in permanent supply & return lines
• Locations with limited/low water volume available
• Economical replacement for an existing or outdated CIP
• Installations where available floor space is limited
• Not appropriate for “once through” non-recirculated processes
ADVANTAGES
• Reduce water usage • Lower chemical consumption
• Eliminate installation costs • Increase flexibility
Sani-Matic has in-house programmers and authorized UL 
panel shop who design, manufacture, pre-test, startup and 
support of all types of Control Systems for cleaning systems. 
Because the team specializes in cleaning applications,  
Sani-Matic has developed expertise and efficiencies that have 
advantages over other fabricators or process integrators.  
Sani-Matic has designed, manufactured and supported  
thousands of CIP systems and other cleaning related systems.
Understanding the unique aspects of an effective cleaning 
program, Sani-Matic developed a very flexible & easy-to- 
understand OP-Code Recipe Editor that allows the customer 
to manipulate the system hardware to optimize their cleaning 
programs. This can result shorter total cycle time, lower water 
& chemical usage, more precise control to setpoints and  
detailed alarms which reduce troubleshooting time.
Soon to be released, the new Sani-Trend Data Acquisition 
System collects and stores cleaning cycle data, events/alarms, 
and operator information onto a PC. Operating usage of 
water, chemical, and utilities may be calculated and trended. 
Sani-Trend reports are in easy to use Excel format, and provide 
reliable, secure information giving you valuable insight on your 
cleaning process.
CIP Washers
UltraFlow The Sani-Matic UltraFlow CIP is patented technology which uses an eductor, vortex air separation chamber and modulating 
valves to control the CIP supply and return flows. This unique 
CIP design successfully brings air & water back in the return 
flow, separates the air, keeping the supply pump primed. The 
UltraFlow uses much less water than traditional CIPs and is 
flexible to clean a wide variety of circuits.
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DESCRIPTION 12 11 10 9 8 7 6 2 15 14 12 11 10 9 8 6 5 2 1
1 **PROGRAM  END** 1 0 0 0 0 1 0 0 0 0
2 **SAN PROGRAM START** 2 0 0 0 0 2 0 0 0 0
3 **CIP PROGRAM END** 3 0 0 0 0 3 0 0 0 0
4 4 0 0 0 0 4 0 0 0 0
5 PRE RINSE TO DRAIN 5 1 0 1 0 0 5 1 1 1 C 8 0 0
6 6 0 0 0 0 6 0 0 0 0
7 BURST PRE RINSE TO DRAIN 7 1 0 1 0 0 7 1 1 1 1 D 8 0 0
8 8 0 0 0 0 8 0 0 0 0
9 DETERGENT WASH 9 1 1 1 1 1 C 0 4 9 1 1 1 1 C 2 0 2
10 ACID WASH 10 1 1 1 8 0 0 10 1 1 1 C 1 0 0
11 CHASE RINSE TO DRAIN W/ DETERGENT 11 1 1 0 4 0 4 11 1 1 1 1 C 2 0 2
12 CHASE RINSE TO DRAIN W/ ACID 12 0 0 0 0 12 1 1 1 C 1 0 0
13 CHASE RINSE TO DRAIN W/ DETERGENT AND CONDUCTIVITY HOLD 13 1 1 0 4 0 4 13 1 1 1 1 C 2 0 2
14 CHASE RINSE TO DRAIN W/ ACID AND CONDUCTIVITY HOLD 14 0 0 0 0 14 1 1 1 C 1 0 0
15 CHEMICAL SANITIZE 15 1 0 1 0 0 15 1 1 1 C 0 0 4
16 16 0 0 0 0 16 0 0 0 0
17 17 0 0 0 0 17 0 0 0 0
18 18 0 0 0 0 18 0 0 0 0
19 19 0 0 0 0 19 0 0 0 0
20 20 0 0 0 0 20 0 0 0 0
21 PUMPBACK TO DRAIN 21 0 0 0 0 21 1 4 0 0 0
22 PUMPBACK W/ DETERGENT RECOVERY 22 1 0 0 0 4 22 1 1 4 0 4 0
23 PUMPBACK W/ ACID RECOVERY 23 0 0 0 0 23 1 4 0 0 0
24 RINSE TO DRAIN 24 1 0 1 0 0 24 1 1 1 C 4 0 0
25 RINSE TO DRAIN WITH RETURN CONDUCTIVITY HOLD 25 1 0 1 0 0 25 1 1 1 C 4 0 0
26 RINSE WITH DET RECOVERY AND RETURN CONDUCTIIVITY HOLD 26 1 1 0 1 0 4 26 1 1 1 1 C 4 4 0
27 RINSE WITH ACID RECOVERY AND RETURN CONDUCTIVITY HOLD 27 1 0 1 0 0 27 1 1 1 C 4 0 0
28 RINSE W/ DETERGENT RECOVERY 28 1 1 0 1 0 4 28 1 1 1 1 C 4 4 0
29 RINSE W/ ACID RECOVERY 29 1 0 1 0 0 29 1 1 1 C 4 0 0
UltraFlow technical 
brochure available 
separately.
Easier/Faster to Validate
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1915 S. Stoughton Road  •  P.O. Box 8662  •  Madison, WI  53708 
Phone: 608-222-2399  •  Fax: 608-222-5348  •  info@sanimatic.com
www.sanimatic.com
CIP CLEAN-IN-PLACE
CIP Features
Spray Devices
Custom Engineered  
and Precision Drilled
• Operation and maintenance manuals
• Recommended spare parts list
• Instrument lists
• Instrumentation calibration procedures
• Performance data
• Material certificates
• Weld qualification and inspection records
• Inspection test results, reports and certificates
• ASME data
• Component catalog cut sheets
• As built assembly drawings
• As built process and instrumentation diagrams 
• As built electrical drawings
• Annotated PLC ladder diagrams
OPTIONAL  
• (FRS/FDS) Functional Design Specifications 
• Control System Design Specification (HRS and SRS)
• (FAT) Factory Acceptance Test report
• (SAT) Site Acceptance Test document
• IQ/OQ installation and operation qualification
• Cleaning and passivation report
• Weld video record (Boroscope)
• Custom engineered in 3D
• Precision drilled 
• Pass Riboflavin testing first time
• Documented for future replacement without re-validating
Sani-Matic personnel are  
active participants in the  
following organizations:
ISPE-International Society of  
Pharmaceutical Engineers
Co-developer & Co-leader of    
“Cleaning Technology” course
ASME-American Society of  
Mechanical Engineers
BPE (Bio Processing Equipment) 
CIP task group
AWS-American Welding Society 
D18 Team committee for sanitary 
welding
3A-Sanitary Standards
Member of board of directors 
and task committees
In-house engineering and opera-
tions
Custom engineered to order 
– solidworks 3D Cadd designs
Electrical design and program-
ming in-house
Manufacturing work team dedi-
cated to Bio-Pharm
Authorized UL panel shop
ASME certified shop – welding 
inspector and trainer
Project Management – manage 
Gantt scheduling, change orders, 
FAT
Complete Technical  
Service Staff offering:
Documentation
Field start-up and training
Factory support after start-up
Pharm CIP-5536 3/07
®
Sani-Matic designs and manufactures a complete range of 
sprayballs and associated solution tubes and tank fittings.
Utilizing the latest technology, Sani-Matic has engineered 
a method to model a process vessel in 3D and design the 
most effective spray device and drill pattern to ensure 
proper coverage of all ports and surfaces. With decades of 
experience in spray technology and Bio-Pharm CIP applications, 
the Sani-Matic team understands the spray dynamics required 
to ensure adequate flows, pressures and geometries will 
dependably clean your process equipment. 
Sani-Matic provides complete documentation and ID marking 
for ease of validation and future replacement. Responsive 
service and reliable delivery make Sani-Matic the preferred 
supplier of Spray Devices in the market today.
Documentation
Faster & Easier Validation
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Integritest® 4N Integrity Test Instrument 
Central Instrument Management Tool
Installation and Operators Manual
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 Monoclonal Antibody Production via Fluidized Bioreactor Technology 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix I: MSDS Sheets 
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Material Safety Data Sheet
Phosphoric acid, 85% MSDS
Section 1: Chemical Product and Company Identification
Product Name: Phosphoric acid, 85%
Catalog Codes: SLP5569, SLP4555, SLP1732
CAS#: Mixture.
RTECS: Not applicable.
TSCA: TSCA 8(b) inventory: Phosphoric Acid; Water
CI#: Not available.
Synonym:   Phosphoric Acid 85%; Phosphoric Acid;
Orthophosphoric acid
Chemical Name: Not applicable.
Chemical Formula: Not applicable.
Contact Information:
Sciencelab.com, Inc.
14025 Smith Rd.
Houston, Texas 77396
US Sales: 1-800-901-7247
International Sales: 1-281-441-4400
Order Online: ScienceLab.com
CHEMTREC (24HR Emergency Telephone), call:
1-800-424-9300
International CHEMTREC, call: 1-703-527-3887
For non-emergency assistance, call: 1-281-441-4400
Section 2: Composition and Information on Ingredients
Composition:
Name CAS # % by Weight
Phosphoric Acid 7664-38-2 85-88
Water 7732-18-5 12-15
Toxicological Data on Ingredients: Phosphoric Acid: ORAL (LD50): Acute: 1530 mg/kg [Rat]. DERMAL (LD50): Acute: 2740
mg/kg [Rabbit]. DUST (LC50): Acute: &gt;850 mg/m 1 hours [Rat].
Section 3: Hazards Identification
Potential Acute Health Effects:
Very hazardous in case of skin contact (irritant), of eye contact (irritant), of ingestion, . Hazardous in case of skin contact
(corrosive, permeator), of eye contact (corrosive). Slightly hazardous in case of inhalation (lung sensitizer). Liquid or spray
mist may produce tissue damage particularly on mucous membranes of eyes, mouth and respiratory tract. Skin contact may
produce burns. Inhalation of the spray mist may produce severe irritation of respiratory tract, characterized by coughing,
choking, or shortness of breath. Severe over-exposure can result in death. Inflammation of the eye is characterized by
redness, watering, and itching. Skin inflammation is characterized by itching, scaling, reddening, or, occasionally, blistering.
Potential Chronic Health Effects:
CARCINOGENIC EFFECTS: Not available. MUTAGENIC EFFECTS: Not available. TERATOGENIC EFFECTS: Not available.
DEVELOPMENTAL TOXICITY: Not available. The substance may be toxic to blood, liver, skin, eyes, bone marrow. Repeated
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or prolonged exposure to the substance can produce target organs damage. Repeated or prolonged contact with spray mist
may produce chronic eye irritation and severe skin irritation. Repeated or prolonged exposure to spray mist may produce
respiratory tract irritation leading to frequent attacks of bronchial infection. Repeated exposure to a highly toxic material may
produce general deterioration of health by an accumulation in one or many human organs.
Section 4: First Aid Measures
Eye Contact:
Check for and remove any contact lenses. In case of contact, immediately flush eyes with plenty of water for at least 15
minutes. Cold water may be used. Get medical attention immediately.
Skin Contact:
In case of contact, immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing
and shoes. Cover the irritated skin with an emollient. Cold water may be used.Wash clothing before reuse. Thoroughly clean
shoes before reuse. Get medical attention immediately.
Serious Skin Contact:
Wash with a disinfectant soap and cover the contaminated skin with an anti-bacterial cream. Seek immediate medical
attention.
Inhalation:
If inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical
attention immediately.
Serious Inhalation:
Evacuate the victim to a safe area as soon as possible. Loosen tight clothing such as a collar, tie, belt or waistband. If
breathing is difficult, administer oxygen. If the victim is not breathing, perform mouth-to-mouth resuscitation. WARNING: It may
be hazardous to the person providing aid to give mouth-to-mouth resuscitation when the inhaled material is toxic, infectious or
corrosive. Seek immediate medical attention.
Ingestion:
Do NOT induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an unconscious
person. If large quantities of this material are swallowed, call a physician immediately. Loosen tight clothing such as a collar,
tie, belt or waistband.
Serious Ingestion: Not available.
Section 5: Fire and Explosion Data
Flammability of the Product: Non-flammable.
Auto-Ignition Temperature: Not applicable.
Flash Points: Not applicable.
Flammable Limits: Not applicable.
Products of Combustion: Not available.
Fire Hazards in Presence of Various Substances: of metals
Explosion Hazards in Presence of Various Substances: Non-explosive in presence of open flames and sparks, of shocks.
Fire Fighting Media and Instructions: Not applicable.
Special Remarks on Fire Hazards:
Reacts with metals to liberate flammable hydrogen gas. Formation of flammable gases with aldehydes, cyanides, mercaptins,
and sulfides.
Special Remarks on Explosion Hazards: Mixtures with nitromethane are explosive. (Phosphoric Acid)
Section 6: Accidental Release Measures
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Small Spill:
Dilute with water and mop up, or absorb with an inert dry material and place in an appropriate waste disposal container. If
necessary: Neutralize the residue with a dilute solution of sodium carbonate.
Large Spill:
Corrosive liquid. Poisonous liquid. Stop leak if without risk. Absorb with DRY earth, sand or other non-combustible material.
Do not get water inside container. Do not touch spilled material. Use water spray curtain to divert vapor drift. Use water spray
to reduce vapors. Prevent entry into sewers, basements or confined areas; dike if needed. Call for assistance on disposal.
Neutralize the residue with a dilute solution of sodium carbonate. Be careful that the product is not present at a concentration
level above TLV. Check TLV on the MSDS and with local authorities.
Section 7: Handling and Storage
Precautions:
Do not ingest. Do not breathe gas/fumes/ vapor/spray. Never add water to this product. In case of insufficient ventilation,
wear suitable respiratory equipment. If ingested, seek medical advice immediately and show the container or the label. Avoid
contact with skin and eyes. Keep away from incompatibles such as oxidizing agents, combustible materials, metals, alkalis.
May corrode metallic surfaces. Store in a metallic or coated fiberboard drum using a strong polyethylene inner package.
Storage: Keep container tightly closed. Keep container in a cool, well-ventilated area.
Section 8: Exposure Controls/Personal Protection
Engineering Controls:
Provide exhaust ventilation or other engineering controls to keep the airborne concentrations of vapors below their respective
threshold limit value. Ensure that eyewash stations and safety showers are proximal to the work-station location.
Personal Protection:
Face shield. Full suit. Vapor respirator. Be sure to use an approved/certified respirator or equivalent. Gloves. Boots.
Personal Protection in Case of a Large Spill:
Splash goggles. Full suit. Vapor respirator. Boots. Gloves. A self contained breathing apparatus should be used to avoid
inhalation of the product. Suggested protective clothing might not be sufficient; consult a specialist BEFORE handling this
product.
Exposure Limits:
Phosphoric Acid TWA: 1 STEL: 3 (mg/m3) from ACGIH (TLV) [United States] TWA: 1 STEL: 3 (mg/m3) from OSHA (PEL)
[United States] TWA: 1 STEL: 3 (mg/m3) from NIOSH TWA: 1 STEL: 3 (mg/m3) [Mexico]Consult local authorities for
acceptable exposure limits.
Section 9: Physical and Chemical Properties
Physical state and appearance: Liquid. (Syrupy liquid Viscous liquid.)
Odor: Odorless.
Taste: Acid.
Molecular Weight: Not applicable.
Color: Clear Colorless.
pH (1% soln/water): Acidic.
Boiling Point: 158°C (316.4°F)
Melting Point: 21°C (69.8°F)
Critical Temperature: Not available.
p. 4
Specific Gravity: 1.685 @ 25 C (Water = 1)
Vapor Pressure: 0.3 kPa (@ 20°C)
Vapor Density: 3.4 (Air = 1)
Volatility: Not available.
Odor Threshold: Not available.
Water/Oil Dist. Coeff.: Not available.
Ionicity (in Water): Not available.
Dispersion Properties: See solubility in water.
Solubility:
Easily soluble in hot water. Soluble in cold water.
Section 10: Stability and Reactivity Data
Stability: The product is stable.
Instability Temperature: Not available.
Conditions of Instability: Incompatible materials
Incompatibility with various substances: Reactive with oxidizing agents, combustible materials, metals, alkalis.
Corrosivity:
Extremely corrosive in presence of copper, of stainless steel(304), of stainless steel(316). Highly corrosive in presence of
aluminum. Non-corrosive in presence of glass.
Special Remarks on Reactivity:
Reacts with metals to liberate flammable hydrogen gas. Incompatible with sodium tetrahydroborate producing a violent
exothermic reaction. Heat generated with: alcohols, glycols, aldehydes, amides, amines, azo-compounds, carbamates,
caustics, esters, ketones, phenols and cresols, organophosphates, epoxides, combustible materials, unsaturated halides,
organic peroxides. Formation of flammable gases, with aldehydes, cyanides, mercaptins, and sulfides. Formation of toxic
fumes with cyanides, fluorides, halogenated organics, sulfides, and organic peroxides. Do not mix with solutions containing
bleach or ammonia. Incompatible with nitromethane, chlorides + staiinless steel.  (Phosphoric Acid)
Special Remarks on Corrosivity:
Minor corrosive effect on bronze. Severe corrosive effect on brass. Corrosive to ferrous metals and alloys.
Polymerization: Will not occur.
Section 11: Toxicological Information
Routes of Entry: Absorbed through skin. Dermal contact. Eye contact. Inhalation. Ingestion.
Toxicity to Animals:
Acute oral toxicity (LD50): 1530 mg/kg [Rat]. Acute dermal toxicity (LD50): 2740 mg/kg [Rabbit].
Chronic Effects on Humans: May cause damage to the following organs: blood, liver, skin, eyes, bone marrow.
Other Toxic Effects on Humans:
Extremely hazardous in case of inhalation (lung corrosive). Very hazardous in case of skin contact (irritant), of ingestion, .
Hazardous in case of skin contact (corrosive, permeator), of eye contact (corrosive).
Special Remarks on Toxicity to Animals: Not available.
Special Remarks on Chronic Effects on Humans: Not available.
Special Remarks on other Toxic Effects on Humans:
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Acute Potential Health Effects: Skin: Corrosive and causes severe skin irritation and can cause severe skin burns. May affect
behavior (somnolence or excitement) if absorbed through skin. Eyes: Corrosive. Liquid or vapor causes severe eye irritation
and can cause severe eye burns leading to permanent corneal damage or chemical conjunctivitis. Ingestion: May be harmful
if swallowed. Causes irritation and burns of the gastrointestinal (digestive) tract. Causes severe pain, nausea, vomiting,
diarrhea hematemesis, gastrointestinal hemmorrhaging, and shock. May cause corrosion and permanent tissue destruction
of the esophagus and digestive tract. May affect behavior and urinary system, liver (hepatocellular damage, hepatic enzymes
increased), blood (blood dyscrasia). May also
Section 12: Ecological Information
Ecotoxicity: Not available.
BOD5 and COD: Not available.
Products of Biodegradation:
Possibly hazardous short term degradation products are not likely. However, long term degradation products may arise.
Toxicity of the Products of Biodegradation: The products of degradation are less toxic than the product itself.
Special Remarks on the Products of Biodegradation: Not available.
Section 13: Disposal Considerations
Waste Disposal:
Waste must be disposed of in accordance with federal, state and local environmental control regulations.
Section 14: Transport Information
DOT Classification: Class 8: Corrosive material
Identification: : Phosphoric acid (Phosphoric Acid) UNNA: 1805 PG: III
Special Provisions for Transport: Not available.
Section 15: Other Regulatory Information
Federal and State Regulations:
Connecticut hazardous material survey.: Phosphoric Acid Illinois toxic substances disclosure to employee act: Phosphoric
acid Illinois chemical safety act: Phosphoric acid New York release reporting list: Phosphoric acid Rhode Island RTK
hazardous substances: Phosphoric acid Pennsylvania RTK: Phosphoric acid Minnesota: Phosphoric acid Massachusetts
RTK: Phosphoric acid Massachusetts spill list: Phosphoric acid New Jersey: Phosphoric acid New Jersey spill list: Phosphoric
acid Louisiana spill reporting: Phosphoric acid California Director's list of hazardous substances: Phosphoric acid TSCA 8(b)
inventory: Phosphoric Acid; Water SARA 313 toxic chemical notification and release reporting: Phosphoric acid CERCLA:
Hazardous substances.: Phosphoric acid: 5000 lbs. (2268 kg)
Other Regulations: OSHA: Hazardous by definition of Hazard Communication Standard (29 CFR 1910.1200).
Other Classifications:
WHMIS (Canada): CLASS E: Corrosive liquid.
DSCL (EEC):
R34- Causes burns. S26- In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S45-
In case of accident or if you feel unwell, seek medical advice immediately (show the label where possible).
HMIS (U.S.A.):
Health Hazard: 3
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Fire Hazard: 0
Reactivity: 0
Personal Protection:
National Fire Protection Association (U.S.A.):
Health: 3
Flammability: 0
Reactivity: 0
Specific hazard:
Protective Equipment:
Gloves. Full suit. Vapor respirator. Be sure to use an approved/certified respirator or equivalent. Wear appropriate respirator
when ventilation is inadequate. Face shield.
Section 16: Other Information
References: Not available.
Other Special Considerations: Not available.
Created: 10/10/2005 08:47 PM
Last Updated: 05/21/2013 12:00 PM
The information above is believed to be accurate and represents the best information currently available to us. However, we
make no warranty of merchantability or any other warranty, express or implied, with respect to such information, and we assume
no liability resulting from its use. Users should make their own investigations to determine the suitability of the information for
their particular purposes. In no event shall ScienceLab.com be liable for any claims, losses, or damages of any third party or for
lost profits or any special, indirect, incidental, consequential or exemplary damages, howsoever arising, even if ScienceLab.com
has been advised of the possibility of such damages.
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SIGMA-ALDRICH sigma-aldrich.com 
SAFETY DATA SHEET 
Version 4.9 
Revision Date 04/05/2014 
Print Date 04/10/2014 
 
1. PRODUCT AND COMPANY IDENTIFICATION 
1.1 Product identifiers 
Product name : EX-CELL® ACF CHO Medium without L-glutamine, 
animal component free 
 
Product Number : C9098 
Brand : Sigma 
REACH No. : A registration number is not available for this substance as the substance 
or its uses are exempted from registration, the annual tonnage does not 
require a registration or the registration is envisaged for a later 
registration deadline. 
1.2 Relevant identified uses of the substance or mixture and uses advised against 
Identified uses : Laboratory chemicals, Manufacture of substances 
1.3 Details of the supplier of the safety data sheet 
Company : Sigma-Aldrich 
3050 Spruce Street 
SAINT LOUIS MO  63103 
USA 
 
Telephone : +1 800-325-5832 
Fax : +1 800-325-5052 
1.4 Emergency telephone number 
Emergency Phone # : (314) 776-6555 
 
2. HAZARDS IDENTIFICATION 
2.1 Classification of the substance or mixture 
 
Not a hazardous substance or mixture. 
2.2 GHS Label elements, including precautionary statements 
Not a hazardous substance or mixture. 
2.3 Hazards not otherwise classified (HNOC) or not covered by GHS - none 
 
3. COMPOSITION/INFORMATION ON INGREDIENTS 
3.2 Mixtures 
Synonyms : CHO Medium 
 
 
No ingredients are hazardous according to OSHA criteria. 
No components need to be disclosed according to the applicable regulations. 
 
4. FIRST AID MEASURES 
4.1 Description of first aid measures 
If inhaled 
If breathed in, move person into fresh air. If not breathing, give artificial respiration. 
In case of skin contact 
Wash off with soap and plenty of water. 
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In case of eye contact 
Flush eyes with water as a precaution. 
If swallowed 
Never give anything by mouth to an unconscious person. Rinse mouth with water. 
4.2 Most important symptoms and effects, both acute and delayed 
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11 
4.3 Indication of any immediate medical attention and special treatment needed 
no data available 
 
5. FIREFIGHTING MEASURES 
5.1 Extinguishing media 
Suitable extinguishing media 
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide. 
5.2 Special hazards arising from the substance or mixture 
Nature of decomposition products not known. 
5.3 Advice for firefighters 
Wear self contained breathing apparatus for fire fighting if necessary. 
5.4 Further information 
no data available 
 
6. ACCIDENTAL RELEASE MEASURES 
6.1 Personal precautions, protective equipment and emergency procedures 
Avoid dust formation. Avoid breathing vapours, mist or gas. 
For personal protection see section 8. 
6.2 Environmental precautions 
Do not let product enter drains. 
6.3 Methods and materials for containment and cleaning up 
Sweep up and shovel. Keep in suitable, closed containers for disposal. 
6.4 Reference to other sections 
For disposal see section 13. 
 
7. HANDLING AND STORAGE 
7.1 Precautions for safe handling 
Provide appropriate exhaust ventilation at places where dust is formed. 
For precautions see section 2.2. 
7.2 Conditions for safe storage, including any incompatibilities 
Keep container tightly closed in a dry and well-ventilated place.  
Recommended storage temperature: 2 - 8 °C 
7.3 Specific end use(s) 
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated 
 
8. EXPOSURE CONTROLS/PERSONAL PROTECTION 
8.1 Control parameters 
Components with workplace control parameters 
Contains no substances with occupational exposure limit values. 
8.2 Exposure controls 
Appropriate engineering controls 
General industrial hygiene practice. 
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Personal protective equipment 
Eye/face protection 
Use equipment for eye protection tested and approved under appropriate government standards such as 
NIOSH (US) or EN 166(EU). 
Skin protection 
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without 
touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after 
use in accordance with applicable laws and good laboratory practices. Wash and dry hands. 
 
Body Protection 
Choose body protection in relation to its type, to the concentration and amount of dangerous substances, and 
to the specific work-place., The type of protective equipment must be selected according to the concentration 
and amount of the dangerous substance at the specific workplace. 
Respiratory protection 
Respiratory protection is not required. Where protection from nuisance  levels of dusts are desired, use type 
N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and approved under 
appropriate government standards such as NIOSH (US) or CEN (EU). 
Control of environmental exposure 
Do not let product enter drains. 
 
9. PHYSICAL AND CHEMICAL PROPERTIES 
9.1 Information on basic physical and chemical properties 
a) Appearance Form: powder 
b) Odour no data available 
c) Odour Threshold no data available 
d) pH no data available 
e) Melting point/freezing 
point 
no data available 
f) Initial boiling point and 
boiling range 
no data available 
g) Flash point no data available  
h) Evapouration rate no data available 
i) Flammability (solid, gas) no data available 
j) Upper/lower 
flammability or 
explosive limits 
no data available 
k) Vapour pressure no data available 
l) Vapour density no data available 
m) Relative density no data available 
n) Water solubility no data available 
o) Partition coefficient: n-
octanol/water 
no data available 
p) Auto-ignition 
temperature 
no data available 
q) Decomposition 
temperature 
no data available 
r) Viscosity no data available 
s) Explosive properties no data available 
t) Oxidizing properties no data available 
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9.2 Other safety information 
no data available 
 
10. STABILITY AND REACTIVITY 
10.1 Reactivity 
no data available 
10.2 Chemical stability 
Stable under recommended storage conditions. 
10.3 Possibility of hazardous reactions 
no data available 
10.4 Conditions to avoid 
no data available 
10.5 Incompatible materials 
Strong oxidizing agents 
10.6 Hazardous decomposition products 
Other decomposition products - no data available 
In the event of fire: see section 5 
 
11. TOXICOLOGICAL INFORMATION 
11.1 Information on toxicological effects 
Acute toxicity 
no data available 
Inhalation: no data available 
Dermal: no data available 
no data available 
Skin corrosion/irritation 
no data available 
Serious eye damage/eye irritation 
no data available 
Respiratory or skin sensitisation 
no data available 
Germ cell mutagenicity 
no data available 
 
 
Carcinogenicity 
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as 
probable, possible or confirmed human carcinogen by IARC. 
ACGIH: No component of this product present at levels greater than or equal to 0.1% is identified as a 
carcinogen or potential carcinogen by ACGIH. 
NTP: No component of this product present at levels greater than or equal to 0.1% is identified as a 
known or anticipated carcinogen by NTP. 
OSHA: No component of this product present at levels greater than or equal to 0.1% is identified as a 
carcinogen or potential carcinogen by OSHA. 
Reproductive toxicity 
no data available 
no data available 
Specific target organ toxicity - single exposure 
no data available 
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Specific target organ toxicity - repeated exposure 
no data available 
Aspiration hazard 
no data available 
Additional Information 
RTECS: Not available 
 
 
12. ECOLOGICAL INFORMATION 
12.1 Toxicity 
no data available 
12.2 Persistence and degradability 
no data available 
12.3 Bioaccumulative potential 
no data available 
12.4 Mobility in soil 
no data available 
12.5 Results of PBT and vPvB assessment 
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted 
12.6 Other adverse effects 
no data available 
 
13. DISPOSAL CONSIDERATIONS 
13.1 Waste treatment methods 
Product 
Offer surplus and non-recyclable solutions to a licensed disposal company.  
Contaminated packaging 
Dispose of as unused product.  
 
14. TRANSPORT INFORMATION 
DOT (US) 
Not dangerous goods 
 
IMDG 
Not dangerous goods 
 
IATA 
Not dangerous goods 
 
15. REGULATORY INFORMATION 
REACH No. : A registration number is not available for this substance as the substance 
or its uses are exempted from registration, the annual tonnage does not 
require a registration or the registration is envisaged for a later 
registration deadline. 
SARA 302 Components 
SARA 302: No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302. 
SARA 313 Components 
SARA 313: This material does not contain any chemical components with known CAS numbers that exceed the 
threshold (De Minimis) reporting levels established by SARA Title III, Section 313. 
SARA 311/312 Hazards 
No SARA Hazards 
Massachusetts Right To Know Components 
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No components are subject to the Massachusetts Right to Know Act. 
Pennsylvania Right To Know Components 
 
EX-CELL® ACF CHO Medium 
CAS-No. 
 -  
Revision Date 
 
New Jersey Right To Know Components 
 
EX-CELL® ACF CHO Medium 
CAS-No. 
 -  
Revision Date 
 
California Prop. 65 Components 
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other 
reproductive harm. 
 
16. OTHER INFORMATION 
HMIS Rating 
Health hazard: 0 
Chronic Health Hazard:  
Flammability: 0 
Physical Hazard 0 
NFPA Rating 
Health hazard: 0 
Fire Hazard: 0 
Reactivity Hazard: 0 
Further information 
Copyright 2014 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only. 
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a 
guide. The information in this document is based on the present state of our knowledge and is applicable to the 
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the 
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling 
or from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing 
slip for additional terms and conditions of sale. 
 
Preparation Information
Sigma-Aldrich Corporation 
Product Safety – Americas Region 
1-800-521-8956 
 
Version: 4.9 Revision Date: 04/05/2014 Print Date: 04/10/2014 
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Material Safety Data Sheet
Sodium chloride MSDS
Section 1: Chemical Product and Company Identification
Product Name: Sodium chloride
Catalog Codes: SLS3262, SLS1045, SLS3889, SLS1669,
SLS3091
CAS#: 7647-14-5
RTECS: VZ4725000
TSCA: TSCA 8(b) inventory: Sodium chloride
CI#: Not applicable.
Synonym:   Salt; Sea Salt
Chemical Name: Sodium chloride
Chemical Formula: NaCl
Contact Information:
Sciencelab.com, Inc.
14025 Smith Rd.
Houston, Texas 77396
US Sales: 1-800-901-7247
International Sales: 1-281-441-4400
Order Online: ScienceLab.com
CHEMTREC (24HR Emergency Telephone), call:
1-800-424-9300
International CHEMTREC, call: 1-703-527-3887
For non-emergency assistance, call: 1-281-441-4400
Section 2: Composition and Information on Ingredients
Composition:
Name CAS # % by Weight
Sodium chloride 7647-14-5 100
Toxicological Data on Ingredients: Sodium chloride: ORAL (LD50): Acute: 3000 mg/kg [Rat.]. 4000 mg/kg [Mouse].
DERMAL (LD50): Acute: &gt;10000 mg/kg [Rabbit]. DUST (LC50): Acute: &gt;42000 mg/m 1 hours [Rat].
Section 3: Hazards Identification
Potential Acute Health Effects: Slightly hazardous in case of skin contact (irritant), of eye contact (irritant), of ingestion, of
inhalation.
Potential Chronic Health Effects:
CARCINOGENIC EFFECTS: Not available. MUTAGENIC EFFECTS: Mutagenic for mammalian somatic cells. Mutagenic for
bacteria and/or yeast. TERATOGENIC EFFECTS: Not available. DEVELOPMENTAL TOXICITY: Not available. Repeated or
prolonged exposure is not known to aggravate medical condition.
Section 4: First Aid Measures
Eye Contact:
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Check for and remove any contact lenses. In case of contact, immediately flush eyes with plenty of water for at least 15
minutes. Cold water may be used. Get medical attention.
Skin Contact:
Wash with soap and water. Cover the irritated skin with an emollient. Get medical attention if irritation develops. Cold water
may be used.
Serious Skin Contact: Not available.
Inhalation:
If inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical
attention if symptoms appear.
Serious Inhalation: Not available.
Ingestion:
Do NOT induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an unconscious
person. Loosen tight clothing such as a collar, tie, belt or waistband. Get medical attention if symptoms appear.
Serious Ingestion: Not available.
Section 5: Fire and Explosion Data
Flammability of the Product: Non-flammable.
Auto-Ignition Temperature: Not applicable.
Flash Points: Not applicable.
Flammable Limits: Not applicable.
Products of Combustion: Not available.
Fire Hazards in Presence of Various Substances: Not applicable.
Explosion Hazards in Presence of Various Substances:
Risks of explosion of the product in presence of mechanical impact: Not available. Risks of explosion of the product in
presence of static discharge: Not available.
Fire Fighting Media and Instructions: Not applicable.
Special Remarks on Fire Hazards: When heated to decomposition it emits toxic fumes.
Special Remarks on Explosion Hazards:
Electrolysis of sodium chloride in presence of nitrogenous compounds to produce chlorine may lead to formation of explosive
nitrogen trichloride. Potentially explosive reaction with dichloromaleic anhydride + urea.
Section 6: Accidental Release Measures
Small Spill:
Use appropriate tools to put the spilled solid in a convenient waste disposal container. Finish cleaning by spreading water on
the contaminated surface and dispose of according to local and regional authority requirements.
Large Spill:
Use a shovel to put the material into a convenient waste disposal container. Finish cleaning by spreading water on the
contaminated surface and allow to evacuate through the sanitary system.
Section 7: Handling and Storage
Precautions:
Keep locked up.. Do not ingest. Do not breathe dust. Avoid contact with eyes. Wear suitable protective clothing. If ingested,
seek medical advice immediately and show the container or the label. Keep away from incompatibles such as oxidizing
agents, acids.
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Storage: Keep container tightly closed. Keep container in a cool, well-ventilated area. Hygroscopic
Section 8: Exposure Controls/Personal Protection
Engineering Controls:
Use process enclosures, local exhaust ventilation, or other engineering controls to keep airborne levels below recommended
exposure limits. If user operations generate dust, fume or mist, use ventilation to keep exposure to airborne contaminants
below the exposure limit.
Personal Protection:
Splash goggles. Lab coat. Dust respirator. Be sure to use an approved/certified respirator or equivalent. Gloves.
Personal Protection in Case of a Large Spill:
Splash goggles. Full suit. Dust respirator. Boots. Gloves. A self contained breathing apparatus should be used to avoid
inhalation of the product. Suggested protective clothing might not be sufficient; consult a specialist BEFORE handling this
product.
Exposure Limits: Not available.
Section 9: Physical and Chemical Properties
Physical state and appearance: Solid. (Solid crystalline powder.)
Odor: Slight.
Taste: Saline.
Molecular Weight: 58.44 g/mole
Color: White.
pH (1% soln/water): 7 [Neutral.]
Boiling Point: 1413°C (2575.4°F)
Melting Point: 801°C (1473.8°F)
Critical Temperature: Not available.
Specific Gravity: 2.165 (Water = 1)
Vapor Pressure: Not applicable.
Vapor Density: Not available.
Volatility: Not available.
Odor Threshold: Not available.
Water/Oil Dist. Coeff.: Not available.
Ionicity (in Water): Not available.
Dispersion Properties: See solubility in water.
Solubility:
Easily soluble in cold water, hot water. Soluble in glycerol, and ammonia. Very slightly soluble in alcohol. Insoluble in
Hydrochloric Acid.
Section 10: Stability and Reactivity Data
Stability: The product is stable.
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Instability Temperature: Not available.
Conditions of Instability: Incompatible materials, high temperatures.
Incompatibility with various substances: Reactive with oxidizing agents, metals, acids.
Corrosivity: Not considered to be corrosive for metals and glass.
Special Remarks on Reactivity:
Hygroscopic. Reacts with most nonnoble metals such as iron or steel, building materials (such as cement) Sodium chloride is
rapidly attacked by bromine trifluoride. Violent reaction with lithium.
Special Remarks on Corrosivity: Not available.
Polymerization: Will not occur.
Section 11: Toxicological Information
Routes of Entry: Inhalation. Ingestion.
Toxicity to Animals:
WARNING: THE LC50 VALUES HEREUNDER ARE ESTIMATED ON THE BASIS OF A 4-HOUR EXPOSURE. Acute oral
toxicity (LD50): 3000 mg/kg [Rat.]. Acute dermal toxicity (LD50): >10000 mg/kg [Rabbit]. Acute toxicity of the dust (LC50):
>42000 mg/m3 1 hours [Rat].
Chronic Effects on Humans: MUTAGENIC EFFECTS: Mutagenic for mammalian somatic cells. Mutagenic for bacteria and/
or yeast.
Other Toxic Effects on Humans: Slightly hazardous in case of skin contact (irritant), of ingestion, of inhalation.
Special Remarks on Toxicity to Animals: Lowest Published Lethal Dose (LDL) [Man] - Route: Oral; Dose: 1000 mg/kg
Special Remarks on Chronic Effects on Humans:
Causes adverse reproductive effects in humans (fetotoxicity, abortion, ) by intraplacental route. High intake of sodium chloride,
whether from occupational exposure or in the diet, may increase risk of TOXEMIA OF PREGNANCY in susceptible women
(Bishop, 1978). Hypertonic sodium chloride solutions have been used to induce abortion in late pregnancy by direct infusion
into the uterus (Brown et al, 1972), but this route of administration is not relevant to occupational exposures. May cause
adverse reproductive effects and birth defects in animals, particularly rats and mice (fetotoxicity, abortion, musculoskeletal
abnormalities, and maternal effects (effects on ovaries, fallopian tubes) by oral, intraperitoneal, intraplacental, intrauterine,
parenteral, and subcutaneous routes. While sodium chloride has been used as a negative control n some reproductive
studies, it has also been used as an example that almost any chemical can cause birth defects in experimental animals
if studied under the right conditions (Nishimura & Miyamoto, 1969). In experimental animals, sodium chloride has caused
delayed effects on newborns, has been fetotoxic, and has caused birth defects and abortions in rats and mice (RTECS, 1997).
May affect genetic material (mutagenic)
Special Remarks on other Toxic Effects on Humans:
Acute Potential Health Effects: Skin: May cause skin irritation. Eyes: Causes eye irritation. Ingestion: Ingestion of large
quantities can irritate the stomach (as in overuse of salt tablets) with nausea and vomiting. May affect behavior (muscle
spasicity/contraction, somnolence), sense organs, metabolism, and cardiovascular system. Continued exposure may
produce dehydration, internal organ congestion, and coma. Inhalation: Material is irritating to mucous membranes and upper
respiratory tract.
Section 12: Ecological Information
Ecotoxicity: Not available.
BOD5 and COD: Not available.
Products of Biodegradation:
Possibly hazardous short term degradation products are not likely. However, long term degradation products may arise.
Toxicity of the Products of Biodegradation: The product itself and its products of degradation are not toxic.
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Special Remarks on the Products of Biodegradation: Not available.
Section 13: Disposal Considerations
Waste Disposal:
Waste must be disposed of in accordance with federal, state and local environmental control regulations.
Section 14: Transport Information
DOT Classification: Not a DOT controlled material (United States).
Identification: Not applicable.
Special Provisions for Transport: Not applicable.
Section 15: Other Regulatory Information
Federal and State Regulations: TSCA 8(b) inventory: Sodium chloride
Other Regulations: EINECS: This product is on the European Inventory of Existing Commercial Chemical Substances.
Other Classifications:
WHMIS (Canada): Not controlled under WHMIS (Canada).
DSCL (EEC):
R40- Possible risks of irreversible effects. S24/25- Avoid contact with skin and eyes.
HMIS (U.S.A.):
Health Hazard: 1
Fire Hazard: 0
Reactivity: 0
Personal Protection: E
National Fire Protection Association (U.S.A.):
Health: 1
Flammability: 0
Reactivity: 0
Specific hazard:
Protective Equipment:
Gloves. Lab coat. Dust respirator. Be sure to use an approved/certified respirator or equivalent. Splash goggles.
Section 16: Other Information
References:
-Hawley, G.G.. The Condensed Chemical Dictionary, 11e ed., New York N.Y., Van Nostrand Reinold, 1987. -SAX, N.I.
Dangerous Properties of Indutrial Materials. Toronto, Van Nostrand Reinold, 6e ed. 1984. -The Sigma-Aldrich Library of
Chemical Safety Data, Edition II.
Other Special Considerations: Not available.
Created: 10/11/2005 12:33 PM
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Last Updated: 05/21/2013 12:00 PM
The information above is believed to be accurate and represents the best information currently available to us. However, we
make no warranty of merchantability or any other warranty, express or implied, with respect to such information, and we assume
no liability resulting from its use. Users should make their own investigations to determine the suitability of the information for
their particular purposes. In no event shall ScienceLab.com be liable for any claims, losses, or damages of any third party or for
lost profits or any special, indirect, incidental, consequential or exemplary damages, howsoever arising, even if ScienceLab.com
has been advised of the possibility of such damages.
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Material Safety Data Sheet
Sodium hydroxide, Pellets, Reagent ACS MSDS
Section 1: Chemical Product and Company Identification
Product Name: Sodium hydroxide, Pellets, Reagent ACS
Catalog Codes: SLS4090
CAS#: 1310-73-2
RTECS: WB4900000
TSCA: TSCA 8(b) inventory: Sodium hydroxide
CI#: Not available.
Synonym:   Caustic Soda
Chemical Name: Sodium Hydroxide
Chemical Formula: NaOH
Contact Information:
Sciencelab.com, Inc.
14025 Smith Rd.
Houston, Texas 77396
US Sales: 1-800-901-7247
International Sales: 1-281-441-4400
Order Online: ScienceLab.com
CHEMTREC (24HR Emergency Telephone), call:
1-800-424-9300
International CHEMTREC, call: 1-703-527-3887
For non-emergency assistance, call: 1-281-441-4400
Section 2: Composition and Information on Ingredients
Composition:
Name CAS # % by Weight
Sodium hydroxide 1310-73-2 100
Toxicological Data on Ingredients: Sodium hydroxide LD50: Not available. LC50: Not available.
Section 3: Hazards Identification
Potential Acute Health Effects:
Very hazardous in case of skin contact (corrosive, irritant, permeator), of eye contact (irritant, corrosive), of ingestion,
of inhalation. The amount of tissue damage depends on length of contact. Eye contact can result in corneal damage or
blindness. Skin contact can produce inflammation and blistering. Inhalation of dust will produce irritation to gastro-intestinal or
respiratory tract, characterized by burning, sneezing and coughing. Severe over-exposure can produce lung damage, choking,
unconsciousness or death. Inflammation of the eye is characterized by redness, watering, and itching. Skin inflammation is
characterized by itching, scaling, reddening, or, occasionally, blistering.
Potential Chronic Health Effects:
CARCINOGENIC EFFECTS: Not available. MUTAGENIC EFFECTS: Not available. TERATOGENIC EFFECTS: Not available.
DEVELOPMENTAL TOXICITY: Not available. The substance is toxic to lungs. Repeated or prolonged exposure to the
substance can produce target organs damage. Repeated exposure of the eyes to a low level of dust can produce eye irritation.
Repeated skin exposure can produce local skin destruction, or dermatitis. Repeated inhalation of dust can produce varying
degree of respiratory irritation or lung damage.
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Section 4: First Aid Measures
Eye Contact:
Check for and remove any contact lenses. In case of contact, immediately flush eyes with plenty of water for at least 15
minutes. Cold water may be used. Get medical attention immediately.
Skin Contact:
In case of contact, immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing
and shoes. Cover the irritated skin with an emollient. Cold water may be used.Wash clothing before reuse. Thoroughly clean
shoes before reuse. Get medical attention immediately.
Serious Skin Contact:
Wash with a disinfectant soap and cover the contaminated skin with an anti-bacterial cream. Seek medical attention.
Inhalation:
If inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical
attention immediately.
Serious Inhalation:
Evacuate the victim to a safe area as soon as possible. Loosen tight clothing such as a collar, tie, belt or waistband. If
breathing is difficult, administer oxygen. If the victim is not breathing, perform mouth-to-mouth resuscitation. WARNING: It may
be hazardous to the person providing aid to give mouth-to-mouth resuscitation when the inhaled material is toxic, infectious or
corrosive. Seek immediate medical attention.
Ingestion:
Do NOT induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an unconscious
person. If large quantities of this material are swallowed, call a physician immediately. Loosen tight clothing such as a collar,
tie, belt or waistband.
Serious Ingestion: Not available.
Section 5: Fire and Explosion Data
Flammability of the Product: Non-flammable.
Auto-Ignition Temperature: Not applicable.
Flash Points: Not applicable.
Flammable Limits: Not applicable.
Products of Combustion: Not available.
Fire Hazards in Presence of Various Substances: of metals
Explosion Hazards in Presence of Various Substances:
Risks of explosion of the product in presence of mechanical impact: Not available. Risks of explosion of the product in
presence of static discharge: Not available. Slightly explosive in presence of heat.
Fire Fighting Media and Instructions: Not applicable.
Special Remarks on Fire Hazards:
sodium hydroxide + zinc metal dust causes ignition of the latter. Under proper conditions of temperature, pressure and state
of division, it can ignite or react violently with acetaldehyde, ally alcohol, allyl chloride, benzene-1,4-diol, chlorine trifluoride,
1,2 dichlorethylene, nitroethane, nitromethane, nitroparaffins, nitropropane, cinnamaldehyde, 2,2-dichloro-3,3-dimethylbutane.
Sodium hydroxide in contact with water may generate enough heat to ignite adjacent combustible materials. Phosphorous
boiled with NaOH yields mixed phosphines which may ignite spontanously in air. sodium hydroxide and cinnamaldehyde +
heat may cause ignition. Reaction with certain metals releases flammable and explosive hydrogen gas.
Special Remarks on Explosion Hazards:
Sodium hydroxide reacts to form explosive products with ammonia + silver nitrate. Benzene extract of allyl benzenesulfonate
prepared from allyl alcohol, and benzene sulfonyl chloride in presence of aquesous sodium hydroxide, under vacuum
distillation, residue darkened and exploded. Sodium Hydroxde + impure tetrahydrofuran, which can contain peroxides, can
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cause serious explosions. Dry mixtures of sodium hydroxide and sodium tetrahydroborate liberate hydrogen explosively at
230-270 deg. C. Sodium Hydroxide reacts with sodium salt of trichlorophenol + methyl alcohol + trichlorobenzene + heat to
cause an explosion.
Section 6: Accidental Release Measures
Small Spill:
Use appropriate tools to put the spilled solid in a convenient waste disposal container. If necessary: Neutralize the residue with
a dilute solution of acetic acid.
Large Spill:
Corrosive solid. Stop leak if without risk. Do not get water inside container. Do not touch spilled material. Use water spray
to reduce vapors. Prevent entry into sewers, basements or confined areas; dike if needed. Call for assistance on disposal.
Neutralize the residue with a dilute solution of acetic acid. Be careful that the product is not present at a concentration level
above TLV. Check TLV on the MSDS and with local authorities.
Section 7: Handling and Storage
Precautions:
Keep container dry. Do not breathe dust. Never add water to this product. In case of insufficient ventilation, wear suitable
respiratory equipment. If you feel unwell, seek medical attention and show the label when possible. Avoid contact with skin
and eyes. Keep away from incompatibles such as oxidizing agents, reducing agents, metals, acids, alkalis, moisture.
Storage: Keep container tightly closed. Keep container in a cool, well-ventilated area. Do not store above 23°C (73.4°F).
Section 8: Exposure Controls/Personal Protection
Engineering Controls:
Use process enclosures, local exhaust ventilation, or other engineering controls to keep airborne levels below recommended
exposure limits. If user operations generate dust, fume or mist, use ventilation to keep exposure to airborne contaminants
below the exposure limit.
Personal Protection:
Splash goggles. Synthetic apron. Vapor and dust respirator. Be sure to use an approved/certified respirator or equivalent.
Gloves.
Personal Protection in Case of a Large Spill:
Splash goggles. Full suit. Vapor and dust respirator. Boots. Gloves. A self contained breathing apparatus should be used to
avoid inhalation of the product. Suggested protective clothing might not be sufficient; consult a specialist BEFORE handling
this product.
Exposure Limits:
CEIL: 2 from ACGIH (TLV) [United States] [1995] Consult local authorities for acceptable exposure limits.
Section 9: Physical and Chemical Properties
Physical state and appearance: Solid.
Odor: Odorless.
Taste: Not available.
Molecular Weight: 40 g/mole
Color: White.
pH (1% soln/water): 13.5 [Basic.]
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Boiling Point: 1388°C (2530.4°F)
Melting Point: 323°C (613.4°F)
Critical Temperature: Not available.
Specific Gravity: 2.13 (Water = 1)
Vapor Pressure: Not applicable.
Vapor Density: Not available.
Volatility: Not available.
Odor Threshold: Not available.
Water/Oil Dist. Coeff.: Not available.
Ionicity (in Water): Not available.
Dispersion Properties: See solubility in water.
Solubility: Easily soluble in cold water.
Section 10: Stability and Reactivity Data
Stability: The product is stable.
Instability Temperature: Not available.
Conditions of Instability: Not available.
Incompatibility with various substances:
Highly reactive with metals. Reactive with oxidizing agents, reducing agents, acids, alkalis, moisture.
Corrosivity: Not available.
Special Remarks on Reactivity:
Hygroscopic. Much heat is evolved when solid material is dissolved in water. Therefore cold water and caution must be
used for this process. Sodium hydroxide solution and octanol + diborane during a work-up of a reaction mixture of oxime
and diborane in tetrahyrofuran is very exothermic, a mild explosion being noted on one occassion. Reactive with water,
acids, acid chlorides, strong bases, strong oxidizing agents, strong reducing agents, flammable liquids, organic halogens,
metals (i.e aluminum, tin, zinc), nitromethane, glacial acetic acid, acetic anhydride, acrolein, chlorohydrin, chlorosulfonic acid,
ethylene cyanohydrin, glyoxal, hydrochloric acid, sulfuric acid, hydrosulfuric acid, nitric acid, oleum, propiolactone, acylonitrile,
phorosous pentoxide, chloroethanol, chloroform-methanol, tetrahydroborate, cyanogen azide, 1,2,4,5 tetrachlorobenzene,
cinnamaldehyde. Reacts with formaldehyde hydroxide to yield formic acid, and hydrogen.
Special Remarks on Corrosivity: Very caustic to aluminum and other metals in presence of moisture.
Polymerization: Will not occur.
Section 11: Toxicological Information
Routes of Entry: Absorbed through skin. Dermal contact. Eye contact. Inhalation. Ingestion.
Toxicity to Animals:
LD50: Not available. LC50: Not available.
Chronic Effects on Humans: Causes damage to the following organs: lungs.
Other Toxic Effects on Humans:
Extremely hazardous in case of inhalation (lung corrosive). Very hazardous in case of skin contact (corrosive, irritant,
permeator), of eye contact (corrosive), of ingestion, .
Special Remarks on Toxicity to Animals:
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Lowest Published Lethal Dose: LDL [Rabbit] - Route: Oral; Dose: 500 mg/kg
Special Remarks on Chronic Effects on Humans: May affect genetic material (mutagenic). Investigation as a mutagen
(cytogenetic analysis), but no data available.
Special Remarks on other Toxic Effects on Humans:
Acute Potential Health Effects: Skin: May be harmful if absorbed through skin. Causes severe skin irritation and burns. May
cause deep penetrating ulcers of the skin. Eyes: Causes severe eye irritation and burns. May cause chemical conjunctivitis
and corneal damage. Inhalation: Harmful if inhaled. Causes severe irritation of the respiratory tract and mucous membranes
with coughing, burns, breathing difficulty, and possible coma. Irritation may lead the chemical pneumonitis and pulmonary
edema. Causes chemical burns to the respiratory tract and mucous membranes. Ingestion: May be fatal if swallowed. May
cause severe and permanent damage to the digestive tract. Causes severe gastrointestinal tract irritation and burns. May
cause perforation of the digestive tract. Causes severe pain, nausea, vomiting, diarrhea, and shock. May cause corrosion and
permanent destruction of the esophagus and digestive tract.
Section 12: Ecological Information
Ecotoxicity: Not available.
BOD5 and COD: Not available.
Products of Biodegradation:
Possibly hazardous short term degradation products are not likely. However, long term degradation products may arise.
Toxicity of the Products of Biodegradation: The product itself and its products of degradation are not toxic.
Special Remarks on the Products of Biodegradation: Not available.
Section 13: Disposal Considerations
Waste Disposal:
Waste must be disposed of in accordance with federal, state and local environmental control regulations.
Section 14: Transport Information
DOT Classification: Class 8: Corrosive material
Identification: : Sodium hydroxide, solid UNNA: 1823 PG: II
Special Provisions for Transport: Not available.
Section 15: Other Regulatory Information
Federal and State Regulations:
Illinois toxic substances disclosure to employee act: Sodium hydroxide Illinois chemical safety act: Sodium hydroxide New
York release reporting list: Sodium hydroxide Rhode Island RTK hazardous substances: Sodium hydroxide Pennsylvania
RTK: Sodium hydroxide Minnesota: Sodium hydroxide Massachusetts RTK: Sodium hydroxide New Jersey: Sodium hydroxide
Louisiana spill reporting: Sodium hydroxide California Director's List of Hazardous Substances: Sodium hydroxide TSCA 8(b)
inventory: Sodium hydroxide CERCLA: Hazardous substances.: Sodium hydroxide: 1000 lbs. (453.6 kg)
Other Regulations:
OSHA: Hazardous by definition of Hazard Communication Standard (29 CFR 1910.1200). EINECS: This product is on the
European Inventory of Existing Commercial Chemical Substances.
Other Classifications:
WHMIS (Canada): CLASS E: Corrosive solid.
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DSCL (EEC):
HMIS (U.S.A.):
Health Hazard: 3
Fire Hazard: 0
Reactivity: 2
Personal Protection: j
National Fire Protection Association (U.S.A.):
Health: 3
Flammability: 0
Reactivity: 1
Specific hazard:
Protective Equipment:
Gloves. Synthetic apron. Vapor and dust respirator. Be sure to use an approved/certified respirator or equivalent. Wear
appropriate respirator when ventilation is inadequate. Splash goggles.
Section 16: Other Information
References: Not available.
Other Special Considerations: Not available.
Created: 10/09/2005 06:32 PM
Last Updated: 05/21/2013 12:00 PM
The information above is believed to be accurate and represents the best information currently available to us. However, we
make no warranty of merchantability or any other warranty, express or implied, with respect to such information, and we assume
no liability resulting from its use. Users should make their own investigations to determine the suitability of the information for
their particular purposes. In no event shall ScienceLab.com be liable for any claims, losses, or damages of any third party or for
lost profits or any special, indirect, incidental, consequential or exemplary damages, howsoever arising, even if ScienceLab.com
has been advised of the possibility of such damages.
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MATERIAL SAFETY DATA SHEET 
SECTION 1 - IDENTIFICATION OF THE MATERIAL AND SUPPLIER 
Material Name: Phosphate buffered saline, pH 7.4 
Catalogue Number: APBS-1L 
Other Names: Sorenson's Saline; Phosphate Buffered Saline. 
Recommended Use: Used as a buffer or cell wash dilution in microscopy in hospital and pathology 
laboratories. 
 
Supplier Name: ProSciTech 
Street Address:  1/11 Carlton Street, Kirwan, Qld. 4817 Australia 
Telephone Number: (07) 4773 9444 - 8:30am – 5:00pm, Monday to Friday (excluding Public Holidays) 
Emergency Contact: (07) 4773 9444 - 8:30am – 5:00pm, Monday to Friday (excluding Public Holidays) 
 
SECTION 2 - HAZARDS IDENTIFICATION 
Hazard Classification: 
Not classified as hazardous according to criteria for Classifying Hazardous Substances [NOHSC:1008]. 
Hazardous and/or Dangerous Nature: 
NON-HAZARDOUS SUBSTANCE. NON-DANGEROUS GOODS. 
Risk Phrases: 
None allocated. 
Safety Phrases: 
S24/25: Avoid contact with skin and eyes. 
 
Refer to Section 15 for Poisons Schedule. 
 
SECTION 3 - COMPOSITION /INFORMATION ON INGREDIENTS 
Mixture Substance: 
Ingredients Cas Number(s) Proportion (%) 
SODIUM CHLORIDE 7647-14-5 0.8 
POTASSIUM DIHYDROGEN PHOSPHATE 7778-77-0 0.02 
DISODIUM HYDROGEN ORTHOPHOSPHATE 7558-79-4 0.1 
POTASSIUM CHLORIDE 7447-40-7 0.02 
WATER 7732-18-5 99 
 
SECTION 4 - FIRST AID MEASURES 
Ingestion: If swallowed, DO NOT induce vomiting. If victim is conscious give water. If sickness 
persists transport to hospital or doctor. 
Inhalation: Move victim to fresh air. Apply resuscitation if victim is not breathing - If trained 
personnel available administer oxygen if breathing is difficult. 
Eye Contact: If material is splashed into eyes, immediately, flush with plenty of water for 15 minutes, 
ensuring eye lids are held open. If irritation persists transport to hospital or doctor. 
Skin Contact: If material is splashed onto the skin, remove any contaminated clothing and wash skin 
thoroughly with water and soap if available. If irritation persists transport to hospital or 
doctor. 
First Aid Facilities: Eyebath/eyewash, Safety shower & general washroom facilities. 
Medical Attention & Special Treatment: 
Treat symptomatically. 
Additional Information: 
Not available. 
 
SECTION 5 - FIRE FIGHTING MEASURES 
Suitable Extinguishing Media: 
Use extinguishing media suitable for surrounding fire situation. This material is not a flammable or combustible 
liquid. 
Hazards from Combustion Products: 
Decomposes on heating emitting oxides of carbon. 
Precautions for Fire Fighters: 
Fire fighters to wear Self-contained breathing apparatus (SCBA) in confined spaces, in oxygen deficient 
atmospheres or if exposed to products of decomposition. Full protective clothing is also recommended. If safe to 
do so, move undamaged containers from fire area. 
Part Number(s): 
54-111-04, 54-111-05 
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1.  Product and Company Identification 
Trade Name & Synonyms 
Sterilizable cheek retractor 
MSDS Code Number 
CKE 12, 2S 
Chemical Name 
Polyethersulfone-polymer. Chemical family: Polyethersulfone. 
Manufacture / Distributor 
GAC International Inc.  
C.A.S. Number 
25154-01-2 
Address 
355 Knickerbocker Ave. 
Bohemia, NY USA 11716 
Grades or Minor Variant Identities 
NA 
Information Telephone Number 
1-631-419-1700 
Product Use (for Canada) 
NA 
Emergency Telephone Number 
1-631-419-1700 
 
2. Composition of Ingredients 
Hazardous Components C.A.S. Number Exposure Limits % 
Polyethersulfone 25154-01-2 N/A NA 
 
3. Hazard Identification 
Emergency Overview 
This product has non-hazardous ingredient as defined under the criteria of the federal OSHA hazard communication standard 29 CFR 1910.1200. 
Routes of 
Exposure 
Signs and Symptoms 
 
Single, Repeated, or 
Lifetime Exposure 
Severity (Mild, 
Moderate, Severe) 
Acute and Chronic 
Health Effect(s) 
Target 
Organ(s) 
Eye 
 
NA NA NA Acute: Mechanical irritation. 
Chronic:  None 
NA 
Skin NA NA NA NA NA 
Inhalation 
 
NA NA NA Acute: No significant health 
hazard. 
Chronic: None. 
NA 
Ingestion 
 
NA NA NA NA NA 
Other NA NA NA NA NA 
Medical Conditions Aggravated by Exposure 
None.  Human effects and symptoms of over exposure: None 
Carcinogenicity  (IARC, NTP) 
None 
Potential Environmental Effects 
Potential health effects: None. Exposure limits: None. 
 
4. First Aid Measures 
Routes of Exposure First Aid Instructions Immediate Medical Attention Delayed Effects 
Eye N/A NA NA 
Skin N/A NA NA 
Inhalation 
 
N/A NA NA 
Ingestion 
 
N/A NA NA 
Other 
 
NA NA NA 
Note to Physicians (Treatment, Testing, and Monitoring) 
NA 
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5. Fire and Explosion Data 
Flashpoint & Method: 
°C / °F  Non-flammable 
Flammable (Explosive) Limits in Air 
LEL:   N/A                   UEL: N/A 
Autoignition Temperature 
 NA 
Flame Propagation or Burning  
NA 
Properties Contributing to 
Fire Intensity 
 NA 
Flammability Classification 
Health- 0, Flammability-0 , Reactivity-
0 
Other   
NA 
Extinguishing Media 
N/A 
Extinguishing Media to Avoid 
NA 
Protection and Procedures for Firefighters 
None 
Unusual Fire and Explosion Hazards 
NA 
 
6. Accidental Release Measures 
Containment Techniques 
NA 
Spill/Leak Clean-Up Procedures and Equipment 
Remove by mechanical means. 
Evacuation Procedures 
NA 
Special Instructions 
NA 
Reporting Requirements 
NA 
 
7. Handling and Storage 
Handling Practices and Warnings 
None 
Storage Practices and Warnings 
 (qC / qF).  Storage temperature: Ambient.  
Shelf life: 3 years.  
 
8. Exposure Control/Personal Protection 
Ventilation 
None 
Other Engineering Controls 
NA 
Routes of Entry: Personal Protective Equipment (PPE) for Normal Use:  PPE for Emergencies: 
Eye/Face None NA 
Skin None NA 
Inhalation None NA 
General Hygiene Considerations and Work Practices 
NA 
Protective Measures During Repair and Maintenance of Contaminated Equipment 
NA 
Other Protective Measures and Equipment 
None 
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9. Physical and Chemical Characteristics 
Appearance 
Color: Various F.D.A allowable colors. 
Odor 
Odorless 
Normal Physical State:  
                 Liquid            Gas 
 
                 Solid                    (Other) 
Boiling Point       °C /  °F   N/A 
 
Melting Point      °C /  °F   N/A 
     
Freezing Point     °C /  °F  N/A 
Specific Gravity or Density (H20=1) 
1.37 g/cm3 
Solubility in Water 
Insoluble 
pH 
N/D 
Vapor Pressure (mm Hg @ 20°C) 
N/A 
Vapor Density (AIR= 1) 
 NA 
Evaporation Rate (Butyl Acetate = 1) 
 NA 
Other 
Bulk density: Approximately 10.01 LBS /CM3.  
% Volatile by volume: N/A 
 
10.  Stability and Reactivity Data 
Incompatibility (Materials to Avoid) 
None known. 
Hazardous Products Produced During Decomposition 
By fire; carbon monoxide, carbon dioxide. 
Hazardous Polymerization?  
 May Occur                            May Not Occur 
Conditions to Avoid 
°C / °F    NA 
Stability?  
 Stable                                    Unstable 
Conditions to Avoid 
°C / °F None known. 
 
11.  Toxicological Information 
Toxicity Data, Epidemiology Studies, Carcinogenicity, Neurological Effects, Genetic or Reproductive Effects, or Structure Activity Data 
 No component of this product present at levels greater than 0.1 % is identified as a carcinogen by the U.S. National toxicology program, the U.S. 
occupational safety and health act, or the international agency on research on cancer (IARC). 
  
12.  Ecological Information 
Toxicity, Environmental Fate, Physical/Chemical Data, or Other Data Supporting Environmental Hazard Statements 
N/A 
 
13.  Disposal Considerations 
Regulations 
Waste disposal method: In accordance to federal, state or local regulations. 
Properties (Physical/Chemical) Affecting Disposal 
NA 
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14.  Transport Information 
Regulated for shipping? 
 Yes                      No 
Proper Shipping Name 
Sterilizable cheek retractor 
Packing Group 
NA 
Do changes in quantity, packaging, or shipment method change product classification?     
 Yes                      No   NA 
Hazard Class 
Not regulated 
Identification Number 
NA 
Other 
Freight class bulk: Not regulated. 
Freight class package: Not regulated. 
Product label: Not regulated. 
Hazard class division number: Not regulated 
 
 
15.  Regulatory Information 
Federal Regulations 
Sara title III: This product is not reportable under section 302.4 of SARA and 40 CFR part 355. 
Hazardous substances: None. 
Section 311/312 
Hazard categories: None. 
Section 313 Toxic chemicals: None 
RERA Status: Non-hazardous. 
International Regulations 
 NA 
Other 
 NA 
 
16.  Other Information 
Supplier Number:  31/ 54                     Supplier Release:  NA 
N/A = not applicable. NA = not available, N/E = not established. N/D = not determined.  
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RepliGen 
MATERIAL SAFETY DATA SHEET: 
Recombinant Protein A (Revision 1) 
 
SECTION 1 – PRODUCT IDENTIFICATION 
 
Supplier: RepliGen Corporation 
 41 Seyon Street, Building #1, Suite 100 
 Waltham, MA 02453  
 Phone: (781) 250-0111; Fax: (781) 250-0115 
 
Product Name:  Recombinant Protein A 
Synonyms  rPA50, srPA50, rSPA, rProteinA, rProtein A, Protein A 
Catalog No(s):  10-1001, 10-1501, 10-2001 
 
 
SECTION 2 – COMPOSITION / INFORMATION ON INGREDIENTS 
 
Purified Recombinant Protein A, derived from genetically modified Escherichia coli.  Product is 
provided frozen in an aqueous buffer.   
 
 
SECTION 3 – HAZARDS IDENTIFICATION 
 
Emergency Overview:  No specific hazards identified 
 
HMIS:    Health Hazard: 0 (No significant risk to health.) 
    Flammability: 0 (Will not burn) 
    Reactivity: 0 (Stable) 
 
NFPA:    Health Hazard: 0 (Poses no health hazard,) 
    Fire:  0 (Will not burn) 
    Reactivity: 0 (Stable, not reactive with water) 
 
Potential Health Effects:  No health effects have been identified.  
    May be harmful if inhaled, swallowed, or absorbed through skin.  
    May cause eye irritation.  
 
 
SECTION 4 – FIRST AID MEASURES 
 
If swallowed:   Induce vomiting. Get medical attention 
In case of eye contact  Flush eyes with clean water for at least 15 minutes 
Skin contact   Flush skin with water 
If inhaled   Move to fresh air. Get medical attention 
 
 
SECTION 5 – FIRE FIGHTING MEASURES 
 
Non Flammable   No specific fire hazard 
Flash point:   N/A 
Ignition point:   N/A 
Fire Extinguishing media Use any suitable media as for the surrounding fire 
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SECTION 6 – STEPS TO BE TAKEN IN THE EVENT OF A SPILL OR DISCHARGE:  
 
Personal Protection  Wear lab coat, gloves and eye protection. 
    Treat with procedures appropriate for biological materials. Soak  
    up spill with absorbent material and collect in a closed container  
    suitable for incineration. Clean the affected area with disinfectant  
    solution. Do not allow material to enter soil, waterways or drains. 
 
Disposal procedure:  Dispose of in accordance with all applicable federal, state, and  
    local environmental regulations. 
 
 
SECTION 7 – HANDLING AND STORAGE 
 
Ventilation:    Keep in a well ventilated area 
Respiratory Protection:  N/A 
Eye/skin Protection  Standard laboratory practices recommended. 
Storage:   Keep container closed. Store frozen for optimum shelf life. 
Special precautions:   N/A 
 
 
SECTION 8 – EXPOSURE CONTROLS/PERSONAL PROTECTION 
 
General   Standard laboratory practices recommended. Clean any exposed 
    skin after handling, before leaving the working area, and before  
    eating, smoking or using the lavatory.  
    Dispose of, or clean any contaminated clothing before re-use. 
 
PPE    Personal protective equipment should be selected to provide  
    adequate protection based upon the procedures being   
    performed. 
    Wear laboratory coat, gloves and safety glasses when handling. 
    Respiratory protection not required 
 
 
SECTION 9 – PHYSICAL AND CHEMICAL PROPERTIES 
 
Appearance:   Frozen aqueous solution 
pH    pH 5 - 8 
Flash point   Will not burn 
Ignition point   Will not ignite 
Explosion limits   No risk of explosion 
Solubility   Soluble in water 
 
 
SECTION 10 – STABILITY AND REACTIVITY 
 
Stability:    Stable 
Hazardous polymerization: Will not occur 
Decomposition products: No known hazardous decomposition products 
 
 
SECTION 11 – TOXICOLOGICAL INFORMATION 
 
Acute toxicity:   No known significant effects 
Irritation:   No known significant effects. May be a skin or eye irritant. 
Sensitization:   No known significant effects 
Carcinogenicity   No known significant effects 
Mutagenicity   No known significant effects  
Teratogenicity   No known significant effects 
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SECTION 12 – ECOLOGICAL INFORMATION 
 
No known hazards 
 
 
SECTION 13 – DISPOSAL CONSIDERATIONS 
 
Dispose of in accordance with all applicable federal, state, and local environmental regulations. 
Do not allow spilled material to enter soil, waterways or drains 
 
 
SECTION 14 – TRANSPORT INFORMATION 
 
IATA   Not classified 
DOT Road Transport Not Regulated
 
 
SECTION 15 – REGULATORY INFORMATION 
 
OSHA/SARA/CWA/CAA: No known hazards 
 
EU Risk and Safety Statements: 
• Not classified 
 
 
SECTION 16 – OTHER INFORMATION 
 
The material published in this Material Safety Data Sheet has been compiled from our experience 
and data presented in various technical publications. It is the user's responsibility to determine the 
suitability of this information for the adoption of necessary safety precautions. 
 
Repligen makes no warranty or representation about the accuracy or completeness nor fitness for 
purpose of the information contained herein. 
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Material Safety Data Sheet
Sodium bicarbonate MSDS
Section 1: Chemical Product and Company Identification
Product Name: Sodium bicarbonate
Catalog Codes: SLS3241, SLS2446, SLS3868
CAS#: 144-55-8
RTECS: VZ0950000
TSCA: TSCA 8(b) inventory: Sodium bicarbonate
CI#: Not available.
Synonym:   Baking Soda; Bicarbonate of soda; Sodium
acid carbonate; Monosodium carbonate; Sodium hydrogen
carbonate; Carbonic acid monosodium salt
Chemical Name: Sodium Bicarbonate
Chemical Formula: NaHCO3
Contact Information:
Sciencelab.com, Inc.
14025 Smith Rd.
Houston, Texas 77396
US Sales: 1-800-901-7247
International Sales: 1-281-441-4400
Order Online: ScienceLab.com
CHEMTREC (24HR Emergency Telephone), call:
1-800-424-9300
International CHEMTREC, call: 1-703-527-3887
For non-emergency assistance, call: 1-281-441-4400
Section 2: Composition and Information on Ingredients
Composition:
Name CAS # % by Weight
Sodium bicarbonate 144-55-8 100
Toxicological Data on Ingredients: Not applicable.
Section 3: Hazards Identification
Potential Acute Health Effects: Slightly hazardous in case of skin contact (irritant), of eye contact (irritant), of ingestion, of
inhalation.
Potential Chronic Health Effects:
CARCINOGENIC EFFECTS: Not available. MUTAGENIC EFFECTS: Not available. TERATOGENIC EFFECTS: Not available.
DEVELOPMENTAL TOXICITY: Not available. Repeated or prolonged exposure is not known to aggravate medical condition.
Section 4: First Aid Measures
Eye Contact:
Check for and remove any contact lenses. In case of contact, immediately flush eyes with plenty of water for at least 15
minutes. Cold water may be used. Get medical attention if irritation occurs.
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Skin Contact:
Wash with soap and water. Cover the irritated skin with an emollient. Get medical attention if irritation develops. Cold water
may be used.
Serious Skin Contact: Not available.
Inhalation:
If inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical
attention.
Serious Inhalation: Not available.
Ingestion:
Do NOT induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an unconscious
person. Loosen tight clothing such as a collar, tie, belt or waistband. Get medical attention if symptoms appear.
Serious Ingestion: Not available.
Section 5: Fire and Explosion Data
Flammability of the Product: Non-flammable.
Auto-Ignition Temperature: Not applicable.
Flash Points: Not applicable.
Flammable Limits: Not applicable.
Products of Combustion: Not available.
Fire Hazards in Presence of Various Substances: Not applicable.
Explosion Hazards in Presence of Various Substances:
Risks of explosion of the product in presence of mechanical impact: Not available. Risks of explosion of the product in
presence of static discharge: Not available.
Fire Fighting Media and Instructions: Not applicable.
Special Remarks on Fire Hazards: When heated to decomposition it emits acrid smoke and irritating fumes.
Special Remarks on Explosion Hazards: Not available.
Section 6: Accidental Release Measures
Small Spill:
Use appropriate tools to put the spilled solid in a convenient waste disposal container. Finish cleaning by spreading water on
the contaminated surface and dispose of according to local and regional authority requirements.
Large Spill:
Use a shovel to put the material into a convenient waste disposal container. Finish cleaning by spreading water on the
contaminated surface and allow to evacuate through the sanitary system.
Section 7: Handling and Storage
Precautions:
Do not ingest. Do not breathe dust. If ingested, seek medical advice immediately and show the container or the label. Keep
away from incompatibles such as acids.
Storage: Keep container tightly closed. Keep container in a cool, well-ventilated area.
Section 8: Exposure Controls/Personal Protection
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Engineering Controls:
Use process enclosures, local exhaust ventilation, or other engineering controls to keep airborne levels below recommended
exposure limits. If user operations generate dust, fume or mist, use ventilation to keep exposure to airborne contaminants
below the exposure limit.
Personal Protection: Safety glasses. Lab coat. Dust respirator. Be sure to use an approved/certified respirator or equivalent.
Gloves.
Personal Protection in Case of a Large Spill:
Splash goggles. Full suit. Dust respirator. Boots. Gloves. A self contained breathing apparatus should be used to avoid
inhalation of the product. Suggested protective clothing might not be sufficient; consult a specialist BEFORE handling this
product.
Exposure Limits: Not available.
Section 9: Physical and Chemical Properties
Physical state and appearance: Solid.
Odor: Odorless.
Taste: Saline. Alkaline.
Molecular Weight: 84.01g/mole
Color: White.
pH (1% soln/water): Not available.
Boiling Point: Not available.
Melting Point: Not available.
Critical Temperature: Not available.
Specific Gravity: Density: 2.159 (Water = 1)
Vapor Pressure: Not applicable.
Vapor Density: Not available.
Volatility: Not available.
Odor Threshold: Not available.
Water/Oil Dist. Coeff.: Not available.
Ionicity (in Water): Not available.
Dispersion Properties: See solubility in water.
Solubility:
Soluble in cold water. Slightly soluble in alcohol. Solubility in Water: 6.4, 7.6, 8.7, 10.0, 11.3, 12.7, 14.2, 16.5, 19.1 g/100
solution at 0, 10, 20, 30, 40, 50, 60, 80, adn 100 deg. C, respectively. Solubility in Water: 6.9, 8,2, 9.6, 11.1, 12.7, 14.5, 16.5,
19.7, and 23.6 g/100g water at 0, 10, 20, 30, 40, 50, 60, 80, 100 deg. C, respectively.
Section 10: Stability and Reactivity Data
Stability: The product is stable.
Instability Temperature: Not available.
Conditions of Instability: Incompatible materials, Moisture. Stable in dry air, but slowly decomposes in moist air.
Incompatibility with various substances: Reactive with acids.
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Corrosivity: Non-corrosive in presence of glass.
Special Remarks on Reactivity:
Reacts with acids to form carbon dioxide. Dangerous reaction with monoammonium phosphate or a sodium-potassium alloy.
Special Remarks on Corrosivity: Not available.
Polymerization: Will not occur.
Section 11: Toxicological Information
Routes of Entry: Inhalation. Ingestion.
Toxicity to Animals: Acute oral toxicity (LD50): 3360 mg/kg [Mouse].
Chronic Effects on Humans: Not available.
Other Toxic Effects on Humans: Slightly hazardous in case of skin contact (irritant), of ingestion, of inhalation.
Special Remarks on Toxicity to Animals: Not available.
Special Remarks on Chronic Effects on Humans:
Sodium Bicarbonate as produced genetic effects in rats (unscheduled DNA synthesis). However, no affects have been found
in humans.
Special Remarks on other Toxic Effects on Humans:
Acute Potential Health Effects: Skin: May cause mild skin irritation. Eyes: May cause mild eye irritation. Inhalation: May
cause respiratory tract irritation. Symptoms may include coughing and sneezing. Ingestion: Symptoms of overexposure to
Sodium Bicarbonate include thirst, abdominal pain, gastroenteritis, and inflammation of the digestive tract. Chronic Potential
Health Effects: Skin: Repeated or prolonged skin contact may cause irritation, drying or cracking of the skin. Ingestion and
Inhalation: Chronic toxicity usually occurs within 4 to 10 days following ingestion of very large amounts. Repeated or prolonged
ingestion or inhalation of large amounts may cause metabolic abnormalities, and sodium retention. Metabolic abnormalities
such as acidosis, hypernatremia, hypochloremia, alkalosis, hypocalcemia, or sodium retention may affect the blood, kidneys,
respiration (cyanosis, apnea secondary to metabolic acidosis or pulmonary edema), and cardiovascular system (tachycardia,
hypotension). Severe toxicity may also affect behavior/central nervous system/nervous system. Neurological changes may
result from metabolic abnormalities. These may include fatigue, irritability, dizziness, mental confusion, paresthesia, seizures,
tetany, cerebral edema Medical Conditions Aggravated by Exposure: Persons with pre-existing skin conditions might have
increased sensitivity. Predisposing conditions that contribute to a mild alkali syndrome include, renal disease, dehydration, adn
electrolyte imbalance, hypertension, sarcoidosis, congestive heart failure, edema, or other sodium retaining conditions.
Section 12: Ecological Information
Ecotoxicity: Not available.
BOD5 and COD: Not available.
Products of Biodegradation:
Possibly hazardous short term degradation products are not likely. However, long term degradation products may arise.
Toxicity of the Products of Biodegradation: The product itself and its products of degradation are not toxic.
Special Remarks on the Products of Biodegradation: Not available.
Section 13: Disposal Considerations
Waste Disposal:
Waste must be disposed of in accordance with federal, state and local environmental control regulations.
Section 14: Transport Information
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DOT Classification: Not a DOT controlled material (United States).
Identification: Not applicable.
Special Provisions for Transport: Not applicable.
Section 15: Other Regulatory Information
Federal and State Regulations: TSCA 8(b) inventory: Sodium bicarbonate
Other Regulations: Not available.
Other Classifications:
WHMIS (Canada): Not controlled under WHMIS (Canada).
DSCL (EEC):
This product is not classified according to the EU regulations. Not applicable.
HMIS (U.S.A.):
Health Hazard: 1
Fire Hazard: 0
Reactivity: 0
Personal Protection: E
National Fire Protection Association (U.S.A.):
Health: 1
Flammability: 0
Reactivity: 0
Specific hazard:
Protective Equipment:
Gloves. Lab coat. Dust respirator. Be sure to use an approved/certified respirator or equivalent. Safety glasses.
Section 16: Other Information
References: Not available.
Other Special Considerations: Not available.
Created: 10/10/2005 08:26 PM
Last Updated: 05/21/2013 12:00 PM
The information above is believed to be accurate and represents the best information currently available to us. However, we
make no warranty of merchantability or any other warranty, express or implied, with respect to such information, and we assume
no liability resulting from its use. Users should make their own investigations to determine the suitability of the information for
their particular purposes. In no event shall ScienceLab.com be liable for any claims, losses, or damages of any third party or for
lost profits or any special, indirect, incidental, consequential or exemplary damages, howsoever arising, even if ScienceLab.com
has been advised of the possibility of such damages.
MATERIAL SAFETY DATA SHEET 
REF: 91/155/EEC AND AMENDMENTS WITH RESPECTIVE NATIONAL IMPLEMENTATIONS 
SODIUM CITRATE 
1.0 SUBSTANCE IDENTIFICATION 
1.1 Commercial product name: Sodium Citrate including anhydrous, dehydrate etc 
1.2 Chemical characterisation: Trisodium salt of 2-hydroxypropane-1,2,3, tricarboxylate 
1.3 Formula: 
1.4 Molecular weight: approx 258 - 294
1.5 CAS No: 6132-04-3 
1.6 EINECS No.: 200-675-3
1.7 FOR USE IN FOOD  as a food aditive
1.8 Manufactured by: Archer Daniels Midland Company, 4666 Faries Parkway, 
Decatur, Illinois 62526, U.S.A. 
1.9 Supplied by: ADM Australia Pty Ltd, PO Box 281, Suite 1003, Level 10, 
1 Newland Street, Bondi Junction, NSW 2022 
1.10 Australian Emergency Telephone Number: 0417285396 
2.0 COMPOSITION 
2.1 Totally 100% sodium citrate 
2.2 Volatile matter 6-12 % maximum after drying for 4 hours at 180°C 
2.3 Sodium ion content typically 23 - 24% 
3.0 HAZARDS IDENTIFICATION 
3.1 Sodium citrate is not classified as a Dangerous Substance within the definitions of EC 
Directive 67/584 
3.2 Contact with eyes (e.g. dust particles) may cause irritation. 
4.0 FIRST AID MEASURES 
4.1 Flush affected parts with plenty of water 
5.0 FIRE FIGHTING MEASURES 
5.1 All types of fire extinguisher are suitable 
5.2 Firefighters wear protective clothing and NIOSH approved respirator 
6.0 ACCIDENTAL RELEASE MEASURES 
6.1 After spillage/leakage :  Recover by vacuum, or broom and shovel. Flush area with water to 
remove final traces. 
Effective: 10 April, 2009 Page 1 of 3 Replaces 10/5/04 
7.0 HANDLING AND STORAGE
7.1 Store in tightly closed containers, away from extreme heat and humidity. Maximum 25°C and 50% 
relative humidity. 
7.2 Industrial Hygiene: Good ventilation required if process creates the formation of dust. 
8.0 EXPOSURE CONTROLS / PERSONAL PROTECTION 
8.1 Personal precautions: Avoid breathing dust. 
Avoid contact with eyes. 
8.2 Respiratory protection: Approved nuisance dust mask 
8.3 Hand protection: Standard work gloves 
8.4 Eye protection: Goggles or safety glasses 
9.0 PHYSICAL AND CHEMICAL PROPERTIES 
9.1 Appearance: Crystals 
9.2 Colour: Colourless 
9.3 Odour: Odourless 
9.4 Molecular weight: 258 - 294 
9.5 Change in physical state: Loss of water above 180°C, with decomposition 
9.6 Specific gravity Bulk density: 1.97 920-1150 kg/m3 (typical range) 
9.8 Vapour pressure: N/A - solid 
9.9 Viscosity: N/A - solid 
9.10 Solubility - in water (25°C) 40 - 60% w/w 
- in ethanol (25°C) Insoluble 
9.11 pH (5% solution) (25°C) 7 - 9 
9.12 Flash point N/A 
9.13 Explosive properties N/A 
9.14 Flammability: Requires external heat to burn 
9.12 Thermal decomposition: Above 230°C may evolve carbon monoxide 
and carbon dioxide 
10.0 STABILITY AND REACTIVITY 
10.1 Shelf life : Sodium citrate is chemically stable if stored under cool, dry 
conditions; 25°C maximum and 50% relative humidity.  It 
deliquesces in moist air. Physical properties may change on 
storage: re-test recommended periodically based on actual 
storage conditions. 
10.4 Reactivity: Sodium citrate is a neutral salt with low activity. 
11.0 TOXICOLOGICAL INFORMATION 
11.1 LD50 (dog): Not available
12.0 ECOLOGICAL INFORMATION 
12.1 Not Available
12.2 Not AVailable
Effective: 10 April, 2009  Page 1 of 3 Replaces 10/5/04
13.0 DISPOSAL CONSIDERATIONS
13.1 Sodium citrate is suitable for landfill or disposal to sewer depending 
upon local regulations.
14.0 TRANSPORT INFORMATION
14.1 No special considerations
15.0 REGULATORY INFORMATION
15.1 Sodium citrate is an EU permitted Food Additive (E 332).  Conditions of use:
Quantum Satis. The US Food and Drug Administration classifies potassium citrate as 
a GRAS (Generally Recognised As Safe) food ingredient.
15.2 According to the Joint Expert Committee on Food Additives of WHO/FAO potassium
Citrate may be used without limitation according to Good Manufacturing Practices.
16.0 ADDITIONAL INFORMATION
16.1 See Product Data Sheet.
Effective: 10 April, 2009 Page 1 of 3 Replaces 10/5/04 
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Material Safety Data Sheet
Sodium phosphate tribasic MSDS
Section 1: Chemical Product and Company Identification
Product Name: Sodium phosphate tribasic
Catalog Codes: SLS2650, SLS4072
CAS#: 7601-54-9
RTECS: TC9490000
TSCA: TSCA 8(b) inventory: Sodium phosphate tribasic
CI#: Not available.
Synonym:   Trisodium Phosphate Anhydrous; Phosphoric
Acid, Trisodium Salt; Trisodium Orthophosphate
Chemical Name: Sodium Phosphate Tribasic
Chemical Formula: Na3PO4
Contact Information:
Sciencelab.com, Inc.
14025 Smith Rd.
Houston, Texas 77396
US Sales: 1-800-901-7247
International Sales: 1-281-441-4400
Order Online: ScienceLab.com
CHEMTREC (24HR Emergency Telephone), call:
1-800-424-9300
International CHEMTREC, call: 1-703-527-3887
For non-emergency assistance, call: 1-281-441-4400
Section 2: Composition and Information on Ingredients
Composition:
Name CAS # % by Weight
Sodium phosphate tribasic 7601-54-9 100
Toxicological Data on Ingredients: Sodium phosphate tribasic: ORAL (LD50): Acute: 4150 mg/kg [Rat [information from
other supplier]]. DERMAL (LD50): Acute: &gt;7940 mg/kg [Rabbit [information from other supplier]]. &gt;300 mg/kg [Rabbit
[Registry of Toxic Effects of Chemical Substances database]].
Section 3: Hazards Identification
Potential Acute Health Effects:
Hazardous in case of skin contact (irritant), of eye contact (irritant), of ingestion, of inhalation. Slightly hazardous in case
of skin contact (permeator). Corrosive to eyes and skin. The amount of tissue damage depends on length of contact. Eye
contact can result in corneal damage or blindness. Skin contact can produce inflammation and blistering. Inhalation of dust
will produce irritation to gastro-intestinal or respiratory tract, characterized by burning, sneezing and coughing. Severe over-
exposure can produce lung damage, choking, unconsciousness or death.
Potential Chronic Health Effects:
CARCINOGENIC EFFECTS: Not available. MUTAGENIC EFFECTS: Not available. TERATOGENIC EFFECTS: Not available.
DEVELOPMENTAL TOXICITY: Not available. Repeated exposure of the eyes to a low level of dust can produce eye irritation.
Repeated skin exposure can produce local skin destruction, or dermatitis. Repeated inhalation of dust can produce varying
degree of respiratory irritation or lung damage.
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Section 4: First Aid Measures
Eye Contact:
Check for and remove any contact lenses. In case of contact, immediately flush eyes with plenty of water for at least 15
minutes. Cold water may be used. Get medical attention immediately.
Skin Contact:
In case of contact, immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing
and shoes. Cover the irritated skin with an emollient. Cold water may be used.Wash clothing before reuse. Thoroughly clean
shoes before reuse. Get medical attention immediately.
Serious Skin Contact:
Wash with a disinfectant soap and cover the contaminated skin with an anti-bacterial cream. Seek medical attention.
Inhalation:
If inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical
attention immediately.
Serious Inhalation: Not available.
Ingestion:
Do NOT induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an unconscious
person. Loosen tight clothing such as a collar, tie, belt or waistband. Get medical attention if symptoms appear.
Serious Ingestion: Not available.
Section 5: Fire and Explosion Data
Flammability of the Product: Non-flammable.
Auto-Ignition Temperature: Not applicable.
Flash Points: Not applicable.
Flammable Limits: Not applicable.
Products of Combustion: Not available.
Fire Hazards in Presence of Various Substances: Not applicable.
Explosion Hazards in Presence of Various Substances:
Risks of explosion of the product in presence of mechanical impact: Not available. Risks of explosion of the product in
presence of static discharge: Not available. Slightly explosive in presence of heat.
Fire Fighting Media and Instructions: Not applicable.
Special Remarks on Fire Hazards: Not available.
Special Remarks on Explosion Hazards: Containers may explode when heated
Section 6: Accidental Release Measures
Small Spill:
Use appropriate tools to put the spilled solid in a convenient waste disposal container. If necessary: Neutralize the residue with
a dilute solution of acetic acid. Finish cleaning by spreading water on the contaminated surface and dispose of according to
local and regional authority requirements.
Large Spill:
Corrosive solid. Stop leak if without risk. Do not get water inside container. Do not touch spilled material. Use water spray
to reduce vapors. Prevent entry into sewers, basements or confined areas; dike if needed. Call for assistance on disposal.
Neutralize the residue with a dilute solution of acetic acid. Be careful that the product is not present at a concentration level
above TLV. Check TLV on the MSDS and with local authorities.
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Section 7: Handling and Storage
Precautions:
Keep container dry. Do not ingest. Do not breathe dust. Never add water to this product. Wear suitable protective clothing. In
case of insufficient ventilation, wear suitable respiratory equipment. If ingested, seek medical advice immediately and show the
container or the label. Avoid contact with skin and eyes. Keep away from incompatibles such as moisture.
Storage: Keep container tightly closed. Keep container in a cool, well-ventilated area. Do not store above 23°C (73.4°F).
Section 8: Exposure Controls/Personal Protection
Engineering Controls:
Use process enclosures, local exhaust ventilation, or other engineering controls to keep airborne levels below recommended
exposure limits. If user operations generate dust, fume or mist, use ventilation to keep exposure to airborne contaminants
below the exposure limit.
Personal Protection: Safety glasses. Synthetic apron. Gloves (impervious).
Personal Protection in Case of a Large Spill:
Splash goggles. Full suit. Boots. Gloves. Suggested protective clothing might not be sufficient; consult a specialist BEFORE
handling this product.
Exposure Limits:
TWA: 15 (mg/m3) from OSHA (PEL) [United States] Inhalation Total. TWA: 5 (mg/m3) from OSHA (PEL) [United States]
Inhalation Respirable. TWA: 5 STEL: 5 (mg/m3) from AIHA InhalationConsult local authorities for acceptable exposure limits.
Section 9: Physical and Chemical Properties
Physical state and appearance: Solid.
Odor: Odorless.
Taste: Not available.
Molecular Weight: 163.94 g/mole
Color: White.
pH (1% soln/water): 11.9 [Basic.]
Boiling Point: Not available.
Melting Point: 75°C (167°F)
Critical Temperature: Not available.
Specific Gravity: 1.62 (Water = 1)
Vapor Pressure: Not applicable.
Vapor Density: Not available.
Volatility: Not available.
Odor Threshold: Not available.
Water/Oil Dist. Coeff.: Not available.
Ionicity (in Water): Not available.
Dispersion Properties: See solubility in water.
Solubility:
Easily soluble in hot water. Soluble in cold water.
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Section 10: Stability and Reactivity Data
Stability: The product is stable.
Instability Temperature: Not available.
Conditions of Instability: Moisture
Incompatibility with various substances: Reactive with moisture.
Corrosivity: Non-corrosive in presence of glass.
Special Remarks on Reactivity: Hygroscopic. Sodium Phosphate Tribasic forms a strong caustic solution similar to soda lye
Special Remarks on Corrosivity: When wet, mild steel and brass may be corroded by sodium phosphate tribasic.
Polymerization: Will not occur.
Section 11: Toxicological Information
Routes of Entry: Absorbed through skin. Inhalation. Ingestion.
Toxicity to Animals:
Acute oral toxicity (LD50): 4150 mg/kg [Rat [information from other supplier]]. Acute dermal toxicity (LD50): >300 mg/kg
[Rabbit [Registry of Toxic Effects of Chemical Substances database]].
Chronic Effects on Humans: Not available.
Other Toxic Effects on Humans:
Extremely hazardous in case of skin contact (corrosive), of eye contact (corrosive), of inhalation (lung corrosive). Hazardous in
case of skin contact (irritant), of ingestion, . Slightly hazardous in case of skin contact (permeator).
Special Remarks on Toxicity to Animals: Not available.
Special Remarks on Chronic Effects on Humans: May affect genetic material (mutagenic)
Special Remarks on other Toxic Effects on Humans:
Acute Potential Health Effects: Skin: Causes skin irritation with possible burning pain and corrosive damage. It may be
absorbed through the skin. Eyes: Causes eye irritation. It causes immediate and severe pain followed by conjunctival edema
and corneal clouding. Later cataract formation may occur. This substance may cause eye burns. Inhalation: May be harmful
if inhaled. Inhalation of dust may Cause respiratory tract and mucous membrane irritation with coughing, sneezing, choking,
difficulty breathing, and pulmonary edema. Ingestion: May be harmful if swallowed. May cause severe gastrointestinal
(digestive) tract irritation with severe nausea, vomiting, abdominal discomfort, violent purging, diarrhea, and burning sensation.
Ingestion of large amounts may induce hypcalcemia or hypnatremia characterized by tetanus-like spasms, due to the
sequestration of calcium ions by the phosphate moiety. It may also cause caustic burns of the mouth oropharnyx, esophagus,
or gastrointestinal tract.
Section 12: Ecological Information
Ecotoxicity:
Ecotoxicity in water (LC50): 220 mg/l 96 hours [Bluegill sunfish]. 120 mg/l 96 hours [Rainbow Trout]. 177 mg/l 50 hours
[Daphnia].
BOD5 and COD: Not available.
Products of Biodegradation:
Possibly hazardous short term degradation products are not likely. However, long term degradation products may arise.
Toxicity of the Products of Biodegradation: The products of degradation are as toxic as the original product.
Special Remarks on the Products of Biodegradation: Not available.
Section 13: Disposal Considerations
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Waste Disposal:
Waste must be disposed of in accordance with federal, state and local environmental control regulations.
Section 14: Transport Information
DOT Classification: Not a DOT controlled material (United States).
Identification: : Not available. UNNA: 9148 PG: III
Special Provisions for Transport: Not applicable.
Section 15: Other Regulatory Information
Federal and State Regulations:
New York release reporting list: Sodium phosphate tribasic Pennsylvania RTK: Sodium phosphate tribasic Minnesota: Sodium
phosphate tribasic Massachusetts RTK: Sodium phosphate tribasic New Jersey: Sodium phosphate tribasic California
Director's List of Hazardous Substances: Sodium phosphate tribasic TSCA 8(b) inventory: Sodium phosphate tribasic
CERCLA: Hazardous substances.: Sodium phosphate tribasic: 5000 lbs. (2268 kg)
Other Regulations:
OSHA: Hazardous by definition of Hazard Communication Standard (29 CFR 1910.1200). EINECS: This product is on the
European Inventory of Existing Commercial Chemical Substances.
Other Classifications:
WHMIS (Canada): CLASS E: Corrosive solid.
DSCL (EEC):
R35- Causes severe burns. S1/2- Keep locked up and out of the reach of children. S26- In case of contact with eyes, rinse
immediately with plenty of water and seek medical advice. S36/37- Wear suitable protective clothing and gloves. S39- Wear
eye/face protection. S45- In case of accident or if you feel unwell, seek medical advice immediately (show the label where
possible).
HMIS (U.S.A.):
Health Hazard: 2
Fire Hazard: 0
Reactivity: 0
Personal Protection: C
National Fire Protection Association (U.S.A.):
Health: 2
Flammability: 0
Reactivity: 2
Specific hazard:
Protective Equipment:
Gloves (impervious). Synthetic apron. Wear appropriate respirator when ventilation is inadequate. Safety glasses.
Section 16: Other Information
References: Not available.
Other Special Considerations: Not available.
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Last Updated: 05/21/2013 12:00 PM
The information above is believed to be accurate and represents the best information currently available to us. However, we
make no warranty of merchantability or any other warranty, express or implied, with respect to such information, and we assume
no liability resulting from its use. Users should make their own investigations to determine the suitability of the information for
their particular purposes. In no event shall ScienceLab.com be liable for any claims, losses, or damages of any third party or for
lost profits or any special, indirect, incidental, consequential or exemplary damages, howsoever arising, even if ScienceLab.com
has been advised of the possibility of such damages.
 
 
TEAc-N 
Perfluoroalkyl Ethyl Acrylates (Narrow Distribution) 
 
Revised 03- November-2009 
 
1. PRODUCT AND COMPANY IDENTIFICATION 
Material Identification 
 Product name:  TEAc-N (narrow distribution) 
 Chemical name:   Perfluoroalkyl ethyl acrylates, mixture 
    1H,1H,2H,2H-Perfluoroalkyl-1-acrylates 
 Chemical formula:  CH2=CHC(O)OCH2CH2(CF2CF2)nF, n = 3, 4, 5,  ; 
mostly n = 4 
   CnH7FmO2; n = 9,11,13,15 ; m = 2n-9 
Company Identification 
 Distributor  Top Fluorochem Co., Ltd. 
  Building C2, 3rd Floor 
  479 Chun Dong Road 
  XinZhuang Industrial Park 
  Minhang District 
  Shanghai, P. R. China 201108 
 Manufacturer  Fuxin Hengtong Fluorine Chemicals Co., Ltd. 
  Fuxin Chemicals Community 
  West Pingan St. 
  Haizhou District 
  Fuxin City, Liaoning Province, P. R. China 
 Emergency Call  +86-21-54833399 
 
2. COMPOSITION AND INFORMATION ON INGREDIENTS 
Components 
Material CAS Number EINECS TSCA Listed Amount 
Perfluoroalkylethyl acrylates 65605-70-1 NA NA  
2,6-Di-tert-butyl-4-methylphenol 128-37-0 204-881-4 Yes 30 ppm 
 
 
3. HAZARDS IDENTIFICATION 
Potential Health Effects 
 Skin contact:  May cause irritation.  
 Eye contact:  May cause irritation. 
 Inhalation of spray or mist:  May cause nasal, throat, or lung irritation.  
 Inhalation of large amounts:  May be toxic to the lungs.  
 Symptoms:  May be modest initially, followed in hours by severe 
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shortness of breath requiring prompt medical 
attention. 
Carcinogenicity Information: None of the components present in this material at 
concentrations equal to or greater than 0.1 % are 
listed by IARC, NTP, OSHA or ACGIH as a 
carcinogen. 
 
4. FIRST AID MEASURES 
Inhalation: If inhaled, remove to fresh air.  If not breathing, give 
artificial respiration.  If breathing is difficult, give 
oxygen.  Call a physician. 
Skin Contact:  Flush skin with water after contact.  Wash 
contaminated clothing before reuse. 
Eye Contact: In case of contact, immediately flush eyes with plenty 
of water for at least 15 minutes.  Call a physician. 
Ingestion: If swallowed, do not induce vomiting.  Immediately 
 give 2 glasses of water.  Never give anything by 
 mouth to an unconscious person.  Call a physician. 
Note to Physicians: Activated charcoal mixture may be administered.  
To prepare activated charcoal mixture, suspend 50 
grams activated charcoal in 400 mL water and mix 
thoroughly.  Administer 5 mL/kg, or 350 mL for an 
average adult. 
 
5. FIRE FIGHTING MEASURES 
Flammable Properties 
 Flash point:  > 110 °C (> 230 °F) 
 Method:  PMCC 
Hazardous Decomposition Products:  Hazardous decomposition products include carbon 
dioxide, carbon monoxide, and hydrogen fluoride.  
Toxic gases or particles may be formed during 
combustion.  These products may cause severe 
eye, nose, throat, and lung irritation or toxic effects. 
Extinguishing Media: Water spray, foam, dry chemical, CO2. 
Fire Fighting Instructions: Evacuate personnel to a safe area.  Keep personnel 
removed and upwind of fire.  Wear self-contained 
breathing apparatus.  Wear full protective 
equipment.  Avoid breathing decomposition 
products. 
 
6. ACCIDENTAL RELEASE MEASURES 
Safeguards (Personnel) 
 NOTE:  Review FIRE FIGHTING MEASURES and 
HANDLING (Personnel) sections before proceeding 
with clean-up.  Use appropriate personal protective 
equipment during clean-up. 
 Spill clean up: Soak up with sawdust, sand, oil dry or other 
absorbent material.  Shovel or sweep up. 
TEAc-N MSDS 
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7. HANDLING AND STORAGE 
Handling Requirements: Avoid breathing vapors or mist.  
 Avoid contact with eyes, skin, or clothing.  
 Wash thoroughly after handling.  
Do not store or consume food, drink, or tobacco in 
areas where they may become contaminated with 
this material.  
Avoid circumstances that produce respirable 
particles unless suitable ventilation and respirator 
are used. 
Storage conditions: Keep container and store in a cool place.  
  Keep container tightly closed. 
 
8. EXPOSURE CONTROLS AND PERSONAL PROTECTION 
Engineering Controls: Keep container tightly closed.  Use only with 
adequate ventilation.  Vent heated extruder or dryer 
fumes outside work area.  Do not aerosolize.  In 
spray applications, use airless type pressure spray 
equipment at less than 60 psi, and exhaust ducts, 
drip pans, or other design features to minimize 
worker exposure to mists and overspray. 
Personal Protective Equipment 
 Eye/face protection: Wear safety glasses or cover-all chemical splash 
goggles. 
 Respirators: Where there is potential for airborne exposures wear 
NIOSH approved respiratory protection. 
 Protective clothing: Where there is potential for skin contact have 
available and wear as appropriate impervious gloves, 
apron, pants, and jacket. 
Exposure Guidelines 
 PEL (OSHA):  None established. 
 TLV (ACGIH): None established. 
 
9. PHYSICAL AND CHEMICAL PROPERTIES 
Refractive Index nD25  = 1.3332 
Solubility in Water Negligible 
Boiling Point 100 to 220 °C (212 to 428 °F) @ 10 mm Hg 
Approx. 
Melting Point -1 to 25 °C 
Flash Point > 110 °C 
pH 3 to 5 @ 20 °C 
Density 1.6 g/mL @ 25 °C 
Odor Mild acrylic 
Form Semi-solid 
Color Pale to medium yellow 
TEAc-N MSDS 
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10. STABILITY AND REACTIVITY 
Chemical Stability: Stable at normal temperatures and storage 
conditions.  Air inhibits polymerization.  
 Incompatible with peroxides and free radical 
sources. 
Decomposition: Decomposes with heat.  Hazardous decomposition 
products include carbon dioxide, carbon monoxide, 
and hydrogen fluoride.  Toxic gases or particles 
may be formed during combustion.  These products 
may cause severe eye, nose, throat, and lung 
irritation or toxic effects. 
Polymerization: Polymerization can occur.  Conditions leading to 
polymerization are free radical sources, heat, and UV 
light. 
 
11. ECOLOGICAL INFORMATION 
General:   Take care to prevent chemicals from entering the 
ground, water courses or drainage systems. 
 
12. DISPOSAL CONSIDERATIONS  
Disposal Operations:  Material should be disposed of in accordance with 
local, state and federal regulations. 
Disposal of Packaging:   Dispose of as special waste in compliance with local 
and national regulations.  Observe all federal, state 
and local environmental regulations. 
 The user's attention is drawn to the possible 
existence of regional or national regulations 
regarding disposal. 
 
13. TRANSPORTATION INFORMATION 
Mode DOT/IMDG/IATA 
UN Number None.  Non-hazardous for transport. 
Class (Subsidiary) None.  Non-hazardous for transport. 
Proper Shipping Name None.  Non-hazardous for transport. 
Hazard Label (Subsidiary) None.  Non-hazardous for transport. 
Packing Group None.  Non-hazardous for transport. 
Shipping Hazard Label None.  Non-hazardous for transport. 
 
14. REGULATORY INFORMATION 
U.S. Federal Regulations TITLE III 
 HAZARD CLASSIFICATIONS SECTIONS 311, 
312 
Acute :  Yes 
Chronic :  No 
Fire :  No 
TEAc-N MSDS 
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Reactivity :  No 
Pressure :  No 
Incompliance with TSCA Inventory requirements. 
 
15. OTHER INFORMATION 
Personal Protection rating: To be supplied by user depending on use conditions. 
 NPCA-HMIS Rating: Health:  2 
 Flammability:  1 
 Reactivity:  1 
Legal Disclaimer:  For R&D use only.  Not for drug, household, or other 
uses.  The previous information is based upon our 
current knowledge and experience of our product 
and is not exhaustive.  It applies to the product as 
defined by the specifications.  In case of 
combinations or mixtures, one must confirm that no 
new hazards are likely to exist.  In any case, the 
user is not exempt from observing all legal, 
administrative and regulatory procedures relating to 
the product, personal hygiene, and integrity of the 
work environment.  Unless noted to the contrary, 
the technical information applies only to pure 
product. 
 To our actual knowledge, the information contained 
herein is accurate as of the date of this document.  
However, neither Top Fluorochem, nor any of its 
affiliates makes any warranty, express or implied, or 
accepts any liability in connection with this 
information or its use.  This information is for use by 
technically skilled persons at their own discretion and 
risk and does not relate to the use of this product in 
combination with any other substance or any other 
process.  This is not a license under any patent or 
other proprietary right.  The user alone must finally 
determine suitability of any information or material for 
any contemplated use, the manner of use and 
whether any patents are infringed.  This information 
gives typical properties only and is not to be used for 
specification purposes. 
 
 
 
 
 
End Of MSDS 
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Material Safety Data Sheet for Hamster Cell Cultures 
(Biosafety Level 1) 
 
 
1. Product Identification 
 
Name of cell line: CHO-K1 (CLS order no. 603480) 
Designation: Chinese-Hamster-Ovary cell line, permanent cell line 
 
 
2. Company Identification 
 
CLS Cell Lines Service GmbH 
Dr. Eckener-Str. 8 
D-69214 Eppelheim 
Germany 
 
Emergency phone number: +49 (0)6221 700799 
 
3. Composition / Ingredients 
 
Unit: cryovial; frozen liquid 
 
Hazardous Ingredient(s)  CAS no.  Percentage EC no. 
Dimethyl Sulfoxide 67-68-5 10 200-664-3 
 
Non-Hazardous Ingredient(s)    Percentage 
DMEM, supplemented for freezing  60-80 
FBS (Fetal Bovine Serum)  10-20 
Cells  1 
 
4. Hazards Identification 
 
Chinese-Hamster source cell line 
Categorized as non-infectious and non-toxic 
 
5. First Aid Measures 
 
Skin contact: 
Wash off immediately with plenty of water and soap. 
Eye contact: 
Flush eyes immediately with water for 10-15 minutes. 
Ingestion: 
If the material was swallowed, rinse the mouth with water. 
 
6. Accidental Release Measures 
 
Use personal protective equipment 
Do not flush into surface water. 
Clean contaminated surface thoroughly. Autoclave before disposal into appropriated containers. 
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7. Handling and storage 
Handling: 
Open only under a sterile workbench. Wear protective equipment. Handle as if containing infectious 
material. 
Storage:  
Keep the cryovial at -150°C (freezer) or at -196°C (liquid nitrogen vapour phase). 
 
8. Personal Protection 
 
Hygienic measures 
Avoid the contact with skin, eyes and clothing. Keep away from food and drinks. Wash hands immediately 
after handling the product.  
 
Normally, no respiratory protective equipment is required. 
 
Use protective gloves and safety goggles and wear a lab coat while handling the product. 
 
9. Physical and Chemical Properties / Reactivity  
 
Form: 
Liquid 
 
DMSO is stable. It is incompatible with a very wide range of materials, including acid chlorides, strong 
acids, strong oxidizing agents, strong reducing agents, phosphorus halides, moisture, copper wool + 
trichloroacetic acid, hygroscopic. 
 
10. Toxicological Information 
 
Not hazardous according to Directive 67/548/EC. 
 
Toxicity data for DMSO: 
 
ORL-RAT LD50 14500 mg kg-1  ORL-MAM LD50 21400 mg kg-1  
IVN-MAN TDLO 686 mg kg-1  IPR-RAT LD50 8200 mg kg-1  
IVN-MUS LD50 3100 mg kg-1  ORL-BWD LD50 100 mg kg-1  
IVN-DOG LD50 2500 mg kg 
 
11. Transportation Information 
 
Non-hazardous for air, sea and road freight. 
 
12. General Information 
 
Recommended use: 
For in vitro research use only. 
 
Disclaimer: 
The information provided in the present Material Safety Data Sheet is believed to be correct at the date of 
publication. No guarantee is given for its accuracy or completeness, but is intended as guidance only. 
Biological material may be hazardous and should be used with caution. 
CLS · Cell Lines Service shall not be held liable for any damage resulting from handling or from contact 
with the product.  
 
 
 
